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Abstract
The oncogene v-fos, is the transforming agent of the FBJ-MuSV and the FBR-MuSV 
osteosarcoma virus that elicits cellular responses through activation of the multigenic 
transcription factor AP-1. The Suppressive Subtractive Hybridisation (SSH), technique has been 
employed to identify differentially expressed downstream direct and indirect target genes of the 
AP-1 transcription factor in a rat fibroblast cell system by using FBJ-MuSV v-fos transformed 
208F fibroblasts and the normal parental fibroblast 208F cell lines.
444 clones were isolated from the up-regulated and down-regulated libraries of which 
206 were sequenced on at least one strand. Protein, nucleotide, and EST computational 
analysis revealed 83% of the sequenced clones represented known genes whereas 17% were 
novel. A proportion of the up- and down-regulated genes encode proteins which alter ECM, 
adhesion, motility and transcription and may enhance/suppress invasive phenotype respectively. 
Many of the clones encode for genes whose function has not been associated with 
transformation and invasion. The differential expression patterns of the AP-1 direct and indirect 
target genes have been characterised by Northern Blot analysis in oncogenically and 
mitogenically transformed cells.
A down-regulated clone matched to the known gene, Follistatin-related protein(FRP), a 
TGF0 induced gene, which is down-regulated in association with oncogenic transformation in 
several cancer cell lines and is extinguished in several human tumours. The cDNA was cloned 
into a 3’ Myc tagged expression vector and transient transfections into oncogenically 
transformed and parental untransformed fibroblasts shows FRP has a peri-nuclear cytoplasmic 
localization. Stable expression of FRP in FBR cell line does not effect cell proliferation, 
anchorage-independence or revert transformed morphology. The FRP expressing cells are 70% 
less invasive than wild type transformants in a matrigel invasion assay highlighting that a down- 
regulated AP-1 target gene blocks invasion.
A 208F cDNA library was contructed then screened for the full-length cDNA of a novel 
testis-specific down-regulated clone, DIF1, which matches to 7.5day embryo ectoplacental EST 
which exhibited homology to the helix-loop-helix transcription factor Alf1. The cDNA was cloned 
into a 3’ Myc tagged expression vector and transient transfections into parental untransformed 
fibroblasts shows DIF1 has a nuclear localisation. It proved very difficult to transfect 
oncogenically transformed cells with the DIF1-myc expression vector therefore it was cloned into 
a GFP fusion vector. Transient transfections into oncogenically transformed cells indicated a 
cytoplasmic localisation that resulted in a disruption of characteristic cellular morphology.
One down-regulated clone, CD10 exhibited homology to the apoptosis associated 
frizzled related protein FrpAP, and northern blotting revealed two abundantly expressed 
transcripts in 208F RNA. The 208F cDNA library was screened for full-length transcripts and the 
shorter transcript of 1.4Kb was cloned. This was found to have an identical ORF to that of the 
published FrpAP sequence, but the 3’ untranslated region was truncated.
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Chapter 1 
Introduction
1
1.1 ONCOGENES AND TUMOUR SUPPRESSOR GENES
Cancer is a leading cause of death in most first and second world countries, 
manifesting itself from a wide variety of host tissues in various clinical forms. Ongoing 
advances into the mechanism of the disease has revealed its complexity and elusive 
nature. Benign tumours, such as warts and moles, grow by simple expansion and 
often remain encapsulated by a layer of connective tissue and are rarely life 
threatening. Malignant tumours or cancers arise from the unrestricted progressive 
growth of a clone of cells, in a particular tissue known as the primary site. The 
movement of these cells through the circulatory systems can result in secondary 
tumour formation at distal sites, metastasis. The cells can also invade into local 
surrounding tissue. Almost all malignant tumours result from the transformation of a 
single cell, which being free of normal homeostatic controls, proliferates, invades and 
may metastasise. Transformation is a relatively rare event in the 1014 cells a human 
body contains, and requires a cell or its predecessor to have undergone several 
independent carcinogenic changes. Therefore exposure to a carcinogen may prime 
many cells for transformation, but a malignancy may not develop until decades later 
when one of these cells undergoes a penultimate transformation event.
Cancer is a multi-stage disease and can arise from acquired multiple mutations 
in two distinct classes of nuclear genes. The proto-oncogenes are positive regulators 
of cell growth, survival, invasion, and metastasis, whereas tumour suppressor genes 
(TSGs), are negative regulators. More than 50 different oncogenes and more than 
twenty different tumour suppressors have been identified, and it has become 
increasingly apparent that cancer-inducing mutations target conserved signalling 
pathways. The contributing factors to tumour initiation includes exposure to chemical 
carcinogens and ionising radiation, infection by oncogenic viruses and familial genetic 
predisposition. All of these factors can influence the potential of cancer developing 
through their ability to damage DNA, or affect its replication or repair. In addition, 
gene products which function to repair DNA damage, are often inactivated during 
tumourigenesis, although they do not directly function to enhance selective growth, 
survival or invasion.
The mutations that occur between proto-oncogenes and TSGs are distinct. 
Proto-oncogenes frequently undergo point mutations, that result in a missense 
mutation in the gene product and leads to its activation, or a new function. In contrast, 
TSGs mutations can lead to a loss of function, or can result in a dominant-negative 
function of the protein. This disparity extends to chromosomal aberrations, such as
2
those found in tumours, namely deletions, translocations, amplifications and 
aneuploidy, that result in the activation of oncogenes and the inactivation of TSGs. 
The different mutational profiles of these two distinct classes of genes accounts for the 
characteristic dominance of oncogenes, (oncogenic alleles transform cells in the 
presence of wild-type alleles), compared to the characteristic recessiveness of TSGs, 
(both alleles of a TSG require inactivation for tumourigenesis). Although the activation 
of cellular oncogenes permits transformed cells to thrive in the absence of growth 
stimulus, the inactivation of tumour suppressor genes which function to restrain growth 
is also fundamental to neoplasia and tumour progression.
Furthermore, recurrent mutations in these activating genes that normally 
function in the regulation of signalling pathways that incur constitutive activity, coupled 
with the inactivation of downstream target genes, ascribes a critical and causal 
functional role in neoplasia. Increasingly these alterations in downstream target gene 
expression have been consistently linked to tumourigenesis, thus the argument that 
these have a causal role in cancer becomes more compelling.
1.1.1 Oncogenes
The discovery of oncogenes was prerequisite to the understanding of the 
molecular mechanisms of tumourigenesis. A summary of the major classes of 
oncogenes and their identification class is tabulated in Table 1.1.
The retroviral oncogenes are almost exclusively transduced versions of cellular 
proto-oncogenes whereby their expression and activity is altered (Table 1.1 {i}). This 
was initially identified by the discovery that v-src, the transforming agent of the Rous 
sarcoma virus, was a homologue of c-src (Stehelin eta!., 1974).
The discovery that proviral insertion mutagenesis could activate oncogenes 
(Hayward et at., 1981), (Tablel.1 {ii}), was through activation of the myc proto­
oncogene in over 80% of ALV-induced chicken bursal lymphomas, and that proviral 
DNAs were integrated upstream of the lymphoma myc genes.
Oncogenes have also been isolated from spontaneous or carcinogen-induced 
mutations in proto-oncogenes, accounting for sporadically occurring tumours. This 
was evident from gene transfer experimentation, which suggested that approximately 
20% of tumours contain DNA sequences with transforming ability. The isolated DNA 
sequences included the known oncogenes H-ras, K-ras, ros and raf, and also novel 
oncogenes predominantly of the src and ras superfamilies (Tabin et al., 1982; 
Taparowsky et al., 1982; and Santos et al., 1982). These findings substantiated the 
belief that spontaneous arising neoplasms, are due to mutational activation of proto­
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oncogenes. The novel oncogenes identified through gene transfer can be classified 
into those which are activated in the tumours from which they are derived, and those 
activated by re-arrangements during the gene transfer process, (Table 1.1{iii}).
The association of oncogenes with chromosomal abnormalities has also led to 
their identification. The activation of oncogenes by translocation is comparable to 
insertional mutagenesis whereby oncogene sequences are adjacent to previously 
separated and unrelated sequences, (Table 1.1 {iv}). This can result in the 
inappropriate expression of the oncogene via a proximal enhancer sequence or 
through protein fusion products, and is characteristic of cancers of the haematopoietic 
system (Adams et al., 1986). Chromosomal abnormalities arising from amplifications 
of genomic DNA has also led to the identification of novel oncogenes (Schwab et al., 
1983; Wong eta!., 1986).
In addition, further identification of novel oncogenes has been achieved 
through sequence homology to existing oncogenes. Cross hybridisation with DNA 
probes to known oncogenes and amplification by PCR using degenerate 
oligonucleotide primers has been used to isolate new family members from genomic 
and cDNA libraries (Table 1.1{v}).
i) Oncogenes in acute transforming viruses
ABL, AKT, CBL, CRK, ERB-A, ERB-B, ETS, FES/FPS, FGR, FMS, FOS, JUN, 
KIT, MUJRAF, MOS, MYB, MYC, H-RAS, K-RAS REL, ROS, SEA, SIS, SKI,
SRC, YES
ii) Retrovirally integrated oncogenes
AHI1, BMI1, DSI1, EVI1, FIM1, FIS1, FLI1, FLVI1, GIN1, INT1/WNT1, INT2, 
INT3, INT4/WNT3, LCK, MIS1, MIS2, MIS3, MIS4, MLVI2, MLVI3, PIM1, SPI,
TIAM1, TPL2, VIN1
iii) Gene transfer identified oncogenes
activated in the tumours from which they were derived:
N -RAS, A/EL/, METTRK 
activated during gene transfer:
DBL, FGF5, HST, LBC, MAS, B-RAF, RET, TRE, VAV
iv) Oncogenes associated with chromosomal aberrations
translocation:
4
ALL 1/MLL/HRX, BCL1/PRAD1/CCND1, BCL2, BCL3, BCR, TAL1, TAL2, TAN1
amplification:
L-MYC, N-MYC, GLI1, ERB-B2, AIB1/SCR1
v) Oncogenes identified by cross hybridisation or degenerate PCR
ELK1, ELK2, EPH, ERB-B3, ERB-B4, ERG, FOSB, FRA1, FRA2, HCK, JUNE,
JUND, LYN,
Table 1.1 
Table of identification of novel oncogenes.
(See Hesketh, 1994 for the majority of these entries).
The proto-oncogenes and TSGs are evolutionary conserved with homologues 
being discovered in eukaryotes spanning from yeast, worms, flies, frogs and mice to 
humans. Extensive fundamental research into the function of these genes, as with 
their oncogenic counterparts in cancer research, has established critical roles in many 
aspects of cell behaviour. This includes differentiation, proliferation, motility, invasion, 
replicative senescence and apoptosis. In fact, many of the proto-oncogenes function 
as components of signal transduction pathways, which transmit extracellular signals 
that initiate at the cell surface via specific receptor-ligand interactions that are relayed 
through the cytosol to the nucleus.
Fos encodes a component of the transcription factor AP-1. It is a member of a 
family of related genes (Cohen and Curran, 1988; Dobrzanski etal., 1991) that have a 
leucine zipper domain adjacent to a basic DNA binding domain (Landschulz et al., 
1988), which heterodimerize with members of the Jun family (Ryder et al., 1989; Hirai 
et al., 1989) to form the AP-1 transcription factor. All of the Fos-Jun heterodimers bind 
to the consensus AP-1 binding site, TGAc/gTCA, found in the promoter region of AP-1 
responsive genes (Angel etal., 1988).
Figure 1.1 presents a schematic overview of the signal transduction pathways 
that function upstream of AP-1 and includes prot-oncogenes as signalling 
components. The nuclear transcription factors permit the cell to alter the expression of 
target genes which elicit a response to the original signal. Proto-oncogenes function 
at various positions in these pathways, thus abnormal activity can profoundly alter the 
interpretation of the signalling pathway, contributing to deregulated proliferation and 
neoplasia. However, the interaction of oncogenes in signal transduction pathways is 
very complex. The oncogene products can be classified according to their function in 
signal transduction cascades. The functional classification of the most prominent 
oncogene products are described in Table 1.2.
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Figure 1.1
Activation of AP-1 in fibroblasts through extracellular and intracellular 
signals, and through oncogenic Ras.
The Integrins signal through the ECM through insoluble ligands which activate 
Focal Adhesion Kinase (FAK). The extracellular signal of the growth factors functions 
through Receptor Tyrosine Kinases. These signalling pathways function through the 
cytosolic Grb-2 (Growth factor receptor-bound protein 2), that binds to the cytosolic 
guanine nucleotide-releasing factor Sos-1, facilitating the activation of Ras. The Ras 
or oncogenic Ras then activates Raf-1, which subsequently activates MEK-1 and the 
phosphorylation cascade to the nucleus via ERKS. The phosphorylation of TCF/Elk-1 
in the fos promoter stimulates transcriptional activity, inducing AP-1. The AP-1 
induced complexes can initiate transcription through binding to AP-1 sites in the target 
gene’s promoter as shown, or perhaps can prevent transcription through 
transrepression by binding to the target gene’s promoter turning transcription off (not 
shown).
(Diagram adapted from Blenis, 1993; and Karin, 1995).
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. 7
FUNCTION ONCOGENE
Ligands FGF5, INT2, HST1, SHH, SIS/PDGFB, 
WNT1, WNT3
Receptor tyrosine kinases EPH, ERB-B/EGFR, FMS, KIT, MET, 
NEU/HER2/ERB-B-2, RET, ROS, SEA, 
TRK
Non-receptor tyrosine kinases INT3/NOTCH4, TAN1/NOTCH1
Non-catalytic receptors 
Membrane associated:
Cytoplasmic:
SRC, FGR, FYN, HCK, LCK, LYN, TKL, 
YES
ABL, FPS/FES
Lipid kinases PI3K
Cytoplasmic regulators of protein activity 
SH2/SH3 Containing adapters:
Guanine nucleotide exchange factors:
CRK, NCK, SHC
DBL, ECT2, LBC, TIAM1, VAV CBL
Membrane-associated G proteins H-RAS, K-RAS2, N-RAS, GSP, GIP2
Cytoplasmic protein serine/threonine kinases AKT, BCR, MEK1/2, MOS, PIM1, RAF/MIL, 
TPL2
DNA-binding nuclear proteins 
(Transcription Factors)
ALL1/MLL, ERB-A/THRA, ETS1, ETS2, 
FOS, JUN, MYC, MYB, REL, TAL1, SKI
Transcriptional co-activator 
(acetyl transferase)
AIB1/SCR1
Table 1.2
Tabulated oncoprotein classification pertaining to biochemical role in 
signal transduction
(Adapted from Hesketh 1994).
The cellular homologue (c-fos), of the retroviral oncogene investigated in this 
study, FBR v-fos is highly conserved with 70% homology at the nucleotide level 
(between mouse and human), (Van Straaten et al., 1983). This high evolutionary 
conservation suggests an important role in normal cellular physiology. C-Fos is a 
nuclear protein that is a component of the Activator Protein 1 (AP-1), transcription 
factor which is the nuclear termini of several signal transduction pathways. Thus, AP- 
1 activation regulates gene expression in response to activation of the original cellular
8
stimuli. Its viral counterpart, v-Fos, constitutively activates AP-1, directly regulating 
gene expression and when inappropriately expressed, transforms cells.
1.1.2 Tumour Suppressor Genes
The TSGs are also known as recessive oncogenes, anti-oncogenes and 
growth suppressor genes. Several TSGs function by directly opposing the action of 
oncoproteins. That is they constrain cellular proliferation and survival by impeding 
mitogenic signalling pathways, blocking cell cycle progression, promoting terminal 
differentiation and maturation arrest or by inducing apoptosis. TSGs that suppress the 
invasive and metastatic potential of tumour cells also exist, and are inactivated during 
tumour progression. In addition, the capping of the replicative life span of a cell is also 
a target of tumour suppression, and three TSGs, RB1, TP53 and CDKN2A/p16INK4A 
play a role in replicative senescence.
The concept of TSGs was born out of early experiments involving the fusion of 
normal somatic cells and tumour cells (Harris et al., 1969; Stanbridge et al., 1976), 
whereby the normal x  tumour or less malignancy x more malignant hybrids exhibited a 
normal phenotype establishing that malignancy was a recessive trait. These findings 
were consistent with the hypothesis that tumour cells had lost critical functions as 
opposed to gaining dominant transforming functions. The genetic basis to cancer was 
highlighted from the normal x tumour hybrids, as the hybrid cells frequently and 
randomly lost chromosomes, although the segregation of certain chromosomes was 
predominantly associated with a malignant phenotype (Jonasson et al., 1977; Klinger 
etal., 1980; Evans et al., 1982). This enabled the mapping of TSGs to chromosomes 
that most likely contained genes of a suppressive function. Additionally, the concept of 
tumour suppression was proposed by Knudson’s (1971), “two-hit” hypothesis of 
transformation around the same time in relation to the clinical data pertaining to 
Retinoblastoma. This hypothesis stated that the sequential mutation of at least two 
independent genes is essential for transformation of normal retinoblasts to their 
malignant form. The data collected from the hereditary form revealed that the first hit 
was from the chromosome 13 deletion, with the second hit a random event in 
susceptible retinal cells. As the cells in both retinas carry the first hit mutation, the risk 
of tumour formation is high. In the sporadic form, two random mutations must occur 
within the same retinoblast, and as either mutation alone is unlikely, there is an 
extremely low probability for both mutation events to occur in the same cell.
The tumour suppressor genes can be classified into two groups; Class I, in 
which loss of function results from mutation or deletion of DNA, and Class II, in which
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a loss of function is from a regulatory block to expression. The class II suppressor 
genes are assumed to be regulated by a Class I tumour suppressor. Therefore, they 
are class I tumour suppressor effector genes. The tumourigenicity of several types of 
human cancers is enhanced by the inactivation, through mutation of several class I 
TSG families including p53, Rb and APC (Levine, 1993). The identification and 
isolation of class I TSGs was through unwieldy pedigree and cytogenetic analyses 
(Sager, 1989). The down-regulation of class II genes, such as non-muscle a-actinin, 
tropomysin I, CLP, retinoic acid receptor |3, and interferon regulatory factor 1 (Gluck et 
al., 1993; Hirada et al., 1993; Houel et al., 1993; and Mishra et al., 1994), in tumour 
cells has indicated a functional role in tumour suppression. In recent years, the 
discovery of TSGs has dramatically increased with the advent of differential screening 
(or differential hybridisation), differential display and subtractive hybridisation. 
Additional TSGs have been identified through using these techniques to identify genes 
that are down-regulated in tumour cells including the mapsin gene, lysyl oxidase {rrg), 
and N03 (Contente etal., 1990; Ozaki and Sakiyama, 1994; Zou etal., 1994).
Reintroduction of a TSG family member into a tumour cell can reverse the 
transformed phenotype and can block specific characteristics of transformation. This 
supports the possibility for novel therapies in the treatment of cancer by using a TSG 
to block specific tumour characteristics such as proliferation or invasion or even to 
reverse transformation.
The TSGs have been further characterised by Kinzler and Vogelstein (1997), 
as either “gatekeepers” or “caretakers”. The gatekeepers such as RB1, TP53, and 
CDKN2A among others, control cellular proliferation by directly inhibiting growth or 
promoting death. Accordingly, restoration of the missing gatekeeper function to 
cancer cells leads to suppression of tumour growth. In contrast, the caretakers, 
susceptibility genes that indirectly suppress tumourigenesis function in the 
maintenance of the genome and include the mismatch repair genes, nucleotide 
excision repair genes and genes like ATM, BLM, and WRN which maintain 
chromosome integrity after DNA damage and recombination. The inactivation of a 
gatekeeper TSG directly manifests a growth advantage to the affected cell. However, 
tumour initiation is not a direct result of inactivation of a caretaker gene, but the 
potential of tumour progression being relayed through the increase in the mutation rate 
of all genes, including gatekeepers, through promoting genomic instability and is 
equivalent to a constant exposure to mutagens. It is this Mutator phenotype that 
confers an increased risk of tumourigenesis. The restoration of function of a caretaker
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in a transformed cell does not affect its growth as these indirectly acting genes are not 
required for tumourigenesis.
More recently Kinzler and Vogelstein (1998), have further proposed a second 
class of caretaker genes by recent studies in the defective genes of juvenile polyposis 
syndromes (JPS), (Howe etal., 1998), and in ulcerative colitis (UC). The increased 
cancer susceptibility due to inherited mutations in JPS is the result of an abnormal 
stromal environment and thus an altered terrain for epithelial cell growth and can be 
thought of as a “landscaper” effect.
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1.2 THE FBJ AND FBR MURINE SARCOMA VIRUSES
1.2.1 Virus isolation
The oncogene v-fos was initially identified through experimentation into the 
induction of osteosarcomas by Finkel and co-workers (Finkel etal., 1966), in which two 
viral isolates that induced osteosarcomas were isolated from cell-free filtrates of 
spontaneous or 90Sr induced murine osteosarcomas.
The Finkel-Biskis-Jinkins Murine Sarcoma Virus (FBJ-MuSV), was isolated 
from a spontaneous osteosarcoma in a 270 day old male CF1/An1 mouse. Sterile 
extracts prepared from the tumour resulted in spinal osteosarcomas, upon 
interperitoneal or subcutaneous injection into newborn CF1 mice (Finkel et al., 1966). 
Subsequent subcutaneous injection of sterile extracts prepared from the spinal 
osteosarcomas into four newborn CF1 mice litters resulted in osteosarcomas within 71 
days, and preparation of more sterile extracts from these osteosarcomas was 
performed with filtration through 0.45 pm pores. Further injection of crude extracted 
material and filtrated extracts into CF1 mice, resulted in the outcome of osteosarcoma 
development at 35 and 61 days respectively (Finkel et al., 1966). These experiments 
indicated that tumourigenicity was a product of a virus and the subsequent decrease in 
incubation period was a consequence of an increase in titer. The presence of C-type 
viral particles were later validated through electron microscopy and the virus was 
termed FBJ-MuSV (Levy et al., 1973), and subsequent tissue culture experiments 
demonstrated that the FBJ virus was in fact a mixture of a low titer focus forming virus, 
FBJ-MSV, and a helper virus, the high titer plaque forming FBJ-MLV virus (Levy et al., 
1973).
The other viral isolate was recovered from a 90Sr-induced osteosarcoma in a 
X/Gf mouse, the Finkel-Biskis-Reilly Murine Sarcoma Virus (FBR-MuSV), and was 
passaged in a similar manner as the FBJ-MuSV virus (Finkel et al., 1975). The FBR- 
MuSV was also shown to be a complex of a type-C replicative defective, acutely 
transforming virus and a replication competent helper virus of a different pseudotype to 
that of the FBJ-MuSV (Curran and Verma, 1984). The inoculation of newborn mice 
with FBR-MuSV induced tumours of a similar ilk to those of the FBJ-MuSV (Finkel et 
al., 1975). In addition, FBJ-MuSV has been shown to morphologically transform all 
rodent fibroblasts and fibroblast-like cells of mesodermal origin. Furthermore, in tissue 
culture assays the virus can rapidly transform fibroblast cells which can be further 
enhanced with corticosteroid treatment (Lee etal., 1979).
Tissue culture experiments revealed that the FBJ-MuSV induces 
transformation but not immortalisation, whereas FBR-MuSV induces both (Jenuwein et
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al., 1985). The characteristic of FBR-MuSV in both transformation and immortilisation 
of cells in tissue culture are not shared by any other retroviral oncogene.
In addition to transforming cells of mesenchymal origin, the v-fos oncogene can 
transform other cell types including those of epithelial origin and lymphocytes (Lee et 
al., 1993; Valge-Archer etal., 1990). Interestingly, the histological characteristics of v- 
fos induced osteosarcomas indicated that the local invasive cells attached to bone 
tissue were of mesoderm origin suggesting that fibroblastic cells were the target of v- 
fos oncogene, although electron microscopy studies confirmed the presence of a 
variety of cell types (Yumoto et al., 1970). It was noted in further studies performed by 
Ward and Young (1976), that v-fos induced tumours are mainly localised in the 
periosteum, as opposed to the deep bone cortex, the localisation site of human 
osteosarcomas. Therefore, the histological variation and cellular pleimorphism found 
in the v-fos induced tumours indicated that the type of osteosarcoma formed were of a 
parosteal type of bone tumour as suggested by Verma (Verma and Graham, 1987).
1.2.2 Viral fos and cellular fos identification
The FBJ-MuSV was first isolated from the generation and use of a non­
producer (NP), cell line (Curran and Teich 1982a), 208F fibroblasts which were a 
derivative of thioguanine-resistant Rati cells (Quade, 1979), transformed with FBJ- 
MuSV viral complex. The transformed NP cells formed foci and colonies in soft agar, 
and when injected into synergistic mice, tumour formation ensued. The Tumour 
Bearing Rats Sera (TBRS), from these mice were used to precipitate material from 35S 
labeled FBJ-MuSV NP cells, that resulted in a 39kD protein of cellular origin. The 
isolated protein, c-Jun, was exclusively expressed in the FBJ-MuSV NP cells, and was 
absent in 208F cell line, and in 208F cells transformed by Kirsten-MuSV, Moloney- 
MuSV, Abelson-MuSV, or Rausher-MuSV. Furthermore, antisera that recognised 
structural FBJ-MuSV proteins did not cross-hybridise with the 39kD protein and in vivo 
labeling with subsequent tryptic peptide analysis revealed no structural relationship to 
the envelope proteins of the FBJ-MuSV (Curran and Teich 1982a).
A later report by Curran and Teich (1982b), identified the transforming 
component of the FBJ-MuSV through the precipitation of two proteins, one of 39 kD 
and a novel protein of 55kD, using TBRS. The p55 v-Fos was also specific to the FBJ- 
MuSV NP cells, and was undetectable in 208F cell line, and the 208F cell line 
transformed by Kirsten-MuSV, Moloney-MuSV, Abelson-MuSV, or Rausher-MuSV. 
The separation of 35S labeled fingerprints from cell extracts by two-dimensional gels 
revealed that the two precipitated proteins were not the same as those from the gag
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and env encoded products (Curran and Teich, 1982b). Peptide mapping of the in vitro 
translation of viral RNA in a reticulocyte lysate and immunoprecipitation confirmed that 
the p55 v-Fos was specific to the FBJ complex. The phosphorylation of the p55 v-Fos 
on Serine but not Tyrosine residues and the absence of protein kinase activity was 
deciphered from phospho-amino acid analysis (Curran and Teich, 1982b).
Reverse transcribed labeled cDNA of viral RNA from FBJ-MuSV complex was 
utilised in the molecular cloning of the FBJ-MuSV by the screening of Southern blots 
containing DNA from non-producer FBJ-MuSV transformed cell lines (Curran and 
Teich, 1982b). The biologically active segment of proviral DNA was identified and 
isolated and was found to contain an extensive region of non-homology with helper 
virus DNA which was expressed as a 3.5Kb mRNA in transformed cells. This non- 
homologous region was similar to a cellular homologue which was conserved in 
several different vertebrate species (Curran and Teich, 1982b). The putative 
oncogene was named v-fos and the proto-oncogene c-fos from FBJ derived 
OsteoSarcoma, (FOS).
The cloning of the FBJ-MuSV permitted similar analysis on the FBR viral 
isolate that identified a 75kDa phosphoprotein, antigenically related to p55 v-Fos. The 
proviral genome of FBR-MuSV was cloned into a plasmid and shown to be 
transforming. Analysis of the DNA sequence revealed that the FBR v-fos gene was a 
fusion of c-fos sequences and the 5’ viral gag gene and contained unknown murine 
cellular sequences at the 3’ end, that resulted in the larger p75 v-Fos as opposed to 
the p55 v-Fos (van Beveren etal., 1984).
1.2.3 Viral fos and cellular fos structure
The DNA sequence analysis of both v-fos oncogenes and the c-fos proto­
oncogene highlighted their similarity (van Straaten et al., 1983; Curran et al., 1983; 
van Beveren et al., 1983; and van Beveren et al., 1984), and their comparison is 
demonstrated schematically by Figure 1.2.
The murine and human c-fos genes have a similar intron/exon structure and 
exhibit near homologous identity at both the nucleotide and amino acid level. The 27 
single amino acid differences are throughout the 380 amino acid length of the protein. 
C-fos mRNA encodes a 2.2Kb transcript from the assembly of four exons from a 3.5Kb 
transcription unit (Curran etal., 1983).
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Figure 1.2 
Comparison of c-fos and both v-fos Genes
Structure of the c-fos (mouse), gene and FBJ-MuSV and FBR-MuSV proviral 
DNAs. Top and bottom: 5’ and 3’ long terminal repeat sequences (LTR), of FBJ- and 
FBR-MuSV are depicted by open boxes, other noncoding regions are indicated by a 
solid line. Stippled boxes indicate the portions of the v-fos and gag-fos genes 
encoding the viral homologue to c-fos, (Middle). The exons are depicted by stippled 
boxes, introns 5’ and 3’ untranslated regions are indicated by a solid line. Indicated 
below or in each exon are the length (in amino acids), of the segment of the fos 
protein it encodes. Also indicated in the figure are the TGA termination codon used by 
c-fos, the TAG termination codon used by v-fos, and the location of the TATA box, 5’- 
cap, CRE, AP-1, DSE, SCM, and poly (A) signal.
(Adapted from Ransone and Verma, 1990).
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Comparison of c-fos and both v-fos Genes
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The FBJ-MuSV is 4026bp flanked by two 617bp Long Terminal Repeats (LTR). 
V-fos is substituted for the retroviral gag-pol-env genes and contains 1639bp of 
cellular sequences located in the centre of the viral genome (van Beveren et al.,
1983). The open reading frame (ORF), encases these substituted cellular sequences 
and encodes a 381 amino acid protein (van Beveren etal., 1983). The 48 amino acids 
at the C-terminus of the human and murine c-Fos proteins are not homologous to 
those of FBJ v-fos (Curran et al., 1983). The FBJ v-fos nucleotide sequence has a 
104bp deletion at the 3’ end of the ORF (van Beveren et al., 1983), that results in a 
frameshift and a distinct C-terminal 48 amino acid in relation to c-Fos. However, the 
remainder of the protein is similar to murine c-fos with only five amino-acid 
substitutions (van Beveren etal., 1983).
The FBR-MuSV provirus is somewhat shorter at 3791 bp, of which 709bp are 
derived from the c-fos gene and 437bp originated from unidentified cellular sequences 
(van Straaten et al., 1983). The ORF encodes a gag-fos fusion protein, p75 9a9'fos. 
The protein has a 24 amino acid truncation at the N-terminus and a 98 amino acid 
truncation at the C-terminus as compared to c-Fos (van Straaten et al., 1983). Two 
small internal deletions of 39 and 27 amino acid are also present. There are five 
amino acid substitutions and these are different to the five substitutions present in FBJ 
v-Fos (van Straaten etal., 1983).
1.2.4 Viral Jun and cellular jun identification
Similar to v-fos, the v-jun oncogene was isolated from a replicative defective, 
acutely transforming retrovirus, which had no homology to previously identified GTP 
binding or protein kinase oncogenes and was found to localise at the nucleus (Maki et 
a!., 1987; Vogt et al., 1987). Studies using two-dimensional gel electrophoresis 
indicated that Fos proteins complexes with a basic 39kDa cellular protein (Franza et 
a!., 1987), that was originally identified by Curran and co-workers (Curran and Teich, 
1982a; Curran et al., 1985).
The cellular homologue of v-jun, c-jun was identified by screening a genomic 
DNA library with an oligonucleotide designed from the coding sequence of v-jun 
oncogene (Bohmann et al., 1987). A sequence homology at the C-terminal 66 amino 
acid region between the cellular homologue, c-Jun to the DNA binding domain of yeast 
transcription factor, GNC4, was observed (Maki et al., 1987; Vogt et al., 1987). In 
addition, this region was homologous to c-Fos and c-Myc, albeit to a lesser degree 
(Maki et al., 1987), and had a predicted a-helical character. This suggested that c- 
Jun, like GCN4 could function as a sequence specific transcription factor, and in fact a
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domain swap experiment performed in yeast where the GCN4 DNA binding domain 
was replaced by the homologous region of c-Jun, resulted in no loss of function 
(Struhl, 1987). The DNA sequence to which yeast GCN4 binds is very similar to that 
of the AP-1 consensus binding site (Curran and Franza, 1988), and thus the 
relationship between c-Jun and the AP-1 transcription factor was investigated. In the 
experiments conducted by Angel and co-workers (1988), partially purified AP-1 was 
shown to react with anti-Jun antisera, and that bacterially expressed c-Jun and v-Jun 
bound to the same DNA sequences as AP-1 (Angel et al., 1988). Furthermore, in a 
transient transfection assay, v-Jun activated transcription via TPA responsive elements 
(Angel etal., 1988).
Curran and co-workers demonstrated that Fos family proteins shared a 
common DNA binding site with AP-1 in the promoters of cellular and viral genes by 
using DNA-affinity precipitation assays followed by high resolution, two-dimensional 
electrophoresis (Franza et al., 1988). The ensuing studies involving electrophoretic 
mobility shift analysis and photoaffinity cross-linking, demonstrated that the FSE could 
efficiently bind Fos proteins (Rausher et al., 1988a), and that p39 is in fact the c-jun 
proto-oncogene (Rauscher et al., 1988b). The conduction of immunoprecipitation 
experiments using Fos- and Jun- specific antibodies subsequently identified p39/Jun 
as an AP-1 associated protein (Sassone-Corsi etal., 1988).
This data provided compelling evidence that Fos and Jun proteins were a 
major component of the AP-1 transcription factor complex, and as a result of this 
association could activate transcription in vitro and in vivo. This suggested a co­
operatively between the actions of the Fos and Jun proteins.
1.2.5 Fos and Jun AP-1 family members
Studies of Fos protein complexes using immunoprecipitation and 
immunoblotting on one and two dimensional gels resulted in the observation of a set of 
immunologically related proteins, designated Fos related antigens (Franza et al., 
1987). Similar to c-Fos, these proteins were induced by serum stimulation but 
exhibited different expression patterns (Franza etal., 1987; Cohen and Curran, 1988). 
This indicated that c-Fos belonged to a family of related genes.
Fos-fielated Antigen-1, fra-1, was the first gene isolated with homology to c-fos 
(Cohen et al., 1989). Fra-1 was isolated by screening a Xgt11 library generated from 
cells that were serum stimulated for 75 minutes, with antibodies raised to a synthetic 
peptide derived from a highly conserved c-fos sequence that had previously been 
shown to cross react with several Fras (Cohen and Curran, 1988). The sequence
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analysis of the cDNA clone that encoded a 35kDa antigen revealed significant 
homology to c-Fos at the amino acid level, but less homology was exhibited at the 
nucleotide level (Cohen et al., 1989). The Bzip domain (Refer to Figure 1.3), of the 
fra-1 exhibited a 77% homology to c-fos, including a conserved cysteine in the basic 
DNA binding domain (Cohen and Curran, 1988), and the C-terminal 40 amino acid 
portion of Fra-1 is 65% homologous to c-Fos (Gius et al., 1990). Further studies on 
Fra-1 observed heterodimerisation with c-Jun, but in keeping with c-Fos, it was unable 
to dimerise with itself or any other Fos family members (Cohen et al., 1989). Fra-1 is 
rapidly phosphorylated on serine residues after which it localises to the nucleus 
(Cohen et al., 1989). In FBR v-fos transformed 208F fibroblasts the Fra-1 mRNA and 
protein is up-regulated compared to untransformed 208F fibroblasts (Hawker, 
McGarry, Ozanne, unpublished observations). The fra-1 gene has been shown to be 
positively controlled by AP-1 in a Fos-ER expression system in fibroblasts (Bergers et 
al, 1995). In addition, Fra-1 is also found to be up-regulated in ras, raf and MEK1 
transformed cells (Mechta etal., 1997; Cook etal., 1999; Treinies etal., 1999).
The low stringency screening of a human cDNA library with a c-fos probe 
resulted in the cloning of an additional /bs-f?elated Antigen-2, fra-2. Transcription of 
the fra-2 gene was induced upon phorbol ester (TPA), stimulation of U937 human 
monocytic cells. (Matsui et al., 1990). The isolation of Fra-2 from chicken where it 
encoded a 45kDa antigen, and subsequent experimentation found that Fra-2 was 
oncogenic in chick cells (Suzuki etal., 1991). The mouse fra-2 gene was isolated from 
genomic cDNA clones encoding the homologue and also induced the transformation of 
chicken embryo fibroblasts (Foletta et al., 1994).
FosB was discovered by low stringency screening of positive clones isolated 
from the differential screening of serum stimulated NIH 3T3 fibroblasts using a 
synthetic oligodeoxynucleotide probe derived from the putative DNA binding site of c- 
fos (Zerial et al., 1989). FosB is a nuclear protein of 388 amino acids with 70% 
homology to c-Fos , with high conservation in the BZip and C-terminal regions (Zerial 
et al., 1989). FosB was also induced by serum, heterodimerises with Jun family 
members, and binds to and activates from AP-1 sites indicating that the Fos family 
members share biological and biochemical functions (Zerial et al., 1989; Dobranski et 
al., 1991). In addition, fosB can transform rat fibroblasts (Schuermann et al., 1991; 
Wisdom et al., 1992). A short form of fosB was cloned. It results from alternative 
splicing which generates a protein lacking the C-terminal 101 amino acids (Nakabeppu 
and Nathans, 1991; Mumberg et al., 1991; Yen et al., 1991; and Dobrzanski et al., 
1991). The truncated protein functions as a negative regulator of cellular 
transformation and suppresses /bs-induced transformation (Mumberg etal., 1991).
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The Jun family member, junB was discovered by the screening of serum 
stimulated cDNA libraries with probes derived from stimulated-cell RNA. JunD was 
isolated by the screening of serum stimulated cDNA libraries with junB or c-jun probes 
at moderate to low stringency (Lau and Nathans, 1987; Ryder etal., 1989; and Hirai et 
al., 1989). JunB and JunD are extensively homologous to c-Jun in the BZip region and 
in the N-terminal transactivation domain (Ryder et al., 1989). The proteins can 
homodimerise and form heterodimers with other members of the Fos and Jun families. 
Similar to c-jun, junB is inducible by serum and TPA (Lau and Nathans, 1985), whilst 
junD is constitutively expressed throughout the cell cycle in a wide variety of cell types 
(Ryder et al., 1989; Chiu etal., 1989; and Hirai etal., 1989).
Furthermore, both Jun and Fos family members can form heterodimers with 
ATF transcription factor family members (Benbrook and Jones, 1990; Hai and Curran, 
1991). The ATF family are a set of leucine zipper transcription factors that were 
identified by virtue of their interacting with DNA sequences which mediate 
transcriptional activation in response to cAMP or Adenovirus E1A (Ziff, 1990). The 
cAMP (CRE), response element, TGACGTCA, differs from TPA response promoter 
element, TGACTCA by one nucleotide (Sassone-Corsi et al., 1990). AP-1 and ATF 
co-purify on DNA affinity columns and are immunologically related (Hai etal., 1988).
Therefore, AP-1 is not simply a dimerisation of c-Fos and c-Jun but can be 
regarded as a much more intricate transcription factor complex with the feasible 
binding of several Fos, Jun and ATF family members, each with different DNA binding 
specificities. Thus, through the various potential homodimeric and heterodimeric 
complexes that can be formed, AP-1 elicits a high degree of transcriptional control.
In v-fos transformed 208F fibroblasts Fra-1, Fra-2, JunD and c-Jun are the 
predominate AP-1 components. FosB and JunB are detectable but at a lesser extent 
(McGarry, Ozanne, unpublished observations).
1.2.6 Function of Fos proteins
The p55 c-Fos protein is composed of distinct functional domains that mediate 
transactivation, dimerisation with Jun/ATF family members, DNA-binding and cellular 
transformation. The functional domains are shown in Figure 1.3A.
The N-Terminal Activation domain (N-TA), is an independent domain involved 
in transactivation and transformation (Jooss et al., 1994). Adjacent to N-TA is the 
basic/zipper region (BZip region), that functions to dimerise with the Jun family 
proteins and binds DNA. The bZip domain includes the basic region that contacts 
DNA and the leucine repeat which forms the characteristic Leucine Zipper helical
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wheel that stabilises the protein dimers via a scissor grip model. A heterodimeric DNA 
binding configuration of c-Fos and c-Jun is depicted in Figure 1.3B.
The HOB domains at the C-terminus are conserved between the different Fos 
family members and function as transactivation domains. The HOB1 motif is deleted 
in the FBR v-Fos protein (Sutherland et al., 1992), and the TATA-binding motif at the 
C-terminus of c-Fos is deleted in the FBJ and FBR v-Fos proteins (Metz et a l, 1994a; 
1994b). The C-TM domain is present in both the c-Fos and FBJ v-Fos proteins, but is 
deleted in FBR v-Fos. However, the transforming potential is fortified by the cellular 
fox sequences, that partially substitute the C-terminus for the wild-type c-Fos protein 
(Funk et al., 1997). The studies conducted to demonstrate the function of these 
regions are further detailed below.
The region between amino acids 41 and 73 at the N-terminus of FosB and 
FosB/sf were found to be highly conserved and deletion compromised the 
transforming ability of FosB (Wisdom and Verma, 1993). This indicated that in 
addition to the BZip region, the N-terminus of Fos family members is required for 
transformation. Similarly, in the c-jun proto-oncogene different regions of the protein 
were shown to be required for the transcriptional activity, that is amino acids 68-91, 
which encodes the N-TA ( Angel et al., 1989). This region is homologous to the 
transactivation domain of Fos proteins that were identified through deletion analyses 
as imperative for transformation (Jooss et al., 1994). It is highly conserved throughout 
the Fos family including the viral Fos proteins and contains Proline and Glutamine 
residues commonly found in transactivation domains. This N-terminal domain region 
homologous between the Fos and Jun family members is regulated by Serine 
phosphorylation. The Serine 70 amino acid in Fos protein corresponds to the Serine 
73 found in the c-Jun protein that is phosphorylated by Stress Activated Protein 
Kinases (SAPK/JNK), and is required for transactivation and transformation (Alani et 
al., 1991; Binetruy et al., 1991; Smeal et a l, 1991; and Pulverer et al., 1991). The 
conserved motifs at the N-termini of Fos and Jun proteins that contain the conserved 
Proline, Glutamine and Serine residues is highlighted in Table 1.3 below.
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c-Jun human ASPELER L I IQ
Fos/aa 66-79 SPDLQWLVQP
c-Fos human TSPDLQWLVQP
FosB human TSQDLQWLVQP
Fra-1 rat TSQELQWMVQP
Fra-2 human TSQDLQWMVQP
FBJ-MuSV TSPDLQWLVQP
FBR-MuSV TSPDLQWLVQP
Table 1.3
Conserved N-termini motifs of Fos and Jun proteins
The conserved N-termini motifs are shown underlined with the Proline,
Glutamine and Serine residues highlighted in bold. The Serine residues can
potentially be phosphorylated by MAP kinases (Jooss etal., 1994).
This indicates a further complexity of AP-1, by the regulation of the 
transactivation and transrepression potential of Fos and Jun proteins by in vivo 
phosphorylation.
Fos and Jun family members function co-operatively in transactivation and 
DNA-binding to an AP-1 binding site, also known as the TRE (TPA-Responsive 
Element), through their physical interaction (Angel etal., 1988; Chiu etal., 1988; and 
Sassone-Corsi et al., 1988). Investigations using in vitro translation products were 
conducted to identify the DNA-binding potential of Fos and Jun proteins, and to identify 
the nature of the dimers formed during in vitro translation. Jun was found to bind to 
the TRE forming dimers with itself and with other Jun family members, JunB and 
JunD; and as heterodimers with Fos family members (Kouzarides and Ziff, 1988; 
Halazonetis et al., 1988; Nakabeppu et al., 1988; and Rauscher et al., 1988c). The 
Fos-Jun heterodimers display an increased binding affinity for the TRE as compared to 
Jun homodimers indicating further the complexity of AP-1 transforming potential 
(Schutte etal., 1989a). The Fos family members do not homodimerise.
The Leucine zipper region orchestrates the physical interaction between the 
Fos and Jun family members and was initially identified in the liver CCAAT enhancer 
binding protein (Landschulz et al., 1988). The leucine zipper forms a coiled coil in 
which the Leucine residues are located in a canonical structure spaced at seven amino 
acid intervals along the polypeptide chain. This structure favours the interactions of
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Figure 1.3 
Functional domains of c-fos and heterodimer DNA binding configuration
A: The p55 c-Fos protein functional domains includes the N-terminal 
transactivation domain (N-TA, Pink), the Leucine zipper/basic region (bZip, Yellow), 
the HOB1 and HOB2 and C-TM domains (Blue, Blue/Pattern), and the TATA-binding 
domain (TBD, Pink). A colour coded key indicating the domains function are shown 
below.
B: The simplified scissor grip model of c-Fos and c-Jun physical interaction, 
and their binding to the TRE is depicted. The c-Jun and c-Fos proteins are shown in 
pink and blue respectively.
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leucine residue repeats from two different polypeptides permitting their dimerisation. 
The Leucine residue repeats are common to the Fos and Jun family members and are 
also present in other transactivators including GCN4, CREB and C/EBP in which they 
are found in the same conserved positions. In addition, site-directed mutagenesis 
directed at the Leucine zipper has also identified this regions importance in DNA- 
binding (Kouzarides and Ziff, 1988; Gentz et al., 1989; and Neuberg et al., 1989). 
Thus, the leucine zipper domain is necessary for dimerisation and DNA binding.
The characterisation of the regions of the FBR v-fos oncogene detected that 
the region spanning amino acids 111 to 220 is critical for the induction of 
transformation. This region encodes the acidic domain, the basic domain which is 
involved in DNA contact, and the Leucine zipper (Jenuwein and Muller, 1987). 
Similarly, the corresponding homologous region in the FBJ v-fos oncogene that spans 
amino acids 111 to 206 is also essential for transformation (Yoshida et al., 1989).
Functional analysis of Fos proteins with regards to their interaction with Jun 
proteins revealed that the majority of the Leucine residues contribute to the formation 
of an intact, functional zipper. A single mutation in residue Leu-179 in the highly 
transforming v-Fos protein E300, resulted in a slight decrease in zipper function, 
whereas mutation of residue Leu-165 completely abolished binding to c-Jun and 
repressed the transformation ability (Schuermann et al., 1989). Therefore, the 
Leucine zipper is also required for the in vitro induction of transformation.
Additional experimentation involving the mutation of various FBR v-Fos protein 
domains further confirmed the inhibitive properties of Leucine zipper mutants in 
transformation (Wick et al., 1992). However, although the transforming properties of 
FBR v-fos was partially suppressed, the proliferative properties of the cell lines 
expressing the dominant negative mutants remained unaltered (Wick et al., 1992). In 
addition, the Leucine zipper/Basic region mutants of Fos proteins were also found to 
inhibit transformation by other oncogenes, and could inhibit EJ Ha-ras transformation 
two-fold. This observation suggested that the retroviral v-fos oncogenes are part of 
the ras signal transduction pathway which correlated with previous microinjection 
studies, whereby injection of ras proteins induced c-fos expression in vitro (Stacey et 
al., 1987).
The c-fos gene was undetected in quiescent cells but was rapidly induced to 
high levels after the addition of growth factors or serum, but declined soon after 
mitogenic stimulation (Greenberg and Ziff, 1984; Kruijer etal., 1984; and Muller et al.,
1984). Down-regulation of c-Fos protein levels by degradation is conducted by the C- 
terminus of the c-Fos protein and not by transrepression of mRNA levels. The FBJ v- 
Fos protein has a different reading frame in this region resulting from the frame-shift
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mutation, and thereby escapes regulatory control (Van Beveren et al., 1983; and Van 
Straaten et al., 1983). Further studies pertaining to the of 3’ sequences of c-fos 
whereby they were replaced with FBJ coding sequences resulted in the induction of 
transformation (Miller et al., 1984; Meijlink et al., 1985). This indicated that structural 
modifications to the c-fos proto-oncogene can confer oncogenic potential. Additional 
evidence revealed that the 3’ sequences of c-fos destabilised the message (Lee etal., 
1988; Wilson and Treisman, 1988), and substitution of this region with those of the 
FBJ v-fos oncogene resulted in the stabilisation of the c-fos/v-fos mRNA.
An additional function to the transforming potential of FBR v-fos is the ability to 
immortalise, a prerequisite during the passage of rodent cultures towards a neoplastic 
stage. In contrast, the FBJ v-Fos protein can transform early passage cells, but 
cannot immortalise them (Jenuwein et al., 1985). The generation of chimeric Fos 
proteins and extensive detailed analysis of the FBJ-FBR-c-fos chimeras revealed that 
two different alterations determine the transformation potential of the FBR v-Fos 
protein (Jenuwein and Muller, 1987). The first mutation involved in the induction of 
immortalisation is an amino acid change at position 138 from a polar Glutamine to a 
Valine, and when this point mutation was introduced into FBJ v-Fos it confers 
immortilisation potential. Furthermore, the introduction of this point mutation in c-fos 
results in an increase in transactivation (Lucibello et al., 1991). The presence of 
another point mutation, a Glutamine 175 to Lysine in the FBJ v-Fos protein results in a 
decrease in transformation by 80%.
A secondary alteration that contributes to the transforming potential of FBR v- 
fos is the two internal deletions at the C-terminus. The re-introduction of the deletions 
with the corresponding c-fos sequences into FBR v-Fos protein results in a reduction 
of the transforming ability (Jenuwein and Muller, 1987). Further analysis using a five 
times TRE construct, that permits the monitoring of the transcriptional activity of Fos 
proteins, revealed a co-operation between the FBR-specific point mutations and the 
two C-terminal deletions. The replacement of the deletions failed to affect the 
transactivation potential, but significantly suppressed transformation (Lucibello et al., 
1991). These observations further clarified previous findings whereby the 
transactivating domain of Fos is located at the C-terminus of the protein (Lucibello et 
al., 1988; Sassone-Corsi et al., 1988), and an expression plasmid encoding a C- 
terminally truncated FBR v-fos protein inhibited transactivation of a TRE-containing 
construct (Lucibello etal., 1988).
The HOB1 and the TATA-Binding Domain (TBD), which exert a positive 
regulatory role in Fos transcriptional activation are deleted in the FBR v-fos oncogene 
(Sutherland et al., 1992; Metz et al., 1994b). The transforming capacity was rescued
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by the alternative domains, N-TA and C-TM (Jooss etal., 1994; Funk etal., 1997), and 
by the addition of C-terminal cellular fox sequences (Jenuwein and Muller, 1987). 
Detailed analysis of the C-terminal region of c-fos, FosB and FBJ v-fos revealed a 
conserved motif of hydrophobic amino acid residues with the transcriptional activation 
domain of the viral transactivator VP16 (Funk et al., 1997). The C-TM domain co- 
operatly functions with the N-TA module to activate transcription.
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1.3 FOS BIOLOGICAL MODELS IN CARCINOGENESIS
1.3.1 Cell growth regulation by fos
The induction of c-fos when cells transit from G0 to Gi indicates a cell cycle 
function. This assumption was supported by antisense (Holt et al., 1986; Nishikura 
and Murray, 1987), or antibody micro-injection (Riabowol et al., 1988; Kovary and 
Bravo, 1991a), experiments that showed a decrease in the number of cells entering S 
phase under antagonistic c-fos expression. Micro-injection of double stranded AP-1 
oligonucleotides into primary human diploid fibroblasts prohibited S phase initiation 
(Riabowol, 1992). The micro-injection of antibodies specific to individual Fos and Jun 
family members into Swiss 3T3 fibroblasts and subsequent monitoring of DNA 
synthesis revealed that S phase was reduced in cells injected with combinations of 
antisera directed against the Fos or Jun families in either serum stimulated or 
asynchronously growing cells (Kovary and Bravo, 1991b).
These studies provided compelling evidence for a critical role of c-fos in 
inducing the expression of genes that are required for cell cycle progression. 
However, c-fos is also expressed in non-proliferative cells such as neuronal cells 
whereby induction of c-fos in response to a wide variety of signals results in 
depolarisation (Sager et al., 1989), and the activation of mature macrophages with 
interferon y (Higuchi etal., 1988). C-fos expression has also been implicated in the in 
vitro differentiation of F9 teratocarcinoma cells, TPA and DMSO induced differentiation 
of HL-60 cells and in the NGF stimulated differentiation of PC12 cells (Holt etal., 1986; 
Ito et al., 1989). This suggests that the biological consequence of c-fos expression is 
dependent upon cell type, differentiation status and cellular micro environment. 
Therefore, c-fos through AP-1 and variable heterodimer combinations regulates 
distinct sets of target genes at different developmental stages resulting in different 
biological effects.
The recent advent of recombinant DNA technology facilitated the generation of 
knock-out embryonal stem (ES), cells of c-fos (Field et al., 1992; Brusselbach et al., 
1995), and c-jun (Hilberg and Wagner, 1992).
The proliferative potential of ES fos -I- cells remained unaltered in comparison 
with wild type cells, both in terms of saturation densities and doubling times. Serum 
induction of quiescent fos -/- fibroblast cultures indicated that they retain the same 
proliferative potential and that they can also spontaneously differentiate in vitro similar 
to the parental wild type fos +/+ cells (Field etal., 1992). Further studies exhibited that 
proliferation and serum re-entry of fos -/- cells into the cell cycle was similar to that of
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fos +/+ ES and fibroblast-like cells (Brusselbach et al., 1995). The analysis of 
proliferation using growth curves between fos +/+ and fos -/- fibroblasts showed that 
their was no proliferative difference, and FACS analysis revealed that cell-cycle 
progression and re-entry was not impaired in the fos deficient fibroblasts. The 
parameters of AP-1 activation was also examined and DNA-binding to a TRE 
consensus, TRE-dependent trans-activation in transfection assays indicated that there 
was no difference between the fos -/- and wild type cells (Brusselbach etal., 1995).
Similar studies conducted using c-jun knock-outs (Hilberg and Wagner, 1992), 
produced similar results. These studies converged upon the idea that the AP-1 
components, c-fos and c-jun, are not essential for cell proliferation In vitro, 
contradicting previously published evidence that suggested cell proliferation was 
affected when the expression (Holt et al., 1998), or the function of fos and jun was 
impaired in vitro (Riabowol etal., 1988; Kovary and Bravo 1991a; 1991b).
The in vivo targeted disruption of fos and jun genes suggested a direct role in 
development and differentiation, indicating an essential function in murine 
development. Targeted disruption of c-jun in vivo results in embryonic lethality and the 
omission of fos is associated with bone defects (Wang et al., 1992; Johnson et al., 
1992a).
1.3.2 In vivo models of Fos carcinogenesis
The development of transgenic mice carrying the c-fos transgene controlled 
under a regulatable metallothionein promoter (MT), demonstrated that high levels of 
fos could be induced in different cellular backgrounds and these mice did not develop 
bone neoplasms (Ruther et al., 1985). The targeted expression of a c-fos transgene in 
mice under an H2-Kb MHC promoter impaired the immune system, however no 
lymphoid or thymic neoplasms developed (Ruther etal., 1988).
Chimeric mice were generated using ES cells transfected with a MT c-fos 
transgene and high expression was maintained during development resulting in the 
formation of chondrogenic sarcomas irrespective of the degree of chimerism (Wang et 
al., 1991). An important observation was the specificity of the tumour formation. 
Although the MT fos oncogene was expressed in other tissues there was no tumour 
development. These results are in contrast with previous findings of the same 
laboratory as they previously indicated that the target was the osteogenic progenitor 
cells and not chondroblasts (Ruther et al., 1989). The study conducted by Wang and 
co-workers (1991), whereby the fos genes were expressed ectopically early in
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development demonstrated that Fos could transform specific cell types different to 
those commonly targeted by the v-fos oncogene.
The expression of c-fos under the control of an H2-Kb MHC promoter coupled 
with a 3’ FBJ-MuSV LTR resulted in osteosarcoma formation with a short latency 
(Grigoriadis et al., 1993). The tumours grew rapidly in all bones with evidence of 
osteoblastic activity. They exhibited a high degree of neovascularisation and were 
highly invasive with an increased mitotic index. Cell lines derived from these tumours 
were morphologically transformed and displayed the characteristics of osteoblastic 
gene expression (Grigoriadis et al., 1993). Substitution of c-fos for fosB or c-jun does 
not result in osteosarcoma formation (Grigoriadis et al., 1993), contradictory to 
previous evidence that highlighted a transforming role for the fosB gene when 
expressed under the transcription signals of the FBR-MuSV LTR (Schuermann et al., 
1991).
The mouse epidermis has been successfully used as a model to investigate the 
role of oncogenes in neoplastic development (Balmain et al., 1984; Quintanilla et al., 
1984; Brown et al., 1986; Greenhalgh and Yuspa 1988). Fos oncogenes have been 
implicated in the formation of epidermal tumours. The introduction of the v-fos 
oncogene into papilloma cell lines expressing an activated Ha-ras oncogene resulted 
in tumour formation when injected into nude mice. In contrast papilloma cell lines 
expressing E1A or myc oncogenes did not form tumours, implying a role for v-fos in 
the generation of these epidermoid malignancies. These investigators proposed and 
later confirmed that the tumours formed through a co-operation event with v-ras and a 
nuclear oncogene with the properties of a transcriptional activator, such as the v-fos 
oncogene. The co-operative link was established through the injection of 
keratinocytes infected with v-ras and v-fos MuSVs into nude mice which induced the 
formation of squamous cell carcinomas (Greenhalgh etal., 1990).
Collectively, these studies indicate the role of fos oncogenes and AP-1 family 
member components in experimental models of oncogenesis and a role for ras and fos 
oncogenes in this In vivo model of oncogene co-operation.
The disruption of c-fos in mice by homologous recombination (Johnson et al, 
1992b; Wang et al., 1992), resulted in mice with retarded growth and a low survival 
rate (Johnson et al., 1992b). In addition, the disruption of the c-fos proto-oncogene 
conferred abnormalities in bone formation, reduction of the cartilaginous tissues and 
hypertrophy of the chondrocytes, and furthermore, FACS analyses demonstrated an 
impaired function of haemopoetic cells (Wang etal., 1992).
Cells derived from the fos -/- mice were used to investigate the role of AP-1 in 
tumourigenesis. The proliferative rate of 3T3-like cells from fos -I- mice were not
30
substantially different from fos +/+ mice (Hu etal., 1994), suggesting a redundant role 
of AP-1 components in cellular proliferation, contradictory to other observations (Holt 
et al., 1986; Nishikura and Murray, 1987; Riabowol et al., 1988). In fos -/- cells the 
expression of other fos family members, fra-1 and fra-2 as well as jun family members 
were variable after induction by growth factors and phorbol esters, but the level of AP- 
1 binding activity remained unchanged (Hu et al., 1994). Transformation studies with 
fos -I- mice showed that there was no significant difference in foci formation induced 
by oncogenes that function upstream of AP-1 in the signal transduction cascade 
including v-raf, v-src, and v-raf, as compared to wild type fos +/+ cells.
The previously discussed co-operation of ras and fos oncogenes as an 
essential factor in the development of epidermal neoplasia was further examined using 
the fos null mice. In these studies, fos -/- mice were treated with phorbol esters that 
resulted in the formation of epidermal tumours. The fos -I- cells isolated from these 
mice were transfected with a virus encoding the ras oncogene and grafted onto the 
skin of recipient mice and no tumours formed (Saez et al., 1995). The result indicated 
that the fos null mutation impairs the initiating signals from the viral ras oncogene and 
that c-fos was required for tumourigenicity in vivo.
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1.4 SIGNALLING PATHWAYS THAT FUNCTION THROUGH AP-1
The induction of c-fos and c-jun transcription is one of the earliest nuclear 
responses to a wide variety of extracellular stimuli and is thought to be crucial in 
mediating cellular proliferation (Curran and Franza, 1988; Herschman, 1991).
A simple diagrammatic representation of the growth factor and oncogene 
signal transduction pathways that function upstream of AP-1 with regards to EGF and 
ras are detailed in Figure 1.1. The Integrin signalling pathway through the extracellular 
matrix (ECM), is also highlighted. The signal transduction pathway described shows 
that the transactivation and down-regulation of AP-1 target genes can function through 
growth factor receptors, i.e., EGF and oncogenic ras.
1.4.1 ras signal transduction pathway
The expression of c-fos in mammalian cells and ensuing AP-1 activity is 
regulated by a signal transduction pathway that involves the small GTP-binding protein 
p21rasand downstream kinases (Karin, 1995). The protein kinase Raf-1 is a direct 
target of the ras proto-oncogene (Leevers et al., 1994), and activated Raf-1 regulates 
the c-fos promoter in a signal-dependent manner (Jamal and Ziff, 1990). The 
activation of Raf-1 by p21ras results in the phosphorylation of MEK-1, a dual specificity 
MAP kinase kinase that phosphorylates Mitogen Activated Protein Kinases (MAP 
Kinases), on Tyrosine and Threonine residues. MAP kinases were originally identified 
as insulin regulated kinases that were activated by phosphorylation on Tyrosine and 
Threonine residues (Ray and Sturgill, 1987). The MAP kinases can phosphorylate a 
host of substrates, and upon mitogenic stimulation the MAP kinases translocate to the 
nucleus (Chen et al., 1992), where they phosphorylate their target proteins such as the 
transcriptional activators. Elk-1 is a transcriptional activator that is a member of the 
Ternary Complex Factors (TCF), complexes with SRF (Hipskind et al., 1991). The 
phosphorylation of TCF/Elk-1 by MAP kinases in the c-fos promoter stimulates 
transcriptional activity, regulating c-fos induction (Karin, 1995). The JNK/SAPK 
pathway is a stress response system activated by extracellular signals such as growth 
factors, cytokines and UV irradiation (Fanger et al., 1998). The pathway is activated 
through the MAPK cascade resulting in the phosphorylation of JNK/SAPK. The JNKs 
phosphorylate the transcriptional activation domains of the transcription factors ATF2, 
Elk-1 and c-Jun, increasing their transcriptional activity.
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1.4.2 Epidermal growth factor signal transduction pathway
The mitogen stimulation of c-fos transcription is a paradigm for a gene 
regulated via the ras pathway. Mitogens such as EGF relay their signals from the cell 
surface to the nucleus by a biochemical pathway that includes cellular proto­
oncogenes as key components. These series of events are triggered by the 
interaction of EGF with its cognate receptor, c-ErbB resulting in the activation of 
receptor and non-receptor tyrosine kinases (Pazin and Williams, 1992). The signal 
being relayed through c-ras via accessory proteins such as Ptdlns 3-kinase (PI3 
kinase), through the above described Raf-1 and MAP kinase cytoplasmic signalling 
cascade (Bollag and McCormick, 1991).
1.4.3 c-jun Tam-67 dominant-negative deletion mutant
The c-jun proto-oncogene can transform rat-1 and primary embryo cells when it 
is transcriptionally driven under Mo-MuSV LTR and co-expressed with ras oncogene 
(Schutte etal., 1989a; 1989b).
Deletion analysis of c-jun revealed that the N-terminus contains a 
transactivation domain (Angel et al., 1989). Alani and co-workers (1991), performed 
investigative transactivation and transformation assays of c-jun deletion mutants. 
These experiments demonstrated a direct correlation between c-jun induced 
transformation and the N-terminal transactivation domain. Similar N-terminal deletion 
mutant studies conducted with the v-jun oncogene reversed transformation induced by 
ras, src, Polyoma-mT and v-fos oncogenes in vitro (Lloyd et al., 1991). The deletion 
mutant efficiently suppressed transcriptional activation by oncogenes and phorbol 
esters and furthermore reduced Cathepsin L mRNA abundance, an AP-1 target gene.
The c-jun deletion mutant Tam-67 lacks the amino acids 1 to 123 that encodes 
for the N-terminal transactivation domain of the c-jun proto-oncogene. Tam-67 has 
been shown previously to suppress transformation by SV40, ras, and phorbol esters 
(Brown et al., 1993; Brown et al., 1994). This signified a role for the truncated 
dominant negative deletion mutant of c-jun, Tam-67 in the regulation of oncogenic 
transformation by the AP-1 transcription factor.
The mechanism of inhibition by c-jun deletion mutant, Tam-67 was elucidated 
using chimeric proteins whereby the leucine zipper of Tam-67 was replaced with the 
leucine zippers of GCN4 and c-fos. The DNA binding, inhibition of c-jun induced 
transactivation and TPA/ras-induced transformation studies of the chimeric protein 
revealed that only the Tam/Fos protein inhibited AP-1 induced transactivation and
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TPA/ras-induced transformation. The Tam/Fos protein is an equally potent inhibitor of 
transactivation and transformation, with respect to Tam-67 protein. The results of 
these studies suggests that Tam-67 inhibits AP-1 mediated processes by interacting 
with endogenous Jun or Fos family members, by which it interferes with AP-1 function, 
via a quenching mechanism. In contrast, the Tam/GCN4 proteins fail to inhibit the 
transcriptional activation of an AP-1 reporter gene in vivo which indicates that blocking 
of all the available AP-1 sites would require a very high concentration of Tam/Tam 
homodimers (Brown etal., 1994). Therefore, the inhibition of AP-1 function by Tam-67 
is more easily achieved by quenching the transcription factor activity, rather than 
blocking the enhancer or promoter elements of the AP-1 responsive genes.
A previously described model for a blocking and quenching mechanism of 
Tam-67, (Brown et al., 1993), is shown by Figure 1.4. In the blocking mechanism, 
shown in the top half of Figure 1.4, the Tam-67 homo-dimerises and binds DNA at AP- 
1 sites, thus blocking the binding of AP-1 proteins, the Jun and Fos family members, 
to the DNA. The Tam-67 homodimers have no transactivation domain so AP-1 
transcription would blocked. In the quenching mechanism, shown in the lower half of 
Figure 1.4, the Tam-67 dimerises with a wild-type Fos family member to produce an 
inactive or less active dimer that can bind DNA, but cannot, or can only weakly activate 
transcription. The effects of the wild-type AP-1 components, the Fos family members, 
would be quenched, as they would be inactivated through the formation of dimers with 
Tam-67. In addition, the quenching mechanism also blocks the binding of unbound 
wild type Fos/Jun pairings to AP-1 sites that are already bound by Tam-67/Fos 
heterodimer.
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Figure 1.4 
Tam-67 inhibits activation of AP-1 responsive genes
Potential mechanisms to explain inhibition of AP-1 via Jun and/or Fos function 
by the dominant-negative c-jun mutant, Tam-67. The RNA polymerase and general 
transcription factors are shown interacting with a target gene’s promoter. The Jun and 
Fos proteins represent the various members of the families of leucine zipper proteins, 
are shown forming, Tam/Fos and Tam/Tam dimers that are binding DNA at an AP-1 
site.
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1.4 AP-1 DOWNSTREAM TARGET GENES
AP-1 is an essential component in transformation by oncogenes which function 
up-stream of the growth factor-ras-raf-signal transduction pathway. Oncogenic 
transformation of fibroblasts is largely dependent upon AP-1 activity. Through AP-1, v- 
fos can adapt a variety of cell functions. AP-1 binds to DNA consensus sequences of 
downstream effector genes thereby controlling transcriptional regulation of effector 
genes. It was postulated that through this method of regulatory control AP-1 can 
induce or repress the expression of effector genes responsible for the transformed 
phenotype directly or indirectly through secondary signal transduction targets. In 
addition, v-fos exerts control upon signal transduction pathways that permits 
communication between the plasma membrane and the nucleus (Bortner, 1993).
The malignant transformation of cells requires altered patterns of gene 
expression and the regulation of transcriptional control can be altered by the 
transcription factor-type oncogenes such as v-fos (Bortner 1993). The identities of the 
genes regulated by the v-fos oncogene can provide an insight into the changes at the 
cellular level that accompany the altered gene expression during the multi-step 
process of carcinogenesis. It can also identify potential targets for therapeutic 
intervention (Aoyama and Klemenz, 1993). The extracellular proteases and the 
components of the ECM are de-regulated by the oncogene v-fos and their expression 
can have important consequences on invasive and metastatic behavior.
Our laboratory (Hennigan et al., 1994; Lamb et al., 1997a; 1997b), and others 
(Braselmann et al., 1992; Jooss and Muller, 1995; Rupp et al., 1998), have identified 
several direct and indirect AP-1 target genes which encode regulatory proteins, 
cytoskeletql and structural proteins several of which contain functional AP-1 binding 
sites that have been linked with the process of metastasis. This includes Ezrin, CD44, 
profilin, talin, collagenase, transin, c-jun, fra-1, interleukin-2, cathepsin L, laminin 
binding protein and mac2, all of which are involved in morphological transformation. A 
negative regulatory effect is exerted by v-fos upon the c-fos, and erg-1 promoters, 
heat shock 70 promoter, the glucocorticoid receptor and the TGF-|3 inhibitory element 
in the transin gene promoter (Jooss and Muller, 1995).
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1.5 CELL LINES
The cell lines used herein were all derived from the parental untransformed 
208F fibroblast cell line, itself a derivative of fibroblast Rat-1 cells. Figure 1.5 details 
the morphology of confluent and sub-confluent cell lines used in this study viewed with 
phase contrast optics at 100x magnification.
The 208F cells (Figure 1.5, [a]), are flat in appearance, undergo density 
dependent growth arrest and do not form foci at confluence. The FBR cell line (Figure
1.5 [b]), are FBR v-fos transformed 208F fibroblasts and are highly retractile, bipolar 
cells that readily form foci and their growth is not density arrested. 208F cells 
mitogenically stimulated with EGF growth factor at 24 and 48 hours (not shown), 
results in transformation of 80% of the culture. These cells are of a bipolar 
morphology, they form foci and their growth is not density arrested. The RAS cell line 
(Figure 1.5 [c]), are K-ras transformed 208F cells that are of an irregular transformed 
morphology. They form foci and their growth is not density arrested. The FBR TAM67 
cell line (Figure 1.5 [d]), are FBR cells expressing the dominant negative deletion 
mutant of c-jun, Tam-67. These cells are flat revertants.
The transformation characteristics of the described cell lines are summarised in 
Table 1.4.
The FBR cell line consitutively express v-fos, therefore AP-1 activity is also 
constitutive. The EGF treatment of 208F cell line increases AP-1 activity through the 
previously described growth factor signal transduction cascade. The RAS cell line 
increases AP-1 activity through the previously described ras oncogene signal 
transduction pathway. The FBR TAM67 cell line inhibits AP-1 activity.
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Figure 1.5
Morphological characteristics of cell lines
This figure details the morphology of confluent and sub-confluent cell lines 
used in this study viewed with phase contrast optics at 100x magnification, (a), depicts 
208F fibroblasts, (b), depicts FBR fibroblasts, (c), depicts FBR TAM67 fibroblasts and 
(d), depicts RAS fibroblasts at sub-confluent and confluent densities.
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Transformation
Characteristic 208F FBR
208F 
& EGF RAS
FBR
TAM67
Agar Growth - +++ ++ +++ -
Transformed
Morphology
- +++ ++ +++ -
Focus
Formation
- +++ + +++ -
Tumourigenicity 
In vitro
- +++ ND +++ ND
Invasion
+++ +++ ++
Table 1.4
Transformation characteristics of cell lines
(Muller et al., 1984; Hawker et al., 1993; Hennigan etal., 1994; Lamb etal., 1997b).
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1.6 AIMS
The detailed research over the previous twenty years is now progressing from 
the signal transduction pathways that relay the signal to the nuclear transcriptional 
regulators, to the identity and function of their target genes. The uncovering of known 
and novel effector genes, that are probably critical to front-line tumourigenesis, 
represents a new frontier of tumour molecular and cellular biology.
The overall aim of this project was to determine the function of AP-1 in 
transformation and invasion by the identification of genes differentially expressed as a 
consequence of FBR v-fos transformation. This would be achieved using the FBR v- 
fos transformed rat fibroblasts as compared to the 208F untransformed parental rat 
fibroblasts. The aims would be accomplished by:
1: The isolation and identification of up-regulated novel and known AP-1 direct and 
indirect target genes. This would provide an insight to the biological function of each 
identified gene with regards to transformation and invasion.
2. The isolation and identification of down-regulated novel AP-1 direct and indirect 
target genes would indicate the role of AP-1 in down-regulation, potentially through a 
transrepression mechanism. Furthermore, the biological function of these genes is 
that they may act as suppressors of transformation and growth.
3: The project aims to characterise the expression of a sub-set of the up-regulated and 
down-regulated AP-1 targets in transformed phenotypes through which AP-1 is active.
4: The project would focus on up- and down-regulated AP-1 target genes to ascertain 
their function in transformation and invasion.
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Chapter 2 
Materials and Methods
2.1 MATERIALS
2.1.1 Chemicals and reagents
All chemicals not individually listed were obtained (AnalaR grade), from BDH 
Chemicals Ltd., Poole, Dorset, UK. Solutions and buffers were prepared using de­
ionized water obtained from a Millipore MilliQ P|US system.
CHEMICAL
[a-32P]dCTP~3000Ci/mmol
Agarose, ultrapure, 
electrophoresis grade 
Bicinchoninic acid solution 
Bovine serum albumin (BSA) 
Bromophenol blue 
Butan-1-ol
CsCI
CHAPS
Chloroform
CuS04
Deoxyribonucleotides
DEPC
Dimethyl formamide
Dithiothreitol
EGTA
Ethanol
Ethidium bromide 
Ficoll
SOURCE
Amersham International pic., 
Amersham, Bucks., UK
Sigma Chemical Co. Ltd.,
Poole, Dorset, UK
Fisher Scientific, UK Ltd., 
Loughborough, UK 
Boehringer Mannheim UK 
Lewis, East Sussex, UK
Sigma Chemical Co Ltd
Promega Corporation 
Southampton, UK 
Sigma Chemical Co. Ltd.
Fluka Chemika-Biochemika AG, 
Buchs, Switzerland
James Burrough Ltd.,
Witham, Essex, UK 
Sigma Chemical Co. Ltd 
Fisher Scientific UK. Ltd., 
Loughborough, UK
Formaldehyde(39%)
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Hepes 
Lysozyme 
MES 
MOPS 
RNAzol B
NaV
Paraformaldehyde 
Polyacrylamide 
PMSF 
Propan-1-ol
PVP
TEMED
Tris
T riton-X 100 
Tween 20 
Vectashield
Xylene cyanol FF 
Torula yeast RNA type IV
Biogenesis Ltd.,
Poole, Dorset, UK
Sigma Chemical Co. Ltd.
Severn Biotech Ltd., 
Kidderminster, UK
Life Technologies, Ltd., 
Paisley, UK
Sigma Chemical Co. Ltd.
Vector Laboratories 
Peterborough, UK
Sigma Chemical Co. Ltd
2.1.2 Enzymes
All DNA modifying enzymes and their buffers, except those listed below, were 
obtained from Life Technologies Ltd., Paisley, UK.
ENZYME
AmpliTaq DNA Polymerse
Calf Alkaline phosphatase
DNA’ase free RNA’ase A 
Klenow Polymerase 
M-MLV Reverse Transcriptase
SOURCE
PE Applied Biosystems 
Warrington, UK 
Boehringer Mannheim UK, 
Lewes, East Sussex, UK 
Sigma Chemical Co. Ltd.
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Pfu DNA Polymerase 
T4 DNA ligase
2.1.3 Kits
KIT
ABI PRISM DNA Sequencing Kit
Advantage cDNA Polymerase Mix
ECL western blotting detection kit
QiaFilter Midi/Maxi Plasmid Kits
Qiagen Mini Plasmid Kit
Oligolabelling Kit
PCR-Script Cloning Kit 
PCR-SELECT cDNA Subtraction Kit
PolyATract mRNA isolation system II
TA-cloning kit
ZAP-cDNA Gigapack III Gold Cloning 
ZAP-cDNA Synthesis Kit
2.1.4 General Plasticware
ITEM
Filter pipette tips 
Falcon tubes 
5ml bijous
Stratagene Ltd.
Northumbria Biologicals Ltd. 
Cramlington, Northumberland, UK
SOURCE
PE Applied Biosystems, 
Warrington, UK
CLONTECH laboratories UK Ltd. 
Basingstoke, UK 
Amersham International pic., 
Amersham, Buckinghamshire, UK 
Qiagen L td , Crawley,
West Sussex, UK 
Qiagen Ltd , Crawley,
West Sussex, UK 
Pharmacia Biotech Ltd.
St. Albans, Herts., UK 
Stratagene Ltd.
CLONTECH laboratories UK Ltd 
Basingstoke, UK 
Promega Corporation 
Invitrogen,
NV Leek, Netherlands.
Stratagene Ltd.
Stratagene Ltd.
SOURCE
Greiner Labortechnik Ltd., 
Gloucestershire, UK 
Becton-Dickinson Labware, 
Plymouth, UK 
Bibby-Sterilin Ltd.,
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20ml universals 
microcentrifuge tubes 
pipette tips
2.1.5 Miscellany
ITEM
S-200 Columns 
S-300 Columns 
S-400 Columns
SuperFect Transfection Reagent
2.1.6 Molecular weight markers
MARKER
Prestained SDS-PAGE standards
<|)X174 DNA/ Hae III fragments 
X DNA/ Hind III fragments 
100bp DNA ladder 
0.24-9.5 Kb RNA ladder
2.1.7 Membranes, paper, and X-i
ITEM
Hybond nylon membranes 
Immobilon-P 
3MM filter paper 
X-ray film (X-OMAT-AR)
Staffordshire, UK 
Elkay,
Galway, Eire
SOURCE
Pharmacia Biotech Ltd 
St Albans, Herts., UK
Qiagen Ltd , Crawley,
SOURCE
Bio-Rad Laboratories, 
Hercules, CA, USA 
Life Technologies Ltd., 
Paisley, UK
film
SOURCE
Amersham International pic., 
Amersham, Buckinghamshire, UK 
Millipore (UK) Ltd.,
Watford, Hertfordshire, UK 
Whatmann International Ltd., 
Maidstone, Kent, UK 
Eastman Kodak Co.,
Rochester, New York, USA
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2.1.8 Antibodies
ANTIBODY
anti-mouse IgG (whole molecule)-
FITC-conjugate
anti-myc antibody
horseradish peroxidase conjugated anti­
mouse Ig secondary antibody
SOURCE
Sigma Chemical Co. Ltd.,
Poole, Dorset, UK 
Genevieve Stapleton, BICR 
Amersham International pic., 
Amersham, Buckinghamshire, UK
2.1.9 Microbial host, media, and supplies
Sterile glassware and Luria-broth (LB), were prepared by BICR central services 
personnel.
ITEM SOURCE
Petri dishes Bibby-Sterilin Ltd.,
20 x 20 cm Plates Staffordshire, UK
Bacto-agar
Bacto-peptone
Bacto-yeast extract
DH5a competent E. Coli Life Technologies,
[supE44 AlacU169(cp80 lacZAM15) hsdR17 Paisley, UK 
recA1 endA1 gyrA96thi-1 relA1]
Ex-Assist Stratagene Ltd
INVaF' competent E. Coli Invitrogen,
[F' supE44 AlacU169(cp80 lacZAM15) NV Leek, Netherlands. 
hsdR17 recA1 endA1 gyrA96thi-1 relA1]
SOLR strain Stratagene Ltd
[e14-(mcrA),A(mcrCB-hsdSMR-mrr)171, 
sbcC, recB, recJ, umuC@::Tn5(kanr) uvrC, 
lac, gyrA96, relA1, thi-1, endA1, lR[F’ proAB 
laclq ZAM15]Su- (nonsuppressing)
XL-1 Blue MRF’ competent E.coli Stratagene Ltd.
[A(mcrA)183A(mcrCB-hsdSMR-mrr)173 Cambridge, UK
endA1 supE44 thi-1 recA1 gyrA96 relA1 
lac[F’ proAB laclq ZAM15 Tn10 (TetR)]
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NZY broth 
Tryptone
Ampicillin Sigma Chemical Co. Ltd.,
Kanamycin Poole, Dorset, UK
Tetracycline
2.1.10 Plasmid vectors
VECTOR
pBluescript SK (+/-) 
pBSK(+) rFRP 
pCR2.1
pCR-Script
pcDNA3.1 (-)/Myc-HisA/B 
pEGFP-N1
SOURCE 
Stratagene Ltd. 
Innogenetics 
Invitrogen,
NV Leek, Netherlands 
Stratagene Ltd 
Invitrogen,
NV Leek, Netherlands. 
Clontech Laboratories UK
2.1.11 Cell culture media and supplies
Sterile glassware, PE, PBS, and water were prepared by BICR central services 
personnel.
ITEM
Freezing vials 
Round coverslips (19mm) 
Cell culture plastic dishes 
FCS
Dimethyl sulphoxide (DMSO) 
L-glutamine
SOURCE 
A/S Nunc,
Roskilde, Denmark 
Merck Ltd.,
Lutterworth, Leics.,UK 
Becton-Dickinson Labware, 
Plymouth, UK 
Bioclear UK Ltd.
Devizes, Wilts, UK 
Fisher Scientific UK. Ltd., 
Loughborough, Leicestershire, UK
Life Technologies, Paisley, UK
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DMEM Sigma Chemical Co. Ltd.,
Trypsin Poole, Dorset, UK
Sodium bicarbonate 
Sodium pyruvate
2.1.12 Cell lines
208F cell line was obtained from Dr.C.Quade and is a subclone of the Rat-1 
fibroblast cell line. FBR cell line was originally obtained from Dr. Tom Curran and are 
transformed, non-producer 208F’s infected with FBR-MuSV. The Ras transformants 
used in this study were generated by Lynn McGarry at BICR, by transfection of 208F’s 
with c-Ha-ras expressing plasmid, PI1-2rasA, obtained from Dr. Dimitrios A Spandidos. 
The FBR Tam67 revertants used in this study were generated by Kostas D.Katsanakis 
at the BICR by transfection of FBR cell line with c-jun dominant negative mutant, TAM- 
67 expressing plasmid, pCMV-Tam67, obtained from Dr. Michael Birrer. Cos-7 cells 
were obtained from Joe Winnie, BICR.
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2.2 METHODS
2.2.1 Mammalian cell culture
All cells were maintained in DMEM supplemented with 10% FCS, 0.3% sodium 
bicarbonate, 1 mM sodium pyruvate and 2mM glutamine and were passaged every 3-4 
days as a 1:5 or 1:10 split ratio using 0.25%trypsin in PBS, with the exception of FBR. 
The FBR cell line were aspirated off the culture plate.
All cell lines were stored in DMEM supplemented with 20% FCS, 0.3% sodium 
bicarbonate, 1mM sodium pyruvate and 2mM glutamine, 10% DMSO as frozen stocks 
in liquid N2.
2.2.2 RNA isolation from cultured mammalian cells
Extraction of total RNA from mammalian cells was carried out by following the 
manufacturer’s instructions for RNAzol B. For adherent cells, medium was aspirated 
from sub-confluent cultures in 10cm petri dish and 2.5ml of RNAzol B was added to 
lyse the cells which were further perturbed by brisk scraping. Lysed cellular material 
was transferred to a sterile 12ml polypropylene tube containing 500ml of chloroform. 
After vigorous shaking the RNAzol B/CHCI3 mix was kept on ice for 5 minutes and then 
spun in a cold (4°C), centrifuge at 5,640g for 15 minutes. Approximately 3ml of upper 
aqueous phase was carefully removed and added to a fresh tube containing 3ml of 
cold isopropanol, and this was kept on ice for 15 minutes before subsequent 
centrifugation at 10,000g for 15 minutes in a cold microfuge. The RNA pellet was 
washed with 5ml of 70% ethanol and traces of ethanol were removed by aspiration. 
The RNA pellet was then partially air dried before being resuspended in 50^1 of DEPC- 
treated sterile H20. This total RNA preparation was quantified by UV- 
spectrophotometry at 260nm and 10|ig was run on a Northern gel. The integrity of the 
28S and 18S ribosomal RNA species were examined by visual inspection. Intact total 
RNA was considered suitable for use in the isolation of polyA+ mRNA.
2.2.3 PolyA+ mRNA isolation
PolyA+ mRNA was isolated using the components provided by the Promega 
PolyATract mRNA isolation kit (small-scale). A sterile 1.5ml polypropylene tube 
containing up to 1mg of total RNA, in 500ml of Rnase-free H20, was heated for 10 
minutes at 65°C. Biotinylated poly d(T), oligonucleotide was quickly added to the RNA
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that was mixed gently and allowed to cool to room temperature, during which time the 
biotinylated polydT annealed to the polyA tail at the 3’-end of mRNAs. Streptavidin 
magnetic particles were washed thoroughly in low strength SSC buffer and the 
RNA/biotinylated polydT was added to the particles. The biotinylated poly d(T), with 
bound mRNA, bound to the streptavidin-coated magnetic particles. Careful washing of 
the magnetic particles ensured that non-mRNAs were removed from the preparation 
and mRNAs were finally eluted in 250pl of Rnase-free H20. One tenth volume of 3M 
NaOAc (pH 5.2), and three volumes of 100% ethanol were added to the mRNA which 
was stored at -70°C for one hour. It was then spun for 20 minutes at 12,000g in a 
microfuge (4°C), and washed in 70% ethanol. Traces of ethanol was removed by 
aspiration and the mRNA was partially dried by lyophilisation in a speedivac. The 
mRNA was solubilised in 10-12pl of Rnase-free H20  and quantified by UV- 
spectophotometry at 260nm.
2.2.4 Northern analysis of RNA
Total RNA samples (1 Opig), in Rnase-free H20  were mixed to a volume of 15pl 
with RNA loading buffer (50% formamide, 33.3% formaldehyde, 5% 5X MOPS {0.1 M 
MOPS, 50mM sodium acetate, 5mM EDTA, [pH 8.0]}), and heated for 10 minutes at 
65°C. The sample was snap cooled and 0.5pl RNA loading dye (50% Ficoll, 1mM 
EDTA, 0.4% bromophenol blue, 0.4% xylene cyanol), 0.5pl 10mgml'1 ethidium bromide 
was added. The samples were loaded onto a 1% agarose gel containing 10% 5X 
Mops and 18% formaldehyde. Electrophoresis was performed 3-4 hours at 100V at 5V 
cm'1 in IX Mops buffer. The RNA was visualised by UV transillumination and 
photographed before the gel was soaked in de-ionised H20 for 20 minutes to leach out 
the formaldehyde.
RNA was transferred to Hybond N' nylon membrane by upward capillary 
blotting, as described (Maniatis etal.,), using 20X SSC (3M NaCI, 0.3M sodium citrate, 
pH7), solution as transfer buffer. The membrane was UV-crosslinked using a UV 
Stratalinker 1800 (Stratagene).
Radioactive probe was stripped from the membrane by gentle agitation for 10 
minutes in 0.5% SDS solution that had been heated to 100°C. The solution was 
allowed to cool before the membrane was removed. The membrane was stored 
wrapped at 4°C.
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2.2.5 Suppression Subtractive Hybridisation
The 208F and FBR subtracted libraries were prepared using the components 
provided by the PCR-Select cDNA Subtraction kit as per manufacturers instructions. 
The method is outlined below. For each Tester and Driver and Control sample 2 ^g 
poly A+ mRNA was used as a template for synthesis of first strand cDNA with MMLV 
reverse transcriptase. After second-strand synthesis Rsa I was used to create blunt- 
ended cDNA in a size range of 0.1-2Kb. The control skeletal muscle tester was 
prepared by adding 750pg <J>X174/Hae III DNA to 1pJ cDNA.
The FBR/208F subtraction was performed in both forward and reverse. 
Therefore, each mRNA species was used as Testers and Drivers. Each Tester cDNA 
species was prepared by ligating 2\i\ Adapter 1(10^im), and 2\x\ Adapter 2(10jxm), 
independently to a 2\i\ aliquot of a 1:5 dilution cDNA, and were labelled mRNA species 
Tester 1 and Tester 2 respectively. The ligations were performed overnight at 16°C, 
after which ligase was heat inactivated in an EDTA/glycogen mix. The mRNA species 
that were not ligated to adapters were used as Driver cDNA.
The first hybridisation was performed by adding an excess of Driver cDNA to 
each Tester cDNA that was heat denatured then annealed for 8 hours at 68°C, after 
which both hybridised Tester samples were mixed and more heat-denatured Driver 
was added and incubated overnight at 68°C.
The differentially expressed cDNA’s from the forward and reverse FBR/208F 
subtraction and control skeletal muscle/control skeletal muscle <|>X174/Hae III 
subtraction were filled in with a pre-incubation step at 75°C then PCR amplified using a 
Perkin-Elmer DNA Thermal Cycler 480. The first PCR was performed using PCR 
primers to the outer Adapter sequences, Primers 1 and 2, for 30 cycles (each cycle 
comprised 30 seconds at 94°C to denature, 30 seconds at 60°C to anneal and 1 
minute 30 seconds at 72°C to extend). The second PCR was performed using PCR 
primers to the inner Adapter sequences, Nested Primers 1 and 2, using a 1:10 dilution 
of first PCR reaction as a template for 16 cycles (each cycle comprised 30 seconds at 
94°C to denature, 30 seconds at 68°C to anneal and 1 minute 30 seconds at 72°C to 
extend).
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2.2.6 Cloning of PCR products
Components of the TA cloning kit were used to clone secondary PCR reaction 
products of the subtracted cDNA libraries. The ligation mixes were prepared according 
to the kit instructions. The TA cloning transformation procedure would usually result in 
white kanamycin resistant recombinant colonies developing against a background of 
blue non-recombinant colonies on LB bactoagar plates containing 40 i^g ml'1 kanamycin 
and X-Gal. Recombinant colonies were picked by sterile toothpick and propagated, 
with shaking overnight at 37°C, in 3ml of LB medium containing 40pig ml'1 kanamycin. 
The propagated 3ml cultures were then used in further manipulations.
2.2.7 Wiggle PCR of cloned subtracted cDNA library products
One pil of an 3ml overnight bacterial culture was used as a template for PCR as 
per Perkin-Elmer PCR kit instructions using 1 ng ul'1 final Primer concentration. The 
PCR primers used were M13 R and T7 or Nested Primers 1 and 2. The cycling 
parameters were 3 minutes at 94°C; each cycle of 35 comprised 30 seconds at 95°C 
to denature, one minute at 55°C to anneal and 1 minute 30 seconds at 72°C to 
extend; followed by 10 minutes at 72°C.
2.2.8 Southern analysis of DNA
Following electrophoresis of DNA samples, the agarose gel was photographed 
and DNA was depurinated by soaking the gel in 0.25M HCI for 15 minutes with gentle 
shaking. The gel was rinsed in de-ionised H20  and DNA was transferred for 18 hours 
onto Hybond N+ nylon membrane by upward capillary blotting using 0.4M NaOH as the 
transfer buffer. After transfer, the membrane was rinsed in 2X SSC and air-dried 
before hybridisation. Membranes in sandwich boxes were prehybridised for 4 hours at 
65°C with shaking, in buffer containing 5X SSPE (0.9M NaCI, 0.05M sodium 
phosphate and 5mM EDTA, pH7.4); 5X Denhardt’s solution (0.1% BSA, 0.1% PVP and 
0.1% Ficoll); 0.5% SDS and 1mgml'1 torula yeast RNA. The hybridisation solution was 
then replaced with fresh solution containing the radio-labelled probe (prepared as in 
section 2.2,9), at a concentration of 1-3X106 counts ml'1, and hybridised at 65°C 
overnight. The following day, the hybridisation buffer removed and replaced with 1X 
SSC, 0.1% SDS wash buffer for fifteen-minutes at 65°C, followed by 0.1X SSC, 0.1% 
SDS wash buffer for fifteen-minutes at 65°C. The filters were then wrapped in Saran 
wrap, and exposed for a period of time, which was influenced by the strength of signal
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detected by a hand-held mini-monitor, to Kodak X-OMAT AR film, in cassettes with 
intensifying screens, at -70 °C.
The radioactive probe was stripped from the membrane by gentle agitation for 
10 minutes in 0.5% SDS solution which had been heated to 100°C. The solution was 
allowed to cool before the membrane was removed. The membrane was stored 
wrapped at 4°C.
2.2.9 Random-prime synthesis of radioactive probes
The DNA probes, prepared by random-prime, and used in this study were 
either restriction digest fragments or PCR products of subtracted library fragments that 
were approximately 200-800bp in length. The reagents required to label these probes 
by a random-prime technique were provided in the Pharmacia Biotech Oligolabelling 
kit. Fifty ng of DNA in a 34pil volume were denatured by boiling for 5 minutes and 
cooled immediately on wet-ice. Ten jxl of 5X Reagent mix (a buffered solution 
containing dATP, dGTP, dTTP and random hexadeoxyribonucleotides), 5jxl of [a- 
32P]dCTP (1.85 MBq), and 1pJ of Klenow fragment were added to the denatured DNA 
and incubated at 37°C for 60 minutes. Free nucleotides were removed using a 
Sephacryl S-200 HR microspin column. The column was packed by centrifugation at 
3K in a tabletop eppendorf 5415c microfuge for one minute. The random-prime 
reaction was carefully added to the column and a collection tube was fitted below the 
column. The random-prime labelled probe was collected by centrifugation at 3K for 2 
minutes and free nucleotides were retained within the column which was carefully 
removed (to a solid radioactive waste bin). One [il of the labelled probe was added to 
10mls of EcoscintA scintillant and counts per minute were measured in a Beckman 
LS5000CE scintillation counter. Total counts contained in the probe were then 
estimated and it was used immediately or stored at -20°C. Random-prime probes were 
denatured before addition to the hybridisation mix
2.2.10 Synthetic oligonucleotide synthesis and purification
Synthetic oligonucleotides were synthesised by BICR technical services 
personnel on an Applied Biosystems RNA/DNA synthesiser model 392 or 394, using 
phosphoramidite chemistry, according to the manufacturers instructions. 
Oligonucleotides were resuspended in 200pil sterile H20  prior to quantification by UV-
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spectrophotometry at 260nm. Primers were used at 10mM concentration for the PCR 
and sequencing reactions.
2.2.11 cDNA library synthesis and screening
An 208F cDNA library was constructed in the X ZAPII vector using the 
components provided by the ZAP cDNA synthesis kit. Construction, plating and 
screening of this library was carried out as described in the Stratagene instruction 
manual and is outlined below.
Five ng of 208F polyA+ mRNA were used as a template for synthesis of first- 
strand cDNA with StrataScript Rnase H' reverse transcriptase. After second-strand 
cDNA synthesis Klenow polymerase was used to create blunt-ended double-stranded 
cDNA to which Eco Rl adaptors were ligated and then kinased. Xho I digestion then 
ensured that the double-stranded cDNA was ready, after size fractionation on a 
Sephacryl S-400 spin column, for ligation into the Eco RMXho I X ZAPII vector arms in 
a unidirectional manner. Forty-five ng of cDNA from the first column fraction, that 
contained the largest cDNAs, 90 ng from the second fraction, 45 ng from the third 
fraction and 45 ng from the fourth fraction, where each subsequent fraction contained 
smaller cDNAs were ligated into 1 i^g of Eco RMXho I X ZAPII vector.
One \x\ (1/5th volume), of each completed ligation was packaged in the X 
packaging extract provided and 1^ 1 (1/500th volume), of each packaged library was 
serially diluted in SM buffer {100mM NaCI; 15mM MgS04; 50mM Tris-HCI (pH 7.5), 
and 0.01% gelatin}, at 10°,10'1. Diluted library was mixed with 3ml molten top agar, X- 
Gal, IPTG and 200pil of XL1-Blue indicator bacteria and plated on 10cm NZY agar 
plates. In this way, the phage titre of each packaged extract and the ratio of 
recombinant (white plaques), to non-recombinant (blue plaques), phage could be 
determined. The primary library from the first column fraction (F1), contained 9.7X104 
pfuml'1 (plaque forming units per ml), the library from the second column fraction (F2), 
contained 3.1X105 pfuml'1, the library from the third column fraction (F3), contained 
3.3X105 pfuml'1 and the library from the fourth column fraction (F4), contained 8.0X104 
pfuml'1. These titres indicated that all four libraries, which contained a very low number 
of non-recombinants, had been packaged successfully.
The remaining 4/5ths volume of each ligation was also packaged as before, 
and 1X 106 pfu from pooled primary library fractions 1-4 were amplified, harvested and 
titred again. The amplified 208F library contained 7X109 pfu ml' and was now ready to 
screen for cDNAs of Clone KD1 and CD10. To screen, 0.25X10epfus from 208F were
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plated on each of four 200mm square NZY agar plates along with 1.8mls of XL-1 
plating bacteria and 30mls of molten top agar per plate. Agar plates were incubated 
overnight at 37°C and chilled for two hours prior to screening which helped to prevent 
the top agar sticking to the nylon filters. Hybond N+ membranes were then layered onto 
plates containing phage plaques and left for 2 minutes, while a duplicate filter, was 
later laid on for 4 minutes. Three orientation marks were made with a needle through 
the membrane, into the agar, and were also marked on the plate. After transfer, the 
filter was carefully lifted to ensure no dragging of the membrane across the plate, and 
placed plaque side-up on 3MM filter paper pre-wet with denaturation solution (1.5 M 
NaCI, 0.5M NaOH), for 2 minutes, and then transferred to 3MM filter paper wetted with 
neutralisation solution (1.5 M NaCI, 0.5M Tris-HCI, pH 8), for 5 minutes. Finally, the 
filter was rinsed in 2 X SSC, briefly blotted with 3MM filter paper, air-dried and UV- 
crossl inked.
Duplicate filters were prehybridised at 65°C in sandwich boxes, with shaking, in 
a solution consisting of 5X SSPE (0.9M NaCI, 0.05M sodium phosphate and 5mM 
EDTA, pH 7.4); 5X Denhardt’s solution (0.1% BSA, 0.1% PVP and 0.1% Ficoll); 0.5% 
SDS and 1 mg ml'1 torula yeast RNA for four hours. The buffer was refreshed and a 
random prime labelled radioactive probe (see section 2.2.9), at 2X 106counts ml'1 was 
added and the hyridisation continued overnight at 65°C. The next day, as much of the 
hybridisation buffer as possible was removed and replaced with 1X SSC, 0.1% SDS 
wash buffer for fifteen-minutes at 65°C, followed by 0.1X SSC, 0.1% SDS wash buffer 
for fifteen-minutes at 65°C. The filters were then wrapped in Saran wrap, and exposed 
for 48-72 hours to Kodak X-OMAT AR film in cassettes with intensifying screens. 
When developed, duplicate films were orientated against the filters using the needle 
and plate marks, and positive clones determined by matching strong signals on the 
films. Duplicate films were then orientated against the marks on the library plates and 
“positive” plaques were carefully excised from the NZY agar using a scalpel blade. 
Phage particles were eluted from the agar overnight at 4°C in 1 ml of SM buffer so that 
the screening process could continue for a further three rounds until a “positive" plaque 
was purified to homogeneity prior to Bluescript phagemid excision.
2.2.12 Bluescript phagemid excision
Bluescript phagemids were excised from X phage using the method of Vekris 
(1994). For this method cultures of the bacterial strains XL-1 Blue and SOLR at A600=1 
were prepared and equal volumes of both were combined with ExAssist helper phage 
at 108 pfu ml'1 to give rise to a main mix. One hundred and ninety five pi of main mix
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per well were dispensed into a 96-well, round bottom, polystyrene microplate. Five |xl of 
homogeneous X phage suspension was added to the main mix in the microplate which 
was then incubated for two hours with vigorous shaking at 37°C. During this time X 
and ExAssist both infect XL-1 Blue which suppresses amber mutations in gene I and 
gene II of the helper phage and consequently the Bluescript phagemid can be excised 
by gene II product and packaged in filamentous phage particles. The Bluescript 
phagemids infect SOLR and become double-stranded but ExAssist cannot replicate in 
SOLR, so there is no X phage contamination. After the incubation, various volumes 
from the microplate wells were spread on LB agar plates containing ampicillin at 10Opg 
ml'1 and kanamycin at 100mg pf1 and incubated overnight at 37°C. Under these 
selection conditions only SOLR (kanR), containing the excised double-stranded 
Bluescript phagemid (ampR), grew. These bacterial colonies were then grown in 3ml 
cultures of LB medium containing ampicillin or kanamycin from which mini-preparations 
of plasmid DNA were isolated.
2.2.13 Plasmid DNA preparation
Mini-preparations of plasmid DNA were isolated from 3ml bacterial cultures 
grown overnight in LB medium, containing an appropriate antibiotic, by QIAGEN 
plasmid mini-purification kit as per manufacturers instructions.
Cultures were pelleted by centrifugation for one minute in a microfuge at 
12,000g, resuspended in 250pl of Buffer P1 (50mM Tris-CI; 10mM EDTA, pH 8.0; and 
100mg ml'1 RNase A). Bacteria were then lysed by addition of 250pl of Buffer P2 (0.2M 
NaOH; 1% SDS). Tubes were mixed by brisk inversion and put on ice immediately. 
Detergent and protein were precipitated by addition of 350pil of ice-cold Buffer P3 (3M 
KOAc, pH 5.5), with momentary vigorous shaking. The flocculate was removed by 
centrifugation at 12,000g for ten minutes. Eight hundred and fifty pil of supernatant 
containing plasmid DNA were decanted into a QIAprep spin column and centrifuged at 
12,000g for 1 minute then the QIAprep column was washed by adding 750fxl Buffer PE 
and centrifuged twice at 12,000g for 1 minute after which the supernatant was 
discarded. The DNA was eluted from the QIAprep spin column by adding 50pl Buffer 
EB (10mM Tris.CI, pH8.5).
For midi-scale preparations of plasmid DNA from 100 ml bacterial cultures were 
grown overnight in LB medium, containing an appropriate antibiotic, by QIAfilter midi­
plasmid purification kit as per manufacturers instructions. Briefly, cultures were 
pelleted by centrifugation for fifteen minutes at 6,000g, resuspended in 10ml of Buffer
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P1 (50mM Tris-CI; 10mM EDTA, pH 8.0; and 100mg ml'1 RNase A). Bacteria were 
then lysed by addition of 10ml of Buffer P2 (0.2M NaOH; 1% SDS). Tubes were mixed 
by brisk inversion and put on ice immediately, before detergent and protein were 
precipitated by addition of 10ml of ice-cold Buffer P3 (3M KOAc, pH 5.5), and mixed 
gently by inverting 4-6 times. The lysate/flocculate was poured into a QIAfilter cartridge 
and incubated for 10 minutes at room temperature, after which the lysate was pushed 
through the filter bed using the plunger into the QIAGEN-tip 100, pre-equilibriated with 
Buffer QBT (750mM NaCI; 50mM MOPS, pH7.0, 15% isopropanol; 0.15% Triton X- 
100). The QIAGEN-tip 100 was washed twice with 10 ml Buffer QC (1.0mM NaCI; 
50mM mops, pH7.0; 15% isopropanol), then the plasmid DNA was eluted using 5 ml 
Buffer QF (1.25M NaCI, 50mM Tris, TrisCI, pH8.5, 15% isopropanol), then precipitated 
using 0.7 volumes isopropanol and centrifuged immediately for 30 minutes at 15,000g. 
The plasmid DNA was washed with 70% ethanol and resuspended in sterile H20.
2.2.14 Agarose gel electrophoresis
DNA restriction fragments from plasmids or PCR products were separated on 
agarose gels and visualised by staining with ethidium bromide and UV- 
transillumination. Typically, gels were prepared by dissolving between 0.8% and 1.5% 
electrophoresis grade agarose in 1 X TAE (40mM Tris acetate; 1mM EDTA, pH8.0). 
After being heated in a microwave to dissolve the agarose, molten gels were cooled to 
approximately 60°C and ethidium bromide added to a final concentration of 500ngml'1 
before being poured into an appropriate gel tank. Once solid, gels were placed into 
electrophoresis tanks containing 1 X TAE. Samples were mixed with one-fifth volume 
of gel-loading buffer (15% Ficoll; 0.25% bromophenol blue and 0.25% xylene cyanol 
FF), prior to being loaded into the wells of the gel. Electrophoresis was performed at 
5V cm'1. In order to estimate the size of fragments resolved by electrophoresis, 
samples were run alongside aliquots of molecular weight marker, either a Hind III 
digest of bacteriophage X DNA or an Hae III digest of bacteriophage <J>X174 DNA. DNA 
was visualised by UV transillumination and the gel photographed.
2.2.15 Restriction digestion of plasmid DNA
Approximately 250ng of plasmid DNA was digested in a final volume sufficient 
to dilute the volume of restriction enzyme added at least 10-fold. Plasmid digests were 
routinely performed using 10 units of enzyme in each reaction and were incubated at 
the recommended temperature for at least I hour. For digests of DNA requiring the
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addition of two restriction enzymes, either a buffer compatible for both enzymes was 
selected or the DNA was digested by enzyme 1, the digest checked for completion by 
agarose gel electrophoresis, and then the buffer conditions in the reaction modified to 
suit enzyme 2.
2.2.16 Purification of DNA fragments from agarose gels
Plasmid DNA was digested as described above, separated on an agarose gel 
and the fragments visualised under UV-transillumination. Agar slices, containing 
fragments of interest, were excised from the gel using a scalpel blade. The agar slices 
were inserted into Promega Wizard prep columns and these were inserted into 1.5 ml 
tubes and subjected to 5 minutes centrifugation at 12,000g. Approximately 10Opil of 
DNA solution, eluted by centrifugal force, was collected in the 1.5 ml tube and was 
ready for use in further manipulations.
2.2.17 Ligation of DNA fragments into plasmid DNA
The DNA fragment to be inserted was digested as above to produce blunt ends 
or complementary sticky ends to the vector, and then isolated by gel electrophoresis 
and purified as described in section 2.2.16. To prevent the restricted plasmid DNA 
from re-ligating without an insert, it was first dephosphorylated. Plasmid was digested 
with the required restriction enzyme in the presence of 5 units calf intestinal alkaline 
phosphatase. Enzyme was then removed by extraction with an equivalent volume of 
equilibrated phenol/chloroform and plasmid DNA was then ethanol precipitated. For 
ligation, 100ng of vector and three times the molar amount of insert DNA were mixed 
on ice in a reaction containing ligase buffer (66 mM Tris-HCI, pH 7.5; 5mM MgCI2; 
1mM rATP; I mM DTT), and T4 DNA ligase (5-10 units), and incubated overnight at 
12°C.
2.2.18 Transformation of bacterial cells with recombinant plasmid DNA
Competent E. coli were thawed on ice, and 10Opil aliquots transferred to pre­
chilled 6ml polypropylene tubes. Approximately 100ng of recombinant plasmid DNA 
was added to the cells and gently mixed by stirring with a pipette tip. After incubation 
on ice for 30 minutes, cells were heat-shocked at 42°C for 45 seconds and then 
placed on ice for a further 2 minutes. Four hundred and fifty ptl of SOC medium (2%
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bacto-tryptone; 0.5% bacto-yeast extract; 20mM glucose; 10mM NaCI and 10mM 
MgCI2), was then added to the mixture and the cells were incubated at 37°C for 1 hour 
on an orbital shaker at 225 rpm. A selection of cell volumes were then spread on L- 
broth plates containing 2% bactoagar supplemented with the appropriate antibiotic. 
Plates were incubated in an inverted position overnight at 37°C.
2.2.19 Automated chain termination cycle sequencing
Both cloned DNA and PCR products were sequenced using a Biosystems ABI 
373A automated DNA sequencer operated as a core service by staff at the BICR. 
Twenty to one hundred ng of plasmid or 50-1 OOng of a PCR reaction were mixed with 
4mM of sequencing primer and 8pil of 'Dyedeoxy' reaction mix in a total reaction 
volume made up to 20pil with water. DNA was subjected to ‘cycle sequencing’ in a DNA 
thermal cycler for 25 cycles (each cycle comprises 15 seconds at 96°C to denature 
DNA, 1 second at 50°C for annealing, and 4 minutes at 60°C to extend). The products 
were ethanol precipitated, washed with 70% ethanol, and dried in a speedivac prior to 
being re-suspended in loading buffer (95% formamide; 25mM EDTA, pH 8; 1.5mgml'1 
dextran blue). Samples were then denatured by heating at 94°C, chilled on ice, and 
subjected to electrophoresis as advised by the manufacturer.
2.2.20 Transient SuperFect transfection of COS-7 cells
Medium was aspirated from COS-7 cells growing at 60-75% confluence in a 
10cm culture dish and the adherent monolayer was washed once with PBS. A 
transfection mix of 742pil serum-free DMEM, 50jil of SuperFect (3mg ml'1), and 8^g of 
sterile, supercoiled plasmid DNA (1mg ml'1), was vortexed and incubated at room 
temperature for 10 minutes, before the addition of 5.6ml DMEM supplemented with 
10% FCS, and applied to the cells. The cells were then placed in a 37°C incubator for 
three hours, after which the transfection mix was removed by aspiration and the cells 
re-fed with DMEM supplemented with 10% FCS. Following a 72 hour incubation at 
37°C the cells were harvested for expression analysis ( see section 2.2.21).
2.2.21 Western analysis of Myc-tag/ DIF, Myc-tag/ FRP fusion proteins
Medium was aspirated from transiently transfected COS-7 cells and FRP stable 
transfectant FBR cells and washed twice in ice-cold PBS, and lysed in a solution 
comprising 10mM Hepes (pH 7.4); 1mM NaV; 2.5mM MgCI2; 1mM EGTA; 10%
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glycerol; 10Omg ml"1 CHAPS and 1 mM PMSF, using a disposable cell scraper to assist 
homogenisation. Lysates were incubated on ice, for 30 minutes and centrifuged at 
14000rpm for 20 minutes at 4°C in a bench-top microfuge to pellet cell debris. The 
resultant supernatants were designated as the soluble (S), fractions and stored in 
aliquots at -70 °C until needed.
Protein concentrations were determined by performing a bicinchoninic acid 
colourimetric assay. Ten pi aliquots of a 1:9 dilution of soluble and insoluble fractions 
were incubated with 200pl of reaction mix (1 volume of 4% CuS04 to 50 volumes 
bicinchonic acid solution), at 37°C for 30-45 minutes. Absorbency was measured at 
590nm wavelength light using a Dynatech MR7000 Spectrophotometer. The standard 
curve consists of 6 BSA standards (80, 100, 400, 800, 1000, 2000 pg/ml BSA/H20  
concentration).
For detection of Myc-tag/ DIF, Myc-tag/ FRP fusion proteins by immunoblotting, 
80pg of proteins were resolved by electrophoresis through an 10% SDS-PAGE pre­
cast gel. Samples were prepared for electrophoresis by mixing 80pg of protein with 
20% volume of 5X sample buffer (60mM Tris.HCI, pH 6.8; 2% SDS; 0.1% 
bromophenol blue; 25% glycerol), boiling the samples for 10 minutes, chilling briefly on 
ice, and then loading into the wells of the stacking gel alongside an aliquot of Broad 
range or Low range Biorad SDS-PAGE prestained molecular weight standards (205- 
7.6Kd), (employed for protein molecular weight determination). Gels were run 
overnight at 40V. Proteins were then transferred from the gel to ImmobilonP 
membrane via semi-dry electroblotting for I-3 hours using twelve layers of Whatman 
3MM paper which had been soaked in blotting buffer (60mM Tris.HCI; 50mM glycine; 
1.6mM SDS; 20% methanol). Blots were first blocked for 1 hour at room temperature 
in PBS containing 5% non-fat milk powder; 0.1% Tween 20 and subsequently 
incubated in solution with a 1:10 dilution of anti-Myc mouse monoclonal antibody 
overnight at 4°C. Following thorough washing with PBS containing 0.1% Tween 20 and 
incubation with a 1:5000 dilution of a horseradish-peroxidase conjugated anti-mouse Ig 
secondary antibody for one hour, proteins were visualised using enhanced 
chemiluminescence (ECL), according to the manufacturer’s instructions.
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2.2.22 Transient SuperFect transfection of 208F, FBR, RAS and FBR 
Tam 67 cells
Medium was aspirated from cells growing at 60-75% confluence on sterile, 
19mm glass coverslips in a 12 well culture plate and the adherent monolayer was 
washed once with PBS. A transfection mix of 75pil serum-free DMEM, 7.5pil of 
SuperFect (3mg ml'1), and 1.5jxg of sterile, supercoiled plasmid DNA (1mg ml'1), was 
vortexed and incubated at room temperature for 10 minutes, before the addition of 
400pil DMEM supplemented with 10% FCS, and applied to the cells. The cells were 
then placed in a 37°C incubator for three hours. After this the transfection mix was 
removed by aspiration and the cells were re-fed with DMEM+10% FCS. Following a 24 
hour and 48 hour incubation at 37°C the cells were fixed for indirect- 
immunofluorescence expression analysis ( see section 2.2.23).
2.2.23 Indirect-immunofluorescence of Myc-tag fusion proteins in 
transiently transfected cells
Medium was removed, by careful aspiration, from transiently transfected 208F, 
FBR, RAS and FBR Tam 67 cell lines, cultured on 19mm diameter coverslips in 12- 
well plates, at twenty four hours post-transfection. Cells were washed in PBS and 1ml 
of 3% paraformaldehyde (pH 7), was added. After a twenty minute incubation at 37°C 
the PBS wash was repeated and 1ml of PBS/glycine/ 0.01% Triton X-100 
permeabilisation buffer was added to the cells over five minutes. Excess 
permeabilisation buffer was removed by aspiration and the cells were washed 
extensively in PBS. A neat concentration of mouse monoclonal anti-myc was added 
and maintained on the cells for one hour at room temperature, then removed by 
aspiration and three PBS washes. This was followed by the addition of FITC- 
conjugated anti-mouse IgG, 1:200 dilution and TRITC-conjugated phalloidin 1:1,000 
dilution in blocking solution. A one hour incubation followed and excess FITC/TRITC 
was removed by washing and the coverslips were dried in air, mounted on glass slides 
with vectashield reagent and sealed with nail polish. The transfected cells were then 
analysed on a Biorad MRC-600 laser scanning confocal imaging system.
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2.2.24 Stable SuperFect transfection of FBR cells with pCDNA3.1 A/FRP 
and pCDNA3.1A
Medium was aspirated from cells growing at 60-75% confluence on 10cm 
culture dishes and the adherent monolayer was washed once with PBS. A transfection 
mix of 742|liI serum-free DMEM, 50jxl of SuperFect (3mg ml'1), and 8 i^g of sterile, 
supercoiled plasmid DNA (1mg ml'1), was vortexed and incubated at room temperature 
for 10 minutes, before the addition of 5.6mls DMEM supplemented with 10% FCS, and 
applied to the cells. The cells were then placed in a 37°C incubator for 16 hours. After 
which the transfection mix was removed by aspiration and the cells re-seeded by 
splitting to one in three with DMEM+10% FCS supplemented with 400[ig/ml G418 
selection antibiotic. The media was changed every 48 hours. After incubation at 37°C 
for 10-14 days, the untransfected cells died off and the transfected cells formed 
colonies. Twelve FRP expressing colonies, and six neo colonies were harvested by 
ring cloning and propagated. The cells were plated onto sterile glass coverslips and 
fixed for indirect-immunofluorescence expression analysis (see section 2.2.23), and 
the proteins from the positive colony, clone 6, were harvested for western blot analysis 
(see section 2.2.21).
2.2.25. Preparation of conditioned media
Cells were passaged in DMEM supplemented with 10% FCS and grown to 
subconfluence. The medium was removed and the plates were washed 3 times with 
PBS. The medium was changed to serum-free DMEM and the dishes were incubated 
in a tissue culture incubator at 37 °C for 72 hours. After this time the medium was 
harvested and the expression of secreted FRP was analysed by western blotting using 
30[x\ neat conditioned media per well (see section 2.2.21).
2.2.26. Determination of cell proliferation
Determination of cell proliferation was performed according to Tavoloni et al, 
(1994), with minor modifications. Cells were trypsinized, counted and plated at 2x104 
cell density into duplicate 30mm falcon dishes in DMEM supplemented with 10% FCS. 
Cells were counted using a cell counting chamber (Neubauer), every day for six days.
64
2.2.27. Growth in semi-solid medium
Methylcellulose was used to prepare semi-solid growth medium, and was 
prepared by mixing 3g methylcellulose with 200ml H20. The mix was autoclaved and 
following sterilisation it was allowed to cool and then stirred at 4°C for 24 hours in the 
cold room and continuously stirred with a magnetic stirrer.
Cells were trypsinized, counted and resuspended in DMEM supplemented with 
10% FCS. Aliquots of 2x104 cells were mixed with 10-14 ml of semi-solid medium 
(200ml H20 sterile, 3g methylcellulose, as prepared above, 22 ml 10X F10 Ham’s 
Medium, 4ml MEM minimal essential amino acids, 4ml 0.1 M Sodium Pyruvate, 5ml 
Sodium Bicarbonate, 20ml FCS, 5 ml 100X Glutamine), and plated into duplicate 10cm 
bacteriological grade dishes, -solid medium supplemented with FCS and the G418 
selection antibiotic at 400ng/ml for stably transfected clones was replaced every 4 
days.
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Chapter 3
Isolation of Downstream AP-1 Target Genes by 
Suppressive Subtractive Hybridisation
66
3.1 INTRODUCTION
The AP-1 transcription factor not only up-regulates sets of direct and indirect 
target genes involved in the induction and maintenance of transformation but is also 
capable of down-regulation. Previous studies in our laboratory (Hennigan et al., 1994; 
Lamb etal., 1997), and others (Braselmann etal., 1992; Jooss and Muller, 1995; Rupp 
et al, 1998), have identified several AP-1 target genes that encode regulatory, 
cytoskeletal and structural proteins containing functional AP-1 binding sites that have 
been linked with the process of invasion. Invasion is a tightly regulated process used 
by many types of non-tumour cells when it is necessary for them to migrate across 
tissue boundaries under a variety of physiological conditions, such as trophoblast 
implantation, embryogenesis, angiogenesis, wound healing, and immune response. 
The process of invasion is complex and it requires the co-ordinated functioning of 
many dynamic cellular processes such as alterations in gene expression, cell surface 
receptor activation, cell-cell adhesion, cell-extracellular matrix (ECM), adhesion and 
ECM remodelling by extracellular proteases, actin cytoskeleton rearrangements 
mediated by Rho-like GTPases and cell motility. The complexity of invasion indicates 
that it is multigenic process. At least three transcription factors, AP-1, Ets, and NFkB 
have been implicated in the regulation of invasion. Both AP-1 and Ets are required for 
the expression of several genes known to be associated with invasion. This 
suggested that AP-1, in transformed cells, activates a multigenic program, which 
regulates invasion.
This chapter reports the construction of subtracted cDNA libraries specific for 
genes expressed following transformation by FBR v-fos oncogene. One library is 
specific for mRNAs up-regulated in FBR cell line, whereas the other is specific for 
mRNAs that are down-regulated. Both were prepared using the technique 
Suppression Subtractive Hybridisation (SSH), (Diatchenko et al., 1996). The cDNA 
libraries were investigated by sequence analysis and Northern blotting (Refer to 
chapter 4).
This chapter focuses on sequence and computational analysis to identify the 
differentially expressed genes. The identification leads to function and reveals that a 
proportion are associated with transformation and invasion.
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3.2 RESULTS
3.2.1 Suppressive Subtractive Hybridisation (SSH)
The approach that was taken to construct the subtracted cDNA libraries was 
SSH. SSH selectively amplifies target cDNA fragments, such as cell line or tissue 
specific differentially expressed cDNA fragments, whilst simultaneously suppressing 
non-target cDNA amplification, that is, common cDNA fragments in cell lines or 
tissues, such as housekeeping genes. An overview of SSH is shown in Figure 3.1.
The technique is primarily based upon Suppression PCR. This alleviates the 
need for physical separation of cDNAs, common to subtractive hybridisation methods. 
Instead, the hybridisation procedure selectively suppresses the common cDNA 
fragments during the amplification step in PCR. In addition, the subtraction method 
overcomes the problem of differences in mRNA abundance by incorporating a 
normalised (equalised), hybridisation step which results in high and low abundance 
transcripts being equally represented. In one subtractive hybridisation round, a 1,000 
fold enrichment of differentially expressed cDNAs can be achieved.
3.2.1.2 Construction of Up-regulated and Down-regulated libraries
cDNA Synthesis
The libraries were constructed from reverse transcribed cDNA from mRNA 
isolated from logarithmically growing FBR, v-fos transformed and 208F untransformed 
parental fibroblast cell lines. The up-regulated subtraction consisted of FBR mRNA as 
“tester”, and 208F mRNA as “driver”. The down-regulated subtraction consisted of 
208F mRNA as “tester”, and FBR mRNA as “driver”. Differentially expressed cDNAs, 
the target genes, are present in the "tester" cDNA but are significantly reduced or 
absent in the "driver" cDNA population.
Rsa I Digestion and Adaptor Ligation
The ds cDNAs of tester and driver are cleaved with a four-base cutting 
restriction enzyme, Rsa I to yield short, 0.1-2 kb, cDNA fragments, after which the 
tester cDNA fragments are divided and ligated with two different adapters, 1 and 2, 
resulting in two populations of tester, 1 and 2. The adapter ends do not have 
phosphate groups, only permitting the covalent attachment of the longer strand to the 
5’-cDNA ends. Sequence of Adapters 1 and 2, and the complimentary PCR Primer 
and PCR Nested Primers are shown in Figure 3.3.
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Figure 3.1 
Overview of Suppressive Subtractive Hybridisation
This figure describes, in general, the steps of the SSH procedure. The cDNA 
in which specific transcripts are to be found is called the “tester cDNA” and the 
reference cDNA is called “driver cDNA’.
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Templates from PCR amplification are generated 
from differentially expressed sequences
Using Suppression PCR, only differentially 
expressed sequences are amplified exponentially
Tester and Driver cDNA are prepared 
from the two mRNA samples under comparison
Hybridisation kinetics lead to equalisation and 
enrichment of differentially expressed sequences
Background is reduced and differentially 
expressed sequences are further enriched
Two Tester populations are created with different 
adaptors, but driver cDNA has no adaptors
Tester and Driver cDNA are separately digested to 
  obtain shorter, blunt-ended molecules_____
70
Figure 3.2 
Schematic representation of SSH
Solid lines represent the Rsa I- digested tester or driver cDNA. Solid boxes of 
purple/white represent Adapter 1, with the purple representing PCR Primer 1 
sequence and the white nested PCR Primer 1. Solid boxes of red/yellow represent 
Adapter 2, with the red representing PCR Primer 1 sequence and the yellow nested 
PCR Primer 1. The type e molecules are formed only if the sequence is absent from 
the driver cDNA as described in text. Refer to text for detailed description of 
procedure.
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Figure 3.2 Schematic Representation of SSH
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Adapter 1
5' CTA ATA CGA CTC ACT ATA GGG CTC GAG CGG CCG CCC GGG CAG GT 3'
3'GG CCC GTCCA5'
PCR Primer 1 PCR Nested Primer 1
5' CTA ATA CGA CTC ACT ATA GGG C 3 5' CTC GAG CGG CCG CCC GGG CAG GT 3'
Adapter 2
5' TGT AGC GTG AAG ACG ACA GAA AGG GCG TGG TGC GGA GGG CGG T 3'
3'GCCTCCC GCC A 5'
PCR Primer 2 PCR Nested Primer 2
5' TGT AGC GTG AAG ACG ACA GAA 3' 5' AGG GCG TGG TGC GGA GGG CGG T 3'
Figure 3.3 Adapter, PCR primer and PCR nester primer sequence
First Hybridisation
The SSH technique uses two hybridisations. In the first (refer to Figure 3.2 (i)), 
an excess of driver is added to each tester sample , denatured and annealed. The ss 
cDNA tester fraction, (a), (refer to Figure 3.2), is normalised, whereby high and low 
abundance cDNA concentrations become equal. This occurs as the re-annealing 
process for homo-hybrid cDNAs, (b), is more efficient and rapid for the high 
abundance cDNAs, due to the second order kinetics of hybridisation. Also, the ss 
cDNAs tester fraction, (a), is further enriched in cDNAs for differentially expressed 
genes, as "common" non-target cDNAs form hetero-hybrids, (c), with the driver 
population.
Second Hybridisation
The two samples from the first hybridisation are mixed together with the 
addition of fresh denatured driver in the second hybridisation (refer to Figure 3.2 (ii)). 
The normalised and subtracted ss tester cDNAs re-associate to form (b), (c), and (e), 
type hybrids, (refer to Figure 3.2 (ii)). Further addition of the fresh driver during the 
second hybridisation enriches for type (e), hybrids, the differentially expressed genes, 
as "common" tester sequences anneal with "common" driver sequences. Newly 
formed hybrids, (e), have different adaptor sequences at their 5’-ends, one from tester 
sample 1, the other from tester sample 2. In contrast, hybrids (b), and (c), formed
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during the first and second hybridisations have the same adaptor sequences at either 
end, (refer to Figure 3.2 (ii)). The different adaptor sequences of the subtracted and 
normalised type (e). hybrids allows preferential amplification using PCR and a pair of 
primers, P1 and P2, that anneal to the outer part of adaptors 1 and 2 respectively as 
shown by Figure 3.3. A short extension reaction prior to PCR cycling fills in the sticky 
ends of the molecules for primer annealing.
First and Second PCR Amplification
The PCR cycles of the hybridisation mixture results in amplification of type (e), 
hybrids. Type (a), and (d), hybrids do not contain primer binding sites and cannot be 
amplified. Type (b), hybrids contain long inverted repeats on the adapter ends which 
form stable pan-handle like structures after each denaturation-annealing PCR step 
that cannot be use as a template for exponential PCR. This is due to the 
intramolecular annealing of the long adapter sequences being preferential and more 
stable than the intramolecular annealing of the short PCR. In addition, type (c), 
hybrids can only be amplified at a linear rate (refer to Figure 3.2 (iii)). This is the 
suppression PCR effect.
The differentially expressed cDNAs are exponentially amplified during the PCR 
reactions as described above. In the first amplification, only the ds cDNAs with two 
different primer annealing sites, type (e), hybrids are exponentially amplified. In the 
second amplification, nested PCR further reduces background and enriches for 
differentially expressed sequences.
Control Subtraction
A control subtracted library was constructed along with the up- and down- 
regulated library subtractions. The up- and down-regulated and control subtractions 
are outlined in Figures 3.4.1, 3.4.2 and 3.4.3 respectively. For each subtraction, 
unsubtracted tester is ligated to adaptors 1 and 2 and PCR amplified as a negative 
control for subtraction. The control subtraction is performed using skeletal muscle 
cDNA spiked with the Hae III digest ((J)X174 markers), as tester fraction and skeletal 
muscle only as driver fraction. During the SSH procedure tester skeletal muscle is 
hybridised to "common” driver control skeletal muscle, allowing the Hae III digest 
cDNA to form type (e), hybrids that are exponentially amplified. The unsubtracted 
tester control is a negative control for subtraction.
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Figures 3.4.1,3.4.2, and 3.4.3 
Forward subtraction (Up-regulated); Reverse subtraction (Down- 
regulated); and control subtraction
Each different experimental tester cDNA, the 208F, FBR and control skeletal 
muscle, were divided into three aliquots and ligated to the appropriate adaptors as 
shown. These figures also depict the unsubtracted tester control that is ligated to 
Adaptors 1 and 2 and subsequently PCR’d without the hybridisation steps. The 
sequential hybridisation steps of the Up-regulated and Down-regulated experiments 
prior to PCR steps is outlined.
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Figure 3.4.1 
Up-regulated Subtraction
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3.2.2 Control analysis of SSH
The differentially expressed cDNAs from the up-regulated, down-regulated and 
control subtracted libraries (refer to Figure 3.5), are 150-1500 bp in size with the 
majority approximately 150-600 bp. In the control cDNA library (Figure 3.5, lane 4), 
the subtracted Hae III digest fragments run higher than the corresponding (|>X174 
markers (Figure 3.5, lanes 1 & 5), due to the PCR annealing sites on the adaptor 
sequences. As the control subtraction was performed in conjunction with the up- 
regulated (Figure 3.5, lane 3), and down-regulated (Figure 3.5, lane 2), subtractions 
this is demonstrative that the subtraction's were successful. In addition, the banding 
pattern of the unsubtracted cDNA tester control ligated with both adapters was 
completely different to the banding pattern of the experimental subtracted cDNA 
samples (Data not shown). The analysis of subtraction efficiency was performed using 
PCR and Southern blot hybridisation analysis.
3.2.2.1 PCR Analysis Control of SSH
The PCR analysis of subtraction efficiency for the up-regulated and down- 
regulated was performed using PCR primers for the house-keeping gene 
glyceraldehyde phosphate dehydrogenase (GAPDH), and is shown in Figure 3.6. 
Thirty three PCR cycles were required to produce a GAPDH PCR product for the 
subtracted up-regulated library, whereas after only 18 cycles of the unsubtracted up- 
regulated library produced a PCR product. In contrast, even after 33 PCR cycles of 
the subtracted down-regulated library no product was produced, whereas after only 18 
cycles of the unsubtracted down-regulated library a PCR product was produced, albeit 
of lower abundance than the up-regulated library. This result indicated that the SSH 
was successful for both of the libraries due to the reduction in abundance of the 
house-keeping gene GAPDH. However, this result would suggest that the subtraction 
for the down-regulated library was more efficient than the subtraction for the up- 
regulated library, but in fact GAPDH has previously been reported as differentially 
expressed in FBR mRNA as opposed to 208F mRNA during quiescence and growth 
(Hennigan Ph.D. Dissertation, 1993).
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Figure 3.5 
PCR amplified subtracted cDNA libraries
The secondary PCR products are represented for the down-regulated, up- 
regulated and control subtracted libraries. Lane 1 & 5: <^X174/Hae III digest size 
markers. Lane 2: subtracted cDNA library of down-regulated clones. Lane 3: 
Subtracted cDNA library of up-regulated clones. Lane 4: Control subtracted skeletal 
muscle tester cDNA library containing 0.2% (j>X174/Hae III digested cDNA. Refer to 
text for a more detailed explanation on library construction.
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PCR Amplified Subtracted cDNA Libraries
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Figure 3.6
PCR analysis of subtraction efficiency: reduction in GAPDH abundance
Top: PCR was performed on subtracted, lanes 2-5 and unsubtracted, lanes 6 - 
9, up-regulated cDNA library with GAPDH 3’ and 5’ primers. Lanes 1 & 10: <j)X174/Hae 
III digest DNA markers; Lanes 2 & 6 : 18 cycles; Lanes 3 & 7: 23 cycles; Lanes 4 & 8 : 
28 cycles; and Lanes 5 & 9: 33 cycles.
Bottom: PCR was performed on subtracted, lanes 2-5 and unsubtracted, lanes 
6-9, down-regulated cDNA library with GAPDH 3’ and 5’ primers. Lanes 1 & 10: 
(j>X174/Hae III digest DNA markers; Lanes 2 & 6 : 18 cycles; Lanes 3 & 7: 23 cycles; 
Lanes 4 & 8 : 28 cycles; and Lanes 5 & 9: 33 cycles.
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Figure 3.6
PCR Analysis of Subtraction Efficiency: 
Reduction in GAPDH Abundance
3.2.2.2 Southern Blot Analysis Control of SSH
The subtracted and unsubtracted up-regulated and down-regulated cDNA 
libraries were hybridised with 32P-labelled up-regulated and down-regulated cDNA 
libraries independently.
The 32P-labelled cDNA from the up-regulated subtracted library hybridised with 
the following: (1), itself, (2), the unsubtracted up-regulated library and (3), the 
unsubtracted down-regulated library, as each of the unsubracted libraries contain 
common sequences. The up-regulated subtracted cDNA library does not hybridise 
efficiently with the subtracted down-regulated library as the common sequences have 
been significantly reduced during the subtraction procedure. The hybridisation of 32P- 
labelled up-regulated cDNA library to the unsubtracted and subtracted up- and down- 
regulated libraries is shown by Figure 3.7.1.
The 32P-labelled cDNA from the down-regulated subtracted library hybridised 
with the following: (1), itself, (2), the unsubtracted down-regulated library and (3), the 
unsubtracted up-regulated library, as each of the unsubracted libraries contain 
common sequences. The down-regulated subtracted cDNA library does not hybridise 
efficiently with the subtracted up-regulated library as the common sequences have 
been significantly reduced during the subtraction procedure. The hybridisation of 32P - 
labelled down-regulated cDNA library to the unsubtracted and subtracted up- and 
down-regulated libraries is shown by Figure 3.7.2.
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Figure 3.7.1 and 3.7.2
Southern blot analysis of subtraction efficiency
Two |^ g DNA from unsubtracted down-regulated library, subtracted down- 
regulated library, subtracted up-regulated library and unsubtracted up-regulated library 
were electrophoresed on a 1.5% agarose gel, transferred to nylon filters, and 
hybridised with either a down-regulated library cDNA probe or an up-regulated library 
cDNA probe.
Figures 3.7.1 and 3.7.2. Lane 1: unsubtracted down-regulated library; Lane 2: 
subtracted down-regulated library; Lane 3: subtracted up-regulated library; and Lane 4: 
unsubtracted up-regulated library. These were probed with up-regulated library cDNA 
probe and down-regulated library cDNA probe respectively.
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Southern Blot Analysis of Subtraction Efficiency
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3.2.3 Sequencing and Computational homology analysis of differentially 
expressed cDNAs
Once it was established from the subtraction analysis that the up-regulated and 
down-regulated libraries were of good quality, the differentially expressed cDNAs were 
cloned into a T/A cloning vector to sequence individual differentially expressed cDNA 
fragments, which will be referred to as clones. The details of clone preparation and 
sequencing is described in chapter 2, sections 2.2.6, 2.2.7 and 2.2.19.
Approximately 500 clones were chosen at random for PCR amplification of the 
inserts and the products were analysed on agarose gels. Some of the clones had 
multiple inserts with two or more bands present in the same lane in the agarose gel, or 
no inserts with no band in the agarose gel lane, whereas some had inserts too short, 
<200 bp, for automatic sequencing and all of these were discounted. The differentially 
expressed cDNA clones of a suitable size, 200-800 bp, and of single inserts, were 
purified from PCR mixture using resin columns. The cDNA fragments were 
subsequently automatically sequenced using the ABI373 system on both strands using 
either vector primers T7 and M13 reverse primer or nested primers 1 and 2. Eighty- 
four clones from the up-regulated library and one hundred and twenty-one clones from 
the down-regulated library were successfully sequenced.
The sequences of the clones were edited to remove all vector and adaptor 
sequence and also to remove poor quality sequence. Any sequence of a 
heterozygous nature was discarded. Some clones represent the same gene as they 
map to different regions of the same cDNA sequence.
The clone sequences were computationally aligned to the GeneBank nr, and 
EST (Expressed Sequence Tags), databases using the blastx, and blastn programs to 
search for homologies to known genes at the protein and DNA level, and also to 
determine if any of the clones represented novel sequences.
The nr database contains a non redundant merge of Swiss-Prot, PIR, PRF, and 
proteins derived from GenBank coding sequences and PDB atomic co-ordinates and 
excludes the EST, STS and GSS divisions. The EST's are short, 300-500 bp 
sequences from mRNA (cDNA), that are produced during sequencing survey projects. 
They are representative of a mRNA population in a tissue type or at a particular 
developmental stage.
The blastx program translates the unknown nucleotide sequence into the six 
conceptual amino acid reading frames and compares them to known genes. As the 
clone sequences are of rat origin, this program is useful as there will be more similarity 
to sequences from other well represented species i.e. human, mouse. Also, the
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biochemical significance of a match can be better evaluated at the amino acid level. 
Initially, all the clone sequences from the up-regulated and down-regulated libraries 
were submitted to NCBI for alignment to the GenBank nr database using the blastx 
program to determine if any matched known genes. However, many eukaryotic 
sequences have long untranslated regions at the 3'-end and smaller segments at the 
5'-end and any sequence from these regions would not match a protein when 
translated in a blastx search. An example of this is clone C13 from the up-regulated 
library which matches to the untranslated region of Brain-Enriched Membrane- 
Associated Protein Tyrosine Phosphatase (bem)-3 using blastn, but fails to match any 
protein in a blastx program search.
Therefore, a blastn search was performed whereby the unknown clone 
sequences were compared to the GenBank database at the nucleotide level and this 
detects very high scoring matches. The numbered clones from the down-regulated 
library that match known genes are detailed in Table 3.1 and the numbered clones 
from the up-regulated library that match known genes are detailed in Table 3.2.
The clone sequences that failed to match any known genes were classified as 
novel. They were then further analysed using a blastn program search of the 
GenBank EST database EST database entries contain details of the EST clone 
including species, tissue type, developmental stage, cell type, treatment such as NGF, 
and similarity to a particular region or motif of a known gene that can provide 
information on the unknown sequence. The clones from the down-regulated library 
that match EST's are detailed in Table 3.3 and the numbered clones from the up- 
regulated library that match EST's are detailed in Table 3.4. The percentage identity 
to the EST's is shown for all matches.
All the further remaining clones were classified as novel, non-informative, 
having no matches and are detailed by Table 3.5.
Although not all the matches were 100% identical, this can be explained by 
biological errors in reverse transcribing the mRNA prior to subtraction, taq errors 
during the suppression PCR, clone preparation wiggle PCR and sequencing PCR 
steps, and also sequencing errors. Furthermore, the identity was not always to a gene 
of rat origin, but to other species, such as human or murine.
The searches were analysed using local ungapped alignments called high- 
scoring segment pair (HSP). The Karlin-Altschul statistics provides a mathematical 
theory of the expected distribution of random HSP scores and determines the 
probability of a particular sequence aligning in a certain size of database by chance. 
The calculated numerical value of the database matches enabled stringent probability 
analysis. In addition all the matches were analysed at least twice manually for regions
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of homology and identity.
The database identity of the sequenced clones is tabulated in Figure 3.13. A 
total of 205 clones were sequenced of which 171 (83%), represent known genes whilst 
35 (17%), were novel, with 29 (14%), matching to EST's, and 6  (3%), with no matches. 
The percentage database identity of the clones representing the up-regulated and 
down-regulated libraries is tabulated in Table 3.7. Interestingly, the sequenced clones 
from the up-regulated and down-regulated libraries are of similar distribution in 
database identities with 8 8 % and 80% matching known genes, 10% and 17% 
matching EST's respectively, and 2% and 3% respectively had no match. The number 
of clones and their database distribution is detailed in Table 3.7.
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Table 3.1 
Blastx and Blastn matches for Down-regulated clones
This Table details all of the down-regulated clones that matched known genes 
submitted to the Genebank nr databases using the blastx and blastn programs. Refer 
to text for detailed database description and analysis.
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Table 3.2 
Blastx and Blastn matches for Up-regulated clones
This Table details all of the up-regulated clones that matched known genes 
submitted to the Genebank nr databases using the blastx and blastn programs. Refer 
to text for detailed database description and analysis.
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Table 3.3
EST Blastn matches for Down-regulated clones
This Table details all of the down-regulated clones that had no match to known 
genes submitted to the Genebank nr databases using the blastx and blastn programs, 
but matched EST database entries using blastn program. Refer to text for detailed 
database description and analysis.
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Table 3.4
EST Blastn matches for Up-regulated clones
This Table details all of the up-regulated clones that had no match to known 
genes submitted to the Genebank nr databases using the blastx and blastn programs, 
but matched EST database entries using blastn program. Refer to text for detailed 
database description and analysis.
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Table 3.5 
Down-regulated and Up-regulated Clones with no matches
This Table details all of the down-regulated and up-regulated clones that had 
no match to known genes submitted to the Genebank nr databases using the blastx 
and blastn programs and no matches to the EST database entries using blastn 
program.
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Tables 3.6, 3.7, and 3.8
Analysis tables of sequenced clones
The Genebank nr and EST database analysed down-regulated and up- 
regulated clones were tabulated in Figure 3.6 according to their database identity. In 
Table 3.7 the percentage of total down-regulated and up-regulated clones represented 
in a database is detailed. Table 3.8 details the representative distribution of both the 
down-regulated and up-regulated clones collectively in each database as number of 
clones and as a percentage to total clones analysed.
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DATABASE
IDENTITY Up-regulated Down-regulated
TOTAL 84 121
Blastx 54 69
Blastn 20 28
EST 8 20
NONE 2 4
Table 3.6
Table of Up-regulated and Down-regulated Sequenced Clones:Putative Identities
DATABASE
IDENTITY
PERCENTAGE
Up-regulated
PERCENTAGE
Down-regulated
Blastx 64 57
Blastn 24 23
EST 10 17
NONE 2 3
Table 3.7
Up-regulated and Down-regulated Sequenced Clones: 
Percentage Putative Database Identities
.113
DATABASE
IDENTITY Number of Clones 
Sequenced
PERCENTAGE
TOTAL 205 100
Blastx 123 60
Blastn 48 23
EST 28 14
NONE 6 3
Table 3.8
Table of Total Sequenced Clones: 
Percentage and Putative Database Identities
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3.3 DISCUSSION
The plethora of known genes up- and down-regulated by the AP-1 transcription 
factor is potentially vast. Therefore to understand the changes that occur when a 
normal fibroblast becomes transformed, it becomes important to group the genes into 
sub-sets. The functional classifications of the sub-sets would enable the examination 
of their possible roles in transformation and invasion. However, the functional 
classifications to which the genes isolated in this study have been assigned are not 
strict. In fact, several of the genes would fit into more than one class.
Sequence analysis of the cDNA libraries supports the proposal that AP-1 direct 
and indirect target genes contribute to the transformed and motile state of FBR cell 
line. This is more apparent for the genes isolated from the up-regulated library as 
more is known about the activation of transformation than it’s repression. In fact 18 
known genes isolated from the up-regulated library have previously been shown to be 
directly associated with transformation and invasion. This includes cell-cell and cell- 
ECM molecules, ECM modelling proteins including proteases, cytoskeletal proteins 
and enhancers of cell motility.
However, many known genes isolated from the up-regulated library have not 
previously been linked to transformation and invasion indicating that AP-1 does not 
exclusively function in regulation of transformation. This suggests that AP-1 in FBR’s 
has additional regulatory functions, possibly encompassing cell cycle control and cell 
survival.
The identified down-regulated genes includes 20 known growth/tumour 
suppressors and includes components that function to maintain normal phenotype 
including cytoskeletal proteins and cell adhesion molecules. The down-regulated 
library contains many genes that have not previously been ascribed with a 
transformation suppressor function.
The SSH of FBR and 208F was performed to identify transformation and 
invasion related genes and as expected many were isolated. However, in both 
libraries there are genes which have no obvious connection with transformation and 
invasion. This includes genes which encode for vesicle transport proteins such as 
BLVR, endoplasmin precursor, Sec23 homolog isoform B and lysosomal glycoprotein 
type B, and metabolic related proteins including L-lactate dehydrogenase M chain, 
arginosuccinate lyase, thioredoxin peroxidase and phosphoglycerate mutase. 
Furthermore, several of the genes isolated encode for proteins with no distinct 
functional group including heme binding protein, reticulocabin, zinc finger protein 33a, 
ornithine decarboxylase, MRP related ATPase and annexin IX.
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The phenotypic differences between normal and transformed cells contribute to 
the invasive and metastatic properties of malignant cells. Alterations in the phenotype 
are caused by changes in the level of gene expression of a sub-set of proteins, namely 
the transformation sensitive proteins, that may be directly or indirectly involved in cell 
adhesion, attachment and invasion. In addition, many proteins have a fundamental 
role in the maintenance of a normal phenotype and their loss can permit the 
unrestricted growth of a tumour cell.
Therefore, transformation is a complex biological process requiring many 
transformation specific genes to be switched on and off enabling the initiation of 
remodelling and maintenance of cellular phenotype. This provides the transformed 
cell with a more rapid growth, loss of contact inhibition, anchorage independence, 
altered motility, and an increased invasive potential. Thus, conversion from the normal 
to a transformed cellular state involves the co-ordinated up-regulation and down- 
regulation of an unknown number of critical genes. The subtracted libraries 
constructed in this study have identified sets of AP-1 direct and indirect target genes, 
although not exhaustive, of which many have functions ascertaining to transformation 
and invasion.
3.3.1 FBR Murine Provirus
One of the clones isolated from the up-regulated library encodes for the FBR 
Murine provirus. This provides concrete evidence of the differential expression of the 
cDNA libraries with the expression of the actual transforming agent in the FBR mRNA 
population.
3.3.2 Extracellular Matrix and Cytoskeleton remodelling in transformation 
and invasion
The FBR v-fos transformed cells are of a highly refractile bipolar morphology 
and are motile and invasive, whereas the 208F’s are non-transformed with a typical 
fibroblastoid morphology. The morphological changes that occur during Fos 
transformation includes the different expression of ECM proteins during cytokeletal 
remodelling.
Cancer metastasis is a complex process and even after the primary tumour is 
surgically removed, recurrences at distant sites can occur. The process of metastasis 
usually occurs with local invasion of a transformed cancer cell into local surrounding 
tissue, infiltration into vascular and lymphatic system, circulation followed by 
extravasation, and growth at secondary sites (Fidler et al, 1978; Nicolson, 1988; 
Zetter, 1990; Aznavoorian et a/., 1993). The initial step of local invasion requires cell 
motility, the enhancement of which is correlated with metastatic potential in animal
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models and a poor prognosis in human cancers (Hosaka et a\., 1978; Haemmerli and 
Strauli, 1981; Partin etal., 1989).
The transformed state and invasive nature of the FBR cells provides an in vitro 
model from which transformation specific genes can be isolated.
3.3.3 Changes in expression of Extracellular Matrix and Cytoskeleton 
components
Genes that effect ECM and cytoskeleton remodelling are well represented in 
each library. The ECM components Fibronectin and a2 (VIII) Collagen are down- 
regulated in v-fos transformants as are the cytoskeletal proteins actin and tubulin. In 
addition, integral membrane protein Protocadherin 2 (Pcdh2), is also down-regulated. 
The cytoskeleton related cytokeratin 8 polypeptide, vimentin and CD44 are found to be 
up-regulated.
The morphology of the FBR v-fos transformed cells is due in part to gross 
cytoskeleton reorganization and previous studies (Jooss and Muller et al., 1985; 
Hennigan et al., 1994; Lamb et al., 1997a, 1987b), has revealed that AP-1 
transformation changes the cytoskeletal components expression patterns. In v-fos 
transformed fibroblasts the F-actin stress fiber bundles that run in parallel arrays along 
the ventral surface of the cell and focal contacts are lost during remodelling in favour 
of F-actin cable structures along the length of the cells into the pseudopod tip that is 
capped by actin rich bundles. The microtubules form a fine looping filament meshwork 
that extends to the cell periphery from an organised perinuclear microtubule centre. 
However, after v-fos transformation tubulin organises at the pseudopodial tips into a 
compressed central filament with a terminal loop structure that stops short of the actin 
bundle (Hennigan etal., 1994; Spence, unpublished observations).
There are several cellular and extracellular factors that regulate cell motility, but 
the motility of the cell is directly affected by the bundling and subcellular distribution of 
the actin cytoskeleton (Stossel, 1993; Lauffenburger and Horwitz, 1996; Cramer etal., 
1997, Honda et al., 1998). Therefore, the regulation and re-organisation of the actin 
cytoskeleton such as that in FBR v-fos cells may contribute to the increased invasive 
capability of these cells.
The ECM is a complex matrix of scaffolding, consisting of proteins and 
proteoglycans that provides structural rigidity in cells. In vivo, specific ECM structures 
function to structurally support and compartmentalise tissues (Matrisian 1990). The 
ECM components includes Type l-VIII collagens, laminin, fibronectin, gelatins and 
heparin sulphate proteoglycan.
The cytoskeleton is a cytoplasmic network of microfilaments, microtubules and
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intermediate filaments of tubulin, vimentin and actin that also provides the cell with a 
structural support and rigidity to maintain their shape. However it must be noted that 
although cells have rigid support, they are not stationary, but are in fact motile and 
dynamic.
The microtubules and actin microfilament cytoskeletal proteins are essential for 
cellular processes such as cell growth and division, motility, signalling and the 
maintenance of cell shape. The dynamics of microtubules and actin in transformation 
and tumourigenesis earmarks these molecules as potential therapeutic targets in 
cancer treatments (Jordan and Wilson, 1998).
The protocadherin 43 that is found down-regulated in FBR v-fos transformants 
is localised at cell-cell contact sites and functions as a cell-cell adhesion molecule 
(Sano et a/., 1993). The cadherins mediate calcium dependent cell-cell adhesion and 
contain a large extracellular domain at the N-terminus and a small cytoplasmic domain 
at the C-terminus that are connected by a transmembrane region. The extracellular 
domain consists of five motifs, each containing a cadherin-specific sequence, whilst 
the cytoplasmic domain regulates cadherins through interactions with cytoskeletal 
proteins (Sago, et al., 1995). The mammalian E-cadherin and Drosophila fat function 
a suppressors of tumour invasion (Chen and Obrink, 1991; Frixen et al., 1991; 
Mahoney et al., 1991; Vleminckxeta l., 1991).
The transmembrane protein, CD44, up-regulated in FBR v-fos transformants is 
a cell surface hyaluronan receptor but can interact with other ECM components 
(Bennett et al., 1995; Jalkanen and Jalkanen, 1992; Weber et al., 1996). The various 
isoforms are formed through alternative splicing and post-translational modifications in 
the extracellular domain of the native protein (Haynes et al., 1991). Overexpression of 
CD44 isoforms is associated with the metastatic behaviour of several human tumours 
(Mayer et al., 1993; Mulder et al., 1994), and CD44 has also been linked to tumour 
progression by enhancing melanoma cell motility and invasion (Birch et al., 1991; 
Faassen et al., 1992; Thomas et al., 1993). Furthermore, CD44 can confer tumour 
growth and metastatic potential in in vivo models (Gunthert et al., 1991; Guo et al.,
1994). The expression of CD44 is known to be regulated by AP-1 (Hofmann , 1993), 
and was previously shown in our laboratory to be required both for the in vitro invasion 
of Fos transformed and growth factor treated 208Fs using the matrigel invasion assay 
(Lamb et al., 1997a). Recently MMP9, which requires AP-1 for its expression and is 
up-regulated in many transformed cells and tumour derived cell lines, has been shown 
to associate with CD44. CD44 associates with a proteolytic form of MMP-9 at the cell 
surface and this complex promotes cell-mediated Collagen IV degradation in vitro and 
mediates tumour cell invasion of G8 myoblast monolayers. In addition, disruption of
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CD44/MMP-9 cluster formation, by overexpression of soluble or truncated cell surface 
CD44 inhibits tumour invasiveness in vivo (Yu and Stamenkovic, 1998). Furthermore 
Okamoto et al., (1999), reported that in cancer cells CD44 was cleaved at the 
membrane-proximal region of the ectodomain. This cleavage was shown to be 
mediated by a membrane-associated metalloprotease expressed in cancer cells, and 
that a tissue inhibitor of metalloprotease-1 (TIMP-1), as well as metalloprotease 
inhibitors, inhibit CD44 cleavage in a cell-free assay (Okamoto et al., 1999). Thus 
CD44 cleavage is regulated by an intricate balance between some proteases and their 
inhibitors.
The down-regulation of the cytoskeletal components actin and tubulin in FBR’s 
may be due to the gross cytoskeletal re-arrangements that occurs upon transformation 
by v-fos. The deregulation of protocadherin 43 and potential loss of cell-cell adhesion 
is perhaps contributory to the increased cell motility of the FBR cell line. The up- 
regulation of CD44 and the protease MMP-10 is consistent with the motile behaviour 
and invasive characteristics of the FBR cell line.
3.3.4 Matrix Metalloproteinases and the ECM
In the FBR v-fos transformed cells there is an up-regulation of Beta ig-h3; 
MMP-10, also known as transin, oncogene-induced transin and stomelysin2, and their 
degradation targets, the ECM proteogylcans Fibronectin; Type 1 Collagen and 
a2(VIII)Collagen, are found to be down-regulated. This is consistent with the 
morphological remodelling changes that occur upon v-fos transformation of 208F 
fibroblasts.
The invasion of a transformed cell into normal surrounding tissues is regarded 
as a tissue remodelling process in which the ECM and surrounding normal tissue is 
proteolytically degraded by the proteases including the Matrix Metalloproteinases, 
MMPs (Johnsen et al., 1998). The proteolytic remodelling of the ECM in oncogenic 
transformation is known to affect the adhesion, motility and invasiveness of the cell 
(Bortner et al., 1993). In vivo, the MMPs are involved in proteolytic degradation during 
tissue remodelling processes such as wound healing, post-lactation mammary gland 
involution and trophoblast invasion during implantation (Johnsen, etal., 1998).
The MMPs are a family of tightly regulated enzymes that degrade ECM and 
basement membrane components. They are zinc ion containing proteinases that are 
secreted and require activation for proteolytic activity whereby they degrade one or 
more components of the ECM. Inhibition is conferred by chelating agents and also by 
TIMPS, that is specific tissue inhibitors of metalloproteinases (Matrisian, 1990). MMPs 
are characterised into subclasses as to their substrate specificity, Collagenases: MMP-
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1, MMP-8, MMP-13, Gelatinases (Type IV Collagenases): MMP-2, MMP-9, 
Stromelysins: MMP-3, MMP-10, Furin-recognition site MMPs: MMP-11 including 
membrane bound type MMP-14, MMP-15, MMP-16, MMP-17, and the newly 
described: Enamolsin (Matrisian, 1990; Shapiro, 1998). The MMPs selectively 
degrade the various basement membrane and ECM components, Fibronectin, 
Laminin, Enactin, Proteoglycans and Type l-VII, and X Collagens. The Stromelysin2 
(MMP10), promotor region contains a functional AP-1 site (Kerr et al., 1990), and thus 
is regulated by AP-1.
3.3.5 ECM and Cell Adhesions
In this study several ECM components and cell adhesion proteins have been 
found to be down-regulated. This includes LTBP-2, Fibrillin, Fibronectin, Tenascin-X, 
and a2(VIII)Collagen. The ECM stabalizing enzyme Lysyl Oxidase was also found to 
be down-regulated.
The collagens are vital ECM components, with type I showing tumour 
suppressor activity. The down-regulation of important ECM components such 
collagens and tenascin-X as would facilitate cell shape changes and increased cell 
motility as observed in FBRs. The down-regulation of the cell-cell adhesion proteins 
LTBP-2 like protein, Fibrillin-1, and Fibronectin plus the ECM stabilizing enzyme Lysyl 
Oxidase, in FBR v-fos transformants may enhance morphological transformation and 
motility.
Cell adhesion links cells to each other or to the ECM, establishing intracellular 
adhesion plaques with cytoskeletal components that are organised into large 
complexes. These large cell adhesion complexes activate intracellular signalling 
pathways that regulate cell morphology, migration, gene expression, growth and 
differentiation (Yamada and Geiger, 1997; Burridge et al., 1997). This adhesion 
dependent cell-signalling is critically important in preventing tumourogenesis of normal 
cells. In fact, several adhesion molecules have tumour suppressor activity and 
function by maintaining cell-cell and cell-ECM adhesions thereby inhibiting cell motility. 
In vivo this blocks migration and invasion into surrounding tissues that results in 
metastasis (Boudreau and Bissel, 1998; Tlsty, 1998).
The ECM microfibrils contain several structural proteins including Fibrillins, 
LTBPs and microfibral-associated glycoproteins (Mecham et al., 1995). The LTBT-2 
that is found down-regulated in FBR v-fos transformants is a member of the Fibrillin- 
LTBP gene family (Sakai et al., 1986). The Fibrillins and LTBPs have similar domain 
structures and are mainly composed of EGF and 8-cysteine repeats, the former a 
common feature of many extracellular proteins. Most of the EGF like repeats contain
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the consensus sequence for calcium binding (Handford et al., 1991; Gibson et al.,
1995), that stabilises protein structure against proteolytic degradation and also 
stabilises protein-protein interactions (Reinhardt et al., 1997; Fehon et al., 1990; Rao 
et al., 1995). The latter binds via disulphide bridges to heterologous proteins and the 
third 8-Cys repeat of LTBP-1 mediates the binding to latent TGF-|3 (Sahariner et al.,
1996).
The TGF-p family of proteins regulate the growth, differentiation, adhesion and 
migration of many cell types (Roberts et al., 1990, Massague, 1990,; Moses et al., 
1990). It inhibits the growth of most cell types and stimulates the production of ECM 
proteins such as Fibronectin, Collagen, and Tenascin (Chiefetz etal., 1990) The TGF- 
(3s are secreted from cells as a latent complex that is comprised of the homodimeric 
mature growth factor, TGF-|3 latency-associated protein and a LTBP. LTBP-2 down- 
regulation in FBRs may be due to the growth inhibition function of this gene. 
Furthermore, LTBP-2 inhibits ECM protein production. Interestingly the ECM proteins 
that provide structural rigidity, Fibronectin and the a2 (VIII) Collagen are also down- 
regulated in FBRs.
Fibrillins of which there are two forms 1 and 2, are major components of the 
ECM. The fibrillin-1 module, D25 segment (the 25th module of fibrillin-1 D segment), 
and LTBP-2 (Moren et al., 1994), both contain the cell adhesion motif arginyl-glycyl- 
aspartyl (RGD), that mediates integrin-dependent cell adhesion (D’Arrigo etal., 1998), 
to the ECM ligands via integrins. Both Fibrillin-1 and LTBP-2 are susceptible to 
proteolytic processing and release from the ECM (Hyytiainen et al., 1998). A 
characteristic of transformation is the loss of cell adhesion. Thus the down-regulation 
of Fibrillin-1 and LTBP-2 in FBRs probably lends to the de-regulation of cell adhesion 
in addition to other functions.
The insoluble ECM component Fibronectin is a key modulator in 
embryogenesis, wound healing, homeostasis and thrombosis. It is comprised of two 
monomeric subunits attached by two disulphide bonds at the carboxy terminus and is a 
mosaic protein made up with the modular units Fn1, Fn2 and Fn3. The modules form 
functional domains that contain other ECM protein binding sites and cell-surface 
receptors for integrins and blood proteins and through these sites Fibronectin functions 
as a ECM cell-cell adhesion protein through these sites(Potts and Campbell, 1994).
Tenascin-X is an large ECM glycoprotein (Matsumoto et al., 1992a, 1992b; 
Bristow et al., 1993). In vivo tumourigenic assays in nude mice have shown Tenascin- 
X to be down-regulated during tumourigenesis (Sakai et al., 1996). The down- 
regulation of Fibronectin, ECM-cell-cell adhesion protein and Tenascin-X, ECM 
glycoprotein emphasises the de-regulation of cell adhesion molecules in v-fos
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transformation.
Lysyl Oxidase was previously cloned as the ras recision gene, rrg (Contente et 
al., 1990). The human gene has recently been mapped to chromosome 5q23 (Szabo 
et al., 1997), a region of loss in non-functioning pituitary adenomas (Daniely et al., 
1998), and in pancreatic tumours (Achille et al., 1998). It is a copper amino oxidase 
that initiates covalent cross-linking between and within the sub-units of collagen and 
elastin thereby stabilizing the ECM (Smith-Mungo and Kagan, 1998). The enzyme 
Lysyl Oxidase is a Class II suppressor gene (Lee et al., 1991). In FBRs it is down- 
regulated. Lysyl Oxidase expression is also down-regulated in Ki-ras and EJ-ras 
transformed fibroblasts and spontaneous revertant clones have a restoration of Lysyl 
Oxidase expression levels. This restoration of expression suppresses anchorage- 
independent growth effect as opposed to morphological change to a flatter cell shape 
(Hajnal et al., 1993; Oberhuber et al., 1995). It is also down-regulated in several 
malignantly transformed human cell lines (Hamalainen et al., 1995). Recently, an 
Interferon Regulatory Factor- 1 (IRF-1), response element was found in the Lysyl 
Oxidase gene promoter. The IRF-1 transcription factor and its antagonistic repressor 
IRF-2 function as regulators of the IFN system, and in addition IRF-1 functions as a 
tumour suppressor (Sok-Pin Tan, et al., 1996). The regulation of IRF-1 and its down- 
regulation in transformation would result in the loss of Lysyl Oxidase expression, which 
could contribute to the transformation process. Analysis of IRF-1 expression in FBR 
cell line by northern blot detailed a marked down-regulation of IRF-1, however, western 
analysis of protein extracts were inconclusive. Several Lysyl Oxidase-related genes 
have recently been cloned (Kim et al., 1995; Saito et al., 1997), with one gene 
functioning in cellular adhesion and senescence (Saito etal., 1997).
Beta ig-h3 is a Transforming Growth Factor-p-(TGFp), responsive gene which 
contains four regions of the RGD motif, a modulator of cell attachment, and a motif 
similar to an active binding domain of laminin (Skonier etal., 1994). It has been found 
down-regulated in mesenchymal tumour cells (Shenker and Trueb, 1998), and 
decreased tumourigenicity is observed when TGF-p transfected CHO cells were 
injected into nude mice, although no growth inhibition was detected (Skonier et al.,
1994). Beta ig-h3 can also function as an anti-adhesion molecule and has been 
shown to prevent the attachment of several cell types to tissue culture dishes as post- 
translational modification removes the RGD sequences (Skonier etal., 1994), although 
in contrast it has been shown to promote the adhesion of dermal fibroblasts (LeBaron 
et al., 1995). The up-regulation of Beta ig-h3 in v-fos transformed cells is most likely 
related to the protein’s anti-adhesion properties, where it may contribute to increased 
cell motility and invasiveness.
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The Type I Collagen contains the polypeptides a1 (I) and a2(l) in a ratio of 2:1 
and are strictly coordinately regulated and expressed in a tissue-specific manner. The 
down-regulation of a1 (l)Collagen has previously been reported in ras transformed 
fibroblasts (Liau etal., 1985). The transformation by ras blocked the expression of the 
a1 (l)Collagen through an intronic AP-1 site (Slack et al., 1995). The stable 
transfection of a2(l)Collagen in K-ras transformed fibroblasts results in a flatter cell 
morphology with increased substratum adherence, a reduction of colony formation in 
soft agar, slower proliferation kinetics and suppression of tumourigenicity in nude mice 
(Travers et al., 1996). The transformation by ras requires constitutive AP-1 activity 
and if blocked, reversion of transformation occurs (Lloyd etal., 1991; Granger-Schnarr 
et al., 1992; Wick et al., 1992). In SV40 transformed human fibroblasts 
a2(l)Procollagen synthesis is ablated (Parker et al., 1989).
Collectively, the down-regulation of these key proteins that function to maintain 
the normal phenotype through structural constraints, cell adhesion properties or via 
tumour suppressor activity is therefore likely to be a prerequisite to transformation, and 
cell motility in the FBRs.
This would appear to be a co-ordinated down-regulation of genes that function 
as ECM and adhesion proteins perhaps suggesting that AP-1 functions as a multigenic 
switch.
3.3.6 Proteases
Cathepsin B and Cathepsin L (Hennigan etal., 1994), are up-regulated in FBR 
cell line but Cathepsin H clone was isolated from the down-regulated library. Tissue- 
type Plasminogen Activator (tPA), and the protease inhibitor Sorting Nexin 3 are down- 
regulated. The protease component RC6-1 is found to be up-regulated whilst C3 is 
down-regulated.
The Cathepsins are aspartyl or cysteine proteases that are localized in 
lysosomes of normal cells, but their expression and release are dramatically increased 
in transformed cells. The activity, secretion and membrane association of Cathepsin B 
is increased in malignant tumours particularly in cells at the invasive leading edge. 
Cathepsin B functions by degrading basement membrane and ECM components 
(Berquin and Sloane, 1996). The substrates for Cathepsin L also includes the ECM 
components, Laminin, Fibronectin and Collagen but an acidic pH is required for activity 
(Mason etal., 1985). Cathepsin L is overexpressed in many human cancers (Chauhan 
etal., 1991), and expression in Ha -ras transformed NIH 3T3s, murine B16 and human 
A2058 melanoma cells correlates with metastatic ability (Denhardt etal., 1987; Rozhin 
et al., 1989). Overexpression of Cathepsin L in NIH 3T3 cells does not result in
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transformation (Kane et al., 1988). The up-regulation of Cathepsin B cysteine 
protease in FBRs is perhaps correlated with their function in degradation of basement 
membrane and ECM components (Berquin and Sloane, 1996), an important step in 
transformation and cell motility.
The secreted protease Sorting Nexin 3 mediates the binding, internalization 
and degradation of regulatory serine proteases and thus functions as a protease 
inhibitor (Knauer et al., 1983). The deregulation of Sorting Nexin 3, coupled with an 
increase in protease expression, as in FBR v-fos transformants, would perhaps 
prevent the degradation and activity of proteases that are necessary for the 
maintenance of transformed phenotype and invasiveness.
In FBR v-fos transformants there is a down-regulation of tPA, and an up- 
regulation of Plasminogen Activator Inhibitor-1. PAI-1 is an AP-1 target gene (Keeton 
etal., 1991), which is often up-regulated in conjunction with urokinase-plasminogen 
activator. uPA has not yet been isolated in the library, but it is a known target of AP-1 
and is implicated in the invasion by many tumour cells (Niedbala and Sartorelli, 1990). 
Non-neuronal enolase also functions in conjunction with plasminogen activator as a 
cell surface receptor for uPA (Miles et al., 1991). However tPA has been found down- 
regulated in a variety of tumours and may not be associated with invasive behaviour of 
cells.
The changes in expression of proteasome components in FBRs, the up- 
regulation of RC6-1 and the down regulation of C3 suggests that protease specificity 
may also be changed in transformed cells. This possibly adds another level of gene 
regulation to transformation as changes in proteasome components may alter the 
stability of specific proteins.
3.3.7 Genes with Growth/ Tumour Suppressor function
The down-regulation of CRBPI in human breast cancer cells has recently been 
reported (Jing et al., 1996), resulting in the deregulation of RA metabolism, thereby 
abolishing it’s anti-proliferative effects. In FBRs CRBPI is also down-regulated 
although the effect of this growth inhibitor in v-fos transformation has not yet been 
addressed. In FBRs several other genes with a growth/tumour suppressor function 
have been found to be down-regulated. This includes Necdin, PP2A and Sprouty.
The biological functions of Vitamin A (retinol), requires the metabolic 
conversion to retinoic acid (RA), which is regulated by the cellular retinoic acid binding 
protein I (CRBPI). The retinoic acid signalling pathway regulates cell proliferation and 
differentiation and inactivation of one or more proteins in the pathway can induce 
carcinogenesis. The actions of RA is through the nuclear receptor families RAR and 
RXR (Giguer e et al., 1987; Petkovich etal., 1987; Krust et al., 1989; Mangelsdorf et
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al., 1990; Mangelsdorf et al., 1992), that form RAR:RXR heterodimers and RXR 
homodimers (Leid et al., 1992; Marks et al., 1992). These receptors function as 
transcription factors, directly regulating gene expression and indirectly through other 
transcription factors. In a variety of cell types AP-1 activity is inhibited by RA treatment 
(Schuleetal., 1991; Pan etal., 1992; Perez etal., 1994; Van de Klundert etal., 1995; 
Chen etal., 1995).
The post-mitotic neuronal nuclear protein, Necdin was first isolated from a 
subtracted cDNA library of neurally differentiated murine embryonal carcinoma cells 
(Maruyama et al., 1991). It was found to be down-regulated in FBR v-fos 
transformants. Necdin is expressed in all post-mitotic neurons and is contstitutively 
expressed from early embryonal stages until adulthood (Uetsuki et al., 1996). The 
differentiated post-mitotic neurons never undergo cell division and are permanently 
quiescent. Previous studies have implicated the Retinoblastoma protein (Rb), a 
growth suppressor, with neuronal differentiation-associated growth arrest (Lee et al., 
1992). Ectopic expression of Necdin strongly suppresses the growth of NIH3T3 cells 
(Hayashi et al., 1995), suggesting that it may act as a growth suppressor in post­
mitotic neurons.
The nuclear tumour suppressor proteins Rb and p53 interact with small DNA 
tumour viruses, SV40, human papillomavirus, and Adenovirus transforming proteins 
(Weinberg, 1991), that target cellular growth suppressors in normal cells. Rb and 
Necdin both bind independently to the SV40 large T antigen, Adenovirus E1A and also 
to the transcription factor E2F1, that promotes cell cycle progression. Furthermore, 
Necdin can functionally replace Rb as a growth suppressor in Rb-deficient SAOS-2 
cells, indicating that Necdin acts a growth suppressor similarly to Rb (Taniura et al., 
1998).
The' Protein Phosphatase 2A (PP2A), is one of the most abundant intracellular 
protein phosphatases and is a hetereotrimer containing a catalytic (C), subunit, a 
structural (A), subunit and a variable regulatory (B), subunit. The substrate specificity 
and activity of PP2A is largely determined by regulatory B subunit. Three unrelated B 
gene families, each encoding several phosphatase regulatory genes have been 
identified.
In many human tumours, including lung, colon, breast, cervical, head and neck, 
ovarian and also melanomas there is a loss of heterozygosity (LOH), at chromosome 
11q22-24. The re-introduction of normal chromosome 11 or a derivative (X;11), 
chromosome containing 11pter-q23 can reverse the tumourigenic potential of lung, 
breast and cervical carcinoma derived tumour cells when injected into nude mice 
(Saxon et al., 1986; Satoh et al., 1993; Negrini et al., 1994). This data indicated the
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location of one or more tumour suppressor genes at this locus and PP2A was 
subsequently found to map to this region of LOH. In this study PPP2R1B gene 
somatic alterations were found in 15% of primary lung tumours, 6% of lung tumour- 
derived cell lines and 15% of primary colon tumours (Wang et al., 1998), and this 
strongly suggested tumour suppressor activity.
The PP2A protein regulates the MAPK cascade (Santoro et al., 1998), and is 
believed to suppress growth by antagonising protein kinase oncoproteins and its loss 
has been linked to carcinogenesis. It also functions as a G2/mitosis cell cycle 
checkpoint control (Lee et al., 1991), that is disrupted by a HOX11 oncogene 
interaction with PP2A (Kawabe et al., 1997). PP2A can inhibit telomerase activity in 
the nucleus (Zhao, 1997), and is a target of chemical tumour promoters (Kawabe et 
al., 1997). The DNA tumour viruses Polyomavirus T antigen and SV40 small t antigen 
binds PP2A-A subunit and displaces subunit B thereby inhibiting phosphatase activity 
and mediating viral transformation (Pallas et al., 1990; Sontag et al., 1997). In 
addition, the Casein kinase 2a inhibition of cellular transformation by ras oncogene is 
via an increase in PP2A activity (Heriche etal., 1997).
In FBR v-fos transformants there is a down-regulation of PP2A Ba3 isoform. 
This is perhaps due to it’s function as a regulator of the MAPK signalling cascade 
which can lead to AP-1 activation, or perhaps due to its antagonistic function against 
protein kinase oncoproteins.
The Sprouty protein belongs to a new family with a highly conserved cysteine- 
rich domain that is a membrane-associated or secreted signalling protein that function 
as antagonistic inhibitors of FGF. Recent studies of sprouty in Drosophila airway 
developmental patterning using sprouty mutants (Hacohen et al., 1998), discovered 
that it inhibits branch budding in trachea by antagonising the Bnl FGF pathway. The 
mammalian Sprouty homologues are involved with FGF signalling pathways in 
developing tissues and they function as an inhibitor of FGF. Several recently 
discovered branching inhibitors have recently been shown to be tumour growth 
suppressors and they function by blocking angiogenesis (Hanahan and Folkman,
1996).
Recently, the murine homologue of Drosophila Sprouty was cloned and shown 
to have a conserved function in negatively modulating respiratory organogenesis (Tefft 
etal., 1999).
Casci and co-workers (1999), discovered that Spouty is an intracellular inhibitor 
of ras signalling in Drosophila. In contrast to Hacohen and co-workers (1998), who 
reported that Sprouty was extracellular, Casci and co-workers (1999), discovered that 
Sprouty is an intracellular protein that associated with the inner surface of the plasma
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membrane. Furthermore, Sprouty was found to bind to two intracellular components of 
the ras pathway, Drk1 (homologous to mammalian Grb2), and Gap1. Sprouty controls 
Ras/MAPK signalling directly by inhibiting signal transduction between the receptor 
and Ras. The intracellular localisation of Sprouty permits the inhibition of the 
intracellular signal transduction pathway and thus acts upon several receptor tyrosine 
kinases (RTK), (Casci et al., 1999). Interestingly, the expression of Sprouty is 
dependent upon the Ras/MAPK pathway’s activity, therefore suggesting negative 
feedback (Hacohen etal., 1998; Casci etal., 1999).
Several human homologues of Sprouty have been cloned (Hacohen et al., 
1998), and a recent study (Tefft et al., 1999), has reported Sprouty to be an 
antagonistic inhibitor of FGF signaling in the mammalian system. Presumably murine 
Sprouty also functions as an inhibitor of ras signaling.
3.3.8 Regulatory proteins
The regulatory proteins 4-3-3£, and Oncomodulin were found to be up-regulated in 
FBRs. SNAP-23 and Zygin 2 were found to be down-regulated.
The 14-3-3 proteins are a highly conserved family of acidic proteins and several 
mammalian isoforms have been found, p, y, e, r\ and x and are expressed in a tissue- 
specific manner. In vivo, these proteins form homo- and hetero-dimers (Jones et al.,
1995), and contain an annexin-like domain at their centre (Liu et al., 1995). Crystal 
structure analysis reveals a dimeric structure consisting of a-helical bundles arranged 
around an amphipathic groove. Invariant residues line the groove implicating a ligand- 
binding surface on each subunit and this cleft potentially functions as a binding site to 
alter bound protein interactions (Lui et al., 1995; Xiao et al., 1995). Multiple functions 
of 14-3-3 proteins have been reported including activation of enzymatic
neurotransmitter synthesis, interaction of IGF receptor (Furlanetto et al., 1997),
interactions with c-Cbl in a yeast two hybrid screen (Robertson et al., 1997), and the 
regulation of Protein Kinase C (PKC), activity (Aitken etal., 1992). PKC is required for 
focal adhesion formation in fibroblasts (Woods and Crouchman, 1992).
The binding protein 14-3-3^ is a phosphoserine (pSer)-binding protein that 
interacts directly with oncogene products and components of the mitogenic and
apoptotic signalling pathways suggesting a role in growth regulation. In vitro, Raf-1
binds and forms a complex with 14-3-3 (Li et al., 1995), in the cytosol and Raf-1 is 
displaced at the plasma membrane for recruitment and activation by Ras, after which 
Raf-1 is recycled to the cytosol by 14-3-3 (Roy etal., 1998). The 14-3-3 proteins also 
interact with MEKK1, -2 and -3, but do not affect kinase activity (Fanger et al., 1988). 
This data suggests that 14-3-3 proteins regulate signal transduction by acting as a
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scaffold to localise protein kinase activity rather than activating or inhibiting kinase 
activity.
The up-regulation of a 14-3-3^ protein in FBR v-fos transformants is 
presumably two-fold. Firstly it functions in the regulation of PKC thereby decreases 
cell adhesion contacts and increasing motility. Secondly, it also functions in trafficking 
the Raf-1 and MEKK-1, -2 and -3 proteins which are downstream effectors of Ras in 
the mitogenic signalling pathway whereby c-fos and c-jun are induced and AP-1 is 
activated. However in FBRs, not only is c-fos transrepressed but the Raf-1 pathway is 
switched off (K.Katsanakis, unpublished observations), and perhaps the up-regulation 
of 14-3-3^ is caused by the accumulation of these redundant trafficking molecules.
The transport and exocytosis of proteins along the secretory pathway in 
eukaryotic cells requires the docking and fusion of the cytoplasmic vesicles to the cell 
membranes via the trimeric complex of vesicle-associated membrane complex protein 
(VAMP), syntaxin and a SNAP protein (Sollner et al., 1993). The synaptosomal- 
associated protein-23kD, (SNAP23), was identified as a syntaxin 4-binding protein in a 
yeast two-hybrid system screen of a human B lymphocyte cDNA library and is an 
isoform of one of the SNARE proteins SNAP-25 (Ravichandran et al., 1996). In 
various cell types different isoforms of VAMP and syntaxin have been reported 
(Bennett et al., 1993; McMahon et al., 1993; Calakos et al., 1994; Rossetto et al., 
1996; Ravichandran et al., 1996), however SNAP-25 expression is exclusive to 
neuronal tissues (Bark et al., 1995), whereas in contrast SNAP-23 is widely expressed 
in most tissues (Ravichandran et al., 1996). SNAP-23 is also induced by various 
cytokines in vitro (Morikawa et al., 1998). A major signal transduction pathway that 
functions downstream of the cytokines receptors is the Ras-Raf-MAPK cascade that 
induces c-fos and c-jun (Satoh et al., 1992; Duronia et al., 1992; Schlessinger and 
Ullrich, 1992). Recent deletion analysis studies of the be subunit of cytokine receptors 
indicated that SNAP-23 was a downstream target of the Ras-Raf-MAPK pathway 
(Morikawa et al., 1998). The down-regulation of SNAP-23 in FBRs may be due to the 
down-regulation of the Raf-MAPK pathway (K.Katsanakas, unpublished observations), 
and therefore a downstream target of this pathway, SNAP-23 is also down-regulated.
The Zygin 2 protein is also known as FEZ2 (fasciculation and elongation 
protein). The proteins of the FEZ family, FEZ1, FEZ2 and C.elegans unc-76 have poor 
similarity to other proteins and represent a new protein class involved in axonal 
outgrowth. The N-terminal regions of the proteins are highly acidic and structural 
analysis revealed that large regions of the protein would form amphipathic helices, 
although there are no identifiable motifs. The FEZ family members are believed to be 
intracellular due to the absence of a signal sequence or transmembrane domain and
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the cellular localisation of the unc-76 protein is in the cell bodies and axons of most 
neurons. Studies to determine the function of unc-76 using mutants indicated two 
possible functions for the FEZ family members consistent with the intracellular 
localisation and fasicle-specific defects of the mutant protein in developing C.elegans. 
The unc-76 protein may have a structural role in the formation and maintenance of 
fasicles through an intracellular association with a cell surface adhesion molecule, 
axonal membrane or the cytoskeleton. Otherwise, the unc-76 protein could transduce 
signals from cell-surface molecules to the intracellular machinery that regulates axonal 
extension and adhesion (Bloom and Horvitz, 1997). A recent two-hybrid interaction 
screen in yeast with a rat homologue of FEZ1 was shown to bind the C1 regulatory 
domain of protein kinase C types £ and e, and these rat homologues of FEZ1 and 
FEZ2, Zygin I and II were identified as synaptotagmin-binding proteins. As previously 
discussed, PKC is involved in the modulation of adhesion contacts and membrane 
structure, whilst the synaptogtagmins are involved in membrane docking and fusion in 
nonneuronal cells. These interactions coupled with the unc-76 mutant data would 
suggest that FEZ family members are important for the regulation of cellular 
morphology. The functions of Zygin II pertaining to increased cell surface adhesion, 
the maintenance of cytoskeleton, coupled with regulation of outgrowth would 
correspond with the down-regulation found in FBR v-fos transformed cells.
Oncomodulin, is a small, acidic calcium binding protein and was initially 
discovered in rat heptoma (MacManus, 1979), and is up-regulated in AP-1 transformed 
fibroblasts. It’s expression is also found in blastocyst and placental cytotrophoblasts 
(Brewer and MacManus, 1985; Brewer and MacManus, 1987), and is elevated in a 
wide variety of rodent and human tumours but no expression has been detected in 
normal rodent or human adult tissues (MacManus et al, 1984; Durkin et al., 1983). 
Recently, it has been identified as Parvalbumin p-isoform and it’s expression in the 
outer hair cells of the organ of corti of mouse, gerbil, and rat has been reported 
(Sakagichi et al., 1998). Although the function of Oncomodulin has yet to be 
elucidated, it has been discovered that in chemically transformed fibroblasts an 
increase in transcript and protein levels at the G1/S boundary and this would suggest a 
regulatory Ca2+-dependant role in the cell cycle (Blum and Berchtold, 1994). Recent 
studies on cells transfected with Parvalbumin resulted in morphological shape changes 
and an increase in cell motility (Andressen et al., 1995), and the presence of 
Oncomodulin in tumours and in invasive cytotrophoblasts suggests a function of Ca2+- 
dependant motility important for invasive behaviour (Pauls et al., 1996). It is 
postulated that the up-regulation of Oncomodulin in FBR v-fos transformants 
contributes to cell motility and invasiveness.
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3.3.9 Cell Cycle Regulatory proteins
MCM5.CDC46 is down-regulated and Cyclin A2 is up-regulated in FBR v-fos 
transformants.
The cell cycle in eukaryotic cells strictly limits the duplication of the genome to 
once per cycle. The replication of DNA is initiated from sequences called origins which 
ensures the duplication of chromosomes and a block to replication until the 
segregation of chromosomes during mitosis occurs. The conserved minichromosome 
maintenance (MCM), gene family are necessary for DNA replication and can modify or 
license replication-incompetent chromatin to a replication-competent state. They are 
constitutively expressed in the nucleus but only bind chromatin in late mitosis to early 
S phase as DNA replication progresses (Kimura et al., 1994; Kubota et al., 1996; 
Romanowski et al., 1996; Coue et al., 1996). The MCM5/CDC46 DNA replication- 
licensing factor bound to chromatin during G1 blocks DNA replication and the kinase 
CDC7 is required to bypass or inactivate the block (Hardy etal., 1997).
The cell cycle is monitored by a complex biochemical process whereby Cyclin 
Dependent Kinases (CDKs), are sequentially activated by a variety of cyclins. The 
consecutive activation of cyclin/CDK complexes permits the progression of the cell 
through the cell cycle. The protein cyclin A2 accumulates in somatic cells from the 
end of G1 until the metaphase of mitosis. Cyclin A2 binds to and activates CDK2 in 
G1 and S phases and CDK1 in G2 and M (reviewed by Nurse, 1994).
The isolation of cell cycle regulatory genes from the up-regulated and down- 
regulated libraries would suggest that AP-1 may function in the regulation of cell cycle 
control and thus cell survival.
3.3.10 Metabolism and Ribosomal proteins
The differential expression of the metabolic, ribosomal and protein synthesis 
proteins in tumour cells has previously been documented (Zhang etal., 1997; Gress et 
al., 1996). In FBR v-fos transformants there is an up-regulation of lactate 
dehydrogenase, glyceraldehyde-3-phosphate (Hennigan et al., 1994), dehydrogenase, 
and cytochrome oxidase is observed and this has previously been reported in a 
pancreatic cancer-specific expression profile (Gress et al., 1996). This increase in 
aerobic glycolysis pathway proteins is assumed to be a results of increased 
proliferation and energy metabolism of transformed cells. In contrast, several 
metabolic, in particular the dehydrogenases and ribosomal proteins are also down- 
regulated.
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Reverse Northern hybridisation experiments (data not shown), revealed that 
most ribosomal clones were not differentially expressed which would indicate that they 
19 ribosomal protein was previously reported in v-fos transformants, tumour cells 
(Chiao et al., 1992), pancreatic tumours (Gress et al., 1996), and in gastrointestinal 
tumours (Zhang etal., 1997).
3.3.11 EST Homologies to proteins
The analysis of clones that do not match any genes submitted in the Genebank 
nr database were subject to analysis to EST database entries. The EST sequences 
provided more information about the clone and can hint at a possible function. Several 
of the down-regulated clones exhibited homology to EST entries with homology to 
reticulocablin homologue, a gene already found in this library. Reticulocalbin (RCN), is 
a member of the EF-hand Ca(2+)-binding protein family and is a luminal protein of the 
endoplasmic reticulum (ER), (Ozawa and Muramatsu, 1993). Although RCN has six 
repeats of a domain containing an EF-hand motif, the varying degrees of divergence of 
the amino acid sequences of these domains from the EF-hand consensus sequences 
suggested that some domains might have lost their Ca(2+)-binding capability and 
adopted new functions. Another down-regulated clone is similar to lysyl oxidase.
3.3.12 Summary
The changes in expression of the transformation specific proteins upon 
transformation by v-fos would implicate AP-1 as the activation switch to initiate and 
maintain the transformed state.
Interestingly, the transformation specific proteins isolated in this study not only 
includes modulators of the ECM and cytoskeleton such as proteases, MMPs and cell 
adhesion molecules but also regulatory proteins and also growth/tumour suppressor 
proteins. Once a cell has become fully transformed the alterations in gene expression 
reflect the new steady state integration of changes in signal transduction pathways and 
transcription factor activity responsible for the maintenance of transformation.
However, many of the genes isolated in this study encode for proteins that 
have not previously been associated with transformation and invasion. This includes 
proteins associated with protein synthesis, metabolism, vesicle transport, transcription, 
signal transduction and cell cycle regulatory proteins. This would indicate that AP-1 
transcription factor controls additional cellular processes other than transformation and 
invasion.
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Chapter 4
Characterisation Of v-fos Suppressive Subtractive 
Hybridisation cDNA Library Clones
i
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4.1 INTRODUCTION
The sequenced clones from the up-regulated and down-regulated cDNA 
libraries were assumed to be differentially expressed between FBR and 208F cell lines 
based upon the subtraction controls performed. Northern blot analysis was used to 
characterise the sequenced clones to verify and quantify their differential expression. 
It would also reveal the size and splicing patterns of the novel transcripts. The 
differential expression of the clones was extended beyond 208F versus FBR to include 
characterised signal transduction pathways that function upstream of AP-1, to induce 
or inhibit function. This would test the association of the sequenced clones with 
transformation pathways that function through AP-1, such as the ras oncogene and 
EGF growth factor. This included 208F fibroblasts treated with EGF (Epidermal 
Growth Factor), and 208F fibroblasts stably transformed with Kirsten-ras (RAS). FBR 
fibroblasts expressing the dominant-negative jun deletion mutant, Tam-67, were also 
analysed to determine which sequenced clones required AP-1 activity for their 
differential expression.
This chapter reports the expression patterns of a representative fraction of 
sequenced clones from the up- and down-regulated cDNA libraries, that may function 
as transformation effectors of AP-1.
133
4.2 CHARACTERISATION OF EXPRESSION
4.2.1 Northern Blot analysis
Northern blot analysis was performed using 10 pg total RNA samples from 
logarithmically growing 208Fs; FBRs; RAS; EGF treated 208Fs, (refer to methods); 
and FBR-Tam67 partial revertants. The Northern blots were probed with various cDNA 
clones isolated from the up-regulated and down-regulated libraries.
The loading levels were determined from photographs of the RNA gels prior to 
transfer to nylon membranes and by probing with cDNA for the 7S ribosomal RNA, 
(refer to Figure 4.1).
Twenty-two clones from the down-regulated cDNA library were characterised 
by Northern blot analysis, nineteen of which are reported in this Chapter. Their 
expression and loading controls are shown in Figures 4.2-4.11. The remaining three 
down-regulated clones are detailed in subsequent chapters. Fourteen sequenced 
clones from the up-regulated cDNA library were characterised by Northern blot 
analysis, all of which are reported in this Chapter. Their expression and loading 
controls are shown in Figures 4.12-4.18. Exposure times of the hybridised northern 
blot to X-ray film is included as an indication of the relative abundance of a cDNA 
clone in a messenger RNA population.
Quantitation of expression indicates the differentially expressed sequenced 
clones represent abundant and rare mRNAs, based upon densitometric analysis (data 
not shown), and the time of exposure. In addition, the different expression patterns 
and sizes of the mRNAs revealed by northern analysis indicated that the cDNAs 
represent distinct mRNAs as would be expected due to the normalisation step in the 
libraries’ construction.
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Figure 4.1 
Ethidium Bromide Stained RNA Gel prior to Northern Blot Transfer
The gel photograph prior to transfer shows the RNA ladder markers in the first 
lane and the corresponding size on a cm ruler. The subsequent lanes show 10pig of 
total RNA from the various cell lines used as detailed above the lanes.
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Figure 4.1
Ethidium bromide stained RNA gel prior to Northern Blot Transfer
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Figure 4.2-4.18
Northern Blots and 7S Control
These figures detail the scanned X-ray film of the exposed Northern blots and 
the corresponding scanned X-ray film of the exposed 7S Ribosomal loading control. 
The size of the mRNA transcript is indicated by arrows with regards to the RNA ladder 
in kilobases. The clone nomenclature, database identity and exposure times of the 
Northern blots in days are detailed below each blot in the figures.
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4.2.2 Relative differential expression
The differential expression of a few of the clones is easy to compare from the 
Northern blot figures However, the comparison of expression patterns between all of 
the blots is more difficult due to the number of clones characterised. The quantitation 
of expression is tabulated in Tables 4.1 and 4.2 respectively. This indicates the 
relative abundance of the differentially expressed sequenced clones by scoring.
The scoring system was compiled from the relative differential expression of a 
clone in a Northern blot (refer to Figures 4.2-4.18). Hybridisation kinetics and 
exposure times of the Northern blots are not equal. Thus, the comparative expression 
of several clones in an RNA species is not appropriate. The different gradiations of 
the scoring system was as follows:
Black : High Expression
Dark Grey: Moderate Expression
Light Grey Low Expression
White Negligible Expression
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Tables 4.1-4.2 
Differential Expression Patterns of Down-regulated and Up-regulated 
Clones Analysed by Northern Blot
Table 4.1 details the down-regulated genes. Table in 4.2 details the up- 
regulated genes. The clone name and database identity is in the first lane, followed 
horizontally by the expression pattern in the various cell lines tested. The cell lines are 
as previously described (refer to chapter 1).
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Clone Name & Identity 208F&EGF208FFBRRASFBR TAM 67
A D 3 
Protocadher in 43 0 • • • 0
AD  12 
Fibronect in • • O © ©
AD 16 
ST A T -6 © 0 0 • 0
B D 3 
Zygin 11 © C|) o • 0
DD 13
Novel o • o © ©
ED2
E R K 3 / M A P K 9 7 © • o • 0
ED 12 
Novel ID • o © ©
JD2
C aspase-1 1 • • Cl © ©
GD 2 
N ovel • • 0 o 0
1U 3 
Novel • • 0 • ©
JD 12/JD 1 5
N ovel © o CS) • ©
JD 18
Lysyl  0  xidase • • o • ©
K D 8
Latent  TGF-b B P 0 • © © 0
KD 10
M C M 5 / C D C 4 6 0 • • o ©
LD3Lactate Dehydrogenase M i  m l • 0 o 0
0  D 2 
N ovel • 0 IP © ©
P D 6 
CRB PI • o © © ©
PD 18
Novel 0 • © © ©
IRF-1 0 • (!) () ©
Table 4.1
Different ia l Express ion  of Down-Regula ted 
Clones Analysed by Northern B lo t
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Clone Name 208F Q FBR
& Identity & EOF ° 8' ^ TAM 67
A  U  5 
C a t h e p s i n  B
A  U  1 2
F B  R - g a g - F o s
B U 4  
M  M  P - 1 0
B U  1 7 
H u m a n  N . B . P
C U I 6  
P A  I -  1
C  U 1 7 
O  n c o m o d u l i n
D  U 7 
C y t o k e r a t i n  8
D  U 1 2
b - i g - h 3
F U  1 
K r p  1
G  U  8
M  a c 2
0
o
o
o
o
o
o
o
o
o
IP
o
o
o
o
o
]
11
<§ 9  
•  #
•  o •
I U  1
N o v e l 9 0 • 0 •
L  U 5 
N o v e l 9 III • • 9
M  U 5 
N o v e l 0 0 • 0 0
N  U  8 
B E M - 3
© 0 9 • 9
Table 4.2
Differentia l Express ion of Up-Regulated 
Clones Analysed by Northern Blot
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4.3 DISCUSSION
The Northern blot experiments determined the differential expression of 
sequenced clones between the FBR v-fos transformed fibroblasts and 208F parental 
fibroblasts, and in other AP-1 dependent transformed cell types as previously 
described in chapter 1. Sequence analysis of the clones demonstrated that many of 
the identified genes have been previously associated with aspects of transformation.
The expression patterns of a representative fraction of the sequenced clones 
isolated from the down-regulated library revealed that all were down-regulated in FBRs 
and 74% were also down-regulated in K-ras transformed 208Fs, 58% were also down- 
regulated in 208Fs stimulated with EGF. In FBRs Tam-67, only 32% were down- 
regulated.
The expression patterns of a representative fraction of the sequenced clones 
isolated from the up-regulated library revealed that all were up-regulated in FBRs and 
79% were also up-regulated in K-ras transformed 208Fs, and 36% were up-regulated 
in 208Fs stimulated with EGF. In FBR Tam-67 revertants, 79% were down-regulated 
when compared to FBRs.
Most strikingly, all but one of the clones examined by northern blot analysis 
were differentially expressed between the 208Fs and FBRs. Therefore, the Northern 
data presented in this chapter coupled with the library controls performed provides 
credence that all of the genes in the up-regulated and down-regulated libraries are 
differentially expressed, with possibly a few exceptions.
The expression analysis confirms the complexity of change in gene expression 
upon transformation by fos and ras oncogenes, as demonstrated by the sequence 
analysis that essentially all of the genes in the libraries are differentially expressed. In 
some instances, the expression change in some of the cell lines examined for a 
particular clone is only partial. Furthermore, not all genes down-regulated by v-fos are 
also down-regulated by K-ras and EGF stimulation. Likewise, not all genes up- 
regulated in v-fos transformants are also up-regulated in K-ras and EGF 
transformants. It was presumed that some of the isolated clones would be specific for 
v-fos transformation.
One up-regulated clone, AU12 encodes for the FBR-gag-fos polyprotein of the 
FBR-MuSV, and northern analysis reveals it is up-regulated in FBR RNA and also in K- 
ras RNA. The K-ras transformed cells are made through retroviral infections in the 
208F cell line. Therefore, isolation of this cDNA further confirms the differential 
expression between the subtracted 208F and FBR cell lines.
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The clones predominantly down-regulated by v-fos includes AD3, 
protocadherin 43; AD16, STAT-6; IU3, Novel; and JD2, Caspase 11. The clones 
predominantly up-regulated by v-fos includes DU7, Cytokeratin 8 polypeptide; DU12, 
pig-h3; FU1, Krp1; IU1, Novel; and MU5, Novel.
As previously discussed in chapter 1, the growth factor signal transduction 
pathway, such as that elicited through EGF stimulation, can up-regulate and down- 
regulate putative AP-1 target genes. Several of the clones are up-regulated in v-fos 
and K-ras oncogene transformants, but not in EGF transformed cells, such as AU12, 
FBR-gag-fos-gag polyprotein; BU4, MMP-10; BU17, human nucleotide binding protein; 
CU17, Oncomodulin; and FU1,Krp1. Interestingly, only one clone; IU1, Novel, is up- 
regulated in EGF transformed 208Fs, that is not also up-regulated in K-ras 
transformants. Several of the clones, AD12, Fibronectin; JD18, Lysyl Oxidase; KD10, 
MCM5/CDC46; LD3, Novel; OD2, Novel; PD6, CRBPI and IRF-1 are not as 
dramatically down-regulated in EGF transformed cells, as in v-fos and K-ras oncogene 
transformants. This difference in expression patterns for some of the clones analysed 
is accountable. EGF transformation is inducible and transient with 70-80% of the cell 
population transformed and not all of the EGF signal transduction pathway targets are 
Fos/Jun family member AP-1 target genes. In addition, full transformation by Fos 
requires three days in a regulated system as opposed to the forty-eight hours post­
stimulation of EGF. Furthermore, transcription factors and signalling pathway 
intermediates that are direct targets of AP-1 will have their own set of target genes and 
thus not all of the identified clones will be direct AP-1 targets.
Although there are differences in activation of AP-1, morphology, and invasive 
behaviour with the K-ras transformants being less invasive in an in vitro invasion 
assay, 74% of the clones analysed are also down-regulated in K-ras and 79% are also 
up-regulated in K-ras transformants. However, several of the down-regulated clones 
are not down-regulated by K-ras transformation, and in a few cases, AD16, STAT-6; 
BD3, Zygin II; ED2, ERK-3; and JD12/15, Novel; the expression is even higher than 
that found in wild type, the 208F cells. Evidently, from this analysis, not all of the v-fos 
down-regulated genes are also down-regulated through K-ras transformation. The 
RAS cells are autocrine and produce their own growth factors, such as TGF a. 
Therefore, the signalling pathways activated in these RAS cells such as the Jun 
Kinase pathway; and the Ras/MAPK cascade, can lead to the targeting of various 
effector genes. This includes transcription factors, for example Ets. Also, the 
transcription factors and signalling pathway components that are direct targets of AP-1 
K-ras oncogene will have their own set of target genes which may be different to those
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of the v-fos oncogene clones that were analysed. In contrast, the FBR cells are not 
autocrine. Thus in comparison, the signal transduction cascades that function 
upstream of AP-1 in RAS cells is complex. Additionally, post-transcriptional
modifications may also account for the differences in expression for approximately 
20% of the clones analysed.
The Jun dominant-negative deletion mutant Tam-67 is described in chapter 1. 
Briefly, Tam-67 lacks the transactivation domain and can dimerise with itself and with 
Fos and Jun family members to form a stable complex. Tam-67 can bind DNA with 
the same affinity as wild-type Jun and Fos family members but it cannot activate the 
transcription of the AP-1 responsive gene, collagenase. Tam-67 inhibits TPAIras- 
induced transformation, SV40 liras  transformation and also prevents transformation of 
rat embryo cells in co-operation with activated ras (Brown etai., 1993).
This data is consistent with the findings from the northern blot analysis that 
Tam-67 in FBR cells fully or partially inhibits expression of 70-80% of the AP-1 
regulated clones. Interestingly, the Northern data reveals that most of the FBR down- 
regulated clones are similarly down-regulated in FBR Tam-67 cells. Therefore, Tam- 
67 does not reverse the down-regulation effect exerted by v-fos, suggesting a 
mechanism of transcriptional repression.
With respect to the FBR Tam-67 cells, the quenching model of transcriptional 
repression is most appropriate. This can be substantiated on two accounts. Firstly, 
the quenching mechanism would dampen the effect of AP-1 and there would be partial 
inhibition of up-regulation and down-regulation as shown by the northern data. 
Secondly, Tam/Tam homodimers are not preferential binding partners in FBR Tam-67 
cells (McGarry, 1998, unpublished observations), and thus the blocking mechanism 
would not pre-dominate.
Interestingly, the expression of the down-regulated genes in Tam-67 cells is not 
required to maintain the reverted phenotype of these cells. Previous studies in our 
laboratory shows that a decrease in wild type levels of CD44 is not required for 
morphological reversion in FBR v-fos transformed cells. However blocking CD44 
expression blocks invasion in an in vitro invasion assay (Lamb et a i, 1997a). 
Furthermore, a down-regulated clone, FRP (refer to chapter 5), when re-introduced 
into FBR cell line does not induce morphological reversion. However FRP expression 
blocks invasion in an in vitro invasion assay. This highlights the complexity of 
transformation and indicates that each gene may have some role in suppressing or 
enhancing transformation or invasion.
The mechanism of transcriptional repression by AP-1 is not well understood. In 
fos transformants AP-1 may repress transcriptional activation through methylation
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activity. A three-fold increase in dnmtl expression after 48 hours was recently 
reported in a c-fos conditional expression system based on Lacl whereby c-fos is 
rapidly repressed in the presence of IPTG and is rapidly induced in it’s absence (Bakin 
and Curran, 1999). In this system transformation requires 2-3 days.
Dnmtl functions as a catalyst in the transfer of methyl groups from S-adenosyl 
methionine to the C-5 position of cytosines in DNA. An increase in expression has 
previously been observed in tumour cells (Wu et al., 1993), and overexpression in 
fibroblasts results in transformation (Wu et al., 1993). It has been reported that DNA 
methylation is linked to gene silencing, and overexpression of dnmtl can lead to 
progressive methylation of several genes (Baylin et al., 1998). The methylation of 
DNA can repress gene expression through the condensation of chromatin. This 
occurs when the methylated sites on the DNA binds with 5-methylcytosine binding 
protein (MeCP2), which complexes with Sin3A and histone deacetylase (HDAC), and 
this resulting complex subsequently decreases histone acetylation, thus compacting 
chromatin structure (Nan et al., 1998; Jones et al., 1998).
The dnmtl gene is believed to be a direct target of AP-1. The experimental 
evidence to support this includes an increase in transcription rate in a c-/bs-induced 
nuclear run-on assay (Bakin and Curran, 1999), a dominant-negative c-jun reduces 
dnmtl expression in ras-transformed cells (MacLeod et al., 1995; Rouleau et al., 
1995), and finally, the dnmtl gene has AP-1 sites that activate transcription in a ras- 
and /un-dependant manner (MacLeod et al., 1995; Rouleau et al., 1995; Yoder et al., 
1996; and Tucker et al., 1996). In addition, an inhibitor of HDAC, Trichostatin A, 
causes reversion of fos transformation (Bakin and Curran, 1999), suggesting that fos 
transformation is mediated by elevated expression of dnmtl, which represses gene 
expression.
Furthermore, the up-regulated cDNA library clones have been further 
sequenced by Dr.J.Winnie. Two clones, SAP18 and RbAp46 were isolated. Northern 
blotting reveals an up-regulation of SAP18 in v-fos and K-ras transformants (Winnie, 
unpublished data). The understanding of transcriptional repression has recently been 
significantly advanced by the demonstration of a link between transcriptional 
repressors and histone deacetylases. mSin3-accociated polypeptide, SAP18, was 
isolated in an affinity purification experiment of mSin3-containing complexes, and GST 
pull-down assays revealed that SAP18 directly interacts with mSin3 in vitro (Zhang et 
al., 1997). Further experimentation demonstrated that SAP18 exists in a complex with 
mSin3 and HDAC1 in vivo and exerts transcriptional repressive activity. The 
mSin3/HDAC1- mediated transcriptional repression involves the modification of core 
histones and is enhanced by SAP18 (Zhang etal., 1997).
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Development is dependent upon the up-regulation of certain genes and also by 
the repression of others. Recently, the murine homologue of SAP18 was cloned and it 
was demonstrated that the RNA was expressed with stage and lineage specificity in 
the haematopoietic hierarchy, and that alternative polyadenylation sites are used. This 
suggested a role for SAP18 in transcriptional repression during haematopoietic 
development (Boehmelt etal., 1998).
The RbAp46 protein was first identified as a major protein from HeLa cell lysate 
that specifically bound to an Rb affinity column (Huang et al., 1991). Recently, it has 
been demonstrated that RbAp46 complexes with the human histone deacetylases, 
HDAC1, HDAC2 and RbAp48 in the mSin3 complex (Zhang et al., 1987). This 
complex was shown to be functionally important for mSin3-mediated repression of 
transcription (Zhang etal., 1997).
Therefore, with respect to the Northern data presented in this chapter, the 
down-regulation of AP-1 target genes in the FBR v-fos transformants is possibly due to 
dnmtl DNA methylation leading to transcriptional repression, and/or 
SAP18/RbAp46/mSin3/HDAC1 complex transcriptional repression.
The analysis of the expression data of the clones by Northern blotting details 
that 20-25% of the clones are v-fos specific, whilst the remaining 75-80% are 
additionally regulated through the EGF and K-ras oncogene signal transduction 
pathways that function upstream of AP-1. This further emphasizes the important 
function of the proteins encoded by the sequenced clones in. The expression of the 
remaining 20-30% is possibly because the genes do not have an AP-1 responsive 
element in their promoter region, but are in fact secondary targets of AP-1 responsive 
genes.
163
Chapter 5
Role of Follistatin-related Protein in AP-1 
Transformation
5.1 INTRODUCTION
Characterisation of many of the clones from the down-regulated library by 
Northern blotting (refer to chapter 4), and sequence analysis (refer to chapter 3), 
identified genes for further analysis. One such clone MD4, was identified as rat 
Follistatin-related Protein (FRP), originally identified as a TGF-p inducible gene.
The transforming growth factor (TGF)|31 acts as a growth inhibitor in mouse 
osteoblastic MC3T3-E1 cells. FRP mouse homologue TSC-36 was isolated in a 
differential screen for latent TGF-pi induced genes which included the ras-recision 
gene lysyl oxidase (Shibanuma et al., 1993). The expression of TSC-36 was found 
reduced in v-Ki-ras transformed MC3T3 cells or transformed NIH3T3, but its 
expression recovered to normal levels in a flat revertants of ras-transformed cells 
(Shibanuma et al., 1993). Tissue distribution studies of TSC-36 in adult mouse organs 
revealed expression in heart and lung, and further analysis in adult lung sections 
detected expression in alveolar cells, but not in bronchial epithelium or blood vessels 
(Mashimo, et al., 1997). TSC-36 was also found to be down-regulated in v-ras and v- 
myc transformed cell lines, but not fibroblasts transformed by v-src, v-raf or v-abl. No 
expression was detectable in nine human cancer cell lines tested as compared to 
immortalized non-tumourigenic human fibroblasts and this suggested a role in tumour 
suppression (Mashimo, etal., 1997).
Subsequently, the rat homologue, named FRP was partially co-purified with 
superoxide dimutase as an abundant protein in the conditioned media of C6 glioma cell 
line (Zwijsen etal., 1994). The cDNA and protein were isolated. Antiserum was raised 
against the C-terminal predicted peptide of mouse TSC-36 and Western analysis 
detected a polypeptide with a Mr 38kDa in the culture media of MC3T3 cells 
(Shibanuma et al., 1993). The secreted glycoprotein was shown to have no effect on 
the inhibitory action of TGF|31 on CCL-64 cell growth (Zwijsen etal., 1994). Sequence 
searches at the protein level revealed homology to the follistatin-like motif of follistatin 
and agrin (Zwijsen etal., 1994).
The FRP protein sequence similarity to follistatin-like domains of follistatin and 
agrin and SPARC (Shibanuma et al., 1993, Zwijsen et al., 1994), is shown by Figure 
5.1. The comparison of partial amino acid sequences of rat FRP with rat follistatin 
precursor 1, rat Agrin and rat SPARC is shown by Figure 1, panel A. The amino acid 
sequence alignments reveals that the cysteine distribution is similar and is shown by 
Figure 1 panel B. The amino acid identity of FRP to follistatin-like domain of follistatin 
is 21% over a length of 320 amino acids. Sequence identity of FRP to the follistatin-
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like domain of agrin is 47% over a length of 47 amino acids and this similarity is 
situated within the sixth follistatin-like domain of agrin (amino acids 430-496). The 
identity of FRP to the follistatin-like domain of SPARC is 16% over a length of 301 
amino acids.
This chapter reports the Northern blot expression of clone MD4, FRP and the 
cloning of the open reading frame (ORF), into an expression vector with a 3’ Myc Tag. 
Transient transfections into 208F, FBR, RAS and Tam-67 cell lines were performed in 
an attempt to ascertain the role of FRP in suppressing transformation and invasion. 
This was further examined by the generation of a FRP stably expressing FBR clone, 
and a FBR neo clone and they were characterised using a proliferation assay, growth 
in soft agar, and by measuring their invasive capacity in an in vitro invasion assay.
5.2 RESULTS
5.2.1 Northern Blot Analysis
Northern Blotting revealed the expression patterns of FRP in the three 
previously described model systems which activate AP-1 activity and the results are 
shown by Figure 5.2. A transcript of FRP is easily detectable in 208F, whilst in FBR it 
is undetectable. In RAS the FRP transcript is reduced by two-fold. In EGF treated 
208Fs, which morphologically transforms 70-90% of the cell population, results in FRP 
transcript being marginally down-regulated. In FBR Tam-67, the transcript is barely 
detectable.
5.2.2 Cloning FRP into 3’ Myc tagged Expression Vector
Clone MD4 maps to the amino acid positions 172-306 of FRP (data not shown). 
FRP rat sequence in vector pBSK (+) rFRP was a gift from Dr.A.Zwijsen, Innogenetics, 
Belgium. The complete rat nucleic acid sequence and protein translation of the 
complete open reading frame of FRP is shown in Figure 5.3 and the potential N- 
glycosylation sites are highlighted in bold. FRP open reading frame was cloned into 
pcDNA3.1Myc-His A as described in Chapter 2, Methods and is outlined schematically 
in Figure 5.4. The polyhistidine tag would facilitate the purification of recombinant 
protein from conditioned media if necessary.
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Figure 5.1
Sequence similarity alignments of FRP with other follistatin-module
containing proteins
A: This figure details and compares the structure of the FRP protein’s 
functional domains to Follistatin domain proteins, Follistatin, SPARC and Agrin, which 
is highlighted by a red box. Other features of the protein’s are also detailed, signal 
peptide by a black box, Calcium binding region by a yellow /black cross box, and an 
EGF-like domain by a pink box.
B: This figure details the amino acid sequence alignment of FRP to Follistatin 
domain proteins, Follistatin, SPARC and Agrin. The highly conserved regions, 90%, 
are presented in red typeface, and the lower conserved regions, 50%, are presented in 
blue typeface.
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Figure 5.2 
Northern Blot of Clone MD4, FRP
This figure details the one day exposure X-ray film of a Northern blot probed 
with Clone MD4, Follistatin-related protein, in the top panel. The bottom panel details 
the corresponding scanned X-ray film of the 7S ribosomal loading control. Arrows with 
regards to the RNA ladder in kilobases indicate the size of the mRNA transcript. The 
size of the cloned mouse homologue, TSC-36, was 2.8Kb (Shibanuma etal., 1993).
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Clone MD4, Rat Foll is tat in -re la ted Protein, 
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5.2.3 Transient Transfection of Cos 7 cells with Myc tagged FRP
The expression of FRP from the pcDNA3.1A/FRP vector and pcDNA3.1A 
control empty vector was determined by transfection of Cos 7 cells and isolation of 
soluble protein extracts 72 hours post-transfection. The soluble proteins were 
analysed by Western Blotting using mouse anti-Myc as the primary antibody, and 
HRP-conjugated anti-mouse antibody, as secondary. The resulting expression of FRP 
is shown by Figure 5.5, which confirmed that the expression vector was functional and 
coded for a protein of the correct size. The previously reported protein molecular 
mass was of rat FRP was 40-48kDa (Zwijsen et al., 1994), whilst the mouse 
homologue TSC-36 was reported as 38kDa (Shibanuma, et al., 1993). The Myc- 
tagged protein was approximately 40Kda, of which approximately 2.5Kda was the Myc- 
tag.
5.2.4 Transient Transfection of 208F, FBR, RAS AND Tam-67 Cell Lines 
with Myc tagged FRP
The 208F, FBR, RAS and Tam-67 cell lines were transiently transfected with 
the above described Myc tagged FRP expression vector and fixed twenty four hours 
post-transfection. The cells were stained by indirect immunofluorescence using an 
anti-myc primary mouse antibody, followed by an anti-mouse FITC labelled secondary 
antibody. In conjunction, the cells were counter-stained with rhodamine-phalloidin 
(TRITC), to visualise F-actin. The methodology is described in Chapter 2, Section 
2.2.23. The merged pictures of FRP-myc (Green), and F-actin (Red), cellular location, 
in each of the transiently transfected cell lines are shown by Figure 5.6.
The phalloidin staining of 208F shows a normal fibroblastoid actin structure with 
prominent stress fiber arrays that run in parallel along the ventral surface of the cell 
(See arrow, Figure 5.7, panel (e)). The localisation of the FRP in two representatives 
of transfected 208F cells is shown in Figure 5.7. The FRP is of a peri-nuclear, 
cytoplasmic localisation with a slight punctate expression, characteristic of a secreted 
protein in the ER and golgi apparatus, particularly in Panels (b), and (g). Actin rich 
membrane ruffles can sometimes be seen in the FRP transfected and untransfected 
208F cells (not shown). These findings are consistent with previous studies of 208F 
actin structure (Hennigan, 1993). This staining pattern of actin architecture is shown in 
both the transfected and adjoining untransfected FRP cells, is shown by Figure 5.7.
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Figure 5.3 
Nucleic acid and ORF protein sequence of rat Follistatin-related Protein
The figure shows the published nucleotide sequence of rat FRP cDNA, which is 
1370bp long. The amino acid sequence predicted from the open reading frame 
starting from the first ATG Kozak initiation signal at positions 64-981 is also shown. 
The eukaryotic signal sequence between amino acid residue 18 and 19 results in 
EEEQRS as the start of the N-terminal sequence and is underlined. The three 
potential N-glycosylation sites (Asn-Xaa-Ser/Thr), at amino acid positions 124, 155 
and 160 are in bold.
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10 30 50
ctggcctccaactcactgcttccatcctgcccagtgtcctctcgagtcccggacccgagc
70  90 110
acgatgtggaaacgctggctggcgctcgcgctggtgaccatcgccctggtccacggcgag
M W K R W L A L A L V T I A L V H G E
130  150  170
gaggaacaaagaagcaaatccaagatctgcgccaatgtgttttgtggagctggccgggaa 
E E Q R S K S K I C A N V F C G A G R E
190  210  230
tgcgccgtcacggagaagggggagccaacgtgcctctgcattgagcaatgcaaacctcac
C A V T E K G E P T C L C I E Q C K P H
250  270  290
aagaggcctgtgtgtggcagtaatggcaagacctacctcaaccattgtgaacttcacaga
K R P V C G S N G K T Y L N H C E L H R
310  330  350
gacgcctgcctcactggatccaagatccaggttgattatgatgggcactgcaaagaaaag
D A C L T G S K I Q V D Y D G H C K E K
370  390  410
aagtctgtgagtccatccgccagccccgttgtctgctatcaggctaaccgtgatgagctg
K S V S P S A S P V V C Y Q A N R D E L
430  450  470
cggcgccggatcatccagtggctggaagccgagatcattccagatggctggttctctaaa 
R R R I  I Q W L E A E I  I P D G W F S K
490  510  530
ggcagtaactacagtgagatcctagacaagtactttaagagctttgataatggtgactct 
G S N Y S E I  L D K Y F K S F D N G D S
550  570  590
cacctggactccagcgaattcctgaaattcgtggagcagaatgaaacagccgtcaacatc
H L D S S E F L K F V E Q N E T A V N I
610  630  650
accgcttaccccaatcaggagaacaacaaactgctcagaggcctctgtgttgatgccctc
T A Y P N Q E N N K L L R G L C V D A L
670  690  710
attgaactgtccgatgagaacgctgactggaaactcagcttccaagagttcctcaagtgc
I E L S D E N A D W K L S F Q E F L K C
730  750  770
ctcaacccatccttcaaccctcctgagaagaagtgcgccctggaggacgaaacctatgca
L N P S F N P P E K K C A L E D E T Y A
790  810  830
gatggagctgagaccgaggtggactgcaatcgctgtgtctgttcctgtggacactgggtc
D G A E T E V D C N R C V C S C G H W V
850  870  890
tgcacagcgatgacctgtgatggaaagaatcagaagggggtccagacccacacagaggag
C T A M T C D G K N Q K G V Q T H T E E
910  930  950
gagatgacgagatatgcccaggaactccagaagcaccagggaacagcagaaaagaccaag
E M T R Y A Q E L Q K H Q G T A E K T K
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970 990 1010
aaggtgaacaccaaagagatctaagaagaggcacgtagcacctcatctggaacccagcac
K V N T K E I *
1030 1050 1070
ctcctcttcagcgctaagcccagtatacagcgtctgtggcaatcaccgaatcaccagtat
1090 1110 1130
ttgcttgtacggcagcaaatcttatctgtttgttttgcaataaaggaagtgagggtggct
1150 1170 1190
ggctagccagggcaggcaggccacaactttcacttctaggaatgctttaagagacactaa
1210 1230 1250
agggcaccttggggcaggaggcgagtatccggttggcagaggagcagaggcaggtctgaa
1270 1290 1310
tgaaacctttctggggtcagctgtgaggatacaacaggaaaagcatgtgatgttaggggg
1330 1350 1370
aacactgagctggccctgctggaggaaatagggggagcttggtggggagg
Figure 5.3
Nucleic acid and ORF of rat Follistatin-related Protein
Figure 5.4
Rat Follistatin-related Protein primers and cloning strategy into pcDNA3.1 
Myc-His A expression vector
A: The primer sequences used for the isolation of the FRP ORF by PCR are 
described. They were designed to include the Kozak translational start site but not the 
translational stop site of the ORF to enable the 3’ Myc-His tagging of the protein, with 
Kpn I restriction sites prior to the start and at the end of the sequence to facilitate 
insertion, in frame, into the pcDNA3.1 Myc-His A expression vector. The additional 
three bases at either end of the Kpn I sites are to safeguard the essential sequences 
from degradation.
B: Cloning strategy. PCR of the cDNA in the pBSK (+) rFRP vector using Pfu 
polymerase, limited PCR mistakes and generated blunt-ended products. These were 
cloned into pCRScript vector by ligation. The pCRScript vector with FRP cDNA was 
restriction digested using Kpn I and the resulting cDNA fragment was ligated into pre­
digested and alkaline phosphatase treated pcDNA3.1 Myc-His A. The FRP insert and 
joined expression vector was sequenced to confirm that the FRP was in the correct 
orientation and in frame with no PCR mistakes (data not shown).
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cDNA start site Primer
5 ' C G g I g G T  A C c I a C G  ATcJ T G G  AAA CGC T GG C T G GCG 3' 
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Figure 5.4
Rat Follistatin-related Protein Primers and Cloning Strategy 
into pcDNA3.1 Myc-His A Expression Vector
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Figure 5.5
Protein detection by Western blot analysis of pcDNA3.1 (-) Myc-His A/FRP
and pcDNA3.1 (-) Myc-His A after transient transfection in Cos7 cells.
This figure details the protein detection of FRP by Western Blotting after 
transient transfection in Cos7 cells with pcDNA3.1 (-) Myc-His A/FRP and pcDNA3.1 
(-) Myc-His A using an anti-Myc antibody. The empty vector alone resulted in no 
expression whilst the FRP cDNA in an expression vector resulted in a band of 
approximately 40kDa.
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Protein detection by Western Blot analysis of pcDNA3.1(-) 
Myc-His A/FRP and pcDNA3.1 (-) A after Transient 
Transfection in Cos7 cells
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Figure 5.6 
Transient transfections in 208F, FBR, RAS and Tam-67 cell lines: Merged 
pictures of FRP and F-actin staining
The indirect staining of FRP is shown in green and the F-actin is shown in red. 
Panels (a), and (b), are two different 208F cells indirectly stained for FRP and F-actin, 
(c), and (d), are two different FBR cells indirectly stained for FRP and F-actin, (e), and 
(f), are two different RAS cells indirectly stained for FRP and F-actin, and (g), and (h), 
are two different FBR Tam-67 cells indirectly stained for FRP, and F-actin.
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Figure 5.6
Transient Transfections in cell lines:Merged 
pictures of Anti-Myc FRP and F-Actin staining
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The FBR cells have a very different morphology to the 208Fs as they are highly 
retractile, bipolar cells with no stress fibers. The F-actin runs as thick cables along the 
length of the bipolar cell and is concentrated in the cortex and pseudopodia, which are 
capped by actin rich bundles (See arrows, Figure 5.8, panel (a)). The cell on the right 
in Figure 5.8, Panel (a), (b), (c), and (d), although transiently transfected with FRP is a 
good example of the phalloidin staining of FBRs. The actin staining pattern of both the 
transfected and adjoining untransfected FBR v-fos transformed FRP cells is shown by 
Figure 5.8. The FRP stained cell is on the left of the panels, under FRP. The 
localisation of the FRP in transfected FBR cells are shown by Figure 5.8. The 
expression of FRP in all of the transfected cells examined was of a peri-nuclear, 
cytoplasmic localisation with a slight punctate expression, particularly in Panels (a)-(d), 
but the expression in the two cells in Panels(e)-(h), is very high and not punctate. This 
punctate appearance is most likely the expression of FRP associated with the ER and 
golgi bodies during secretion. The expression in FBR FRP transfected cells is 
proximal to the nucleus in the cell body. As the figure exemplifies, no expression was 
seen at the pseudopod tips. The transient transfection of FRP in FBR cells does not 
revert the bipolar, transformed phenotype.
The localisation of the FRP in two transfected RAS cells is shown in Figure 5.9. 
The expression in the RAS cell line was again mostly peri-nuclear and of a punctate 
appearance as the lower transfected cell in Panels (a)-(e), and both of the transfected 
cells in Panels (e)-(h), in Figure 5.9 highlight. The RAS cell line has a very different 
morphology to that of the fibroblastoid parental cells. The RAS cells in a cultured 
population are of an irregular morphology. A cell type commonly present is of a 
somewhat flat irregular triangular or rectangular shape, with multiple short actin rich 
protruding edges (See arrows, Figure 5.9, panel (a)). It is rich in actin bundles and 
sometimes has an actin rich ruffling edge (See arrow, Figure 5.9, panel (b)). This cell 
type can also have weak stress fiber bundles along the ventrical of the cell. Another 
cell type, with a shorter and broader bipolar morphology (See Figure 5.9, panels (e)- 
(h)), has F-actin staining along the edges of the cell with thick actin rich ruffling 
bundles at either end of the cell and weak stress fibers running in parallel along the 
length of the cell (See arrows, Figure 5.9, panel (f)).
The FBR Tam-67 cells have a partially reverted phenotype similar to 208Fs. 
They are of a flat morphology with prominent stress fibers that run in parallel arrays 
along the ventral surface of the cell, but also have actin rich ruffling edges at one or 
both edges of the cell (See arrows, Figure 5.10, panel (e)). This actin staining pattern 
of FBR Tam-67s is seen in both the transfected and adjoining untransfected FRP
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Figure 5.7
208F Transiently Transfected with myc tagged FRP expression vector and
indirectly stained for FRP and F-actin
The panels (a)-(d), and (e)-(h), are sectioned Z-steps from the bottom of the 
cell upwards at 0.5 \xm increments of transiently transfected 208F cells. The FRP 
stained cell is on the left of the panels, under FRP, and the same cell stained for F- 
actin, under F-actin, is on the right. Other cultured but untransfected cells are also 
shown in the F-actin stained right half of the panel.
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208F FRP Transient Transfection: Anti-Myc FRP and 
F-Actin staining
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Figure 5.8
FBR cells Transiently Transfected with myc tagged FRP expression
vector and indirectly stained for FRP and F-actin
The panels (a)-(d), and (e)-(h), are sectioned Z-steps from the bottom of the 
cell upwards at 0.5 pm increments of transiently transfected FBR cells. The FRP 
stained cell is on the left of the panels, under FRP, and the same cell stained for F- 
actin, under F-actin, is on the right. Other cultured but untransfected cells are also 
shown in the F-actin stained right half of the panel.
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Figure 5.9
RAS cells transiently transfected with myc tagged FRP expression vector
and indirectly stained for FRP and F-actin
The panels (a)-(d), and (e)-(h), are sectioned Z-steps from the bottom of the 
cell upwards at 0.5 pm increments of transiently transfected RAS cells. The FRP 
stained cell is on the left of the panels, under FRP, and the same cell stained for F- 
actin, under F-actin, is on the right. Other cultured but untransfected cells are also 
shown in the F-actin stained right half of the panel.
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RAS FRP Transient Transfection: Anti-Myc FRP 
and F-Actin staining
cells and is shown by Figure 5.10. The localisation of the FRP in two representatives 
of transfected FBR Tam-67 cells is shown by Figure 5.10. The expression of FRP in 
all of the transfected cells examined was of a cytoplasmic localisation, proximal to the 
nucleus.
FRP is localised peri-nuclear in the cytoplasm with a punctate expression in all 
of the cell lines. A feature of secreted proteins is the localisation in the ER and golgi 
bodies. The cytoskeletal arrangements of actin was maintained in all of the FRP 
transfected cell lines.. No morphological reversion of the transformed phenotype is 
observed in any of the FRP transiently transfected cells or in the 208Fs or FBR-Tam67 
cells. Control transfections were performed using the expression vector without a 
gene and with a myc-tagged p-gal reporter gene. The empty expression vector did not 
stain for myc, whilst the myc tagged p-gal reporter also localised cytoplasmically. The 
staining patterns for F-actin in the control transfected cell lines was the same as in 
untransfected cells (Data not shown).
5.2.5 Stable Transfection of FBR Cell Line with Myc tagged FRP
To further investigate the effect of expression of FRP-myc in FBR cell line a 
stable clone was generated. The stable cell lines were derived to determine the effect 
of long term FRP expression changes in morphology, proliferation rate, anchorage 
independent growth and invasiveness.
The stable expression of FRP in FBR cell line was achieved as described in 
Chapter 2, section 2.2.24, using the previously described pcDNA3.1-Myc-His A/FRP 
expression vector. A neomycin resistant FBR clone, Neo, was also isolated using the 
empty vector described pcDNA3.1-Myc-His A. After transfection and G418 selection, 
twelve FRP expressing clones and six Neo clones were propagated. The 
homogeneous expression of FRP in the different clones was analysed initially 
immunocytochemically using indirect immunofluorescence. Although all of the clones 
contained cells that expressed myc-tagged FRP, only in clone six, named FRP Clone 
6, were all the cells expressing myc-tagged FRP. Figure 5.11 exemplifies the 
expression of myc-tagged FRP in FRP Clone 6 and also demonstrates the absence of 
expression in Neo Clone 2. The F-Actin staining of the FRP expressing and non­
expressing FBR clones is also shown.
The FRP Clone 6 and Neo Clone 2 were further analysed by Western Blotting 
to further confirm expression in soluble protein extracts and in the conditioned media.
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Figure 5.10 
FBR Tam-67 cells transiently transfected with myc tagged FRP expression 
vector and indirectly stained for FRP and F-actin
The panels (a)-(d), are pictures of the same FBR-Tam-67 cells sectioned in Z- 
steps from the bottom of the cell upwards at 0.5 i^m increments. The panels (e)-(h), 
are pictures of the same FBR Tam-67 cells sectioned in Z-steps from the bottom of the 
cell upwards at 0.5 |xm increments. The FRP stained cell is on the left of the panels, 
under FRP, and the same cell stained for F-actin, under F-actin, is on the right. Other 
cultured but untransfected cells are also shown in the F-actin stained right half of the 
panel with a punctate expression, particularly in Panels (a)-(d). The expression in the 
two cells in Panels(e)-(h), is more pronounced.
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This ensured that the correct size of protein was being produced and secreted. 
The soluble proteins were extracted from cells growing in media supplemented with 
10% serum, and conditioned media from the clones cultured in serum-free conditions 
for four days. The detection of protein by Western blotting was determined using a 
primary mouse Myc antibody and a secondary HRP-conjugated anti-mouse antibody. 
The resulting expression of FRP-myc is shown by Figure 5.12 which confirmed that the 
FRP-myc protein was indeed expressed and secreted in FRP Clone 6 and was of the 
correct molecular mass.
The cDNA sequence of rat FRP predicts an open reading frame from the first 
Kozak ATG initiation signal at positions 64-981. This results in a polypeptide of 306 
amino acids with a calculated molecular mass of 34.6kDa and an isoelectric point of 
5.2. Computer analysis of the amino acid sequence predicts an eukaryotic signal 
sequence with a cleavage site between residues 18 and 19 (positions -1 and 1). that 
suggest it is a secreted protein. The translation starting with the N-terminal amino acid 
sequence of EEEQRS results in a mature product of 32.5kDa and the protein contains 
three potential N-glycosylation sites (Asn-Xaa-Ser/Thr), at amino acid positions 124, 
155 and 160, and 20 Cys residues. Recombinant expression of rat FRP in Cos1 cells 
pulse labeled with [^S] cysteine and subsequent SDS/PAGE analysis revealed a 
diffuse molecular mass pattern of 40-48kDa75kDa (Zwijsen et a!., 1994). The 
concentration of Cos1 cells expressing FRP conditioned media by hydroxyapatite 
chromatography and partially purified by heparin-Sepharose chromatography and 
Superdex G75 gel-filtration chromatography resulted in FRP elution in a fraction of 55- 
75kDa (Zwijsen etal., 1994). Thus, the native molecular mass of FRP is 55-75kDa.
5.2.6 Characterisation of FBR FRP cell line
5.2.6.1 Morphological characteristics
The morphological characteristics of the FRP Clone 6 were examined and 
compared to the typical bipolar FBR like Neo Clone 2 cells, with regards to loss of the 
bipolar shape and retraction of pseudopod extensions into a flatter cell morphology. 
No obvious differences were detected. Figure 5.13 depicts the cultured cells 
photographed using a Nikon Diaphot camera. No apparent change in morphology at 
confluence, or sub-confluence was observed. The cells exhibit a typical FBR-like 
retractile bipolar morphology with no shortening of the pseudopodia extensions.
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Figure 5.11 
FBR Neo Clone 2 and FRP Clone 6 cells indirectly stained for FRP and F- 
actin
The panels (a), (b), and panels (c), (d), are pictures of the same FRP Clone 6 
cells, with the FRP expression shown by panels (a), and (c), with the corresponding F- 
Actin staining shown by panels (b), and (d), respectively. The panels (e), and (f), are 
pictures of the same FBR Neo Clone 2 cells, with the absence of FRP expression 
shown by panel (e), with the corresponding F-Actin staining shown by panel (f).
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Figure 5.12 
Protein detection by Western blot analysis of FBR Neo Clone 2 and FRP 
Clone 6
This figure details the protein detection of FRP by Western blotting in FBR Neo 
Clone 2 and FRP Clone 6 using an anti-Myc antibody. Panel A in the top of the figure 
shows that using soluble protein from exponentially growing cells, the Neo Clone 2 has 
no expression whilst the FRP Clone 6 has protein expression of a specific band around 
40 kDa. Panel B in the bottom of the figure shows that using conditioned media from 
quiescent cells, the Neo Clone 2 has no expression whilst the FRP Clone 6 has an 
excreted native protein of a band around 55 kDa.
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Figure 5.13 
Morphological Characteristics of FRP Clone 6 and FBR Neo 2
The stable cell lines were grown in DMEM supplemented with 10% FCS and 
photographed with a Nikon inverted Diaphot microscope. Panel (a), shows the FBR 
Neo Clone 2 cells at a high density and panel (b), at a lower cell density. Panel (c), 
shows the FBR FRP Clone 6 cells at a high density and panel (d), at a lower cell 
density.
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Figure 5.14 
FBR FRP Clone 6 and FBR Neo Clone 2 indirectly stained for FRP and F- 
actin
The confocal images shown by the panels (a)-(d), (e)-(h), and (i)-(l), are three 
different FRP Clone 6 cells, sectioned in Z-steps from the bottom of the cells upwards 
at 0.5 urn increments. The panels (m)-(p), represent FBR Neo Clone 2 cells sectioned 
from the bottom of the cell upwards at 100 micometer increments. The FRP stained 
cells are on the left of the panels, under FRP, and the same cells stained for F-actin, 
under F-actin, is on the right.
198
anti-myc
FRP
FBR FRP Clone 6
anti-myc 
FRPF-actin
(a)
F-actin
(e)
FBR FRP Clone 6
anti-myc „
PRP F-actin
FBR Neo
F-actinanti-mycFRP
(i) (m)■
0) (n)
(k) (o)
(i) (p)
Figure 5.14
FBR FRP Clone 6 and FBR Neo Clone 2 
indirectly stained for FRP and F-actin
Cells were further examined by immunofluorescence to examine F-actin 
structure and to confirm the expression of FRP-myc. The expression of myc-tagged 
FRP and F-actin in three representative fields of FRP Clone 6 and one representative 
field of Neo Clone 2 is shown by Figure 5.14. Detailed examination of the FRP Clone 
6 reveals that although FRP is expressed, there is no change in the F-Actin 
distribution. In the Neo Clone 2 the F-actin locates as thick cables that run along the 
length of the bipolar cell and is concentrated in the cortex and pseudopodia, that are 
capped by actin rich bundles. The merged pictures of myc tagged FRP (Green), and 
F-actin (Red), localisation for FRP Clone 6 cells is shown by Figure 5.15. FRP is 
localised cytoplasmically in all of the cells examined whilst the cytoskeletal distribution 
pattern of F-Actin is maintained. However, within the cellular population of FRP Clone 
6, a subclone population with a flatter morphology, which at first appeared to be a 
reverted cell type, existed. The merged pictures of myc tagged FRP (Green), and F- 
actin (Red), localisation for FRP Clone 6 cells Figure 5.16 shows that these flatter cells 
are in fact undergoing cell division.
5.2.6.2 Proliferation rate and colony formation in soft agar
FRP is down-regulated in v-fos and K-ras transformed 208F fibroblasts, in v- 
myc transformed NIH3T3 cells and also in various human tumour cells (Mashimo et 
al., 1997). Therefore, it was possible that FRP exhibited a tumour suppressor function 
through negative growth regulation. The proliferation rate of the FBR Neo Clone 2 
was compared to the proliferation rate of FRP Clone 6 over six days to ascertain 
whether FRP suppresses the growth of the v-fos transformed cell line. The results of 
the proliferation rate analysis are shown by Table 5.1. There is no significant 
difference in the rate of proliferation in the cells examined and furthermore, the cells 
were unable to proliferate in low serum, (0.5%), conditions.
DAYS
Table 5.1 Proliferation Rates of FBR Neo Clone 2 and FBR FRP Clone 6
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Figure 5.15
Merged pictures of FRP and F-actin staining
The indirect staining of FRP is shown in green and the F-actin is shown in red. 
Panels (a), and (b), and (c), are different cells of FRP Clone 6 population and panel 
(d), shows a representative cell of FBR Neo Clone 2.
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Figure 5.15
Merged pictures of anti-myc and F-Actin staining in 
FBR Stable expressing FRP and Neo Clone
Figure 5.16
Merged pictures of FRP and F-actin staining
The indirect staining of FRP is shown in green and the F-actin is shown in red. 
Panel (a), shows a FRP Clone 6 cell undergoing division, panel (b), shows two cells 
after mitosis and panel (c), shows the bipolar phenotype of two cells after mitosis
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Figure 5.16
Merged pictures of anti-myc FRP and F-actin 
staining FBR FRP Clone 6 during Cell Division
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Previous work in this laboratory has characterised FBRs as anchorage 
independent, whereas 208Fs are unable to grow in semi-solid media. Flat revertants 
isolated from FBJ-MuSV and FBR-MuSV transformed cell lines failed to form colonies 
in semi-solid medium and do not form tumours after injection into nude mice (Zarbl et 
ai, 1997; Wisdom and Verma, 1991). The anchorage-independent growth of the FBR 
FRP Clone 6 and FBR Neo Clone 2 was examined by determining their ability to form 
colonies in methylcellulose over 18 days. The number of colonies formed were 
counted in ten representative fields of 0.25 cm2 per 10cm petri dish. The number of 
colonies per plate and their morphology are shown by Figure 5.17 which highlights the 
ability of both the FBR Neo Clone 2 and FBR FRP Clone 6 to grow under anchorage- 
independent conditions and additionally the colonies formed in both of the clones 
examined were of similar size and distribution.
5.2.6.3 Response of FRB neo and FBR FRP to Matrigel Invasion Assay
Invasion occurs when cells from the primary tumour site migrate through the 
cellular basement membrane components into surrounding tissues resulting in 
metastasis. A quantitative in vitro inverse invasion assay that determines the ability of 
cells to migrate across a membrane and then into a thick layer of the reconstituted 
ECM, reduced-growth-factor Matrigel, can be used to measure invasion (Hennigan et 
al., 1994). In this assay, FBR cells are constitutively invasive (growth factor 
independent), whereas 208F parental cells are conditionally invasive being dependent 
upon growth factor stimulation, i.e. EGF, PDGF (Lamb etal., 1997a).
The in vitro invasion assay was performed using FBR cell line as compared to 
FBR clone 6, and also using FBR neo 2 as compared to FBR clone 6. Cells were 
plated at equal density, 1 x 104 per well, and incubated for three days, after which the 
cells were fixed in the matrigel and the nucleus stained with propidium iodide. The 
invasion of the cells through the matrigel was quantified using confocal microscopy by 
examining the number of cells at ten [im intervals above the filter. As shown in Figure 
5.18 FRP can suppress in vitro invasion of FBR cells. In this experiment the invasion 
of FBR FRP clone 6 cells are impaired by 70% as compared to FBRs and FBR neo 
clone 2.
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Figure 5.17 
Comparative Growth of FBR Neo Clone 2 and FBR FRP Clone 6 in 
Methylcellulose
Cells were grown in methylcellulose containing 10% FCS for 18 days, and 
photographed with an inverted Nikon Diaphot microscope at 100x magnification. In 
section A, panel (a), the FBR Neo Clone 2 and panel (b), the FBR FRP Clone 6 
represents colony size and distribution of the cell colonies.
In section B the number of colonies per 10cm dish in duplicate for each of the 
clones examined is tabulated.
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\  Morphological Characteristics
FBR Neo Clone 2 FBR FRP Clone 6
Table of Colony Growth
FBR Neo 2 3780/3379
FBR FRP 6 3635/3428
Figure 5.17
FBR Stable expressing FRP and Neo Clone: 
Growth in Methylcellulose
IFigure 5.18 
In vitro Inverse Invasion Assay of FBR Neo 2 and FBR FRP Clone 6
A: The migration of FBRs and FBR FRP clone 6 is detailed. The confocal 
images are of propidium iodide-stained cell nuclei above the filter. The various 
micrometer points above the filter in the in vitro invasion assay is shown.
B: The bar graphs exemplifies the relative number of cells invading through the 
matrigel, as quantified with a Bio-Rad program (Cosmos), as percentage of total cells 
of FBR neo clone 2 and FBR FRP clone 6.
(This experiment was performed by Prof.Brad Ozanne)
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In vitro Inverse Invasion Assay of 
FBR Neo 2 and FBR FRP Clone 6
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5.3 Discussion
FRP is a secreted glycoprotein (Zwijsen et al., 1994), and 24 hours post 
transient transfection followed by indirect immunoflourescence using anti-myc primary 
antibody locates FRP peri-nuclear in the cytoplasm in all of the cell lines examined, 
208F, FBR, RAS, and FBR Tam-67. In most of the cells the expression was of a 
strong punctate appearance, similar to other overexpressed secreted proteins. This 
punctate appearance is most likely the secretion of the protein from the ER to the golgi 
bodies translocating the protein out of the cell. No expression was detected in the 
nucleus, at the cell membrane or at the tips of the FBR pseudopod extensions in any 
of the transiently transfected cells. No commercial antibody was available to locate 
protein expression in these cells, although no cellular protein has previously been 
detectable (Shibanumaeta!., 1993).
The biological functions of FRP are hinted at by the extinguished expression in 
ras-transformed cells that is recovered to a normal level in flat revertants plus the fact 
that TSC-36 was isolated as a TGF-[31 effector gene (Shibanuma et al., 1993), itself a 
potent inhibitor of growth in various cell types. In addition, FRP expression is also 
down-regulated in v-ras and v-myc transformants and also in human cancer cell lines 
(Mashimo et ai, 1997), suggesting a role in the negative regulation of tumour 
progression. The sequence similarity of FRP with the follistatin modules of follistatin 
(Shibanuma et al., 1993; Zwijsen et ai, 1994), that have a structural motif for growth- 
factor binding, would also suggest a function in the growth regulation of cells.
Follistatin (reviewed by Phillips and de Krester, 1998), was first discovered 
during ovarian inhibin and activin purification from follicular fluid, where it was identified 
as suppressing FSH secretion, but with properties distinct from inhibin. However, 
follistatin is not only an activin-binding protein but can also bind to other members of 
the TGF-p superfamily, namely BMP-4 and BMP-7 (Fainsod etal., 1997; Yamashita et 
al., 1995), and also the serum protein a2-macroglobulin (Phillips et al., 1997). 
Characterisation of the follistatin gene promoter found it to contain an AP-1 site 
(Miyanaga and Shimasaki, 1993).
The follistatin family (reviewed by Phillips and de Krester, 1998), of which there 
are thirteen, are based upon the presence of a highly conserved module sequence 
and are not based upon follistatin-like activity. The modular structure has sequence 
similarity with EGF, and with the Kazal family of enzyme inhibitors, such as ovomucoid. 
In most of the family members an insertion in the ovomucoid-like inhibitory loop 
ablates the protease activity in the follistatin domain.
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The follistatin modules of agrin, to which FRP exhibits sequence identity 
(Shibanuma et al., 1993; Zwijsen et al., 1994), have a proposed growth factor affinity 
with a suggested role in the regulation of the activity of growth factors from the TGFp 
and PDGF families (Patthy and Nikolics, 1993).
SPARC, also known as osteonectin, BM-40 and 43K protein regulates cellular- 
matrix interactions during vasculation, morphogenesis, wound healing and 
tumourigenesis (reviewed Lane et al., 1994; Motamed and Sage, 1997). However 
ascribing the various functions of SPARC to defined protein modules has mapped 
biological function outwith the follistatin domains (Hasselaar and Sage, 1992; Lane et 
al., 1994).
However, the homology that exists between FRP, Follistain, SPARC, and Agrin 
is limited. The common domain that all the proteins have is follistatin, whilst the 
remainder of the sequences are unrelated.
The sequence similarities of the mouse TSC-36 homologue, rat and human 
FRPs, plus their induction by TGFp, suggests a growth-factor binding capacity and a 
biological function in the modulation of action of some growth factors on cell 
proliferation and differentiation.
To examine the possible role and function of FRP in v-fos transformants a 
stable cell clone expressing FRP was isolated after transfection with pcDNA3.1 Myc- 
His/FRP conferring G418, neomycin resistance. A stable cell clone conferring 
neomycin resistance was also isolated after transfection with pcDNA3.1 Myc-His 
vector alone.
The expression of FRP was confirmed immunocytochemically and by Western 
blot analysis. The cellular location of FRP in the stably expressing FBR clone was 
similar to that found in transient expression, with peri-nuclear cytoplasmic expression 
and no detectable expression in the nucleus, cell membrane or in the pseudopod 
extensions and tips in any cells examined. In several of the stable transfected cells 
the expression was of a strong punctate appearance, albeit at a lower intensity than 
the transiently transfected cells. As shown by Western blot analysis, a protein of 
approximately 41kDa was detected in Triton-X soluble protein extracts, whilst the 
protein detected in serum-free conditioned media was of approximately 55kDa.
Revertant cell lines of the transformed phenotype have a flat morphology 
mainly due to alterations in their cytoskeletal components (Weber et al., 1975; Pollack 
et al., 1975). Although most of the FBR FRP Clone 6 cells remained transformed in 
culture, with a characteristic FBR bipolar phenotype under phase contrast microscopy, 
a small portion of the cells appeared revertant with a flat morphology. Therefore, the
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F-actin cytoskeleton architecture was studied as it would possibly reveal a correlation 
between oncogenic transformation and the appearance of cytoskeletal actin, to serve 
as a marker for reversion. In the bipolar phenotype cells, there was no change in the 
thick actin cables running along the length of the cells or the actin rich bundles at the 
pseudopod tip. However, it became apparent upon F-actin staining that the cell 
population with a flatter morphology were in fact undergoing cell division. Thus FRP 
expression does not morphologically revert v-fos transformants. A previous report of 
constitutive expression of FRP homologue, mouse TSC-36, in MC3T3 cells also 
detailed that the morphology was not significantly affected (Mashimo etal., 1997).
FBR-MuSV and FBJ-MuSV transformed 208F cells are anchorage independent 
and can grow in soft agar, whereas 208F cells cannot (Hennigan et al., 1994). In 
contrast, flat revertants of FBR-MuSV and FBJ-MuSV isolated from transformed cell 
lines do not form colonies in semi-solid medium or form tumours upon injection into 
nude mice (Zarbl et al., 1997; Wisdom and Verma, 1990). The colony formation of 
FBR FRP Clone 6 and FBR neo clone in methylcellulose is of no significant difference 
with similar colony numbers of similar sizes forming. Therefore FRP expression does 
not affect anchorage independence of FBR cells.
As FRP sequence identity to Follistatin and follistatin like domains of Agrin 
suggested FRP had a role in the negative regulation of growth and tumour 
progression, the growth characteristics of the FBR FRP clone 6 cells were analysed in 
a proliferation assay. FRP expression did not affect proliferation of FBR cells in 
comparison to the FBR neo clone, in line with previous reportings of no significant 
growth changes in MC3T3 cells overexpressing FRP mouse homologue TSC-36 
(Mashimo et al., 1997). The FRP expressing clone maintains a transformed 
phenotype in serum-free media is not density inhibited and forms multiple layers of 
cells at confluence. These findings in conjunction with that of others (Mashimo et al., 
1997), dictates that FRP does not regulate cell growth, anchorage-independent growth 
or revert the transformed bipolar phenotype of FBR-MuSV transformed 208F 
fibroblasts.
However, the isolation of the FRP homologue TSC-36 after TGF-p induced 
stimulation (Shibanuma et al., 1993), and ablation of expression in several human 
cancer cell lines, and in v-ras and v-myc transformed mouse fibroblasts (Mashimo et 
al, 1997), indicated that down-regulation is required for tumour progression.
Another aspect of transformation that correlates with tumourigenesis is 
increased cell motility and invasion. The invasiveness of FBR and 208F cells was 
previously measured using a quantitative in vitro invasion assay which determines the
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ability of cells to migrate across a membrane and into a thick layer of reduced growth 
factor Matrigel, reconstituted ECM (Hennigan et al., 1994). In this assay, 208F 
fibroblasts are conditionally invasive requiring growth factors such as EGF, PDGF to 
invade efficiently, whereas FBRs are constitutively invasive (Hennigan et al., 1994; 
Lamb etal., 1997a).
AP-1 in transformed cells activates a multigenic invasion program. This 
rationale would dictate that genes which are found down-regulated by AP-1 may be 
involved in suppressing invasive behaviour as well as other transformation associated 
characteristics. Previous work in our laboratory details that expression of the 
hyaluronan receptor, CD44, is required for invasion of 208Fs and FBRs in an in vitro 
invasion assay. The blocking of CD44 expression by antisense oligonucleotides 
renders the FBR cells non-invasive. Additionally an increase in CD44 expression is 
dependent upon AP-1 activity in FBRs and in EGF stimulated 208Fs (Lamb et al., 
1997a). Furthermore, Ezrin, which associated with CD44 is up-regulated in v-fos 
transformants, and is required for pseudopod extension and cell motility which are two 
important aspects of invasion (Jooss and Muller, 1995; Lamb et al., 1997b). Work by 
others has recently shown MMP-9, an AP-1 transactivated gene, which is up-regulated 
in many transformed cells and tumour derived cell lines associates with CD44 and this 
association is necessary for invasion (Yu and Stamenkovic, 1998). Therefore, the role 
of some of the v-fos up-regulated genes were examined and have been shown to be 
involved in invasive behaviour and transformation.
The most striking observation from the characterisation studies conducted in 
this study is that expression of FRP severely impaired invasion by 70 % in FBR cells. 
Interestingly, this dispels a previous correlation between the transformed bipolar 
morphology and the ability to invade (Hennigan, Ph.D. Dissertation, 1993). In our 
laboratory the motility of FBRs has been studied using time lapse phase contrast 
confocal microscopy and it is well documented that the cell extends an elongated 
pseudopod tip at one end with subsequent attachment of this leading projection, 
followed by nuclear translocation and finally the retraction of the tailing end, resulting in 
translocation of the entire cell (Hennigan, Ph.D. Dissertation, 1993; Lamb, personal 
communication). The locomotive state of the cells are similar when moving up through 
the polycarbonate filter pores and through the matrigel. The FBRs when inside or on 
top of the matrigel are more extremely bipolar than those in routine culture (Hennigan, 
Ph.D. Dissertation, 1993). In contrast, the invasive 208F cells that have migrated 
through the polycarbonate filter pores are of a fibroblastoid morphology. Invariably, 
conditionally invading 208Fs inside matrigel are bipolar, which suggested a correlation 
between the bipolar shape and invasiveness (Hennigan Ph.D. Dissertation, 1993).
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However, the FRP expressing clone are almost exclusively bipolar and yet the invasive 
capability is severely retarded. In addition blocked expression of CD44 by antisense 
oligonucleotides in FBRs , does not induce phenotypic changes, but blocks invasion.
The FRP expressing cell line is not failing to invade through morphological 
limitations, growth inhibition, or anchorage dependence. Therefore, the mechanism by 
which FRP blocks invasion is by other means.
The proposed function of FRP has previously been associated with tumour 
suppression, and the sequence homologies to Follistatin and SPARC indicated that 
the FRP mouse homologue TSC-36 has an ability to associate with other extracellular 
proteins (Shibanuma etal., 1993; Mashimo e ta i, 1997). A recent report examined the 
link of FRP homologue mouse TSC-36 with ECM binding whereby it was examined 
whether TSC-36 protein bound heparin sulphate and collagens. The results show that 
TSC-36 protein did not bind type I and type II collagen, activin A, TGF (31, inhibin A , or 
BMP4/7, but had a low affinity to sulfate-cellulofine. This indicated that the binding 
affinity of TSC-36 is different to that of Follistatin and SPARC, although gel-filtration 
analysis highlighted a potential association with other, as yet unidentified, extracellular 
proteins (Mashimo etal., 1997).
This tentative link with extracellular protein binding would suggest that in 208F 
cells, FRP functions as an extracellular autocrine binding protein with tumour 
suppressor activity. The mechanism by which it functions is unknown but the 
homologous regions with follistatin modules of follistatin, agrin and SPARC would 
suggest a conserved binding domain. The high number of cysteine residues (6.5%), 
and their distribution into two separate regions in the sequence indicates the presence 
of several disulphide bridges that would stabilise the protein conformation. PROSITE 
sequence comparisons and two-dimensional PAGE analysis reveals extensive post- 
translational modifications including several phosphorylation sites, six of which are 
CKII phosphorylation sites, the other a protein kinase C phosphorylation site. The 
signalling pathway may function through these phosphorylation sites in the protein. In 
FBRs the AP-1 transrepressed FRP and ablated tumour suppressor signalling pathway 
would be switched off. The over expression of FRP in FBRs would result in a block of 
invasion through this extracellular binding to matrix proteins and subsequent signalling 
pathway.
In summary, the presented studies into the effects of FRP in FBR v-fos 
transformants has revealed that it is not involved in cell morphology, anchorage- 
dependent growth or proliferation. However, it does play a significant role in 
suppressing invasion.
215
Chapter 6
Cloning and Characterisation of two Novel Down- 
regulated cDNAs in AP-1 Transformation
216
6.1 INTRODUCTION
In the down-regulated library many of the genes encode proteins whose 
function have previously been associated with various aspects of transformation. 
Several have known or suggested tumour suppressor activity, and many others have 
functions which alter ECM, cytoskeleton and transcription as discussed in chapter 3.
The expression analysis of these down-regulated gene clones by Northern 
blotting in oncogenic and mitogenic transformed cells as previously described in 
chapter 4, enabled selection of clones for further study. Two such clones were 
selected, KD1 and CD10. KD1 is a novel clone with homology to an EST sequence 
that exhibited a weak similarity to the helix-loop-helix transcription factor, Alf1. 
Sequence analysis of the clone CD10, revealed homology to a frizzled related protein, 
FrpAP.
This chapter reports the Northern blot expression, tissue distribution and 
cloning of the full-length KD1 clone, named as “Down In FBRs” (DIF1) transcript from 
a 208F cDNA library, sequencing and subsequent computational protein analysis. It 
also details the cloning of DIF1 open reading frame into an expression vector with a 3’ 
Myc Tag, and also into an expression vector with a 3’ GFP fusion protein and 
subsequent transient transfections into 208F, FBR, and RAS cell lines, to determine its 
affect and localisation in these cells.
Clone CD10 shares 100% identity to FrpAP, frizzled family member at the 
protein and DNA level over a short region. A full-length cDNA clone was isolated and 
its nucleic acid sequence revealed it to be near identical to FrpAP.. The Northern blot 
expression and tissue distribution of clone CD10 is reported in this chapter.
This chapter also reports the Northern blot expression, tissue distribution and 
cloning of the full-length FrpAp cDNA from a 208F cDNA library, sequencing and 
computational protein analysis.
The extracellular signalling molecules function as inducers of cell proliferation, 
migration, differentiation, and also in tissue morphogenesis during normal 
development. Moreover, they also function in aberrant growth regulatory pathways 
associated with neoplastic development. The Writ family of glycoproteins are one 
such molecule involved in these processes. The Wnt gene products have long been 
recognised as one of the major players of developmentally important signalling 
molecules. Their signalling functions are vital to adult and embryonic pattern formation 
in Drosophila, in the establishment of the dorso-ventral axis in Xenopus embryos and 
also in the development of the central nervous system in mice, whereby targeted
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disruption of the WntA gene results in serious defects of the midbrain and cerebellum, 
are reviewed (Cadigan and Nusse, 1997).
The identification of Frizzled family members of cell surface proteins function as 
Writ receptors or as components of a Writ receptor complex was initially discovered 
through the Drosophila frizzled {Dfz), gene. The experimental evidence was provided 
by mutations in Dfz. This caused tissue or planar polarity defects whereby alignment 
of the epithelial cells in the wing blade was disrupted, resulting in wing hairs pointing in 
several directions, and they also have disruptions of bristles on the notum and legs 
(Alder, 1992). In addition, a subsequently related gene, Dfz2, when expressed in 
various cell lines by transfection, bind wingless, the Drosophila homologue of Wnt, on 
their cell surface. Furthermore, stable transfection of Dfz2 into nonresponsive 
wingless cells, which also lack Dfz2 expression, enables the accumulation of armidillo 
protein, the p-catenin homologue, in an wingless-dependent manner (Bhanot et al., 
1996; Wang etal., 1996; Wang etal., 1997).
The Frizzled family members are integral membrane proteins characterised by 
their large extracellular portion at the NH2 terminal with highly conserved cysteine-rich 
domain (CRD), that is the putative binding site for Wnt ligands (Bhanot et al., 1996). 
They also contain several putative transmembrane domains and a cytoplasmic tail 
(Wang etal., 1996; Vinson etal., 1989).
The complex interaction between the various members of the Wnt and Frizzled 
families (Nusse and Varmus, 1992; Wang et al., 1996; Bhanot et al., 1996; Yang- 
Snyder etal., 1996; and He etal., 1997), is further complicated by additional regulatory 
proteins that can potentially modulate Wnt signalling during developmental stages and 
in specific tissues. Several Frizzled sub-family members which lack the seven-pass 
transmembrane regions but retain the signal sequence and CRD domain have been 
cloned and are referred to as the sFRP family, secreted frizzled related protein 
(Rattner et al., 1997). Each of these encode a protein with all of the characteristic 
features of the original Drosophila frizzled protein with the exception of the 
transmembrane regions, suggesting that they are secreted. The CRD regions of 
frizzled gene products are of special importance as they are ligand binding sites for 
Wnt gene products (Bhanot etal., 1996; He, etal., 1997; and Leyns etal., 1997). The 
sFRP family are interesting molecules as they are secreted and resemble growth 
factors and cytokines. Their expression is tissue specific and is dependent upon the 
physiological state of the cells. The homology the sFRPs exhibit to the family of 
transmembrane receptors, the frizzled proteins is unusual for a family of secreted 
proteins (Melkonyan etal., 1997).
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The Wnts interact with members of the Frizzled family, that transduce the 
signal to the cytoplasm (Bhanot etal., 1996), and activate dishevelled, which promotes 
the inactivation of glycogen synthase kinase 3 (GSK3). This in turn suppresses the 
activity of p-catenin by promoting its degradation, whilst the inactivation of GSK3 in 
response to wnt signalling leads to the accumulation of cytosolic p-catenin pools, p- 
catenin interacts with HMG-box transcription factors altering their DNA-bending 
properties, thus contributing to specific gene expression (Cavallo etal., 1997).
In addition, several components of the Wnt signalling are implicated in cancers. 
In fact the first Wnt gene discovered, mouse Wnt-1 was identified due to it’s property 
of forming mouse mammary tumours when expressed ectopically due to proviral 
insertion (Nusse and Varmus, 1982). Several wnt genes when overexpressed in mice 
can transform epithelial cells in vitro (Wong et al., 1994), and in humans, increased 
expression of wnt2, wnt5a, wnt7b and wnt 10b have been found in proliferative breast 
lesions and breast cancer (Huguet etal., 1994; Lejeune et al., 1995; Bui et al., 1997). 
In colorectal tumours and in some melanomas, mutations in either APC (truncating the 
protein), (Munemitsu etal., 1995), or p-catenin (stabilising it), can lead to an increased 
activity of p-catenin/Tcf-4 transcription complexes (Korinek et al. 1997; Morin et al., 
1997; Rubinfeld et al., 1997), which can potentially promote carcinogenesis. In Rat-1 
fibroblasts, the parental line from which 208F cell line was derived, Wnt-1 induces 
serum-independent cellular proliferation and changes in morphology (Young et al., 
1998). The Wnt signal transduction pathway is activated. The resulting induction and 
accumulation of cytosolic p-catenin and subsequent Tcf/Lef transcriptional activation 
controls down-stream Wnt target genes. In context with the findings of others with 
regards to deregulation of Wnt signalling pathway and carcinogenesis, the proliferative 
responses of Rat-1 fibroblasts to Wnt-1 is through p-catenin and Tcf/Lef transcriptional 
activity (Young et al., 1998). A schematic representation of the carcinogenesis Wnt 
signalling pathway is shown in Figure 6.
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Figure 6 Wnt pathway in carcinogenesis
219
6.2 RESULTS
6.2.1 Sequence analysis
Clone KD1, was identified through the previously detailed database searches in 
chapter 3 as a novel sequence with homology to an EST, mouse 7.5 dpc embryo 
ecoplacental clone. Figure 6.1 details the homology to the EST clone.
>gb|AA409249|AA409249 EST01172 Mouse 7.5 dpc embryo ectoplacental cone cDNA 
library Mus musculus cDNA clone C0006F12 5‘
Length = 470
Minus Strand HSPs:
Score = 109 (30.1 bits), Expect = 3.8e-22, Sum P(2) = 3.8e-22 
Identities = 25/29 (86%), Positives = 25/29 (86%), Strand = Minus / Plus
Query: 234 AGGATGGAACCTACTGACAACAGCCAGGA 206 
Sbjct: 297 AAG ATGGAACCTACT G AG AAC AACCAG AA 325
Score = 348 (96.2 bits), Expect = 3.8e-22, Sum P(2) = 3.8e-22 
Identities = 82/99 (82%), Positives = 82/99 (82%), Strand = Minus / Plus
Query: 199 AACCTCTGGGACATCCCCCAGGCCCAAATCGAAGATAGGGGCCCCGAGGATGCCCAAGGC 140 
Sbjct: 330 AACCTATGGGACATCCCTCGGGCCCAAACTGAAGAAAGGGGNCCCGGGAGTANCCAGGAC 389
Query: 139 CCAATAGCTGAGGCAGGGGAGGTGGAAGCCATTGCCACC 101 
Sbjct: 390 CCTATAGCTGAGGCAGAGGAGGTGGAAGCCATTGCCAAC 428
Figure 6.1 EST Homologies of Clone KD1
6.2.2 Northern blot and tissue blot analysis
The expression pattern of clone KD1 was analysed by Northern blotting. The 
RNA was isolated from previously described cell lines, 208F and EGF, 208F, FBR, 
RAS and FBR TAM-67. The northern blot was hybridised with 32P labelled KD1 clone 
(refer to Figure 6.2A). An RNA species of approximately 1.9Kb was detected in 208F 
mRNA, but no transcript was seen in the FBR mRNA. This data confirms that clone 
KD1 is down-regulated in FBR v-fos transformed cells. As shown no expression of the 
mRNA transcript was found in FBRs or in 208F cells treated with EGF. There is a two­
fold down-regulation in K-ras transformed cell line. In FBR Tam-67 cells the decrease 
in expression is partial.
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Figure 6.2 
Northern blot and rat Tissue blot of clone KD1
A: This figure details the three day exposure X-ray film of Northern blot probed 
with Clone KD1, in the bottom panel the corresponding scanned X-ray film of the 7S 
Ribosomal loading control is shown. The Northern blot for KD1 was performed three 
times with the same result as that shown.
B: The expression of KD1 in rat tissues is detailed. The actin loading control is 
shown on the right hand side. The tissue blot was performed only once using the 
Clontech rat tissue blot. The size of the mRNA transcript is indicated by arrows with 
regards to the RNA ladder in kilobases and was approximately 1,7Kb.
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Figure 6.2
Northern Blot and Rat Tissue Blot of Clone KD1
To determine which tissues KD1 was expressed, a rat tissue blot was 
hybridised with 32P labelled clone KD1. An RNA species of 1.9Kb was detected in the 
testis, suggesting that its expression is testis specific. It should be noted that the RNA 
species of 2.2Kb in the muscle tissue is from another experiment.
6.2.2
6.2.2.1 Library screening and sequence analysis of full-length cDNA of DIF1
To isolate a full length cDNA clone of KD1, a library derived from 208F mRNA 
was screened with KD1. Approximately 1 x 106 plaques were screened (refer to 
Section 2.2.11). Three rounds of sequential screening of positive plaques resulted in 
the isolation of ten single positive plaques. The pBluescript cDNAs were excised from 
phage (refer to section 2.2.12), and analysed using restriction mapping and automatic 
DNA sequencing. The resulting sequences were aligned using GCG GELASSEMBLE 
package to overlap the sequences to determine the full-length transcript. The full- 
length transcript was named DIF1. The complete nucleic acid sequence and putative 
amino acid sequence of DIF1 is shown by Figure 6.3. Nucleic acid sequence analysis 
revealed an ATG at position 345, located within a consensus translation initiation site 
(Kozak, 1987), and therefore this is predicted to be the first methionine. The coding 
region (903bp), is flanked by a 5’ untranslated region and a 3’ untranslated region 
containing a polyadenylation signal as shown. The DIF1 cDNA encodes a predicted 
polypeptide of 300 amino acids.
6.2.2.2 Prosite analysis of ORF protein translation of DIF1
DNA and protein BLAST searches against the various databases failed to 
identify any significant homologies to known genes. No homologies to transcription 
factor families was detected. Thus ascribing DIF1 to a protein family and function 
proved difficult. However, specialised databases can be searched to detect the 
presence of a motif or sequence pattern in a query sequence that can reveal distant 
relationships. Therefore, the ORF protein translation of DIF1 was subject to protein 
families database of alignments (Pfam) and HMMs and also PROSITE analysis to 
determine if DIF1 protein sequence had identity to any known motifs or protein 
patterns. These are shown by Table 6.1.
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Figure 6.3 
Nucleotide and predicted amino acid sequence of DIF1 cDNA
The nucleotides are numbered above the nucleic acid sequence. Amino acids 
are indicated in single letter code with the first predicted methionine at position 345. 
This is located with a translation initiation site AAGATGG (Kozak, 1987). The 
termination codon is denoted by an asterisk at position 1248.
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10 30 50
AAGGGTGAGGTCTACTCAGCAGGCTCTGCATCTGCGGACACATAATTCAGTGCTGGCTCA
70 90 110
CCAGGCTTTCTGAATCCAAGGACTTGGGGGACTCAAACCCTTTTGTAAGGGTCCTCGGAA
130 150 170
GGGGAAGGTGAACCTGTACAGTGTGTGGTATCACCAAACAGCAGACAGAGCTACCAGAGG
190 210 230
GAATTGTGTAGTATCTTCCAACAATCCAGGCATTAGTCTAAAGGAGCTGAAGGACTTGAC
250 270 290 .
TCAAGTCATCAGAGGAAGGATCTGGTACATCAGTGTGAAGGTTTGTGAATCTTCATCCCT
310 330 350
GTGACCTGAACAGTGTCTTGCCTGCTCTTTCCAAGGAAACTCAAGATGGAACCTACTGAC
M E P T D
370 390 410
AACAGCCAGAACTTCAACCTCTGGGACATCCCCCAGGCCCAAATCGAAGATAGGGGCCCC 
N S Q N F N L W D I P Q A Q I E D R G P
430 450 470
GAGGATGCCCAAGGCCCAATAGCTGAGGCAGGGGAGGTGGAAGCCATTGCCACCATATCA 
E D A Q G P I A E A G E V E A I A T I S
490 510 530
GGGGATGTGTCTGCTGGAGAAGAACCTAGTTCTCCTCAGAGAGCCTCCTCTCCTCCCACT 
G D V S A G E E P S S P Q R A S S P P T
550 570 590
GCTATGGGTTTCATTGGAGAGGCATCATTTGGCAATCCTCTAGCAGGGATGCCTGGTACT 
A M G F I G E A S F G N P L A G M P G T
610 630 650
GAATTCCCTGTTCATGGTGAACTAAATGGAAAGATAGTTGATTTGGTGAGATTCTTGCTA 
E F P V H G E L N G K I V D L V R F L L
670 690 710
GTCAAGTTTAGAAGGATGGAGATAACCAGTAAGGAAGAAATGATCCATAGGACCATGAGA 
V K F R R M E I T S K E E M I H R T M R
730 750 770
GATTATGAGGAGCACTACTCTGTGATCTTTAGTAAGGCCGCTGAGTGCATGAAGCTGATT 
D Y E E H Y S V I F S K A A E C M K L I
790 810 830
TTTGGGGTTGACATGATGGAAGTGGACCCTTTTGTCCACTCCTATTTCCTTTACCCTGCT 
F G V D M M E V D P F V H S Y F L Y P A
850 870 890
CTGGGGATCACCTATGATGGGATGCTACATGGAGTTGTAGGCGTACCCAAGACAGGTCTG 
L G I T Y D G M L H G V V G V P K T G L
910 930 950
GTTATAATTGTCCTGTGCATCATCTTTATAGAGGACAATTGTGTCAGTGAGGAGGTATTC 
V I  I V L C  I I F I E D N C V S E E V F
970 990 1010
TGGCATGTAATGAATAGCCTAGGAATGTATGCTGGAGTCGATCATTTCATATTTGGGGAT 
W H V M N S L G M Y A G V D H F I F G D
1030 1050 1070
CCCAGGAGTCTCATCACTGAAGACTTTGTGCAGGAAGGTTATGTGGAATACAGGCAGGTG
P R S L I T E D F V Q E G Y V E Y R Q V
1090 1110 1130
CCCAACAGCCATCCTCCTCGCTTTGAGTTCCTGTGGGGCCCAAGGGCGTATGCTGAAACC 
P N S H P P R F E F L W G P R A Y A E T
1150 1170 1190
ACCAAGATGAAAATCCTGGAGTTTTATGCCAGCATCGTTAGGCAGGATCCCAGATCCTAC 
T K M K I  L E F Y A S I V R Q D P R S Y
1210 1230 1250
CCTGAGAAGTATGCAGAGGCTTTGAGGGAAGAACAAGAGAGGGCCTAGGCCAGAAAAGCC 
P E K Y A E A L R E E Q E R A *
1270 1290 1310
CAGCAGATAATAGATATGACTGCTCTGACCAGCACAATATGTAGTAAACTCAACAGTTTA
1330 1350 1370
TGGTCAGGCAGAACAGTAAAATAAGTGGTAGACCCCCAAATGAGAGCTATTGGAAAGAGA
1390 1410 1430
GTGTAACCCATTCCTTTCTTACTGTTCTGTTTGGGTGACTTAGGCTCATAATTTTTGAAC
1450 .1470  1490
ATTGTTAACTTTTACTATAAGGCTCATTTACTTGAGAATTTTAAAATTAAAAATGACATC
1510 1530 1550
AGTAATGCCTGTGTTGATTTAGGTCAGGAGAATTTTGTTATCATAAAAACAAACAGTTTT
1570 1590 1610
CTAATTTGTAATATGTCACACAATCTGATACCATCAAAGTTGGAATTTCCTGGACAACAG
1630 1650 1670
AAAACATACTGGCATTAATATAAAAAACAGAATAAAATAAAATTTTTGTTGTGTAAAAAA
1690
AAAAAAAAAAAAAAAA
Figure 6.3 
Nucleotide and predicted amino acid sequence of DIF1 cDNA
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The location of the protein patterns in the DIF1 protein sequence is highlighted by 
Figure 6.4. Figure 6.4 also details the Pfam alignment to the Arginase domain at 
positions 143-155.
..................... .... , \t h1 if f  % 1
Protein kinase C phosphorylation site 1 114-116 TSK
2 123-125 TMR
3 265-267 TTK
Casein kinase II phosphorylation site
1 49-52 SAGE
2 114-117 TSKE
3 115-118 SKEE
4 123-126 TMRD
5 284-287 SYPE
Tyrosine kinase phosphorylation site 1 125-131 RDYEEHY
N-myristoylation site
1 76-81 GNPLAG
2 81-86 GMPGTE
3 172-177 GMLHGV
4 179-184 GVPKTG
5 213-218 GMYAGV
Myc-type, “helix-loop-helix’ 
dimerisation domain signature
1 181-189 PKTGLVIIV
Table 6.1 PROSITE protein patterns of DIF1
The predicted molecular weight of DIF1 is 33.8kDa, theoretical pi is 4.65 and 
the amino acid composition contains 15.7% negatively charged residues (Asp & Glu), 
and 8% positively charged residues (Arg & Lys), as determined by ExPASy protparam 
analysis. No nuclear localisation sequences were detected.
The full-length DIF1 clone exhibits no homology to any known sequences 
through blastx or blastn searches but is identical to an EST database entry, 
EST222935 Normalized rat spleen, Bento Soares Rattus sp. cDNA clone RSPCE20 3' 
end, sequence. The homology of DIF1 to EST222935 is shown in Figure 6.5 below.
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Figure 6.4 
PROSITE and Pfam analysis of predicted amino acid sequence of DIF1 
cDNA
A: Amino acids are numbered on the left beginning at the first methionine. The 
Protein kinase C phosphorylation sites are shown in red, Casein kinase II 
phosphorylation sites are shown in bold, Tyrosine kinase phosphorylation site is shown 
in italics, N-myristoylation sites are shown in blue, and Myc-type helix-loop-helix 
dimerisation domain signature is shown underlined.
B: Homology of DIF1 (KD1), amino acid positions 143-155 to the Arginase 
motif. The identical residues are shown by single amino acid code and similar 
residues are shown by +.
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A
I MEPTDNSQNF N L WD I P Q A Q I  EDRGPEDAQG P I AEAGEVEA IATISGDVSA 
51 GEEPSSPQRA SSPPTAMGFI  GEASFGN P L A  GMPGTEFPVH G E L N G K I V D L  
101 VRFLLVKFRR MEITSK.EEMI  H R T M R D Y E E H  Y SVI FSKAAE C M K L I F G V D M  
151 MEVDPFVH SY F L Y P A L GI T Y  D G M L H G  V V G  V  P K T GL V I I V L  CI IF IEDNCV 
201 S EEVF WH VM N SLGM Y A GV D H  FIFGDPRSLI  TEDFVQEG YV EYRQVPNSHP 
251 PRFEFLWGPR A Y A E T T K M K I  LEFYASIVRQ DPRSYPEKYA EALREEQERA 
301 *
B
Alignment of arginase vs OuervSeq/143-155
*->Gs1vglDvVEVNP<-*
+++ g+D +EV+P 
QuerySeq 143 KLIFGVDMMEVDP 155
Figure 6.4 
PROSITE and Pfam analysis of predicted 
amino acid sequence of DIF1 cDNA
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Score = 1845 (509.8 bits), Expect = 5.9e-205, Sum P(2) = 5.9e-205 
Identities = 369/369 (100%), Positives = 369/369 (100%), Strand = Minus / Plus
Query: 1681 TTTTTTTAC AC AACAAAAATTTTATTTTATTCT GTTTTTTAT ATTAAT GCCAGTAT GTTT 1622 
Sbjct: 1 TTTTTTTACAC AACAAAAATTTTATTTTATT CTGTTTTTTATATTAAT GCCAGTAT GTTT 60
Query: 1621 TCTGTTGTCCAGGAAATTCCAACTTTGATGGTATCAGATTGTGTGACATATTACAAATTA 1562 
Sbjct: 61 TCTGTTGTCCAGGAAATTCCAACTTTGATGGTATCAGATTGTGTGACATATTACAAATTA 120
Query: 1561 GAAAACTGTTTGTTTTTATGATAACAAAATTCTCCTGACCTAAATCAACACAGGCATTAC 1502 
Sbjct : 121 GAAAACTGTTTGTTTTTATGATAACAAAATTCTCCTGACCTAAATCAACACAGGCATTAC 180
Query: 1501 TGATGTCATTTTTAATTTTAAAATTCTCAAGTAAATGAGCCTTATAGTAAAAGTTAACAA 1442 
Sbjct: 181 TGATGTCAI I I I IAATTTTAAAATTCTCAAGTAAATGAGCCTTATAGTAAAAGTTAACAA 240
Query: 1441 TGTTCAAAAATTATGAGCCTAAGTCACCCAAACAGAACAGTAAGAAAGGAATGGGTTACA 1382 
Sbjct: 241 TGTTCAAAAATTATGAGCCTAAGTCACCCAAACAGAACAGTAAGAAAGGAATGGGTTACA 300
Query: 1381 CT CT CTTTCCAATAGCT CTC ATTT GGGGGTCTACCACTTATTTTACT GTT CT GCCTG ACC 1322 
Sbjct: 301 CTCTCTTTCCAATAGCTCTCATTTGGGGGTCTACCACTTATTTTACTGTTCTGCCTGACC 360
Query: 1321 ATAAACTGT 1313 
Sbjct: 361 ATAAACTGT 369
Score = 840 (232.1 bits), Expect = 5.9e-205, Sum P(2) = 5.9e-205 
Identities = 169/171 (98%), Positives = 169/171 (98%), Strand = Minus / Plus
Query: 1312 TGAGTTTACTACATATTGTGCTGGTCAGAGCAGTCATATCTATTATCTGCTGGGCTTTTC 1253 
Sbjct: 369 TGAGTTTACTACATATTGTGCTGGTCAGAGCAGTCATATCTATTATCTGCTGGGCTTTTC 428
Query: 1252 TGGCCTAGGCCCTCTCTTGTTCTTCCCTCAAAGCCTCTGCATACTTCTCAGGGTAGGATC 1193 
Sbjct: 429 TGGCCTAAGCCCTCTCTTGTTCTTCCCTCAAAGCCTCTGCATACTTCTCAGGGTANGATC 488
Query: 1192 TGGGATCCTGCCTAACGATGCTGGCATAAAACTCCAGGATTTTCATCTTGG 1142 
Sbjct: 489 TGGGATCCTGCCTAACGATGCTGGCATAAAACTCCAGGATTTTCATCTTGG 539
Figure 6.5 Homology of DIF1 to EST222935
6.2.3 Cloning DIF1 into 3’ Myc tagged expression vector and GFP fusion 
protein expression vector
The open reading frame of DIF1 was amplified by PCR using the primers 
shown in Figure 6.6. The fragment was cloned into pcDNA3.1Myc-His B and pEGFP- 
N1 to produce DIF1-myc and DIF1-GFP, respectively. It is outlined schematically 
along with the primers used, which included the start, but not the stop site, in Figure 
6 .6 .
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Figure 6.6
DIF1 PCR primers and cloning strategy into pcDNA3.1 Myc-His B, and 
pEGFP-N1 expression vectors
A: This figure describes the primer sequences used to PCR amplify the 
complete DIF1 ORF. They were designed to include the following: Kozak start site but 
not the stop site of the ORF to enable the 3’ Myc-His tagging of the protein; Xho I 
restriction sites prior to the start and at the end of the sequence to facilitate insertion, 
in frame, into the pcDNA3.1 Myc-His B, and pEGFP-N1 expression vectors.
B: The cloning strategy is highlighted whereby initial PCR of the cDNA using 
Pfu, limited PCR mistakes and generated blunt-ended products that were cloned into 
pCRScript vector. The pCRScript vector with KD1 inserted was then restriction 
digested with Xho I and the resulting cDNA fragment was ligated into the Xho I site of 
pcDNA3.1 Myc-His B and also pEGFP-N1
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A
cDNA start site Primer
5 ' G C c l c T C  G A G  k A G A T g I g A A  C C T  A C T  G A C  A A C  A GC C A G AA C  3
Xho I * Kozak  
S tart
cDNA end site Primer
3' G C C t T C  G A G l G G C  G G C  C C T  C T C  T T G  T T C  T T C  C C T  5' 
Xho I
B
cDN A PCR Inser t
Ligate Ligate
Xho I Restr ict ion 
yOigest
pcD N A 3.1 
Myc-Hi s  B
pEGFP-N I
pC RScript
Figure 6.6
DIF1 Protein Primers and C lon ing Stratefy into 
pcDNA3.1 Myc-His B, and pEGFP-N1 Express ion  
Vector
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6.2.4 Transient transfection of Cos 7 cells with Myc tagged DIF1
To determine whether pcDNA3.1 A/DIF1 expressed a polypeptide of the correct 
size, this construct was transfected into Cos7 cells. Western blot analysis of the 
soluble cell lysate using an anti-myc primary monoclonal antibody and an anti-mouse 
HRP-linked secondary antibody revealed a band of 43-44kDa. This confirmed that the 
pcDNA3.1 A/DIF1 construct produced a protein of the correct size, as determined from 
the putative amino acid ORF of the clone. Although ExPASy protparam analysis 
reported a protein molecular mass for DIF1 of 33.8kDa, post-translational 
modifications as suggested by PROSITE analysis and the Myc-tag of approximately 
2.5Kda resulted in a Myc-tagged protein of approximately 43-44kDa.
6.2.5 Transient transfection of 208F cell line with Myc tagged DIF1
The 208F, cell line was transiently transfected with the above described Myc 
tagged DIF1 expression vector and fixed twenty four hours post-transfection. The cells 
were stained by indirect immunofluorescence using an anti-myc primary mouse 
antibody, followed by anti-mouse FITC labeled secondary antibody that visualised the 
transfected cells and revealed the cellular localisation of DIF1. In conjunction, the cells 
were counter-stained with rhodamine-phalloidin (TRITC), to visualise F-actin. The 
methodology is described in Chapter 2, Section 2.23.
Control transfections were performed using the expression vector without a 
gene and also using the same expression vector with myc-tagged p-gal reporter gene. 
The empty expression vector did not stain for myc, whilst the myc tagged p-gal 
reporter localised to the cytoplasm. The F-actin staining for the control transfected 
cells and the untransfected cells determined that their was no difference in actin 
architecture (Data not shown).
Figure 6.8 details the localisation of the DIF1 in two transfected 208F cells. 
DIF1 is diffusely distributed throughout the cells. The expression is not excluded from 
the nucleus or cytoplasm. In the left panels, under Anti-Myc DIF1, the “holes” in 
expression may be the nucleolus of the nucleus and the golgi in the cytoplasm. The 
phalloidin staining for actin demonstrates that the 208F cells maintain their normal 
actin distribution. A normal fibroblastoid actin structure, as shown in Figure 6.8, is 
present in the DIF1-myc transfected cells. The merged pictures of DIF1 (green), and 
F-actin (red), staining in the transiently transfected 208F cells as shown by Figure 6.8 
are shown in Panels (a), and (b), of Figure 6.13, and are characteristic of the 
transfected cell population.
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Figure 6.7 
Protein detection by Western blot analysis of pcDNA3.1(-)Myc-His B/DIF1 
and pcDNA3.1(-)Myc-His B after transient transfection in Cos7 cells.
This figure details the protein detection of DIF1-myc by Western blotting. The 
cell extracts are from transient transfection in Cos7 cells with pcDNA3.1 (-)Myc-His 
B/DIF1 and pcDNA3.1 (-)Myc-His B. The empty vector alone has no expression. The 
DIF1-myc cDNA in an expression vector results in a band around 43-44kDa.
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Cos 7 cells 72 hour Transient  Transfect ion 
3' Myc Tagged DIF1 cDNA
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Figure 6.8
208F transiently transfected with myc tagged DIF1 expression vector and
indirectly stained for FRP and F-actin
The confocal images are of transiently transfected 208F cells with myc-tagged 
DIF1. The DIF1 stained cells are pictured on the left, under Anti-Myc DIF1, and the 
same field stained for F-actin, under F-actin, is on the right. Other cultured but 
untransfected cells are also shown in the F-actin stained right half of the panel and the 
transiently transfected cell is marked by a yellow box.
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Figure 6.8
208F Transiently Transfected with DIF1-Myc
6.2.6 Transient transfection of FBR, and RAS Cell Lines with DIF1-GFP 
fusion protein
It proved extremely difficult to transfect FBR and RAS cell lines with DIF1 and 
numerous attempts to transiently and stably transfect FBR and RAS cell lines with the 
above described Myc tagged DIF1 expression vector were unsuccessful. The 
transient transfections were repeated at least ten times and no positively indirect myc 
stained cells were identified by confocal microscopy. Likewise, several attempts at 
generating stable clones proved unfruitful as all cells died during the neomycin 
selection procedure even when the concentration was reduced to 200pg/ml. In an 
attempt to overcome this DIF1 was cloned into the pEGFP-N1 expression vector so 
that DIF1 would be fused to the N-terminus of EGFP, a variant of wild-type GFP.
The GFP-DIF1 fusion transient transfections were also very difficult, although 
some positive cells were detected. Transiently transfected cells were fixed twenty four 
hours post-transfection and were stained with rhodamine-phalloidin (TRITC), to 
visualise F-actin. The methodology is described in Chapter 2, Section 2.23.
Control transfections were performed using empty pEGFP expression vector. 
Upon transfection, the empty expression vector localised in the nucleus. The F-actin 
staining for the control transfected cells and the untransfected cells determined that 
there was no difference in actin architecture (data not shown).
As previously described in chapter 5 the FBRs have a very different 
morphology to the 208Fs. The FBRs are bipolar and have no stress fibers. The F- 
actin runs as thick cables along the length of the bipolar cell and is concentrated in the 
cortex and pseudopodia, which are capped by actin rich bundles. The localisation of 
the GFP-DIF1 fusion protein in two representative fields of transfected FBR cells is 
shown by Figures 6.9 and 6.10. The expression of DIF1 in all of the transfected cells 
examined was of a complete cytoplasmic localisation with slight expression in the 
nucleus which is particularly obvious in the transfected cell as shown in Figure 6.9. In 
all of the FBR transfected cells examined, DIF1-GFP was also expressed throughout 
the pseudopod structures. The expression in FBRs was not only within the cell bodies 
but also in the pseudopods. Although the corresponding F-actin staining, as shown in 
the bottom panel of Figure 6.9, is difficult to determine due to the high population 
density of the cells. No significant change in morphology of the FBRs is apparent from 
the DIF1-GFP fusion expression pattern. The transfected cell, shown in the top panel 
in Figure 6.9, under DIF1-GFP Fusion, is of an unusual FBR appearance with a hint of 
cell flattening, and pseudopods with two to three spikes of various length and 
thickness as opposed to the characteristic bipolar phenotype. DIF1-GFP is also
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expressed in these spike-like structures. The transfected cells shown in the top panel 
in Figure 6.10 are slightly flatter in appearance to a typical FBR and also have spike 
structures. The change in morphology and F-actin staining is difficult to assess due to 
the high density of the transiently transfected cells shown in the bottom panel of Figure 
6.10. In addition, too few cells were successfully transfected to confirm that the 
morphological changes are of biological significance.
The merged pictures of DIF1-GFP and F-actin staining in the transiently 
transfected FBR cells shown by Figures 6.9 and 6.10 are shown in Panels (c), and (d), 
of Figure 6.13. These cells are characteristic of the transfected cell population.
The expression in RAS cell line was again distributed throughout the cell as the 
transfected cell in the top panel, under DIF1-GFP fusion shown by Figure 6.11 
demonstrates. As discussed in the previous chapter the RAS cell line have a very 
different morphology to the fibroblastoid parental cells. They have multiple irregular 
shaped protrusions, often with an actin rich cap. The DIF1-GFP transiently transfected 
RAS cells are shown by Figures 6.11-6.12. These demonstrate that no apparent 
morphological difference exists between the transfected and untransfected cells. The 
cells shown by Figure 6.11 and 6.12, upper panel also have spike-like structures and 
the corresponding F-actin staining boxed in yellow in the lower panel, reveals an actin 
rich cap at the end of these spikes. The merged pictures of DIF1-GFP and F-actin 
staining in the transiently transfected RAS cells shown by Figures 6.11 and 6.12 are 
shown in Panels (e), and (f), of Figure 6.13. Panel (e), shows the merged picture of 
DIF1 GFP fusion protein and F-actin which not only highlights the expression of DIF1 
in the cytoplasm, but also in the spike structures and at their outer edge. These cells 
are characteristic of the transfected cell population.
The difference in the localisation of DIF1 expression between the transformed 
cell lines, FBR and RAS, and untransformed 208F cell line is insignificant. However, 
transient transfections using the pEGFP-DIF1 expression vector should have been 
performed in 208F cell line. The great difficulty experienced in attempting to 
transiently transfect the transformed cell lines coupled with the phenotypic irregularities 
would indicate that DIF1 may be toxic to the transformed cells. However, no stables 
expressing DIF1 were produced and there is insufficient data to determine the toxicity 
of DIF1.
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Figures 6.9 and 6.10
FBR transiently transfected with DIF1-GFP fusion expression vector and
stained for F-actin
The upper panels are enlarged confocal pictures of the DIF1-GFP transiently 
expressed FBR cells under DIF1-GFP fusion. The lower panel are confocal pictures F- 
actin stained FBR cells, under F-Actin. The transfected cell field is shown by a yellow 
box.
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Figure 6.10
FBR Transiently Transfected with DIF1-GFP
242
Figures 6.11 and 6.12
RAS transiently transfected with DIF1-GFP fusion expression vector and
stained for F-actin
The upper panels are enlarged confocal pictures of the DIF1-GFP transiently 
expressed RAS cells under DIF1-GFP fusion. The lower panel are confocal pictures 
F-actin stained RAS cells, under F-Actin. The transfected cell field is shown by a 
yellow box.
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Figure 6.13 
Transient transfections in 208F, FBR and RAS cell lines: Merged pictures 
of DIF1-MYC and DIF-1 -GFP and F-actin staining
Merged confocal images of transiently transfected cell lines. In 208F cells the 
indirect staining of DIF1-myc protein is shown in green, and for the FBR and RAS cells 
the DIF1-GFP fusion protein is also shown in green. The F-actin is shown in red. 
Panels (a), and (b), are two different 208F cells indirectly stained for DIF1, and F-actin, 
panels (c), and (d), are two different FBR fields expressing DIF1-GFP fusion protein 
and stained for F-actin, panels (e), and (f),are two different RAS fields expressing 
DIF1-GFP fusion protein and stained for F-actin.
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6.2.7 Sequence analysis
Clone CD10, was identified through the previously detailed database searches 
in chapter 3 as a clone with homology to rat FrpAP. Figure 6.14 details the homology 
at the nucleic acid level to FrpAP.
>gb|AF012891 |AF012891 Rattus norvegicus frizzled related protein frpAP mRNA, complete cds Length = 1910 
Plus Strand HSPs:
Score = 1947 (538.0 bits), Expect = 1.6e-151, P = 1.6e-151
Identities = 413/444 (93%), Positives = 413/444 (93%), Strand = Plus / Plus
Query: 1 TTATTCATGCCAAAATAAAAGCGGTCCAGAGGAGTGGTTGCAATGAGGTCACAACTGTGG 60
Sbjct: 687 TTATTCATGCCAAAATAAAAGCGGTCCAGAGGAGTGGTTGCAATGAGGTCACAACTGTGG 746
Query: 61 TCGATGTAAAAGAGATCTTCAAGTCTTCATCACCTATCCCTCGAACGCAAGTCCCCCTCA 120 
Sbjct: 747 TCGATGTAAAAGAGATCTTCAAGTCTTCATCACCTATCCCTCGAACGCAAGTCCCCCTCA 806
Query: 121 TCACCAATTCCTCCTGCCAGTGTCCACACATCCTGCCCCATCAAGATGTCCTAATCATGT 180 
Sbjct: 807 TCACCAATTCCTCCTGCCAGTGTCCACACATCCTGCCCCNTCAAGATGTCCTAATCATGT 866
Query: 181 GTTATGAGCGGCGTTCAAGGATGATGCI I I I IGAAAATTGTTTAGTTGAGAAATGGAGAG 240 
Sbjct: 867 GTTATGAGCGGCGTTCAAGGATGATGCTTCTTGAAAATTGTTTAGTTGAGAAATGGAGAG 926
Query: 241 ATCAACTAAGCAGAAGGTCCACACAGTGGGAAGAGAGGCTTCAGGAACAGCAGAGAACAA 300 
Sbjct: 927 ATCAACTAAGCAGAAGGTCCACACAGTGGGAAGAGAGGCTTCAGGAACAGCAGAGAACAA 986
Query: 301 CTCAGGACAAGAAGCAAATAGCCAGCCGCACCAGTCGCAGTAACCCCCCAAAGCCAAAAG 360 
Sbjct: 987 CTCAGGACAAGAAGCAAATAGCCAGCCGCACCAGTCGCAGTAACCCCCCAAAGCCAAAGG 1046
Query: 361 GAAGGTCACCTGCTTCCAAACCTGCCAGTCCCTAAGAAGAACATCAAAGCTAGAATTGCA 420 
Sbjct: 1047 GAAGGTCACCTGCTTCCAAACCTGCCAGTCCTAAGAAGAACATCAAAGCTAGAAGTGCAC 1106
Query: 421 CCCAAAAANTCAACCCCAAGAAAA 444 
Sbjct: 1107 CCAAAAAGTCAAACCCAAAGAAAA 1130
Figure 6.14 Homology of clone CD10 to FrpAP
6.2.8 Northern blot and tissue blot analysis
The expression pattern of clone CD10 was analysed by Northern blotting. The 
RNA was isolated from previously described cell lines, 208F and EGF, 208F, FBR, 
RAS and FBR TAM-67. The Northern blot was hybridised with 32P labelled CD10 clone 
(refer to Figure 6.15A). Two CD10 RNA species of approximately 1.4Kb and 2.4Kb 
were detected in 208F mRNA, but no transcript was seen in the FBR mRNA. This 
data confirms that clone CD10 is down-regulated in FBR v-fos transformed cells. As 
shown no expression of the mRNA transcript was found in FBRs or in FBR Tam-67
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cells. There is a marked down-regulation in K-ras transformed cell line. In EGF 
treated 208F cells the decrease in expression is partial.
To determine which tissues CD10 was expressed, a rat tissue blot was 
hybridised with 32P labelled clone CD10. The two RNA species were detected in the 
tissue blot. The mRNA transcripts are abundantly expressed in skeletal muscle, but 
the transcripts are also expressed in brain, spleen and lung tissues but at a lower level.
6.2.9
6.2.9.1 Library screening and sequence analysis of full-length cDNA of CD10
The complete CD10 cDNA was isolated by screening a library derived from 
208F mRNA with CD10. Approximately 1 x 106 plaques were screened (refer to 
Section 2.2.11). Three rounds of sequential screening of positive plaques resulted in 
the isolation of ten single positive plaques. The pBluescript cDNAs were excised from 
phage (refer to section 2.2.12), and analysed using restriction mapping and automatic 
DNA sequencing. Seven of the ten clones were false positives and the remaining three 
were not full-length. A further ten of the originally isolated clones from the first screen 
were subject to three separate platings, to isolate single positive plaques. Again, 
several of the clones were false positives and the remaining did not contain the full 
open reading frame. A further attempt to isolate the full length CD10 clone was 
performed by screening another 1.5 x 106 plaque forming units from the library. This 
resulted in the isolation of two clones which contained an identical open reading frame 
to FrpAP. The isolated clones were named FrpAP(FBR).
Two of the isolated FrpAP FBR clones contained the ORF for FrpAP but lacked 
the first nucleotide base as detailed in the published sequence, and the 3’ end was 
truncated at 1583bp with a polyadenylation signal. The complete nucleic acid 
sequence and predicted conceptual protein translation of the open reading frame of, 
FrpAP (FBR) is shown by Figure 6.16. The nucleic acid sequence contained the ATG  
start site at position 94, located within a consensus translation initiation site (Kozak, 
1987), and the stop site at position 1140. The coding region (1049bp), is flanked by a 
5’ untranslated region and a 3 ’ untranslated region containing a polyadenylation signal 
as shown. The published FrpAP sequence contains an additional nucleotide at 
position one, with the ORF at positions 95-1141. The FrpAP(FBR) cDNA encodes a 
predicted polypeptide of 348 amino acids.
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Figure 6.15 
Northern blot and rat Tissue blot of clone CD10
In this figure, Panel A details the three day exposure X-ray film of Northern blot 
probed with Clone CD10, in the bottom panel the corresponding scanned X-ray film of 
the 7S Ribosomal loading control is shown. The Northern blot for CD10 was 
performed twice with the same result. B details the expression of CD10 in rat tissues. 
The actin loading control is shown on the right. The tissue blot was performed once 
using a Clontech rat tissue blot. The size of the mRNA transcripts is indicated by 
arrows with regards to the RNA ladder in kilobases and are approximately 2.0 and 
2.8Kb.
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Figure 6.15
Northern Blot and Rat Tissue Blot of Clone CD10
6.2.9.2 Prosite analysis of ORF protein translation of FrpAP
FrpAP was identified as an apoptosis associated gene and was subsequently 
cloned (Wolf, et al., unpublished), and contains a frizzled domain. Genes of the 
frizzled family have been found in many animal species and they have structural 
similarities. The ORF protein translation of FrpAP (FBR), was subject to Pfam, protein 
families database and HMMs alignments to identify the frizzled domain and also 
PROSITE analysis to identify theoretical protein pattern sites. These are detailed in 
Table 6.2 and their position in the amino acid sequence is highlighted in Panel A, 
Figure 6.17. The alignment of FrpAP(FBR) with the ten most closely related other 
frizzled family members in their domain and their amino acid sequence similarity is 
exemplified by Figure 6.18. Panel B in this figure exemplifies the very high homology 
that exists between FrpAP (FBR), sFRP4 and FrpHE. It would appear that the 
published sequence of FrpAP and the FrpAP (FBR), sequence herein described are 
rat homologues of sFRP4 and FrpHE.
ExPASy protparam analysis of FrpAP (FBR), predicts a molecular weight of 
39.7kDa, theoretical pi of 9.04 with the amino acid composition containing 11% 
negatively charged residues (Asp & Glu), and 15% positively charged residues (Arg & 
Lys).
cAMP- and cGMP-dependent protein 1 282-285 RRST
kinase phosphorylation site 2 344-347 KKST
1 281-283 SRR
Protein kinase C phosphorylation site 2 308-310 TST
3 327-329 SPK
1 49-52 STQE
2 118-121 SWPE
Casein kinase II phosphorylation site 3 216-219 T W D
4 285-288 TQW E
5 297-300 TTQE
Table 6.2
PROSITE protein patterns of FrpAP
The above table indicates the PROSITE protein pattern type, their location and motif.
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Figure 6.16
Nucleotide-and predicted amino acid sequence of FrpAP cDNA
The nucleotides are numbered above the nucleic acid sequence. Amino acids 
are indicated in single letter code with the first predicted methionine at position 94. 
This is located with a translation initiation site GCGATGG (Kozak, 1987). The 
termination codon is denoted by an asterisk at position 1140.
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10 30 50
gctcggagcgcacgccctaggtaaagacataaggagatcagagggacttgaagggaaggt
70 90 110
ccccagtgggacgcagcccaggaggacagtgcgatgctcctctccatcctggtagcgtta
M L L S I L V A L
130 150 170
tgcc tgtgcgtgcgcc tggc tc tgggagtgcgcggagcgccc tgcgaggc tgtgcgca tc 
C L C V R L A L G V R G A P C E A V R I
190 210 230
cccatgtgtaggcacatgccctggaacatcacccggatgcccaaccacctgcaccacagc 
P M C R H M P W N I T R M P N H L H H S
250 270 . 290
actcaggagaacgccatcctggccatcgagcagtacgaggagctggtagacgtgaactgc 
T Q E N A I L A I  E Q Y E E L V D V N C
310 330 350
agctctgtactgcgcttctttctctgtgccatgtatgcacccatctgtaccctggagttc 
S S V L R F F L C A M Y A P I C T L E F
370 390 410
ctgcacgatcccatcaaaccctgcaaatctgtgtgccagcgcgcacgcgacgactgcgag 
L H D P I K P C K S V C Q R A R D D C E
430 450 470
ccccteatgaagatgtataaccacagctggccagagagcctggcttgcgatgagctgcct 
P L M K M Y N H S W P E S L A C D E L P
490 510 530
gtctatgaccgtggagtgtgcatctctccggaggcgatagtcactgaccttccggaagat 
V Y D R G V C I S P E A I V T D L P E D
550 570 590
gtgaagtggatagacatcacaccagatatgatggttcaagaaaggtcctttgatgctgac 
V K W I D I T P D M M V Q E R S F D A D
610 630 650
tgtaaacatctgagccctgatcggtgcaagtgcaaaaaggtgaagccaactttggcaacg 
C K H L S P D R C K C K K V K P T L A T
670 690 710
tacctgagcaaaaactacagctatgttattcatgccaaaataaaagcggtccagaggagt 
Y L S K N Y S Y V I H A K I K A V Q R S
730 750 770
ggttgcaatgaggtcacaactgtggtcgatgtaaaagagatcttcaagtcttcatcacct 
G C N E V T T V V D V K E I F K S S S P
790 810 830
atccctcgaacgcaagtccccctcatcaccaattcctcctgccagtgtccacacatcctg 
I P R T Q V P L I T N S S C Q C P H I L
850 870 890
ccccatcaagatgtcctaatcatgtgttatgagcggcgttcaaggatgatgcttcttgaa 
P H Q D V L I M C Y E R R S R M M L L E
910 930 950
aattgtttagttgagaaatggagagatcaactaagcagaaggtccacacagtgggaagag 
N C L V E K W R D Q L S R R S T Q W E E
970 990 1010
aggcttcaggaacagcagagaacaactcaggacaagaagcaaatagccagccgcaccagt 
R L Q E Q Q R T T Q D K K Q I A S R T S
1030 1050 1070
cgcagtaaccccccaaagccaaagggaaggtcacctgcttccaaacctgccagtcctaag 
R S N P P K P K G R S P A S K P A S P K
1090 1110 1130
aagaacatcaaagctagaagtgcacccaaaaagtcaaacccaaagaaaagtacaagctaa
K N I K A R S A P K K S N P K K S T S *
1150 1170 1190
ttactttccaagttgaagccacccttacaggataaggtggtactgcctgggacagccttc
1210 1230 1250
cgaaggccacacaccacttgccttaggacccactgtggttctctttatagacatgtcttg
1270 1290 . 1310
cagcatttctcttaatgatagcttcagtatttctctttaaaccacagatccctgttattt
1330 1350 1370
gtcagttttcttttatggaaaggtacctgtgttcagagtggcctgtgagcatactgtgtg
1390 1410 1430
accttctgctttgagattttgacctaaaatctaccttataaagttcacatactatgtcaa
1450 1470 1490
gcaaaactttttttgacaaaaatattggatatcctttgacttctgttaggaagttagtga
1510 1530 1550
tatataaaatgttattgaaaaaaatgtttttgacaaaggcagaagaatgatacataaaag
1570 1590
accttcatgtgtttgttgtctgcaaaaaaaaaaaaaaa
Figure 6.16
Nucleotide and predicted amino acid sequence of FrpAP cDNA
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Figure 6.17
PROSITE and Pfam analysis of FrpAP amino acid sequence
A: Amino acids are numbered on the left beginning at the first methionine. The 
cAMP- and cGMP-dependent protein kinase phosphorylation sites are shown in red, 
Protein kinase C phosphorylation sites are shown in bold, and the Casein kinase II 
phosphorylation sites are shown underlined. The PSORT II signal sequence 
recognition for cleavable signal peptide is shown between positions 18 and 19 with a 
green forward slash.
B: Homology of FrpAP amino acid positions 24 to 137 to the Frizzled motif by 
pfam alignment program. The identical residues are shown by single amino acid code 
and similar residues are shown by + and the ten invariably spaced cysteine residues of 
the cysteine rich domain (CRD), are shown in red.
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Al MLLSILVALC LCVRLALG/VR GAPCEAVRIP MCRHMPWNIT RMPNHLHHST 
51 o e n a i l a i e q  YEELVDVNCS SVLRFFLCAM YAPICTLEFL HDPIKPCKSV 
101 CQRARDDCEP L M K M Y N H SWP ESLACDELPV YDRGVCISPE AIVTDLPEDV  
151 KW IDITPDMM VQERSFDADC KHLSPDRCKC KKVKPTLATY LSKNYSYVIH  
201 AKIKAVQRSG CNEVTT V V D V KEIFKSSSPI PRTQVPLITN SSCQCPHILP 
251 HQDVLIMCYE RRSRMMLLEN CLVEKWRDQL SRRSTOWEER LOEQORTTOD 
301 KKQIASRTSR SNPPKPKGRS PASKPASPKK NIKARSAPKK SNPKKSTS
B
Alignment of Fz vs FrpAP positions 24-137
QuerySeq 24
*->CepIpatipLCkdlgYNlTrmPNlLgHetqeEAgleveqFkPLvkvk 
Ce+++ ip+C+++++N+TrmPN+L+H+tqe+A+l++eq+++Lv+v+ 
CEAVR--1PMCRHMPWNITRMPNHLHHSTQENAILAIEQYEELVDVN 6 8
QuerySeq
CSpdLkf FLCSlYAPvCtedlphkPIpPC'RslC'ErakdgCaplMekfGFp 
CS+ L+fFLC++YAP+Ct ++ h+PI+PC+s+C+ra+d+C+plM++++++
69 CSSVLRFFLCAMYAPICTLEFLHDPIKPC'KSVCQRARDDCEPLMKMYNHS 118
QuerySeq
WPdsLnCdkFPvqnddpegLCm<-* 
WP+sL+Od++Pv+++ g+C+
119 WPESLAC'DELPVYDR GVCI 137
Figure 6.17
PROSITE and Pfam analysis of FrpAP amino acid sequence
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Figure 6.18
Sequence similarity alignments of FrpAP with related frizzled family 
members
A: This figure indicates the conserved domains between FrpAP closely related 
secreted Frizzled sub-family members and the frizzled protein. The family member 
and their species origin is indicated on the left. They share a common N-terminal 
signal sequence as indicated with a blue box and the cysteine rich extracellular 
domain, CRD, boxed in pink. The /r/zz/eaf-related proteins lack the seven 
transmembrane spanning regions found in Frizzled proteins as shown by a green box. 
The predicted number of amino acids for each protein is indicated to the right
B: The alignments of the frizzled related proteins and frizzled protein sequence 
is shown with the Frizzled sub-family member and species origin indicated in the left. 
The amino acid position is indicated above each row of alignment and the frizzled 
protein is truncated at position 376. Highly homologous regions, greater than 90% are 
shown in red with lower homology regions, 50%, are indicated in blue.
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Figure 6.18A
Sequence sim ilarity alignm ents of FrpAP w ith related frizzled 
fam ily  m em bers
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It
Consensus levels: high=90%RED low=50%BLUE
FrpAP(FBR)Rat 
Sfrp4Mousc 
FrpHEHuman 
FrzbHuman 
SFRP-3M* u 
FrizzledRat
50
MLL SILVALCLCV RLAL VRGAP -- EA RIP
MLR SILVALCLWL RLAL VRGAP  EA.RIP
MFL SILVALCLWL HLAL ,VRGAP EA' RI!
MVCG SPGGMLLLRA GLLALAALCL LRVP . ARAAA EPVRIP
MVCC GPGRMLLGWA GLLVLAALCL LQVP AQAAA -- EPVRIP
MRARSALPRS ALPRLLLPLL LLPAAGPAQF HGEK.ISIPD HGF PESEP
FrpAP(FBR)Rat
Sfrp4Mouse
FrpHEHuman
FrzbHuman
sFRP-3Mouse
FrizzledRat
51
MLRHMPWM11 
M RHMPWMIT 
M RHMPWMIT 
KSLPWHMI 
.. KSLPWNMI 
I. TDIAYMQT
Ri !P1 iHLHHST 
RMPNHLHHST 
RMPMHLHHST 
RMPMHLHHST 
RMPMHLHHST 
I  L.GHTN
. -.IE 
EM I LA IE 
2EMAILAIE. 
QAMAILAIEQ 
A I IILAMEQ 
E G EVH
. EELVDVN 
EELVDVN IS 
LEELVDVN 5 
FEGL.LGTH 
KEG. LGTH ' J 
FYPLVKVQ
100
SVLRF L. AM 
SV. R. !.
AVLRFFFCAM 
PDLLFFL :AM 
PDLLFFL - 
PELRFFL< SM
FrpAP(FBR)Rat
Sfrp4Mouse
FrpHEHuman
FrzbHuman
sFRP-3Mouse
FrizzledRat
101 150
L’LEFL HDPIKP RS RARDD EP LMRMYNHS ESLA .ELPV 
i LEFL HDPIK R RDDCEP LMRMYNHS I ESLA DELP’
/API 'TLEFL HOP IRPCRSV . . D EP LMRMYNHSW1 S A ELPV
ITDFQ HEP IN I I II RHS ENLACEELPV
IDFQ H PIK R 5CEP ILIRYRHSWP ESLA . ELPV
V— L E A P R A LMNRFGFQ R R HF.R
FrpAP(FBR)Rat
Sfrp4Mouse
FrpHEHuman
FrzbHuman
sFRP-3Mouse
FrizzledRat
151
YD-RGV 
YD-RGV 
YD-RGV' ' ISP 
YD-RG ESP 
YD-RGVC 
HGAEQ.
ISP
ESP
ESP
EAEVTDLPED VKWIDITPLM MVQERS FDAD 
TDLPED VRWIDITPE^M MVQERS FDAD 
EAIVTDLPED VKWIDITPDM MVQERPLDVD
A3 T  ADGADFPMD- SSNGM
EAIVT---- ADGADFPMD------- 3STGH
GQ HSEDGTP-- A LLTTAP P SG LQPGAGGTPG
200
CRHLSPDRCK 
CRRLSPDRCK 
CRRLSPDRCK 
R ASSERCK 
R ,A. :SEP.CK 
GPSGGGAPPR
FrpAP(FBR)Rat 
Sfrp4Mouse 
FrpHEHuman 
FrzbHuman 
sFRP-3 i 
FrizzledRat
201
CKRVKPILAT 
CKKVKPTLAT 
CKRVKPrLAT 
CKPIRATQRr 
FPVRATQRP 
YATLEHPFHC
YLSRMY SYVI 
YLSREfY SYVI 
YLSRMY SY'/I 
'/FRMiYNTL'/ I 
YFRNMYMC/I 
PRVLKVPSYL
RAr IKAVQRS 
HA. IFAVQRS 
HA IKAVQRS 
RA VKEIKTK 
RA. VK EVKMK 
SY FLGERDC
GCNEVTTWE,
GCNE/TT/VD
GGNEVTTV/E
-C HDVTAW E
-CHDV3
AAPCEPARP.
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VKEIFKSSSP 
VKEIFKSLSP 
VKEIFKSSSP 
. LKSSLV 
VKEILKASLV 
GSMFFSHHHT
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FrpAP (FBR) Rat-I PiTQ PL I TNSS 
Sfrp4Mouse -IPRTQVPLI TNSS
FrpHEHuman -IPRTQ PLI TNSS
FrzbHuman NEPPDT NL,Y TSSG
sFRP-3Mouse NEPPDT NLY TTSG
FrizzledRat RFAiLWiLTW SVLC
QGPHI 
Qi PHI 
QiSPHI 
LCPPL 
Ll’PPL 
ASTFF
LPHQDVLIMC 
LPHQDVLIMC 
LPHQDVLIMC 
NVNEEYIIMG 
TVNEEYVIMG 
TVTTSLVA IQ
YE--RRSPMM 
YE--WR3PMM 
YE--WRSRMM 
YEDEER3P.LL 
YEDEER8R LL 
RFRYPERPII
300
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Figure 6.18B
Sequence sim ilarity alignm ents of FrpAP with related frizzled 
fam ily  m em bers
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6.3 DISCUSSION
The clone KD1 was initially identified as a novel sequence with homology to the 
EST clone, mouse 7.5dpc ectoplacental clone, that exhibited a weak similarity to the 
helix-loop-helix transcription factor, Alf1. The characterisation of expression by 
Northern blotting revealed the expression patterns of KD1 in three model systems 
which activate AP-1 activity. In v-fos transformed 208F the transcript is undetectable. 
The KD1 transcript is down-regulated two-fold in K-ras transformed 208F fibroblasts. 
The KD1 transcript is not detectable in EGF transformed 208Fs. An approximate two­
fold down-regulated transcript was detected in FBR-Tam67 cells. Collectively, these 
expression profiles indicate that KD1 is transrepressed by AP-1 transcription factor. 
The somewhat incomplete down-regulation by Tam-67 indicated that it may be an 
indirect target, although the quenching mechanism previously proposed for Tam-67 
activity may be responsible.
As the KD1 transcript was significantly down-regulated in the three AP-1 
models analysed by northern blotting, the tissue expression of KD1 in a rat tissue blot 
was examined. The transcript is testis specific. The sequence information coupled 
with the expression data indicated this clone to be an interesting down-regulated gene 
which may encode a novel transcription factor. Thus it was cloned for further analysis. 
The cDNA sequence of DIF1 predicts an open reading frame from the first Kozak ATG 
initiation signal resulting in a polypeptide of 300 amino acids. No nuclear localisation 
signal was detected. Therefore the DIF1 protein probably does not function as a helix- 
loop-helix transcription factor as initially believed.
Unfortunately, there was insufficient time to further study DIF1. The short term 
future work which would be interesting includes the cloning of DIF1 into an inducible 
expression system in attempt to generate stable DIF1 expressing clones. This would 
determine the exact morphological changes that DIF1 induces and would facilitate any 
change in proliferation or anchorage-independent growth to be studied. The 
characterisation of expression of DIF1 should be extended beyond the original tissue 
blot performed, to include more tissue types, as well as tumours from the tissues in 
which it is present versus normal. In addition, the myc-tagged DIF1 expression vector 
could be used to enable the production and purification of DIF1 in a bacterial system, 
to yield enough protein to raise an antibody to DIF1. This would permit histological 
studies to ascertain DIF1 cellular localisation in testis and in any other tissues in which 
it is expressed.
The rat frizzled related protein, FrpAP, was isolated as a frizzled related gene 
up-regulated in physiological apoptosis in corpus luteum of the rat (Wolf, et a i,  1997
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unpublished). The characterisation of expression by Northern blotting revealed the 
expression patterns of FrpAP(FBR), in three model systems which activate AP-1 
activity. In v-fos transformed 208F fibroblasts where AP-1 is consitutively expressed 
none of the two transcripts are detectable even when the blot is exposed for seven 
days. The K-ras oncogene transforms 208F fibroblasts and the concurrent cell 
signalling through the ras pathway activates AP-1, which markedly down-regulates the 
expression of both the FrpAP(FBR) transcripts. The other AP-1 model system, 208F 
treated with EGF which morphologically transforms 70-90% of the cell population 
through activation of cell signalling pathway via extracellular growth factor receptor, 
found the FrpAP(FBR) transcripts marginally down-regulated. No transcript was 
detected in FBR-Tam67 cells. Collectively, these expression profiles indicate that 
FrpAP(FBR) is indeed down-regulated in cells with activated AP-1.
The expression of FrpAp(FBR) in a rat tissue blot indicated a high functional 
activity in skeletal muscle, and low activity in brain, spleen and lung tissue. The tissue 
expression of sFRP family members is varied indicating that their antagonistic function 
is tightly controlled depending upon developmental stage and physiological state.
The cDNA sequence of rat FrpAP(FBR) predicts an open reading frame 
resulting in a polypeptide of 348 amino acids. The eukaryotic signal sequence 
indicating it’s secretion is consistent with the typical signal sequence and secretion of 
other frizzled related family members. The protein contains the classical conserved 
CRD region of 120 amino acids which contains a motif of ten invariantly spaced 
cysteines. The extracellular domain, that binds Wnt gene products is clearly 
highlighted in Figure 6.18, Panel B.
The function of several cloned sFRP genes has been linked with various 
aspects of cellular proliferation, migration, differentiation and tissue morphogenesis 
during normal development (Hoang et al., 1996; Wolf et al., 1997; Mayr et al., 1997; 
Leyns eta l., 1997; Rattner eta l., 1997; Finch et al., 1997; Melkonyan et al., 1997; Hu 
eta l., 1998; and Chang eta l., 1999). The FrpAp(FBR), presented here, is shown to be 
homologous to the mouse Sfrp4 and human FrpHE proteins. No current data is 
available of the function of Sfrp4 or FrpHE.
Two recent publications (Zhou eta l., 1998; Ugolini eta l., 1999) have linked the 
down-regulation of two sFRP family members in breast cancers, and one homologue, 
hsFRP was also up-regulated during apoptosis (Zhou eta l., 1998).
Cell growth and differentiation are tightly controlled by the apoptotic pathway 
and the cell cycle, and it is well documented that de-regulation of the genes involved in 
cell-cycle regulation can contribute to carcinogenesis (Hartwell and Kastan, 1994). 
The hsFRP gene, a new sFRP family member, was found to be up-regulated in
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apoptotic and growth-arrested human immortalised breast epithelial cell line, HBL-100, 
which indicated a possible role in growth regulation through a cell-cycle/apoptotic 
mechanism or through the Writ signalling pathway (Zhou et al., 1998). An increase in 
hsFRP levels during apoptosis resulted in a subsequent decrease in p-catenin, which 
indicates that hsFRP can antagonise p-catenin levels through the Wnt signalling 
pathway. In addition, the down-regulation of hsFRP, up-regulates p-catenin which 
accumulates cytoplasmically, the same consequence as transforming wnt. The 
decrease in hsFRP level and subsequent up-regulation of p-catenin reduces apoptotic 
cell death, a characteristic feature of carcinogenesis. hsFRP may bind wnt and 
thereby antagonise binding to the cell-surface-signalling receptor, Frizzled, thus 
blocking transduction of the wnt signal. When expression of hsFRP is decreased, the 
wnt signal is unblocked thereby enabling signal transduction and can lead to abnormal, 
even transformed cell growth. These results indicated that hsFRP, a frizzled secreted 
sub-family member can block wnt signalling through cytosolic p-catenin, to regulate 
cell proliferation and perhaps transformation (Zhou et al., 1998). The antagonistic 
mechanism of sFRP proteins, Frzb, on Wnt activity and subsequent signalling pathway 
is exemplified in Figure 6.19.
The expression of hsFRP as examined in cells derived from malignant breast 
carcinomas was found to be undetectable, whilst in three immortalized non-malignant 
breast epithelial cell lines it was expressed. Furthermore, lower expression was found 
in 5/5 of breast tumours, 2/4 of ovary tumours and 3/5 kidney tumours when 
expression was compared to adjacent normal tissue. This decreased hsFRP 
expression in breast tumours and carcinoma cell lines suggests a possible involvement 
in cell proliferation and breast tumourigenesis possibly through the Wnt signalling 
pathway.
The isolation of another breast tumour associated sFRP homologue, 
FRP1/FRZB was isolated in a differential expression assay on the short arm of 
chromosome 8p where there are frequent alterations through deletions and mutations 
associated with various types of cancers (Ugolini et al., 1999).
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Figure 6.19
sFRP(Frzb) can antagonise Wnt signalling
A: Frzb can compete and bind Wnt to prevent its interaction with a Frizzled-like 
Wnt receptor. In the absence of a Wnt signal through Frizzled-like receptor, the 
serine/threonine protein kinase GSK-3p phosphorylates cytoplasmic p-catenin, and in 
conjunction with the tumour suppressor protein APC, degrades p-catenin.
B: Wnt binds the Frizzled-like receptor, activating Dishevelled protein, Dsh, 
which inactivates GSK-3p. An increase in p-catenin level ensues, and p-catenin 
accumulates in the nucleus in association with the HMG-box DNA binding protein 
TCF(LEF). This p-catenin-TCF complex transcriptionally activates Wnt responsive 
genes which influence the fate and behaviour of cells.
(This figure was adapted from Zorn, 1997.)
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sFRP can antagonise Wnt s igna l ing
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Recent advances in using cDNA arrays, otherwise known as DNA chips can be 
used to detect and quantify differential gene expression of EST sequences on a large 
scale (for review Jordan 1998). This technology was used to examine the differential 
expression of a set of genes located in the p11 -21 region of the short arm of 
chromosome 8.
The comparative expression analysis using MDA-MB-134 cells derived from 
ductal mammary carcinoma versus normal breast, and also between HBL-100, a cell 
line previously discussed, and breast carcinoma tumour 4885 and normal breast. One 
of the underexpressed transcripts in MDA-MB-134 and 4855 was clone y157a10, 
corresponding to the Frizbee-like protein (Zorn, 1997) called Fr/zz/ed-related protein-1, 
FRP1 (Finch eta l., 1997; Rattner eta l., 1997) or Secreted apoptosis related protein-2, 
SARP2 (Melkonyan et al., 1997), was also undetected in tumour breast cells as 
compared to normal. The expression of FRP1 was examined in ninety breast 
carcinomas, eighty three of ductal origin, six lobular and one medullar; and sixteen 
benign tumours. The FRP1 transcripts was down-regulated in most of the malignant 
tumours and undetectable in 78%, however, in contrast only 19% of the benign 
tumours showed a reduction in expression as compared to normal breast. This 
demonstrated that FRP1 is expressed in normal breast and benign breast tumours, 
whereas it is severely repressed in the majority of breast tumours (Ugolini eta l., 1999). 
In agreement with the findings of hsFRP by Zou et al., 1997; FRP1 has pro-apoptotic 
activity (Melkonyan et al., 1997) and can antagonistically function to inhibit Wnt 
signalling (Finch eta l., 1997; Wang eta l., 1997).
The genomic localisation of FRP1 to the centromic region of chromosome 8 
(p11 -21) between microsatellite markers D8S532 and D8S268 maps it in a subregion 
of loss of heterozygosity, LOH V, in breast cancer. The up-regulation of FRP1 in 
apoptosis, the inactivation by deletion in the genome, combined with the loss of 
expression in breast tumours and breast carcinomas (Melkonyan et al., 1997; Zhou et 
al., 1998; Ugolini et al., 1999) suggests a tumour suppressor role and inactivation is 
linked with breast malignancy.
Previous data pertaining to inappropriate activation of the Wnt pathway 
highlights its significance in human cancers whereby key components of the signalling 
cascade, such as APC, p-catenin or CBP can be altered resulting in abnormal 
proliferation (Pennisi, 1998; He et al., 1998). In addition, the experimental evidence 
discussed above in relation to breast cancer strongly suggests that the inactivation of 
Wnt signalling pathway by the sFRP sub-family negative regulatory molecules may 
lead to carcinogenesis.
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The data reported in this chapter with regards to ablation of FrpAp(FBR), sFRP 
signalling molecule in v-fos transformed fibroblasts and the down-regulation in K-ras 
and EGF transformed fibroblasts coupled with the above findings would suggest Wnt 
signalling is a key component of transformation. In FBR cell line, the down-regulation 
of FrpAP would therefore abolish Wnt negative control, thus allowing expression of 
Wnt signalling and responsive genes, many of which have been implicated in 
carcinogenesis, further supporting the transformed characteristics of these cells. 
Furthermore, the findings of Melkonyan et al., 1997; Zhou et al., 1998; Ugolini et al., 
1999 suggesting that sFRPs have a role as a tumour suppressor genes further 
supports the down-regulation of FrpAP(FBR), in FBRs. The FBR cell line has 
increased cell proliferation, migration, and adhesion, a characteristic of the 
transformed bipolar phenotype and invasive behaviour of these cells. It is fitting that 
the regulatory control mechanism with regards to these processes as previously 
reported for several cloned sFRP genes during normal development would be de­
regulated in transformation by AP-1 transcription factor.
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Chapter 7 
Summary and Future Work
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The FBR v-fos transformed fibroblasts were studied to provide a model of AP-1 
transformation. The approach of SSH was used to identify AP-1 target genes. Two 
libraries containing a wealth of up-regulated and down-regulated genes were isolated. 
This approach isolated numerous down-regulated genes, an area of new territory. In 
total 206 clones were isolated from the SSH libraries that are predominantly 
differentially expressed in FBR v-fos transformants and are putative AP-1 direct and 
indirect target genes. Furthermore, the clones isolated represent a fraction of the 
libraries as Dr. J.Winnie has extended the isolation of new genes from the up- 
regulated library. The sequencing and Northern blotting has identified many previously 
undiscovered differentially expressed genes.
The characterisation of expression patterns of the sequenced clones by 
Northern blotting further confirmed their differential expression. In addition, most of 
the FBR v-fos up-regulated genes were also shown to be up-regulated in K-ras and 
EGF transformed 208F fibroblasts. Most of the FBR v-fos down-regulated genes were 
shown to be down-regulated in K-ras and EGF transformed 208F fibroblasts. 
Interestingly, the results of the Northern blot data using FBR v-fos transformants 
expressing Tam-67 revealed that the expression of both the up-regulated and down- 
regulated genes were somewhat reduced, with a few exceptions.
The mechanism of down-regulation by AP-1 is unknown, but has been hinted at 
by the recent association of dnmtl DNA methylation, resulting in transcriptional 
repression (Bakin and Curran, 1999). The isolation of SAP18 and RbAp46 from the 
up-regulated library further strengthens the case for a transcriptional repression 
mechanism in AP-1 down-regulation.
The characterisation of the isolated genes did not extent to analysing promoter 
regions as it was beyond the scope of this project. However, some of the identified 
genes are known AP-1 targets such as, MMP-10 and CD44. Therefore, from the 
library controls and Northern data it is reasonable to assume that the identified genes 
are AP-1 targets, although many are probably not direct targets.
One of the down-regulated genes FRP when overexpressed in FBR v-fos 
transformants results in a 70% reduction of invasion in an in vitro invasion assay.
The down-regulated gene FRP, when overexpressed in FBR v-fos 
transformants resulted in a 70% reduction of invasion in an in vitro invasion assay. 
The future experiments to follow up this result would include the investigation into FRP 
expression by AP-1. Initially, a fos-inducible system could be used to determine if FRP 
is switched off during fos induction, and at what time point. The FRP promoter region 
could be analysed to identify the AP-1 consensus sequence. The endogenous cellular 
levels of FRP were not assayed in this study as no commercial antibody was available.
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The raising of an antibody to FRP would facilitate the examination of endogenous 
levels and would also determine the localisation of the protein. The mechanism by 
which the secreted protein FRP blocks invasion is unknown. Therefore, interaction 
studies between FRP and ECM, Integrins would enable the identification of possible 
extracellular sites through which FRP functions.
The down-regulated gene DIF-1 was very difficult to transfect into FBR cell line. 
To overcome this, future experimentation should include a regulatable growth system 
to induce DIF-1 expression. This would enable the determination of the effects of DIF- 
1 on transfrormed cell morphology and actin structure.
In addition, the expression of FRP and DIF-1 in tumour and normal tissue 
should be examined.
268
REFERENCES
269
Achille, A., Baron, A., Zamboni, G., Di Pace, C., Orlandini, S., Scarpa, A. Chromosome 5 allelic 
losses are early events in tumours of the papilla of Vater and occur at sites similar to those of 
gastric cancer. (1998) B rJ Cancer 78, 1653-1660.
Adams, J.M., Harris, A.W., Langdon, W.Y., Pinkert, C.A., Brinster, R.L,. Palmiter, R.D., 
Corcoran, L., Alexander, W.S., Graham, M.W., and Cory, S. c-myc-induced lymphomagenesis 
in transgenic mice and the role of the Pvt-1 locus in lymphoid neoplasia. (1986) Curr Top 
Microbiol Immunol 132,1 -8.
Aitken, A., Amess, B., Howell, S., Jones, D., Martin, H., Patel, Y., Robinson, K., Toker, A. The 
role of specific isoforms of 14-3-3 protein in regulating protein kinase activity in the brain. (1992) 
Biochem Soc Trans 20, 607-611.
Alani, R., Brown, P., Binetruy, B, Dosaka, H., Rosenberg, R.K., Angel, P., Karin, M. and Birrer, 
M.J. The transactivating domain of c-Jun proto-oncoprotein is required for cotransformation of 
rat embryo cells. (1991) Mol Cell Biol 11, 6286-6295.
Alder, P.N. The genetic control of tissue polarity in Drosophila. (1992) BioEssays 14, 735-741.
Andressen, C., Gotzos, V., Berchtold, M.W. Pauls, T.L., Schwaller, B., Fellay, B., Celio, M.C. 
Changes in Shape and Motility of Cells Transfected with Parvalbumin cDNA. (1995) 
Experimental Cell Research 219, 420-426.
Angel, P., Hattori, T., Smeal, T., and Karin, M. The jun protooncogene is positively autoregulated 
by its product, Jun/AP-1. (1988) Cell 55, 875-885.
Angel, P., Smeal, T., Meek, J. and Karin, M. Jun and v-Jun contain multiple regions that 
participate in transcriptional activation in an interdependent manner. (1989) New Biol. 1, 35-43.
Aoyama, A., and Klemenz, R. Oncogene-mediated effects on cellular gene expression. (1993) 
Crit Rev Oncog 4, 53-94.
Aznavoorian, S., Murphy, A.N., Stetler-Stevenson, W.G., and Liotta, LA. Molecular aspects of 
tumor cell invasion and metastasis. (1993) Cancer 71, 1368-1383
Bakin, A.V. and Curran, T. Role of DNA 5-Methylcytosine Transferase in Cell Transformation by 
fos. (1999) Science 283, 387-390.
Balmain, A., Ramsden, M., Bowden, G.T., and Smith, J. Activation of the mouse cellular Harvey- 
ras gene in chemically induced benign skin papillomas. (1984) Nature 307, 658-660.
Bark, I.C„ Hahn, K.M., Ryabinin, A.E. and Wilson, M.C. Differential expression of SNAP-25 
protein isoforms during divergent vesicle fusion events of neural development. (1995) Proc Natl 
Acad Sci USA 92,1510-1514
Baylin, S.B., Herman, J.G., Graff, J.R., Vertino, P.M., Issa, J.P. Alterations in DNA methylation: 
a fundamental aspect of neoplasia. (1998) Adv Cancer Res 72, 141 -196.
Benbrook, D,M,, and Jones, N.C. Heterodimer formation between CREB and JUN proteins.
(1990) Oncogene 5, 295-302.
Bennett, K.L., Jackson, D.G., Simon, J.C., Tanczos, E., Peach, R., Modrell, B., Stamenkovic, I., 
Plowman, G., and Aruffo, A. CD44 isoforms containing exon V3 are responsible for the 
presentation of heparin-binding growth factor. (1995) J Cell Biol 128, 687-698.
Bennett, M.K., Garcia-Arraras, J.E., Elferink, L.A., Peterson, K., Fleming, A.M., Hazuka, C.D., 
and Scheller, R.H. The syntaxin family of vesicular transport receptors. (1993) Cell 74, 863-873.
270
Bergers, G., Graninger, P., Braselmann, S., Wrighton, C., and Busslinger, M. Transcriptional 
activation of the fra-1 gene by AP-1 is mediated by regulatory sequences in the first intron. 
(1995) Mol Cell Biol 15, 3748-3758.
Berquin, I.M., and Slone, B.F. Cathepsin B expression in human tumours. (1996) Adv Exp Med 
Biol 389, 281-294.
Bhanot, P., Brink, M., Samos, C.H., Hsieh, J.C., Wang, Y., Macke, J.P., Andrew, D., Nathans, 
J., and Nusse, R. A new member of the frizzled family from Drosophila functions as a Wingless 
receptor. (1996) Nature 382 ,225-230.
Binetruy, B., Smeal, T., and Karin, M. Ha-Ras augments c-Jun activity and stimulates 
phosphorylation of its activation domain. (1991) Nature 351, 122-127.
Birch, M., Mitchell, S., and Hart, I.R. Isolation and characterization of human melanoma cell 
variants expressing high and low levels of CD44. (1991) Cancer Res 51, 6660-6667.
Blenis, J. Signal transduction via the MAP kinases: proceed at your own RSK. (1993) Proc Natl 
Acad Sci USA 90, 5889-5892.
Bloom, L., Horvitz, H.R. The Caenorhabditis elegans gene unc-76 and its human homologs 
define a new gene family involved in axonal outgrowth and fasciculation. (1997) Proc Natl Acad 
Sci USA 94, 3414-3419.
Blum, J.K., and Berchtold, M.W. Calmodulin-like effect of oncomodulin on cell proliferation. 
(1994) J Cell Physiol 160, 455-462.
Bohmann, D., Bos, T.J., Admon, A., Nishimura, T., Vogt, P.K., and Tjian, R. Human proto­
oncogene c-jun encodes a DNA binding protein with structural and functional properties of 
transcription factor AP-1. (1987) Science 238,1386-1392.
Boehmelt, G., Antonio, L., and Iscove, N.N. Cloning of the murine transcriptional corepressor 
component SAP18 and differential expression of its mRNA in the hematopoietic hierarchy.
(1998) Gene 207, 267-75.
Bollag, G., and McCormick, F. Regulators and effectors of ras proteins. (1991) Annu Rev Cell 
Biol 7, 601-632.
Bortner, D.M., Langer, S.J., and Ostrowski, M.C. Non-Nuclear Oncogenes and the Regulation of 
Gene Expression in Transformed Cells. (1993) Critical Reviews in Oncogenesis. 4,137-160.
Boudreau, N., and Bissell, M.J. Extracellular matrix signaling: integration of form and function in 
normal and malignant cells. (1998) Curr Opin Cell Biol 10, 640-646.
Braselmann, S., Bergers, G., Wrighton, C., Graninger, P., Superti-furga, G., and Busslinger. 
Identification of Fos target genes by the use of selective induction systems. (1992J J Cell Sci 
Supplement 16 97-109.
Brewer, L.M., and MacManus, J.P. Localization and synthesis of the tumor protein oncomodulin 
in extraembryonic tissues of the fetal rat. (1985) Dev Biol 112, 49-58.
Brewer, L.M., and MacManus, J.P. Detection of oncomodulin, an oncodevelopmental protein in 
human placenta and choriocarcinoma cell lines. (1987) Placenta 8, 351-363.
Bristow, J., Kian Tee, K., Gitelman, S.E., Mellon, S.H., and Miller, W.L. Tenascin-X: a novel 
extracellular matrix protein encoded by the human XB gene overlapping P450c21 B (1993) J Cell 
Biol 122, 265-278.
271
Brown, K., Quintanilla, M., Ramsden, M., Kerr, I.B., Young, S., and Balmain, A. v-ras genes from 
Harvey and BALB murine sarcoma viruses can act as initiators of two stage mouse skin 
carcinogenesis. (1986) Cell 46, 447-456.
Brown, P.H., Alani, R., Preis, L.H., Szabo, E., and Birrer, M.J. Suppression of oncogene-induced 
transformation by a deletion mutant of c-jun. (1993) Oncogene 8, 877-886.
Brown, P.H., Chen, T.K., and Birrer, M.J. Mechanism of action of a dominant-negative mutant of 
c-jun. (1994) Oncogene 9, 791-799.
Brusselbach, S., Mohle-Steinlein, U., Wang, Z-Q., Schreiber, M., Lucibello, F.C., Muller, R. and 
Wagner E.F. Cell proliferation and cell cycle progression are not impaired in fibroblasts and ES 
cells lacking c-Fos. (1995) Oncogene 10, 79-86.
Bui, T.D., Rankin, J., Smith, K., Huguet, E.L., Ruben, S., Strachan, T., Harris, A.L., Lindsay, S. A 
novel human Wnt gene, WNT10B, maps to 12q13 and is expressed in human breast 
carcinomas. (1997) Oncogene 14, 1249-1253.
Burridge, K., Chrzanowska-Wodnicka, M., and Zhong, C. Focal adhesion assembly. (1997) 
Trends in Cell Biology 7, 342-347.
Cadigan, K.M., and Nusse, R. Wnt signaling: a common theme in animal development. (1997) 
Genes and Dev 11, 3286-3305.
Calakos, N., Bennet, M.K., Peterson, K.E., and Scheller, R.H. Protein-protein interactions 
contributing to the specificity of intracellular vesicular trafficking. (1994) Science 263,1146-1149.
Casci, T., Vinos, J., and Freeman, M. Sprouty, an intracellular inhibitor of Ras signaling. (1999) 
Cell 96, 655-665.
Cavallo, R., Rubenstein, D., Peifer, M. Armadillo and dTCF: a marriage made in the nucleus.
(1997) Curr Opin Genet Dev 7, 459-466.
Chang, J.T., Esumi, N., Moore, K., Li, Y., Zhang, S., Chew, C., Goodman, B., Rattner, A., 
Moody, S., Stetten, G., Campochiaro, P.A., and Zack, D.J. Cloning and characterization of a 
secreted frizzled-related protein that is expressed by the retinal pigment epithelium. (1999) 
Human Molecular Genetics 8, 575-583.
Chauhan, S.S., Goldstein, L.J., Gottesmam, M.M. Expression of cathepsin L in human tumours. 
(1991) Cancer Res 51.1478-1481.
Chen, J.Y., Penco, S., Ostrowski, J., Balaguer, P., Pons, M., Starrett, J.E., Reczek, P., 
Chambon, P., Gronemeyer, H. RAR-specific agonist/antagonists which dissociate 
transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. (1995) 
EM BOJ  14, 1187-1197.
Chen, R-H., Sarnecki.C. and Blenis J. Nuclear localization and regulation of erk- and rsk- 
encoded protein kinases. (1992) Mol Cell Biol 12, 915-927.
Chen, T,K„ Smith, L.M., Gebhardt, D,K,, Birrer, M.J., and Brown, P.H. Activation and Inhibition 
of the AP-1 Complex in Human Breast Cancer Cells. (1996) Molecular Carcinogenesis 15 215- 
226.
Chen, W.C., and Obrink, B, Cell-cell contacts mediated by E-cadherin (uvomorulin) restrict 
invasive behaviour of L-cells. (1991) J Cell Biol 114, 319-327.
Cheifetz, S., Hernandez, H,. Laiho, M., ten Dijke. P., Iwata .K.K., and Massague, J. Distinct 
transforming growth factor-beta (TGF-beta) receptor subsets as determinants of cellular 
responsiveness to three TGF-beta isoforms. (1990) J Biol Chem 265, 20533-20538.
272
Chiao, P.J., Shin, D.M., Sacks, P.G., Hong, W.K., Tainsky, M.A. Elevated expression of the 
ribosomal protein S2 gene in human tumors. (1992) Mol Carcinog 5, 219-231.
Chiu, R., Boyle, W.J., Meek, J., Smeal, T., Hunter, T., and Karin, M. The c-fos protein interacts 
with c-jun /AP-1 to stimulate transcription of AP-1 responsive genes. (1988) Cell 54, 541-552.
Chiu, R., Angel, P., and Karin, M. Jun-B differs in its biological properties from, and is a negative 
regulator of, c-Jun. (1989) Cell 59, 979-986.
Cohen, D.R., and Curran, T. fra-1 : a serum inducible, cellular immediate-early response gene 
that encodes for a Fos-related antigen. (1988) Mol Cell Biol 8, 2063-2069.
Cohen, D., Ferreira, R., Gentz, R., Franza, B.R. Jr, and Curran, T. The product of a fos-related 
gene, fra-1, binds cooperatively to the AP-1 site with jun:Transcription factor AP-1 is composed 
of multiple protein complexes. (1989) Genes and Dev 3,173-174.
Contente, C., Kenyon, K., Rimoldi, D. and Freidman, R.M. Expression of Gene rrg Is Associated 
with Reversion of NIH 3T3 Transformed by LTR-c-H-ras. (1990) Science 249, 796-798.
Cook, S.J., Aziz ,N., and McMahon, M. The repertoire of fos and jun proteins expressed during 
the G1 phase of the cell cycle is determined by the duration of mitogen-activated protein kinase 
activation. (1999) Mol Cell Biol 19, 330-341.
Coue, M., Kearsey, S.E. and Mechali, M. Chromotin binding, nuclear localization and 
phosphorylation of Xenopus cdc21 are cell-cycle dependent and associated with the control of 
initiation of DNA replication. (1996) E M B O J 15, 1085-1097.
Cramer, L.P., M. Siebert, and T.J. Mitchison. Identification of novel graded polarity actin filament 
bundles in locomoting heart fibroblasts. (1997) J Cell Biol 136,1287-1305.
Curran, T., and Teich, N.M. Identification of a 39,000-Dalton protein in cells transformed by the 
FBJ Murine Osteosarcoma Virus. (1982a) Virology 116, 221-235.
Curran,T., and Teich, N.M. Product of the FBJ murine osteosarcoma virus oncogene: 
characterization of a 55,000-dalton phosphoprotein. (1982b) J Virol 42, 114-122.
Curran, T., MacConnell, W.P., van Straaten, F., and Verma, I.M. Structure of the FBJ Murine 
Osteosarcoma Virus genome: Molecular cloning of its associated helper virus and the cellular 
homolog of the v-fos gene form mouse and human cells. (1983) Mol Cell Biol 3, 914-921.
Curran, T. and Verma, I.M. FBR murine osteosarcoma virus. I. Molecular analysis and 
characterization of a 75,000-Da gag-fos fusion product. (1984) Virology 135, 218-228.
Curran, T., Van Beveren, C., Ling, N., and Verma, I.M. Viral and cellular fos proteins are 
complexed with a 39,000 dalton cellular protein. (1985) Mol Cell Biol 5, 167-173.
Curran, T., and Franza, B.R. Jr. Fos and Jun: the AP-1 connection. (1988) Cell 55,395-297.
Daniely, M., Aviram, A., Adams, E.F., Buchfelder, M., Barkai, G., Fahlbusch, R., Goldman, B., 
Friedman, E. Comparative genomic hybridization analysis of nonfunctioning pituitary tumors. 
(1998) J Clin Endocrinol Metab 83,1801 -1805.
D’Arrigo, C., Burl, S., Withers, A.P., Dobson, H., Black C., and Boxer, M. TGF-beta1 binding 
protein-like modules of fibrillin-1 and -2 mediate integrin-dependent cell adhesion. (1998) 
Connect Tissue Res 37, 29-51.
Denhardt, D.T., Greenberg, A.H., Egan, S.E., Hamilton, R.T., Wright, J.A. Cysteine proteinase 
cathepsin L expression correlates closely with the metastatic potential of H-ras-transformed 
murine fibroblasts. (1987) Oncogene 2, 55-59.
273
Denzer, A.J., Schulthess, T., Fauser, C., Schumacher, B., Kammerer, R.A., Engel, J., and 
Ruegg, M.A. Electron microscopic structure of agrin and mapping of its binding site in laminin-1.
(1998) EMBO J 17, 335-343.
Diatchenko, L., Lau, Y-F.C., Campbell, A.P., Chenchik, A., Moqadam, F., Huang, B., Lukyanov, 
S., Lukyanov, K, Gurskata, N., Sverdlov, E.D., and Siebert, P.D. Suppression subtractive 
hybridization: A method for generating differentially regulated or tissue-specific cDNA probes 
and libraries. (1996) Proc Natl Acad Sci USA 93, 6025-6030.
Distel, R.J., Ro, H-S., Rosen, B.S., Groves, D.L., and Spiegelman, M. Nucleoprotein complexes 
that regulate gene expression in adipocyte differentiation: Direct participation of c-fos. (1987) 
Cell 49, 835-844.
Dobrzanski, P., Noguchi, T., Kovary, K., Risso, C.A., Lazo, P.S. and Bravo R. Both products of 
the fosB gene, FosB and its short form FosBS/F are transcriptional activators in fibroblasts
(1991) Mol Cell Biol 11, 5470-5478.
Durkin, J.P., Brewer, L.M., MacManus, J.P. Occurrence of the tumor-specific, calcium-binding 
protein, oncomodulin, in virally transformed normal rat kidney cells. (1983) Cancer Res 43, 
5390-5394.
Duronio, V., Welham, M.J. Abraham, S., Dryden, P., and Schrader, J.W. p21ras activation via 
hemopoietin receptors and c-kit requires tyrosine kinase activity but not tyrosine phosphorylation 
of p21 ras GTPase activating protein. (1992) Proc Natl Acad Sci USA 89,1587-1591.
Edwards, D.R., and Murphy, G. Proteases-invasion and more (1998) Science 394, 527-528.
Evans, E.P., Burtenshaw, M.D., Brown, B.B., Hennion ,R., and Harris, H. The analysis of 
malignancy by cell fusion. IX. Re-examination and clarification of the cytogenetic problem.
(1982) J Cell Sci 56,113-130.
Fainsod, A., Deissler, K., Yelin, R., Marom, K., Epstein, M., Pillemer, G., Steinbeisser, H., Blum, 
M. The dorsalizing and neural inducing gene follistatin is an antagonist of BMP-4. (1997) Mech 
Dev 63, 39-50.
Fanger, G.F., Widmann, C., Porter, A.C., Sather, S., Johnson, G.L., and Vaillancourt, R.R. 14-3- 
3 Proteins interact with Specific MEK Kinases. (1998) J Biol Chem 273, 3476-3483.
Faassen, A.E., Schrager, J.A., Klein, D.J., Oegema, T.R., Couchman, J.R., and McCarthy, J.B. 
A cell surface chondroitin sulfate proteoglycan, immunologically related to CD44, is involved in 
type I collagen-mediated melanoma cell motility and invasion. (1992) J Cell Biol 116, 521 -531.
Fearon, E.R., and Dang, C.V. Tumor suppressor meets oncogene. (1999) Curr Biol 9, R62-65
Fehon, R.G., Kooh, P.J., Rebay, I., Regan, C.L., Xu, T., Muskavitch, M.A,. and Artavanis- 
Tsakonas, S. Molecular interactions between the protein products of the neurogenic loci Notch 
and Delta, two EGF-homologous genes in Drosophila. (1990) Cell 61, 523-534.
Fidler, I.J., Gersten, D,M,, and Hart, I.R. The biology of cancer invasion and metastasis. (1978) 
Adv Cancer Res 28,149-250.
Field, S.J., Johnson, R.S., Mortensen, R.M., Papaioannou, V.E., Spiegelman, B.M. and 
Greenberg, M.E. Growth and differentiation of embryonic stem cells that lack an intact c-fos 
gene(1992). Proc Natl Acad Sci USA 89, 9306-9310.
Finch, P.W., He, X., Kelley, M.J., Uren, A., Schaudies, R.P., Popescu, N.C., Rudikoff, S., 
Aaronson, S.A., Varmus, H.E., and Rubin, J.S. Purification and molecular cloning of a secreted, 
Frizzled-related antagonist of Wnt action (1997) Proc Natl Acad Sci USA 94, 6770-6775.
274
Finkel, M.P., Biskis, B.O., and Jinkins, P.B. Virus induction of osteosarcomas in mice. (1966) 
Science 151, 698-701.
Finkel, M.P., Reilly, C.A., and Biskis, B.O. (1975). Viral etiology of bone cancer. Front Radiat 
Ther Oncol 10, 28-39.
Foletta, V.C., Sonobe, M.H., Suzuki, T., Endo, T., Iba, H., and Cohen, D.R. Cloning and 
characterisation of the mouse fra-2 gene. (1994) Oncogene 9, 3305-3311.
Franza, B.R, Sambucetti, L.C., Cohen, D.R. , and Curran, T. Analysis of Fos protein complexes 
and Fos-related antigens by high-resolution two-dimensional gel electrophoresis. (1987) 
Oncogene 1, 213-221.
Franza, B.R., Rauscher, F.J. Ill, Josephs, S.F., and Curran, T. The fos complex and fos-related 
antigens recognise sequence elements that contain AP-1 binding sites. (1988) Science 239, 
1150-1153.
Frixen, U.H., Behrens, J., Sachs, M., Eberle, G., Voss, B., Warda, A., Lochner, D., and 
Birchmeier, W. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human 
carcinoma cells. (1991) J Cell Biol 113, 173-185.
Funk, M., Poensgen, B., Graulich, W., Jerome, V., and Muller R. A novel, transformation­
relevant activation domain in Fos proteins. Mol Cell Biol (1997) 17, 537-544.
Furlanetto, R.W., Dey, B.R., Lopaczynski, W., and Nissley, S.P. 14-3-3 proteins interact with the 
insulin-like growth factor receptor but not the insulin receptor. (1997) Biochem J  327, 765-771.
Gentz, R., Rauscher F.J. Ill, Abate C., and Curran, T. Parallel association of Fos and Jun 
leucine Zippers juxtaposes DNA binding domains. (1989) Science 243, 1695-1699.
Gibson, M.A., Hatzinikolas, G., Davis, E.C., Baker, E. Sutherland, G.R. and Mecham, R.P. 
Bovine latent transforming growth factor beta 1-binding protein 2: molecular cloning, 
identification of tissue isoforms, and immunolocalization to elastin-associated microfibrils. (1995) 
Mol Cell Biol 15, 6932-6942.
Giguere, V., Ong, E.S., Segui, P., Evans, R.M. Identification of a receptor for the morphogen 
retinoic acid. (1987) Nature 330, 624-629.
Gius, D., Cao, X.M., Rauscher. F.J. 3d, Cohen, D.R., Curran, T., and Sukhatme, V.P. 
Transcriptional activation and repression by Fos are independent functions: the C terminus 
represses immediate-early gene expression via CArG elements. (1990) Mol Cell Biol 10, 4243- 
4255.
Glover, C.J., Hartman, K.D., and Felsted, R.L. Human N-Myristoyltransferase Amino-terminal 
Domain Involved in Targeting the Enzyme to the Ribosomal Subcellular Fraction. (1997) J Biol 
Chem 272, 28680-28689.
Gluck, U., Kwiatkowski, D.J., and Ben-Ze’ev, A. Suppression of tumoreginicity in simian virus 
40-transformed 3T3 transfected with a-actinin (1993) Prot Natl Acad Sci USA 90, 383-387.
Granger-Schnarr, M., Benusiglio, E., Schnarr, M., and Sassone-Corsi, P. Transformation and 
transactivation suppressor activity of the c-Jun leucine zipper fused to a bacterial repressor.
(1992) Proc Natl Acad Sci USA 89, 4236-4239.
Greenberg, M.E., and Ziff, E.B. Stimulation of 3T3 cells induces transcription of the c-fos proto­
oncogene. (1984) Nature 311, 433-438.
Greenhalgh, D.A., and Yuspa, S.H. Malignant conversion of murine squamous papilloma cell 
lines by transfection with the fos oncogene. (1988) Mol Carcinogenesis 1, 134-143.
275
Greenhalgh, D.A., Welty, D.J., Player, A. and Yuspa, S.H. Two oncogenes, v-fos and v-ras, 
cooperate to convert keratinocytes to squamous cell carcinoma. (1990) Proc Natl Acad Sci USA 
87, 643-647.
Gress, T.M., Muller-Pillasch, F., Geng, M., Zimmerhackl, F., Zehetner, G., Freiss, H., Buchler, 
M., Adler, G. and Lehrach H. A pancreatic cancer-specific expression profile. (1996) Oncogene 
13, 1819-1830.
Grigoriadis, A.E., Schellander, K., Wang, Z-Q., and Wagner E.F. Osteoblasts are the target cells 
for transformation in c-fos transgenic mice. (1993) J Cell Biol 122, 685-701.
Guo, Y., Ma, J,. Wang, J., Che, X., Narula, J,. Bigby, M., Wu, M., and Sy, M.S. Inhibition of 
human melanoma growth and metastasis in vivo by anti-CD44 monoclonal antibody. (1994) 
Cancer Res 54, 1561 -1565.
Gunthert, U., Hofmann, M., Rudy, W., Reber, S., Zoller, M., Haussmann, I., Matzku, S., Wenzel,
A., Ponta, H., and Herrlich, P. A new variant of glycoprotein CD44 confers metastatic potential to 
rat carcinoma cells. (1991) Cell 65, 13-24.
Hacohen, N., Kramer, S., Sutherland, D., Hiromi, Y. and Krasnow, M.A. sprouty Encodes a 
Novel Antagonist of FGF Signaling that Patterns Apical Branching of the Drosophila Airways. 
(1998) Cell 92, 253-263.
Haemmerli, G., and P. Strauli. In vitro motility of cells from human epidermoid carcinomas. A 
study by phase-contrast and reflection-contrast cinematography. (1981) Int J Cancer 27, 603- 
610.
Hai, T.W., Liu, F., Allegretto, E.A., Karin, M., and Green, M.R. A family of immunologically 
related transcription factors that includes multiple forms of ATF and AP-1. (1988) Genes and 
Dev 2,1216-1226.
Hai, T., and Curran, T. Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB 
alters DNA binding specificity. (1991) Proc Natl Acad Sci USA 88, 3720-3724.
Halazonetis, T.D., Georgopoulos, K., Greenberg, M.E., and Leder, P. c-jun dimerizes with itself 
and with c-fos, forming complexes of different DNA binding affinities. (1988) Cell 55, 917-924.
Hamalainen, E-R., Kemppainen, R., Kuivaniemi, H., Tromp, G., Vaheri, A., Pihlajaniemi, T. and 
Kivirikko, K.I. quantitative polymerase chain reaction of lysyl oxidase mRNA in malignantly 
transformed human cell lines demonstrates that their low lysyl oxidase activity is due to low 
quantities of its mRNA and low levels of transcription of the respective gene. (1995) J Biol Chem 
270,21590-21593.
Hanahan, N., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch 
during tumourigenesis. (1996) Cell 86, 353-364.
Handford, P.A., Mayhew, M., Baron, M., Winship, P.R., Campbell, I.D., and Brownlee, G.G. Key 
residues involved in calcium-binding motifs in EGF-like domains. (1991) Nature 351, 164-167.
Hardy, C.F.J., Dryga, O., Seematter, S., Pahl, P.M.B. and Sclafani, R.A. mcm5/cdc46-bob1 
bypasses the requirement for the S phase activator Cdc7p. (1997) Proc Natl Acad Sci USA 94, 
3151-3155.
Hartwell, L.H., and Kastan, M.B. Cell-cycle control and cancer. Science (1994) 266,1821-1828.
Harris, H., Miller, O.J., Klein, G., Worst, P., and Tachibana. T. Suppression of malignancy by cell 
fusion. (1969) Nature 223, 363-368.
Hasselaar, P., Sage, E.H. SPARC antagonizes the effect of basic fibroblast growth factor on the 
migration of bovine aortic endothelial cells. (1992) J Cell Biochem 49, 272-283.
276
Hajnal, A., Klemenz, R. and Schafer, R. Up-regulation of lysyl oxidase in spontaneous revertants 
of h-ras-transformed rat fibroblasts. (1993) Cancer Research 53, 4670-4675.
Hawker, K.L., Pintzas, A., Hennigan, .RF., Gillespie, D.A., and Ozanne, B.W. Transformation by 
the fos or jun oncogene does not increase AP-1 DNA-binding activity. (1993) J Virol 67, 5487- 
5495.
Hayashi, Y., Matsuyama, K., Takagi, K., Sugiura, H., and Yoshikawa, K. Arrest of cell growth by 
necdin, a nuclear protein expressed in postmitotic neurons. (1995) Biochem Biophys Res 
Commun 213, 317-324.
Haynes, B.F., Liao, H.X., and Patton, K.L. The transmembrane hyaluronate receptor (CD44): 
multiple functions, multiple forms. (1991) Cancer Cells 3, 347-350.
Hayward, W.S., Neel, B.G., and Astrin, S.M. Activation of a cellular one gene by promoter 
insertion in ALV-induced lymphoid leukosis. (1981) Nature 290,475-80.
He, T.C., Sparks, A.B., Rago, C., Hermeking, H., Zawel, L., da Costa, L.T., Morin, P.J., 
Vogelstein, B., and Kinzler, K.W. Identification of c-MYC as a target of the APC pathway. (1998) 
Science 281, 1509-1512.
He, X., Saint-Jeannet, J.P., Wang, Y., Nathans, J., Dawid, I.B., and Varmus, H.E. A member of 
the Frizzled protein family mediating axis induction by Wnt-5A. (1997) Science 275,1652-1654.
Hennigan, R.F. The role of Fos in transformation. Ph.D. Dissertation. (1993) The Univertsity of 
Texas, Southwestern Medical Center, Dallas, Texas.
Hennigan, R.F., Hawker, K.L., and Ozanne, B.W. Fos-transformation activates genes 
associated with invasion. (1994) Oncogene 9, 3591-3600.
Heriche, J.K., Lebrin, F., Rabilloud, T., Leroy, D., Chambaz, E.M., Goldberg, Y. Regulation of 
protein phosphatase 2A by direct interaction with casein kinase 2alpha (1997) Science 276, 952- 
955.
Herschman, H.R. Primary response genes induced by growth factors and tumor promoters.
(1991) Annu Rev Biochem 60, 281 -319.
Hilberg, F., and Wagner, E.F. Embryonic stem cells (ES) lacking functional c-jun: 
consequences for growth and differentiation. (1992) Oncogene 7, 2371-2380.
Higuchi, Y., Setoguchi, M., Yoshida, S., Akizuki, S., and Yamamoto, S. Enhancement of c-fos 
expression is associated with activated macrophages. (1988) Oncogene 2, 515-521.
Hipskind, R.A,. Rao, V.N., Mueller, C.G., Reddy, E.S., and Nordheim, A. Ets-related protein Elk- 
1 is homologous to the c-fos regulatory factor p62TCF. (1991) Nature 354, 531-534.
Hirada, H., Kitagawa, M ., Tanaka, H., Yamamoto, K., Harada, M., Ishihara, M., and T. 
Taniguchi. Anti-oncogenic and oncogenic potentials of interferon regulatory factor-1 and -2.
(1993) Science 259, 971-974.
Hirai, S.I., Ryseck, R.P., Mechta, F., Bravo, R., and Yaniv, M. Characterization of junD: a new 
member of the jun proto-oncogene family. (1989) EMBO J 8, 1433-1439.
Hoang, B., Moos, M., Vukicevic, S., and Luyten, F.P. Primary structure and tissue distribution of 
FRZB, a novel protein related to Drosophila Frizzled, suggesting a role in skeletal 
morphogenesis. (1996) J Biol Chem 271, 25131 -26137.
277
Hofmann, M., Rudy, W., Gunthert, U., Zimmer, S.G., Zawadzki, V., Zoller, M,. Lichtner, R.B., 
Herrlich. P., and Ponta H. A link between ras and metastatic behavior of tumor cells: ras induces 
CD44 promoter activity and leads to low-level expression of metastasis-specific variants of 
CD44 in CREF cells. (1993) Cancer Res 53, 1516-1521.
Holt, J.T., Venkat-Gopal, T., Moulton, A.D., and Nienhuis, A.W. Inducible production of c-fos 
antisense RNA inhibits 3T3 cell proliferation. (1986) Proc Natl Acad Sci USA 83, 4794-4798.
Honda, K., Yamada, T., Endo, R., Ino, Y., Gotoh, M., Tsuda, H., Yamada, Y., Chiba, H., and 
Hirohashi, S. Actinin-4, a novel actin-bundling protein associated with cell motility and cancer 
invasion. (1998) J Cell Biol 140, 1383-1393.
Hosaka, S., Suzuki, M., Goto, M., and Sato, H. Motility of rat ascites hepatoma cells, with 
reference to malignant characteristics in cancer metastasis. (1978) Gann 69, 273-276.
Houel, B., Rochette-Egly, C., and Bradley, W.E.C. Tumor suppressor effect of the retinoic acid 
receptor |3 in human epidermoid lung cancer cells. (1993) Proc Natl Acad Sci USA 90, 985-989.
Howe, J.R., Roth, S., Ringold, J.C., Summers, R.W., Jarvinen, H.J., Sistonen, P., Tomlinson, 
I.P., Houlston, R.S., Bevan, S.,Mitros, F.A., Stone, E.M., and Aaltonen, L.A. Mutations in the 
SMAD4/DPC4 gene in juvenile polyposis. (1998) Science 280 ,1086-1088.
Hu, E., Mueller, E., Oliviero, S., Ppaioannou, V., Johnson, R. and Spiegelman, B.M. Targeted 
expression of the c-fos gene demonstrates c-fos-dependent and -independent pathways for 
gene expression stimualted by growth factors and oncogenes. (1994) E M B O J 13, 3094-3103.
Hu, E., Zhu, Y., Fredrickson, T., Barnes, M., Kelsell., D., Beeley, L., and Brooks, D. Tissue 
restricted expression of two human Frzbs in preadipocytes and pancreas. (1998J Biochem and 
Biophys Res Comm 247, 287-293.
Huang, S., Lee, W.H., Lee, E.Y. A cellular protein that competes with SV40 T antigen for binding 
to the retinoblastoma gene product. (1991) Nature 350, 160-162.
Huguet, E.L., McMahon, J.A., McMahon, A.P., Bicknell, R., Harris, A.L. Differential expression of 
human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of 
human breast tissue. (1994) Cancer Res 54, 2615-2621
Hyytiainen, M., Taipale, J., Heldin, C.H., and Keski-Oja, J. Recombinant latent transforming 
growth factor beta-binding protein 2 assembles to fibroblast extracellular matrix and is 
susceptible to proteolytic processing and release. (1998) J Biol Chem 273, 20669-20676.
Ito, E., Sonnenberg, J.L., and Narayanan, R. Nerve growth factor-induced differentiation in PC- 
12 cells is blocked by fos oncogene. (1989) Oncogene 4,1193-1199.
Jalkanen, S., and Jalkanen, M. Lymphocyte CD44 binds the COOH-terminal heparin-binding 
domain of fibronectin. (1992) J Cell Biol 116, 817-325.
Jamal, S., and Ziff, E. Transactivation of c-fos and beta-actin genes by raf as step in early 
response to transmembrane signals. (1990) Nature 344, 463-466.
Jenuwein, T., Muller, D., Curran, T., and Muller, R. Extended life span and tumorigenicity of non 
established mouse connective tissue cells transformed by the fos oncogene of FBR-MuSV. 
(1985) Cell 41, 629-637.
Jenuwein, T., and Muller, R. Structure-function analysis of fos protein: A single amino acid 
change activates the immortalizing potential of v-fos. (1987) Cell 48, 647-657.
Jing, Y., Zhang, J., Bleiweiss, I.J., Waxman, S., Zelent, A. and Mira-Y-Lopez, R. Defective 
expression of cellular retinol binding protein type I and retanoic acid receptors a2, |32 and y2 in 
human breast cancer cells. (1996) The FASEB Journal 10, 1064-1070.
278
Johnsen, M., Lund, L.R., R0mer, J., Almholt, K. and Dan0, K. Cancer invasion and tissue 
remodelling: common themes in proteolytic matrix degradation. (1998) Current Biology 10, 667- 
671.
Johnson, R.S., van Lingren, B., Papaioannou, V., and Spiegelman, B.M. A null mutation at the c- 
jun locus causes embryonic cell lethality and retarded cell growth in culture. (1992a) Genes and 
Dev 7, 1309-1317.
Johnson, R.S., Spiegelman, B.M., and Papaioannou, V. Pleiotropic effects of a null mutation in 
the c-fos protooncogene. (1992b) Cell 71, 577-586.
Johnson, R.S., Spiegelman, B.M., Hanahan, D., Wisdom, R. Cellular transformation and 
malignancy induced by ras require c-jun. (1996) Mol Cell Biol 16, 4504-4511.
Jonasson, J. and Harris, H. The analysis of malignancy by cell fusion. VIII. Evidence for the 
intervention of an extra-chromosomal element. (1977) J Cell Sci 24, 255-263.
Jones, D.H., Ley, S., and Aitken, A. Isoforms of 14-3-3 protein can form homo- and 
heterodimers in vivo and in vitro: implications for function as adapter proteins. (1995) FEBS Lett 
368, 55-58.
Jones, P.L., Veenstra, G.J.C., Wade, P.A., Vermaak, D., Kass, S.U., Landsberger, N., 
Strouboulis, J., and Wolffe, A.P. Methylated DNA and MeCP2 recruit histone deacetylase to 
repress transcription. (1998) Nature Genetics 19,187-191.
Jooss, K.U., Funk, M. and Muller, R. An autonomous N-terminal transactivation domain in Fos 
protein plays a crucial role in transformation. (1994) EMBO J 13, 1467-1475.
Jooss, K.U. and Muller, R. Deregulation of genes encoding micofilament-associated proteins 
during Fos-induced morphological transformation. (1995) Oncogene 10, 603-608.
Jordan, B.R. Large-scale expression measurement by hybridization methods: from high-density 
membranes to "DNA chips". (1998) J Biochem (Tokyo) 124, 251-258.
Jordan, M.A., and Wilson, L. Microtubules and actin filaments: dynamic targets for cancer 
chemotherapy (1998) Current Opinion in Cell Biology 10,123-130.
Jourdan-Le Saux, C., Le Saux, O., Donlon, T, Boyd, C.D. and Csiszar, K. The human Lysyl 
Oxidase-Related Gene(LOXL2) Maps between Markers D8S280 and D8S278 on Chromosome 
8p21.2-p21.3. (1998) Genomics 51, 305-307.
Kane, S.E., Troen, B.R., Gal, S., Ueda, K., Pastan, I., Gottesman, M.M. Use of a cloned 
multidrug resistance gene for coamplification and overproduction of major excreted protein, a 
transformation-regulated secreted acid protease. (1988) Mol Cell Biol 8, 3316-3321.
Karin, M. The regulation of AP-1 activity by Mitogen-Activated Protein Kinases. (1995) J Biol 
Chem 270, 16483-16486.
Kawabe, T., Muslin, A.J., Korsmeyer, S.J. HOX11 interacts with protein phosphatases PP2A 
and PP1 and disrupts a G2/M cell-cycle checkpoint. (1997) Nature 385, 454-458.
Keeton, M.R., Curriden, S.A., van Zonneveld, A.J., and Loskutoff, D.J. Identification of regulatory 
sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth 
factor beta. (1991) J Biol Chem 266, 23048-23052.
Kerr, L.D., Miller, D.B., and Matrisian, L. TGF-p-inhibition of transin/stromelysin gene expression 
is mediated through a fos binding sequence. (1990) Cell 61, 267-278.
279
Kim, S-J., and Khan C.R. Insulin regulation of mitogen-activated protein kinase kinase (MEK), 
mitogen-activated protein kinase and casein kinase in the cell nucleus: a possible role in the 
regulation of gene expression. (1997) Biochemical Journal 323, 621-627.
Kim, Y, Boyd, C.D. and Csiszar, K. A New Gene with Sequence and Structural Similarity to the 
Gene Encoding Human Lysyl Oxidase. (1995) J Biol Chem 270, 7176-7182.
Kimura, H., Nozaki, N. and Sugimoto, K. DNA polymerase alpha associated protein P1, a 
murine homolog of yeast MCM3, changes its intranuclear distribution during the DNA synthetic 
period. (1994) EMBO J 13, 4311 -4320.
Kinzler, K.W., and Vogelstein, B. Life (and death) in a malignant tumour. (1996) Nature 379, 19- 
20.
Kinzler, K.W., Vogelstein, B. Cancer-susceptibility genes. Gatekeepers and caretakers. (1997) 
Nature 386, 761-763.
Kinzler, K.W., Vogelstein, B. Landscaping the Cancer Terrain. (1998) Science 280,1036-1037.
Klinger, H.P., Ruoslahti, E. Human chromosome 11 is syntenic with human specific fibronectin 
production in human x mouse cell hybrids. (1980) Cytogenet Cell Genet 28, 271-279.
Knauer, D.J., Thompson, J.A., and Cunningham, D.D. Protease Nexins: cell-secreted proteins 
that mediate the binding, internalization, and degradation of regulatory serine proteases. (1983) 
J Cell Physiol 117, 385-96.
Knudson, A.G. Jr. Mutation and cancer: statistical study of retinoblastoma. (1971) Proc Natl 
Acad Sci USA 68, 820-823.
Kouzarides, T., and Ziff, E. The role of leucine zipper in the fos-jun interaction. (1988) Nature 
336, 646-651.
Korinek, V.,Barker, N.,Morin, P.K., vanWichen, D., deWeger, R., Kinzler, K.W., Volgelstein, B., 
and Clevers, H. Constitutive transcriptional activation by a p-catenin (3 -Tcf complex in APC(-/-) 
colon carcinoma (1997) Science 275,1784-1787.
Kovary, K., and Bravo R. Expression of different Jun and Fos proteins during the G0-to-G1 
transition in mouse fibroblasts: In vitro and in vivo associations. (1991a) Mol Cell Biol 11, 2451- 
2459.
Kovary, K., and Bravo R. The Jun. and Fos protein families are both required for cell cycle 
progression in fibroblasts. (1991 b) Mol Cell Biol 11,4466-4472.
Kovary, K., and Bravo R. Existence of different Fos/Jun complexes during the Go-to-Gi transition 
and during exponential growth in mouse fibroblasts: differential role of Fos proteins. (1992) Mol 
Cell Biol 12, 5015-5023.
Kozak, M. Effects of intercistronic length on the efficiency of reinitiation by eucaryotic ribosomes. 
(1987) Mol Cell Biol 7, 3438-3445.
Kralova, J., Liss, A.S., Bargmann, W., and Bose, H.R. Jr. AP-1 factors play an important role in 
transformation induced by the v-rel oncogene. (1998) Mol Cell Biol 18, 2997-3009.
Kruijer, W., Cooper, J., Hunter, T., and Verma, I.M. Platelet derived growth factor induces rapid 
but transient expression of the c-fos gene and protein. (1984) Nature 312, 711-716.
Krust, A., Kastner, P., Petkovich, M., Zelent, A., Chambon, P. A third human retinoic acid 
receptor, hRAR-gamma. (1989) Proc Natl Acad Sci USA 86,5310-5314.
280
Kubota, Y., Mimura, S., Nishimoto, S., Takisawa, H. and Nojima, H. Identification of the yeast 
MCM3-related protein as a component of Xenopus DNA replication licensing factor. (1995) Cell 
81,601-609.
Kupprion, C., Motamed, K., and Sage, E.H. SPARC (BM-40), Osteonectin) Inhibits the Mitogenic 
Effect of Vascular Endothelial Growth Factor on Microvascular Endothelial Cells. (1998) J Biol 
Chem 273, 29635-29640.
Lauffenburger, D.A., and A.F. Horwitz. Cell migration: a physically integrated molecular process. 
(1996) Cell 84, 359-369.
Lamb, R.F., Ozanne, B.W., Roy, C., McGarry, L., Stipp, C., Mangeat, P., and Jay, D.G. 
Essential functions of ezrin in maintenance of cell shape and lamellipodial extension in normal 
and transformed fibroblasts. (1997a) Current Biology 7, 682-688.
Lamb, R.F., Hennigan, R.F., Turnbull, K., Katsanakis, K.D., MacKenzie, E.D., Birnie, G.D., and 
Ozanne, B.W. AP-1-Mediated invasion requires increased expression of the hyaluronan 
receptor CD44. (1997 b) Mol Cell Biol 17, 963-976.
Landschulz, W.H., Johnson, P.F., and McKnight, S.L. The leucine zipper: a hypothetical 
structure to a new class of DNA binding proteins. (1988) Science 240, 1759-1764.
Lane, T.F., and Sage, E.H. The Biology of SPARC, a protein that modulates cell-matrix 
interactions. (1994) The FASEB Journal 8,163-173.
Lau, L.F., and Nathans, D. Identification of a set of genes expressed during the G0/G1 transition 
of cultured mouse cells. (1985) EMBO J 4, 3145-3151.
Lau, L,F, and Nathans, D. Expression of a set of growth-related immediate early genes in 
BALB/c 3T3 cells: coordinate regulation with c-fos or c-myc. (1987) Proc Natl Acad Sci USA 84, 
1182-1186.
LeBaron, R.G., Bezverkov, K.I., Zimber, M.P., Pavelec, R., Skonier, J., and Purchio, A.F. Beta 
IG-H3, a novel secretory protein inducible by transforming growth factor-beta, is present in 
normal skin and promotes the adhesion and spreading of dermal fibroblasts in vitro. (1995) J 
Invest Dermatol 104, 844-849.
Lee, C.K., Chan, E.W., Reilly, C.A., Panhke, V.A., Rockus, G. and Finkel M.P. In vitro properties 
of FBR Murine osteosarcoma Virus. (1979) Proc Soc Exp Biol Med 162, 214-220.
Lee, E.Y., Chang, C.Y., Hu, N., Wang, Y.C., Lai, C.C., Herrup, K., Lee, W.H., and Bradley, A. 
Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. 
(1992) Nature 359, 288-294.
Lee, M-S., Yang. J-H., Salehi, Z., Arnstein, P., Chen, L-S., Jay. G. and Rhim, J.S. Neoplastic 
transformation of a human keratinocyte cell line by the v-fos oncogene. (1993) Oncogene 8, 
387-393.
Lee, S.W., Tomasetto, C. and Sager R. Positive Selection of candidate tumor-suppressor genes 
by Subtractive Hybridization. (1991) Proc Natl Acad Sci USA 88, 2825-2829.
Lee, T.H., Solomon, M.J., Mumby, M.C., Kirschner, .M.W. INH, a negative regulator of MPF, is a 
form of protein phosphatase 2A. (1991) Cell 64, 415-423.
Lee, W.M., Lin, C., and Curran, T. Activation of the transforming potential of the human fos 
proto-oncogene requires message stabilization and results in increased amounts of partially 
modified fos protein. (1988) Mol Cell Biol 8, 5521 -5527.
Leevers, S.J., Paterson, H.F. and Marshall, C.J. Requirement for Ras in Raf activation is 
overcome by targeting Raf to the plasma membrane. (1994) Nature 369, 411 -414.
281
Leid, M., Kastner, P., Chambon, P. Multiplicity generates diversity in the retinoic acid signalling 
pathways. (1992) Trends Biochem Sci 17, 427-433.
Lejeune, S., Huguet, E.L., Hamby, A., Poulsom, R., Harris, A.L. Wnt5a cloning, expression, and 
up-regulation in human primary breast cancers. (1995) Clin Cancer Res 1,215-222.
Levine, A. The tumour suppressor genes. (1993) Annu Rev Biochem 62, 623-651.
Levy, J.A., Hartley, J.W., Rowe, W.P., and Huebner, R.J. Studies of FBJ osteosarcoma virus in 
tissue culture I. Biological characteristics of the “C” -Type viruses. (1973) J Natl Cancer Inst 51, 
525-539.
Leyns, L., Bouwmeester, T., Kim, S-H., Piccolo, S., and De Robertis, E.M. Frzb-1 is a secreted 
antagonist of Wnt signaling expressed in the Spemann Organizer. (1997) Cell 88, 747-756.
Li, S., Janosch, P., Tanji, M., Rosenfeld, G.C., Waymire, J.C., Mishak, H., Kolch, W., and 
Sedivy, J.M. Regulation of Raf-1 kinase activity by the 14-3-3 family of proteins (1995) EMBO J 
14, 685-696.
Liau, G., Yamada, Y., and de Crombrugghe, B. Coordinate regulation of the levels of type III and 
type I collagen mRNA in most but not all mouse fibroblasts. (1985) J Biol Chem 260, 531-536.
Lin, X., Nelson, P.J., Frankfort, B., Tombler, E., Johnson, R., and Gelman I.H. Isolation and 
characterization of a novel mitogenic regulatory gene, 322, which is transcriptionally suppressed 
in cells transformed by src and ras. (1995) Mol Cell Biol 15, 2754-2762.
Liu, D., Bienkowska, J., Petosa, C., Collier, R.J., Fu, H., and Liddington, R. Crystal structure of 
the zeta isoform of the 14-3-3 protein. (1995) Nature 376, 191-194.
Lloyd, A., Yancheva, M., and Wasylyk, B. Transformation suppressor activity of a jun 
transcription factor lacking its activation domain. (1991) Nature 235, 635-638.
Lucibello, F.C., Neuberg, M., Hunter, J.B., Jenuwein, T., Schuermann, M., Wallich, R., Stein, B., 
Schontal, A., Herllich P. and Muller, R. Transactivation of gene expression by fos protein: 
involvement of a binding site for the transcription factor AP-1. (1988) Oncogene 3, 43-51.
Lucibello, F.C., Neuberg, M., Jenuwein,T., and Muller, R. Multiple regions of v-Fos protein 
involved in the activation of AP-1 dependent transcription: is transactivation crucial for 
transformation ? (1991) New Biol 3, 671-677.
McMahon, H.T., Ushkaryov, Y.A., Edelman, L., Link, E., Binz, T., Niemann, H., Jahn, R„ and 
Sudhof, T.C. Cellubrevin is a ubiquitous tetanus-toxin substrate homologous to a putative 
synaptic vesicle fusion protein. (1993) Nature 364, 346-349.
MacLeod, A.R., Rouleau, J., and Szyf, M. Regulation of DNA methylation by the Ras signaling 
pathway. (1995) J Biol Chem 270, 11327-11337.
MacManus, J.P. Occurrence of a low-molecular-weight calcium-binding protein in neoplastic 
liver. (1979) Cancer Res 39, 3000-3005.
MacManus, J.P., Whitfield, J.F., Stewart. The presence in human tumours of a Mr 11,700 
calcium-binding protein similar to rodent oncomodulin. (1984) Cancer Lett 21, 309-315.
Mahoney, P.A., Weber, U., Onofrechuk, P., Biessmann, H., Bryant, P.J., and Goodman, C.S. 
The fat tumor suppressor gene in Drosophila encodes a novel member of the cadherin gene 
superfamily. (1991) Cell 67, 853-868.
Maki, Y., Bos, T.J., Davis, C., Starbuck, M., and Vogt, PK. Avian sarcoma virus 17 carries the 
jun oncogene. (1987) Proc Natl Acad Sci USA 84, 2848-2852.
282
Mangelsdorf, D.J., Ong, E.S., Dyck, J.A., Evans, R.M. Nuclear receptor that identifies a novel 
retinoic acid response pathway. (1990) Nature 345, 224-229.
Mangelsdorf, D.J., Borgmeyer, U., Heyman, R.A., Zhou, J.Y., Ong, E.S., Oro, A.E., Kakizuka, A., 
Evans, R.M. Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. 
(1992) Genes and Dev 6, 329-344.
Marks, M,S„ Hallenbeck, P.L., Nagata, T., Segars, J.H., Appella, E., Nikodem, V.M., Ozato, K. 
H-2RIIBP (RXR beta) heterodimerization provides a mechanism for combinatorial diversity in the 
regulation of retinoic acid and thyroid hormone responsive genes. (1992) EMBO J  11, 1419- 
1435.
Maruyama, K., Usami, M., Aizawa, T. and Yoshikawa, K. A novel brain-specific mRNA encoding 
nuclear protein (necdin) expressed in neurally differentiated embryonal carcinoma cells. (1991) 
Biochem Biophys Res Commun 178, 291-296.
Mashimo, J., Maniwa, R., Sugino, H. and Nose, K. Decrease in the expression of a novel TGF 
pi-inducible and ras-recision gene, TSC-36, in human cancer cells. (1997) Cancer Letters 113, 
213-219.
Mason, R.W., Green, G.D., Barrett, A.J. Human liver cathepsin L. (1985) Biochem J 226, 233- 
241.
Massague, J. The transforming growth factor-beta family. (1990) Annu Rev Cell Biol 6, 597-641.
Matrisian, L.M. Metalloproteinases and their inhibitors in matrix remodeling (1990) Trends in 
Genetics 6,121-125.
Matsumoto, K., Arai, M., Ishihara, N. Ando, A., Inoko, H., and Ikemuru, T. Cluster of fibronectin 
type III repeats found in the human major histocompatibility complex class III regions shows the 
highest homology with the repeats in an extracellular matrix protein, tenascin (1992a) Genomics 
12, 485-491.
Matsumoto, K., Ishihara, N. Ando, A., Inoko, H., and Ikemuru, T. Extracellular matrix protein 
tenascin-like gene found in human MHC class III region (1992b) Immunogenetics 36,400-403.
Matsui, M., Tokuhara, M., Konuma, Y., Nomura, N., and Ishizaki.R. Isolation of human Fos- 
Related genes and their expression during monocyte-macrophage differentiation. (1990) 
Oncogene 5, 249-255.
Maurer, P., Hohenadl, C., Hohenester, E, Gohring, W., Timpl, R., and Engel, J. The C-terminal 
portion of BM-40 (SPARC/Osteonectin) is an Autonomously Folding and Crystallisable Domain 
that Binds Calcium and Callogen IV. (1995) J Mol Biol 253, 347-357.
Mayer, B., Jauch, K.W., Gunthert, U., Figdor ,C.G., Schildberg, F.W., Funke, I., and Johnson, 
J.P. De-novo expression of CD44 and survival in gastric cancer. (1993) Lancet 342, 1019-1022.
Mayr, T., Deutsch, U., Kuhl, M., Drexler, H.C.A., Lottspeich, F., Deutzmann, R., Wedlich, D., and 
Risau, W. Fritz: a secreted frizzled-related protein that inhibits Wnt activity. (1997) Mech of Dev 
63,109-125
Mechta, F., Lallemand, D., Pfarr, C.M., and Yaniv, M. Transformation by ras modifies AP1 
composition and activity. (1997) Oncogene 14, 837-847.
Mecham, R.P., Broekelmann, T., Davis, E.C., Gibson, M.A., Brown-Augsburger, P. Elastic fibre 
assembly: macromolecular interactions. (1995) Ciba Found Symp 192,172-181; discussion 181- 
184.
283
Meijlink, F.( Curran, T., Miller, A.D., and Verma, I.M. Removal of a 67 base pair sequence in the 
noncoding region of the proto-oncogene fos converts it to a transforming gene. (1985) Proc Natl 
Acad Sci USA 82„4987-4991.
Melkonyan, H.S., Chang, W.C., Shapiro, J.P., Mahadevappa, M., Fitzpatrick, P.A., Kiefer, M.C., 
Tomei, L.D., Umansky, S.R. SARPs: A family of secreted apoptosis-related proteins. (1997) 
Proc Natl Acad Sci USA 94,13636-13641.
Metz, R., Bannister, A.J., Sutherland, J.A., Hagemeier, C., O ’Rourke, E.C., Cook, A. Bravo, R. 
and Kouzarides T. c-Fos-induced activation of a TATA-box-containing promoter involves direct 
contact with a TATA-box-binding-protein. (1994a) Mol Cell Biol 14, 6021 -6029.
Metz, R., Kouzarides T. and Bravo,R. A C-terminal domain in FosB, absent in FosB/sf and Fra- 
1, which is able to interact with the TATA binding protein, is required for altered cell growth. 
(1994b) EM BOJ  13, 3832-3842.
Miles, L.A., Dahlberg, C.M,. Plescia, J., Felez, J., Kato, K., and Plow, E.F. Role of cell-surface 
lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate 
plasminogen receptor. (1991) Biochemistry 30, 1682-1691.
Miller, A.D., Curran, T., and Verma, I.M. c-fos protein can induce cellular transformation: a novel 
mechanism of the activation of a cellular oncogene. (1984) Cell 36, 51 -60.
Mishra, S., Zacharias, D., ans Strehler, E.E. Regulation of the suspected tumor suppressor gene 
product CLP in human breast epithelial cells. (1994) J Cell Biochem 18 .(Suppl.C) 171.
Miyanaga, K., Shimasaki, S. Structural and functional characterization of the rat follistatin 
(activin-binding protein) gene promoter. (1993) Mol Cell Endocrinol 92, 99-109.
Motamed, K., Sage, E.H. Regulation of vascular morphogenesis by the matricellular protein 
SPARC. (1997) Kidney Int 51, 1383-1387.
Moren, A., Olofsson, A., Stenman, G., Sahlin, P., Kanzaki, T., Claesson-Welsh, L., ten Dijke, P., 
Miyazono, K., and Heldin, C.H. Identification and characterization of LTBP-2, a novel latent 
transforming growth factor-beta-binding protein. (1994) J Biol Chem 269, 32469-32478.
Morikawa, Y., Nishida, H., Misawa, K., Nosaka, T., Miyajima, A., Senba, E., and Kitamura, T. 
Induction of Synaptosomal-Associated Protein-23 kD (SNAP-23) by Various Cytokines (1998) 
Blood 92, 129-135.
Morin, P.J., Sparks, A.B., Korinek, V., Barker, N., Clevers, H., Volgelstein, B., and Kinzler, K.W. 
Activation of p-catenin Tcf signaling in colon cancer by mutations in p-catenin or APC. (1997) 
Science 2 7 5 ,1787-1790.
Moses, H.L., Yang, E.Y., and Pietenpol, J.A. TGF-beta stimulation and inhibition of cell 
proliferation: new mechanistic insights. (1990) Cell 63, 245-247.
Mulder, J.W., Kruyt, P.M., Sewnath, M., Oosting, J., Seldenrijk, C.A,. Weidema, W.F., 
Offerhaus, G.J., and Pals, S.T. Colorectal cancer prognosis and expression of exon-v6- 
containing CD44 proteins. (1994) Lancet 344,1470-1472.
Muller, R., Bravo, R., Burckhardt, J., and Curran, T. Induction of the c-fos gene and protein by 
growth factors precedes activation of c-myc. (1984) Nature 312, 716-719.
Mumberg, D., Lucibello, F.C., Schuermann, M. and Muller, R. Alternative splicing of fosB 
transcripts results in differentially expressed mRNA’s encoding functionally antagonistic proteins.
(1991) Genes and Dev 5, 1212-1223.
284
Munemitsu, S.I., Albert, B., Souza, B., Rubinfeld, B., and Polakis, P. Regulation of intracellular 
p-catenin levels by the adenomatous polyposis coli(APC) tumor suppressor protein. (1996) Prot 
Natl Acad Sci USA 92, 3046-3050.
Nakabeppu, Y., Ryder, K., and Nathans, D. DNA binding activities of three murine jun proteins: 
Stimulation byfos. (1988) Cell 55, 907-915.
Nakabeppu, Y. and Nathans, D. A naturally occurring truncated form of fosB that inhibits fos/jun 
transcriptional activity. (1991) Cell 64, 751-759.
Nan, X., Hg, H-H., Johnson, C.A., Laherty, C.D., Turner, B.M., Eisenman, R.N., and Bird, A. 
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone 
deacetylase complex. (1998) Nature 393, 386-389.
Negrini, M., Sabbioni, S., Possati, L., Rattan, S., Corallini, A., Barbanti-Brodano, G., Croce, C.M. 
Suppression of tumorigenicity of breast cancer cells by microcell-mediated chromosome 
transfer: studies on chromosomes 6 and 11. (1994) Cancer Res 54,1331-1336.
Neer, E.J., and Smith, T.F. G protein heterodimers: new structures propel new questions. (1996) 
Cell 84,175-178.
Neuberg, M., Schuermann, M., Hunter, J.B. and Muller, R. Two functionally different regions of 
Fos are required for the sequence specific DNA interactions of the Fos/Jun protein complex. 
(1989) Nature 338, 589-590.
Nicolson, G.L. Cancer metastasis: tumor cell and host organ properties important in metastasis 
to specific secondary sites. (1988) Biochim BiophysActa 948,175-224.
Niedbala, M.J., and Sartorelli, A.C. Plasminogen activator mediated degradation of 
subendothelial extracellular matrix by human squamous carcinoma cell lines. (1990) Cancer 
Commun2, 189-199.
Nishikura, K., and Murray, J.M. Antisense RNA of protooncogene c-fos blocks renewed growth 
of quiescent 3T3 cells. (1987) Mol Cell Biol 7, 639-649.
Nurse, P. Ordering S phase and M phase in the cell cycle. (1994) Cell 79, 547-550.
Nusse, R., and Varmus, H.E. Wnt genes.(1992) Cell 69,1073-1087
Oberhuber, H., Seliger, B. and Schafer R. Partial Restoration of Pre-transformation Levels of 
Lysyl Oxidase and Transin mRNAs in Phenotypic ras Revertants. (1995) Molecular 
Carcinogenesis 12,198-204.
Okabayashi, K., Shoji, H., Onuma, Y., Nakamura, T., Nose, K., Sugino, H., and Asashima, M. 
cDNA Cloning and Distribution of the Xenopus Follistatin-Related Protein. (1999) Biochem 
Biophys Res Comm 254, 42-48.
Okamoto, I., Kawano, Y., Tsuiki, H., Sasaki, J., Nakao, M., Matsumoto, M., Suga, M., Ando, M., 
Nakajima, M., and Saya, H. CD44 cleavage induced by a membrane-associated 
metalloprotease plays a critical role in tumor cell migration. (1999) Oncogene 18, 1435-1446.
Ozaki, T., and Sakiyama, S. Tumor-suppressive activity of N03 gene product in v-src 
transformed rat 3Y1 fibroblasts (1994) Cancer Research 54, 646-648.
Ozawa, M., Muramatsu, T. Reticulocalbin, a novel endoplasmic reticulum resident Ca(2+)- 
binding protein with multiple EF-hand motifs and a carboxyl-terminal HDEL sequence. (1993) J 
Biol Chem 268, 699-705.
285
Pallas, D.C., Shahrik, L.K., Martin, B.L., Jaspers, S., Miller, T.B., Brautigan, D.L., Roberts, T.M. 
Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with 
protein phosphatase 2A. (1990) Cell 60, 167-76.
Pan, L., Chamberlain, S.H., Auble, D.T., Brinckerhoff, C.E. Differential regulation of collagenase 
gene expression by retinoic acid receptors-alpha, beta and gamma. (1992) Nucleic Acids Res 
20, 3105-11.
Parker, M.I., Smith, A.A., and Gevers, W. Absence of a2(1) Procollagen Synthesis in a clone of 
SV40-transformed WI-38 Human (1989) Fibroblasts J Biol Chem 264, 7147-7152.
Partin, A.W., J.S. Shoeniger, L.L. Mohler, and D.S. Coffey. Fourier analysis of cell motility: 
correlation of motility with metastatic potentials. (1989) Proc Natl Acad Sci USA. 86,1254-1258.
Patel, K. Follistatin (1998) The International Journal of Biochemistry and Cell Biology 30, 1087- 
1093.
Patthy, L., Nikolics, K. Functions of agrin and agrin-related proteins. (1993) Trends Neurosci 16, 
76-81.
Pauls, T.L., Cox, J.A., and Berchtold, M.W. The Ca2+(-)binding proteins parvalbumin and 
oncomodulin and their genes: new structural and functional findings. (1996) Biochim Biophys 
Acta 1306, 39-54.
Pazin, M.J., and Williams, L.T. Triggering signaling cascades by receptor tyrosine kinases.
(1992) Trends Biochem Sci 17, 374-378.
Pennisi, E. How a growth control path takes a wrong turn to cancer. (1998) Science 281, 1438- 
1439.
Perez, P., Palomino, T., Schonthal, A., Aranda, A. Determination of the promoter elements that 
mediate repression of c-fos gene transcription by thyroid hormone and retinoic acid receptors.
(1994) Biochem Biophys Res Commun 205, 135-140.
Petkovich, M., Brand, N.J., Krust, A., Chambon, P. A human retinoic acid receptor which 
belongs to the family of nuclear receptors. (1987) Nature 330, 444-450.
Phillips, D.J., and de Krester, D.M. Follistatin: A Multifunctional Regulatory Protein. (1998) 
Fronteirs in Neuroendocrinology, 19, 287-322.
Phillips, D.J., McFarlane, J.R., Hearn, M.T. and de Krester, D.M. Inhibin, activin and follistatin 
bind preferentially to the transformed species of alpha 2-macroglobulin. (1997) J Endocrinol 155, 
65-71.
Pollack, R., Osborn, M., Weber, K. Patterns of organization of actin and myosin in normal and 
transformed cultured cells. (1975) Proc Natl Acad Sci USA 72, 994-998.
Potts, J.R., and Campbell, I.D. Fibronectin structure and assembly (1994) Current Opinion in 
Cell Biology 6, 648-655.
Pulverer, B.J., Kyriakis, J.M., Avruch, J., Nikolakaki E., and Woodjett J.R. Phosphorylation of c- 
jun mediated by MAP kinases. (1991) Nature 353, 670-674.
Quade, K. Transformation of mammalian cells by avian myelocytomatosis virus and avian 
erythroblastosis virus. (1979) Virology 98, 461-465.
Quintanilla, M., Brown, K., Ramsden, M. and Balmain, A. Carcinogen-specific mutation and 
amplification of Ha-ras during mouse skin carcinogenesis. (1984) Nature 78, 78-80.
286
Ransone, L.J., and Verma, I.M. Nuclear proto-oncogenes fos and jun. (1990) Annu Rev Cell Biol 
6, 539-557.
Rao, Z., Handford, P., Mayhew, M., Knott, V., Brownlee, G.G., and Stuart, D. The structure of a 
Ca(2+)-binding epidermal growth factor-like domain: its role in protein-protein interactions.
(1995) Cell 82, 131-141.
Rattner, A., Hsieh, J-C., Smallwood, P.M., Gilbert, D.J., Copeland, N.G., Jenkins, N.A., and 
Nathans, J. A family of secreted proteins contains homology to the cysteine rich ligand-binding 
domain of frizzled receptors. (1997) Proc Natl Acad Sci USA 94, 2859-2863.
Rauscher, F.J. Ill, Sambucetti, L.C., Curran, T., Distel, R.J. & Spiegelman, B.M. Common DNA 
binding site for Fos protein complexes and the transcription factor AP-1. (1988a) Cell 52, 471- 
480.
Rauscher, F.J. Ill, Cohen D.R., Curran T., Bos T.J., Vogt P.K., Bohmann D., Tjian R. and Franza 
B.R.,Jr. Fos-associated protein p39 is the product of the jun proto-oncogene. (1988b) Science 
240, 1010-1016.
Rauscher, F.J. Ill, Voulalas, P.J. Franza B.R. and Curran T. Fos and Jun bind co-operatively to 
the AP-1 site: reconstitution in vitro. (1988c) Genes and Dev 2 , 1687-1699.
Ravichandran, V., Chawla, A., and Roche, P.A. Identification of a novel Syntaxin- and 
SynaptobrevinA/AMP-binding Protein, SNAP-23, Expressed in Non-neuronal Tissues. (1996) J 
Biol Chem, 271,13300-13303.
Ray, L.B., and Sturgill, T.W. Rapid stimulation by insulin of a serine/threonine kinase in 3T3-L1 
adipocytes that phosphorylates microtubule-associated protein 2 in vitro. (1987) Proc Natl Acad 
Sci USA 84, 1502-1506.
Riabowol, K.T., Vosatka, R.J., Ziff ,E.B., Lamb, N.J. and Feramisco, J.R. Microinjection of fos- 
specific antibodies blocks DNA synthesis. (1988) Mol Cell Biol 8, 1670-1676.
Riabowol, K.T. Transcription factor activity during cellular aging of human diploid fibroblasts.
(1992) Biochem Cell Biol 70,1064-1072.
Reinhardt, D.P., Ono, R.N., and Sakai, L.Y. Calcium Stabilizes Fibrillin-1 against Proteolytic 
Degradation. (1997) J Biol Chem 272,1231 -1236.
Roberts, A.B., Heine, U.I., Flanders, K.C., Spom, M.B.Transforming growth factor-beta. Major 
role in regulation of extracellular matrix. (1990) Ann N Y Acad Sci 580, 225-232.
Robertson, H., Langdon, W.Y., Thein, C.B.F., and Bowtell, D.D.L. A c-Cbl Yeast Two Hybrid 
Screen Reveals Interactions with 14-3-3 Isoforms and Cytoskeletal Components. (1997) 
Biochem Biophys Res Comm, 240, 46-50.
Romanowski, P., Madine, M. and Laskey, R. XMCM7, a novel member of the Xenopus MCM 
family, interacts with XMCM3 and colocalizes with it throughout replication.(1996) Proc Natl 
Acad Sci USA 93, 10189-10194.
Rossetto, O., Gorza, L., Schiavo, N, Scheller, R.H., and Montecucco, C. Vamp/synaptobrevin 
isoforms 1 and 2 are widely and differentially expressed in nonneuronal tissues. (1996) J Cell 
Biol 132, 167-179.
Rouleau, J., MacLeod, A.R., and Szyf, M. Regulation of the DNA methyltransferase by the Ras- 
AP-1 signaling pathway (1995) J Biol Chem 270, 1595-1601.
Roy, S., McPherson, R.A., Apolloni, A., Yan, J., Lane, A., Clyde-Smith, J. and Hancock, J.F. 14- 
3-3 Facilitates Ras-Dependent Raf-1 Activation In Vitro and In Vivo. (1998) Mol Cell Biol 18, 
3947-3955.
287
Rozhin, J., Wade, R.L, Honn, K.V., Sloane, B.F. Membrane-associated cathepsin L: a role in 
metastasis of melanomas. (1989) Biochem Biophys Res Commun 164, 556-561.
Rubinfeld, B., Robbins, P., EIGamil, M., Albert, I., Porfiri, E., and Polakis, P. Stabalization of p- 
catenin by genetic defects in melanoma cell lines (1997) Science 275,1790-1792.
Ruther.U., Wagner, E.F. and Muller,R. Analysis of the differentiation-promoting promoting 
potential of the inducible c-fos genes introduced into embryonal carcinoma cells. (1985) EMBOJ 
4, 1775-1781.
Ruther, U., Muller, W., Sumida, T., Tokuhisa, T., Rajewsky, K. and Wagner, E.F. c-fos 
expression interferes with thymus development in transgenic mice. (1988) Cell 53, 847-856.
Ruther, U., Komitowski, D., Schubert, F.R. and Wagner, E.F. c-fos expression induces bone 
tumors in transgenic mice. (1989) Oncogene 4, 861 -865.
Rupp, B., Lorenz, U., Schmidt, J. and Werenskiold, A.K. Discordant effects of Activator-protein-1 
transcription factor on gene regulation, invasion, and metastasis in spontaneous, radiatian- 
induced, and fos-induced osteosarcomas. (1998) Molecular Carcinogenesis 23, 69-75.
Ryder, K., Lanahan, A., Perez-Albuerne, E., and Nathans, D. jun-D: a third member of the jun 
gene family. (1989) Proc Natl Acad Sci USA 86, 1500-1503.
Saez, E., Rutberg, S.E., Mueller, E., Oppenheim, H., Smoluk, J., Yuspa, S.H., and Spiegelman,
B.M. c-fos is required for malignant progression of skin tumors. (1995) Cell 82, 721-732.
Saharinen, J., Taipale, J., and Keski-Oja, J. Association of the small latent transforming growth 
factor-beta with an eight cysteine repeat of its binding protein LTBP-1. (1996) EMBO J  15, 245- 
253.
Sakaguchi, N., Henzl, M.T., Thalmann, I., Thalmann, R., and Schulte, B.A. Oncomodulin Is 
expressed exclusively by outer hair cells in the organ of corti. (1998) J Histochem Cytochem 46, 
29-40.
Sager, R. Tumor suppressor genes: the puzzle and the promise. (1989) Science 246, 1406- 
1412.
Sago, H., Kitagawa, M., Obata, S., Mori, N., Taketani, S., Rochelle, J.M., Seldin, M.F., Davidson, 
M., St.John, T., and Suzuki, S.T. Cloning, Expression, and Chromosomal Localization of a Novel 
Cadherin-Related Protein, Protocadherin-3. (1995) Genomics 29, 631-640.
Saito, H., Papaconstantinou, J, Sato, H. and Goldstein. Regulation of a novel gene encoding a 
Lysyl Oxidase-related protein in cellular adhesion and senescence. (1997) J Cell Biol 272, 8157- 
SI 60.
Sakai, L.Y., Keene, D.R., and Engvall, E. Fibrillin, a new 350-kD glycoprotein, is a component of 
extracellular microfibrils. (1986) J Cell Biol 103, 2499-2509.
Sakai, T., Furukawa, Y., Chiquet-Ehrismann, R., Nakamuru, M., Kitagawa, S., Ikemura, T., and 
Matsumoto, K. Tenascin-X expression in tumor cells and fibroblasts: glucocorticoids as negative 
regulators in fibroblasts. (1996) J Cell Sci 109, 2069-2077
Sambrook, J.; Fritdch, E.F.; and Mainiatis, T. (1989) Molecular Cloning. A laboratory manual (2nd 
edition).
Sano, K., Tanihara, H., Heimark, R.L, Obata, S., Davidson, M,. St John, T., Taketani, S., and 
Suzuki, S. Protocadherins: a large family of cadherin-related molecules in central nervous 
system. (1993) EM BOJ  12, 2249-2256.
288
Santoro, M.F., Annard, R.R., Robertson, M.M., Peng, Y-W., Brady, M.J., Mankovich, J.A., 
Hackett, M.C., Ghayur, T., Walter, G., Wong, W.W., and Giegel, D.A. Regulation of Protein 
Phosphatase 2A Activity by Caspase-3 during Apoptosis. (1998) J Biol Chem 273,13119-12128.
Santos, E., Tronick, S.R., Aaronson, S.A., Pulciani, S., and Barbacid, M. T24 human bladder 
carcinoma oncogene is an activated form of the normal human homologue of BALB- and 
Harvey-MSV transforming genes. (1982) Nature 298, 343-347.
Sassone-Corsi, P., Lamph, W.W., Kamps, M., and Verma, I. M. fos-associated cellular p39 is 
related to nuclear transcription factor AP-1. (1988) Cell 54, 553-560.
Sassone-Corsi, P., Ransone, L.J., and Verma, I.M. Cross-talk in signal transduction: TPA- 
inducible factor jun/AP-1 activates cAMP-responsive enhancer elements. (1990) Oncogene 5, 
427-431.
Satoh, H., Lamb, P.W., Dong, J.T., Everitt, J., Boreiko, C., Oshimura, M., Barrett, J.C. 
Suppression of tumorigenicity of A549 lung adenocarcinoma cells by human chromosomes 3 
and 11 introduced via microcell-mediated chromosome transfer. (1993) Mol Carcinog 7, 157- 
164.
Satoh, T., Nakafuku, M., and Kajiro, Y. Function of ras as a molecular switch in signal 
transduction. (1992) J Biol Chem 267, 24149-24152.
Saxon, P.J., Srivatsan, E.S., Stanbridge, E.J. Introduction of human chromosome 11 via 
microcell transfer controls tumorigenic expression of HeLa cells. (1986) EMBO J 5, 3461-3466.
Schenker, T., and Trueb, B. Down-Regulated Proteins of Mesenchymal Tumor Cells (1998) 
Experimental Cell Research 239,161 -168
Schlessinger, J., and Ullrich, A. Growth factor signaling by receptor tyrosine kinases. (1992) 
Neuron 9, 383-391.
Schuermann, M., Neuberg, M., Hunter, J.B., Jenuwein, T., Ryseck, P-R., Bravo, R. and Muller, 
R. The leucine repeat motif in fos protein mediates complex formation with jun/AP-1 and is 
required for transformation. (1989) Cell 56, 507-516.
Schuermann, M., Jooss, K., and Muller, R. fosB is a transforming gene encoding a 
transcriptional activator. (1991) Oncogene 6, 567-576.
Schule, R., Rangarajan, P., Yang, N., Kliewer, S., Ransone, L.J., Bolado, J., Verma, I.M., Evans, 
R.M. Retinoic acid is a negative regulator of AP-1-responsive genes. (1991) Proc Natl Acad Sci 
USA 88, 6092-6096.
Schutte, J, Minna, J.D. and Birrer, M.J. Deregulated expression of human c-jun transforms 
primary rat embryo cells in cooperation with an activated c-Ha-ras gene and transforms Rat-1 
cells as a single gene. (1989a) Proc Natl Acad Sci USA 86, 2257-2261.
Schutte, J., Viallet, J., Nau, M., Segal, S. , Fedorko, J., and Minna, J. jun-B inhibits and c-fos 
stimulates the transforming and trans-activating activities of c-jun (1989b) Cell 59, 987-997.
Schwab, M., Alitalo, K., Klempnauer, K.H., Varmus, H.E., Bishop, J.M., Gilbert, F., Brodeur, G., 
Goldstein, M., and Trent, J. Amplified DNA with limited homology to myc cellular oncogene is 
shared by human neuroblastoma cell lines and a neuroblastoma tumour. (1983) Nature 2305, 
245-248.
Shapiro, S.D. Matrix metalloproteinase degradation of extracellular matrix: biological 
consequences. (1998) Current Opinion in Cell Biology 10, 602-608.
289
Shibanuma, M., Mashimo, J, Mita, A., Kuroki, T., and Nose, K. Cloning from a mouse 
osteoblastic cell line of a set of transforming-growth-factor- (51 -regulated genes, one of which 
seems to encode a follistatin-related polypeptide. (1993) Eur Biochem 217,13-19.
Shimasaki, S., Koga, M, Esch, F., Cooksey, K., Mercado, M., Koba, A., Ueno, N., Ying, S-Y., 
Ling, N., and Guillemin, R. Primary structure of the human follistatin precursor and its genomic 
organization. (1998) Proc NatnAcad Sci USA 85, 4218-4222.
Skonier, J., Bennet, K., Rothwell, V., Kosowski, S., Plowman, G., Wallace, P., Edelhoff, S., 
Disteche, C., Neubauer, M., Marrquard, H., Rodgers, J., and Purchio, A.F. pig-h3: A 
transforming growth factor-p-responsive gene encoding a secreted protein that inhibits cell 
attachment In Vitro and suppresses the growth of CHO cells in nude mice (1994) DNA and Cell 
Biology A3, 571-584.
Slack, J.L., Parker, M.I., and Bornstein, P. Transcriptional repression of the alpha 1(1) collagen 
gene by ras is mediated in part by an intronic AP1 site. (1995) J Cell Biochem 58(3) 380-392.
Smeal, T., Binetruy, B., Mercola, D.A., Birrer M.J., and Karin, M. Oncogenic and transcriptional 
cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. (1991) Nature 
354, 494-496.
Smith-Mungo, L.I. and Kagan H.M. Lysyl Oxidase: Properties, Regulation and Multiple Functions 
in Biology. (1998) Matrix Biology 16, 387-398.
Sok-Pin Tan, R., Taniguchi, T. and Harada, H. Identification of the Lysyl Oxidase gene as a 
target of the antioncogenic transcription factor, IRF-1, and its possible role in tumor suppression.
(1996) 56, 2417-2421.
Sollner, T., Whiteheart, S.W., Brunner, M., Erdjument-Bromage, H., Geromanos, S., Tempst, P., 
and Rothman J.E. SNAP receptors implicated in vesicle targeting and fusion. (1993) Nature 362, 
318-324.
Sontag, E,, Sontag, J.M., Garcia, A. Protein phosphatase 2A is a critical regulator of protein 
kinase C zeta signaling targeted by SV40 small t to promote cell growth and NF-kappaB 
activation. (1997) EMBO J 16, 5662-5671.
Stacey, D.W., Watson, T. ,Kung, H-F. and Curran, T. Microinjection of transforming ras proteins 
induces c-fos expression. (1987) Mol Cell Biol 7, 523-527.
Stanbridge, E.J. Suppression of malignancy in human cells. (1976) Nature 260,17-20.
Stehelin, D., Varmus, H.E., Bishop, J.M., and Vogt, P.K. DNA related to the transforming 
gene(s) of avian sarcoma viruses is present in normal avian DNA. (1974) Nature 260,170-173.
Stossel, T.P. On the crawling of animal cells. (1993) Science 260,1086-1094.
Struhl K. The DNA-binding domains of the jun oncoprotein an the yeast GCN4 transcriptional 
activator protein are functionally homologous. (1987) Cell 50, 841 -846
Sutherland, J.A., Cook, A., Bannister, A.J., and Kouzarides, T. Conserved motifs in Fos and Jun 
define a new class of activation domain. (1992) Genes and Dev 6,1810-1819.
Suzuki, T., Okuno, H., Yoshida. T., Endo, T., Nishina, H., and Iba, H. Difference in 
transcriptional regulatory function between c-Fos and Fra-2. (1991) Nucleic Acids Res 19, 5537- 
5542.
Suzuki, T., Murakami, M., Onai, N., Fukuda, E., Hashimoto, Y., Sonobe, M.H., Kameda, T., 
Ichinose, M., Miki, K., and Iba, H. Analysis of AP-1 function in cellular transformation pathways.
(1994) J Virol 68, 3257-3235.
290
Szabo, Z., Light, E., Boyd, C.D. and Csiszar, K. The human lysyl oxidase-like gene maps 
between STS markers D15S215 and GHCL.GCT7C09 on chromosome 15. (1997) Human 
Genetics 101, 198-200.
Tabin, C.J., Bradley, S.M., Bargmann ,C.I., Weinberg, R.A., Papageorge, A.G., Scolnick, E.M., 
Dhar, R., Lowy, D.R., and Chang, E.H. Mechanism of activation of a human oncogene. (1982) 
Nature 300,143-149.
Taniura, H., Taniguchi, N., Hara, M., and Yoshikawa, K. Necdin, a postmitotic neuron-specific 
growth suppressor, interacts with viral transforming proteins and cellular transcription factor 
E2F1. (1998) J Biol Chem 273, 720-728.
Taparowsky, E., Suard, Y., Fasano, O., Shimizu, K., Goldfarb, M., and Wigler, M. Activation of 
the T24 bladder carcinoma transforming gene is linked to a single amino acid change. (1982) 
Nature 300,762-765.
Tavoloni, N., Inoue, H., Sabe, H., and Hanafusa, H. v-src transformation of rat embryo 
fibroblasts. Inefficient conversion to anchorage-independent growth involves heterogeneity of 
primary cultures. (1994) J Cell Biol 126 475-483.
Tefft, J.D., Lee, M., Smith, S., Leinwand, M., Zhao, J., Bringas, P. Jr., Crowe, D.L., and 
Warburton, D. Conserved function of mSpry-2, a murine homolog of Drosophila sprouty, which 
negatively modulates respiratory organogenesis. (1999) CurrBiol 9, 219-222.
Thomas, L., Etoh, T., Stamenkovic, I., Mihm, M.C. Jr., and Byers, H.R. Migration of human 
melanoma cells on hyaluronate is related to CD44 expression. (1993) J Invest Dermatol 100, 
115-20.
Tlsty, T.D. Cell-adhesion-dependent influences on genomic instability and carcinogenesis. 
(1998) Current Opinion in Cell Biology 10, 647-653.
Travers, H., French, N.S., and Norton, J.D. Suppression of Tumorigenicity in Ras-transformed 
Fibroblasts by a2(l) Collagen. (1996) Cell Growth and Differentiation 7,1353-1360.
Treinies, I., Paterson, H.F., Hooper, S., Wilson, R., and Marshall, C.J. Activated MEK stimulates 
expression of AP-1 components independently of phosphatidylinositol3-kinase (PI3-kinase) but 
requires a PI3-kinase signal to stimulate DNA synthesis. (1999) Mol Cell Biol 19, 321-329.
Tsuji, Y., Torti, S.V., and Torti, F.M. Activation of the Ferritin H Enhancer, FER-1, by the 
Cooperative Action of Members of the AP1 and Sp1 Transcription Factor Families. (1998) J Biol 
Chem 273, 2984-2992.
Tucker, K.L., Talbot, D., Lee, M.A., Leonhardt, H., and Jaenisch, R. Complementation of 
methylation deficiency in embryonic stem cells by by a DNA methyltransferase minigene. (1996) 
Proc Natl Acad Sci USA 93,12920-12925.
Uetsuki, T., Takagi, K., Sugiura, H., and Yoshikawa, K. Structure and Expression of the Mouse 
Necdin Gene (1996) J Biol Chem 271, 918-924.
Ugolini, F., Adelaide, J., Charafe-Jauffret, E., Nguyen, C., Jacquemier, J., Jordan, B., Birnbaum, 
D., and Pebusque, M.J. Differential expression assay of chromosome arm 8p genes identifies 
Frizzled-related (FRP1/FRZB) and Fibroblast Growth Factor Receptor 1 (FGFR1) as candidate 
breast cancer genes. (1999) Oncogene 18, 1903-1910.
Valge-Archer, V.E., DEViliers, J., Sinskey, A.J., and Rao, A. Transformation of T Lymphocytes by 
the v-fos oncogene. (1990) J Immunol. 145, 4355-4364.
van Beveren, C., van Straaten, F., Galleshaw, J.A., and Verma , I.M. Analysis of the FBJ-MuSV 
provirus and the c-fos (mouse) gene reveals that viral and cellular fos gene products have 
different carboxy termini. (1983) Cell 32, 1241 -1255.
291
Van Beveren, C., Enami S,., Curran ,T., and Verma I.M. FBR murine osteosarcoma virus II. 
Nucleotide sequence of the provirus reveals that the genome contains sequences acquired from 
two cellular genes. (1984) Virology 135, 229-243.
Van de Klundert, F.A., Jansen, H.J., Bloemendal, H. Negative regulation of a special, double 
AP-1 consensus element in the vimentin promoter: interference by the retinoic acid receptor. 
(1995) J Cell Physiol 164, 85-92.
van Straaten, F., Muller, R., Curran T., Van Beveren, C., and Verma, I.M. Complete nucleotide 
sequence of a human c-onc gene : deduced amino acid sequence of the human c-fos protein.
(1983) Proc Natl Acad Sci USA 80, 3183-3187.
Vekris, A. Simplified in vivo subcloning for easy handling of large sets of lambda ZAP clones.
(1994) Nucleic Acids Res 22, 4842-4843.
Verma, I.M. and Graham, W.R. The fos oncogene. Adv Cancer Res. (1987) 49, 29-52.
Vinson, C.R., Conover, S., and Adler, P.N. A Drosophila tissue polarity locus encodes a protein 
containing seven potential transmembrane domains. (1989) Nature 338, 263-264.
Vleminckx, K., Vakaet, L. Jr., Mareel, M., Fiers, W., van Roy, F. Genetic manipulation of E- 
cadherin expression by epithelial tumor cells reveals an invasion suppressor role. (1991) Cell 
66,107-119.
Vogelstein, B. Cancer. A deadly inheritance. (1990) Nature 348, 681-682.
Vogelstein, B., and Kinzler K.W. The multistep nature of cancer. (1993) Trends In Genetics 9, 
138-141.
Vogt, P.K., Bos, T.J., and Doolitle, R.F. Homology between the DNA-binding domain of the 
GCN4 regulatory protein of the yeast and the carboxy-terminal region of a protein coding for by 
the oncogene jun. (1987) Proc Natl Acad Sci USA 84, 3316-3319.
Wang, S.S., Esplin, E.D., Li, J.L., Huang, L., Gazdar, A., Minna, J., and Evans, G.A. Alterations 
of the PPP2R1B Gene in Human Lung and Colon Cancer. (1998) Science 282, 284-287.
Wang, Y., Macke, J., Abella, B., Andreasson, K., Worley, P., Gilbert, D., Copeland, N., Jenkins, 
N., and Nathans, J. A large family of putative transmembrane receptors homologous to the 
product of the Drosophila tissue polarity gene frizzled. (1996) J Biol Chem 271, 4468-4476.
Wang, Y.K., Samos, C.H., Peoples, R., PerezJurado, L.A., Nusse, R., and Francke, U. A novel 
human homologue of the Drosophila frizzled wnt receptor gene binds wingless protein and is in 
the Williams syndrome deletion at 7q11.23. (1997) Hum Mol Genet 6, 465-472.
Wang, Z-Q., Grigoriadis, A.E., Mohle-Stenhlein, U. and Wagner, E.F. A novel target cell for fos- 
induced oncogenesis : development of chondogenic tumors in embryonic stem cell chimeras.
(1991) EMBOJ  10, 2437-2450.
Wang, Z.-Q., Ovitt.,C., Grigoriadis, A.E., Mohle-Steinlein, U., Ruther, U., and Wagner, E.F. Bone 
and haematopoietic defects in mice lacking c-fos. (1992) Nature 360, 741 -745.
Ward ,J.M., and Young, D.M. Histogenesis and Morphology of periosteal sarcomas induced by 
FBJ Virus in NIH Swiss Mice. (1976) Cancer Res. 36, 3985-3992.
Weber, G.F., Ashkar, S., Glimcher, M.J., and Cantor, H. Receptor-ligand interaction between 
CD44 and osteopontin (Eta-1). (1996) Science 271, 509-512.
Weber, K., Lazarides, E., Goldman, R.D., Vogel, A., Pollack, R. Localization and distribution of 
actin fibers in normal transformed and revertant cells. (1975) Cold Spring Harb Symp Quant 
Biol; 39, 363-369.
292
Wedegaertner, P.B., Wilson, P.T., and Bourne, H.R. Lipid modifications of trimeric G proteins.
(1995) J Biol Chem 270, 503-506.
Weinberg, R.A. Tumor suppressor genes. (1991) Science 254, 1138-1146.
Wick, M., Lucibello, F.C., and Muller, R. Inhibition of Fos- and Ras- induced transformation by 
mutant Fos proteins with structural alterations in functionally different domains. (1992) 
Oncogene 7, 859-867.
Wilson, T., and Treisman, R. Fos C-terminal mutations block down-regulation of c-fos 
transcription following serum stimulation. (1988) EMBOJ  7, 4193-4202.
Wisdom, R., Verma, I.M. Revertants of v-fos-transformed rat fibroblasts: suppression of 
transformation is dominant. (1990) Mol Cell Biol 10, 5626-5633.
Wisdom, R., and Verma, I.M. Proto-oncogene FosB: the amino teminus encodes a regulatory 
function required for transformation. (1993) Mol Cell Biol 13, 2635-2643.
Wisdom, R., Yen, J., Rashid, D., and Verma, I.M. Transformation by FosB requires a 
transactivation domain missing in FosB2 that can be substituted by heterologous activation 
domains. (1992) Genes and Dev 6 , 667-675.
Wolf,S.; Artuso V.; Dharmarajan,L., Guo, A.; Bielke.K.; and Friis.R.R. A frizzled related Gene is 
upregulated in Physiological Apoptosis. (1997) Unpublished.
Wolf, V., Ke, G., Dharmarajan, A.M., Bielke, W., Artuso, L., Saurer, S., and Friis, R. DDC-4, an 
apoptosis-associated gene, is a secreted frizzled relative. (1997) FEBS Lett 417, 385-389.
Wong, A.J., Ruppert, J.M., Eggleston ,J., Hamilton, S.R., Baylin, S.B., Vogelstein, B. Gene 
amplification of c-myc and N-myc in small cell carcinoma of the lung. (1986) Science 233, 461- 
464.
Wong, G.T., Gavin, B.J., McMahon, A.P. Differential transformation of mammary epithelial cells 
by Wnt genes. (1994) Mol Cell Biol 14, 6278-6286.
Woods, A., and Crouchman, J.R. Protein kinase C involvement in focal adhesion formation.
(1992) J Cell Sci 101, 277-290.
Wu, J., Issa, J-P., Herman, J., Basset, D.E.Jr, Nelkin, B.D., and Baylin, S.B. Expression of an 
exongenous eukaryotic DNA methyltransferase gene induces transformation of NIH 3T3 cells.
(1993) Proc Natl Acad Sci USA 90, 8891 -8895.
Xiao, B., Smerdon, S.J., Jones, D.H., Dodson, G.G., Soneji, Y., Aitken, A., and Gamblin, S.J. 
Structure of a 14-3-3 protein and implications for coordination of multiple signalling pathways.
(1995) Nature 376, 188-191.
Xu, Y.K., and Nusse, R. The Frizzled CRD domain is conserved in diverse proteins including 
several receptor tyrosine kinases. (1998) Current Biology 8, R405-R406.
Yamada, K.M., and Geiger, B. Molecular interactions in cell adhesion complexes (1997) Current 
Opinion in Cell Biology 9, 76-85.
Yamashita, H,, ten Dijke, P., Huylebroeck, D., Sampath, T.K., Andries, M., Smith, J.C., Heldin,
C.H., Miyazono, K. Osteogenic protein-1 binds to activin type II receptors and induces certain 
activin-like effects. (1995) J Cell Biol 130, 217-226.
Yang-Snyder, J., Miller, J.R., Brown, J.D., Lai, C.J., and Moon, R.T. A frizzled homolog functions 
in a vertebrate Wnt signaling pathway. (1996) Current Biology 6,1302-1306.
293
Yen, J., Wisdom, R.M., Tratner, I., and Verma, I.M. An alternative spliced form of FosB is a 
negative regulator of transcriptional activation and transformation by Fos proteins. (1991) Proc 
Natl Acad Sci USA 88, 5077-5081.
Yoder, J.A., Yen, R-W. C., Vertino, P.M., Bestor, T.H., and Baylin, S.B. New 5’ regions of the 
murine and human genes for DNA (Cytosine-5)-methyltransferase. (1996) J Biol Chem 271, 
31092-31097.
Yoshida ,T., Shindo ,Y., Ohta, K., and Iba, H. Identification of a small region of the v-fos gene 
product that is sufficient for transforming potential and growth-stimulating activity. (1989) 
Oncogene Res 5, 79-89.
Young, C.S., Kitamura, K., Hardy, S., and Kitajewski, J. Wnt-1 induces growth, cytosolic (5- 
catenin, and Tcf/Lef Transcriptional Activation in Rat-1 fibroblasts. (1998) Mol Cell Biol 18, 2474- 
2485.
Yu, Q., and Stamenkovic, I. Localization of matrix metalloproteinase 9 to the cell surface 
provides a mechanism for CD44-mediated tumor invasion. (1999) Genes and Dev 13, 35-48.
Yumoto, T., Poel, W.E., Kodama, T .( and Dmochowski, L. Studies on FBJ Virus-induced bone 
tumors in mice. (1970) Texas Rep Biol Med 28, 145-165.
Zarbl, H,, Latreille, J., Jolicoeur, P. Revertants of v-fos-transformed fibroblasts have mutations in 
cellular genes essential for transformation by other oncogenes. (1987) Cell 51, 357-369.
Zetter, B.R. The cellular basis of site-specific tumor metastasis. (1990) N Engl J Med 322, 605- 
612.
Zerial, M., Toschi, L., Ryseck, R-P., Schuermann, M., Muller, R. and Bravo, R. The product of a 
novel growth factor activated gene, fos B, interacts with JUN proteins enhancing their DNA 
binding activity. (1989) EMBOJ  8, 805-813.
Zhang, L., Zhou, W., Velculescu, V.E., Kern, S.E., Hruban, R.H., Hamilton, S.R., Vogelstein, B. 
and Kinzler, K.W. Gene Expression Profiles in Normal and Cancer Cells (1997) Science 276, 
1268-1272.
Zhang, Y., Iratni, R., Erdjument-Bromage, H., Tempst, P., and Reinberg, D. Histone 
deacetylases and SAP18, a novel polypeptide, are components of a human Sin3 complex.
(1997) Cell 89, 357-364.
Zhao, Y., Boguslawski, G., Zitomer, R.S., DePaoli-Roach, A.A. Saccharomyces cerevisiae 
homologs of mammalian B and B' subunits of protein phosphatase 2A direct the enzyme to 
distinct cellular functions. (1997) J Biol Chem 272, 8256-62
Zhou, Z., Wang, J., Han, X., Zhou, J., and Linder, S. Up-regulation of Human secreted Frizzled 
Homolog in Apoptosis and its down-regulation in breast tumours (1998) Int J Cancer 78, 95-99.
Ziff, E.B. Transcription factors: a new family gathers at the cAMP response site. (1990) Trends 
Genet 6, 69-72.
Zorn, A.M. Cell-cell signalling: Frog Frizbees. (1997) Current Biology 7, R501-R504.
Zou, Z, Anisowicz, A, Hendrix, M.J.C., Thor, A., Nevau, M., Sheng, S., Rafindi, K., Seftor, E., 
and Sager, R. Mapsin, a serpin with tumor-suppressing activity in human mammary epithelial 
cells (1994) Science 263, 526-529.
Zwijsen, A., Blockx, H., Van Arnhem, W., Willems, J., Fransen, L., Devos, K., Raymackers, J., 
Van De Voorde, A., and Siegers, H. (1994) EurJ Biochem 225, 937-946.
294
BIBLIOGRAPHY
Bioinformatics: A practical guide to the analysis of genes and proteins. (Baxevanis, A.D., Francis 
Ouellette, B.F, eds). ©1998, John Wiley and Sons
Biostatistics: Concepts and applications for biologists. Williams, B. ©1993, pp 52-75. Chapman 
and Hall.
Extracellular Matrix Assembly and Structure. Mecham, R. P., and Davis, E. C. (1994) 
(Yurchenko, P. D., Birk, D. E., and Mecham, R. P., eds), pp.281-314, Academic Press, Inc., San 
Diego
Nucleic Acid Hybridization: A Practical Approach. Britten, R.L., and Davidson, E.H. ©1985, pp3- 
15. (Hames, B.D., and Higgins, S.J., eds), IRL, Oxford,
The Oncogene Handbook. Hesketh, R. ©1994, Academic Press Ltd.
